1. TITLE is Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA). SHORT TITLE is Phase2/3 study of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker EBV DNA. INVESTIGATOR NAME is Rupali Nabar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the nasopharynx
Sites are required to complete Step 1 registration before submitting specimens for EBV DNA analysis.

Patients must have detectable pretreatment plasma EBV DNA, determined by the central lab prior to Step 2 registration (see Section 10.2 for details of specimen submission).
For patients who have detectable plasma EBV DNA tested at one of the credentialed central labs (listed on the EBV DNA Testing Specimen Transmittal form) within 28 days prior to Step 1 registration: that test result can be used for eligibility without the need for re-testing. To use this test result for eligibility, the central lab must enter the test result through the pathology portal, and the site must follow the instructions in Section 5.4.
Stage II-IVB disease (AJCC, 7th ed.) with no evidence of distant metastasis, based upon the following minimum diagnostic workup:

History/physical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or ENT, which must include an endoscopic evaluation, a complete list of current medications, and assessment of weight and weight loss in the past 6 months within 21 days prior to registration;
Evaluation of tumor extent required within 28 days prior to registration:
MRI of the nasopharynx and neck; or CT of the nasopharynx and neck with &#8804; 3 mm contiguous slices with contrast and bone windows (to evaluate base of skull involvement).
Note: If a treatment planning CT scan is used, it must be with &#8804; 3 mm contiguous slices with contrast and be read by a radiologist.

Exclusion Criteria:

Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; however, at least 6-weeks recovery is necessary if the last regimen included nitrosourea or mitomycin
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed
&#8805; Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)
Severe, active co-morbidity, defined as follows:

Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy
Unstable angina and/or uncontrolled congestive heart failure within the past 6 months
Myocardial infarction within the last 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that Human Immunodeficiency Virus (HIV) testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception. DESCRIPTION is There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-01-06T22:40:08. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Radiation Therapy Oncology Group, NRG Oncology . DISEASE SITES is Lip, Oral Cavity and Pharynx.
2. TITLE is [BIOREPOSITORY] Hematologic Malignancies Biorepository for human research. SHORT TITLE is BIOREPOSITORY PROTOCOL EXEMPT FROM NCI REPORTING. INVESTIGATOR NAME is Angela G Fleischman. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you have or are being evaluated for a blood disorder

Exclusion Requirements
You cannot participate in this study if you are pregnant.. DESCRIPTION is UC Irvine Medical Center is both a treatment and a research hospital. As a patient here, you may be treated
by some doctors who are also researchers performing studies to improve treatments currently available.

Scientists and clinicians at this institution are working together to discover new ways to treat cancer and
new ways to make current treatments safer and more effective. In order to conduct this research, we need
to study samples of normal and disease tissue obtained from normal volunteers and our patients. In order
to minimize the discomfort and risk to subjects, we are seeking to collect tissue that is left over from studies
that are required for your evaluation and care and are already being done. In certain circumstances (blood
draw and bone marrow aspiration) we are seeking to collect a small amount of tissue in addition to the
sample that would be collected for your routine care. Except for giving samples of blood, you will not be
asked to undergo any procedure solely for the purpose of obtaining a sample for this study. 

You are being asked to take part in this research study because you have or are being evaluated for a
hematologic malignancy, bone marrow disorder, or immune system disorder.

This research study involves the collection and storage of blood and other tissue for later research testing.
It is not currently known how samples donated to the repository will be used at this time. These research tests may be developed during the time you are a patient at UC Irvine Medical Center, or in some cases, years later. Any researcher at UCI or their collaborators (including for-profit entities) may request permission to use samples from the repository. Frozen de-identified samples will be provided to researchers after their plans have been evaluated and approved by the UCI review board that oversees human research (IRB). These tests may provide additional information that will be helpful in understanding cancer and other diseases, but it is unlikely that what we learn from these studies will benefit you directly.

These studies may benefit other patients in the future. The research performed on these samples may
include the study of genetics, including the subject&#8217;s DNA code, parts or the DNA code or even whole
genome sequencing. Samples from the repository will not be used to create cell lines. 

. TREATMENT TYPE DESC is Other. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-03-24T10:07:16. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Non-Hodgkin's Lymphoma, Mycosis Fungoides, Multiple Myeloma, Lymphoid Leukemia, Leukemia, other, Myeloid and Monocytic Leukemia, Other Hematopoietic, Hodgkin's Lymphoma.
3. TITLE is [EXEMPT - REGISTRY TRIAL] Prospective and Retrospective Study of Outcomes for Patients with Malignant Melanoma. SHORT TITLE is Prospective and Retrospective Study of Outcomes for Patients with Malignant Melanoma. INVESTIGATOR NAME is Maki Yamamoto. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is You are eligible to participate in this study if you are at least 18 years old and have a confirmed diagnosis of 
melanoma. . DETAILED ELIGIBILITY is You are eligible to participate in this study if you are at least 18 years old and have a confirmed diagnosis of 
melanoma. . DESCRIPTION is Advances in the treatment of malignant melanoma are being developed in terms of medical information on
diagnosis, surgery, adjuvant therapy and post-treatment surveillance. The purpose of this protocol would be to
create a data repository by collecting key data elements to watch for patterns within melanoma to potentially
help future patients. By collecting this data, we intend to assess trends by watching for patterns of melanoma
inclusive of treatment, criteria for staging, time to recurrence, population, patients at risk for recurrence,
survival of patients, and time to death. The collection of this data will include a retrospective collection of
historical patients and a prospective collection from new patients within the melanoma UC Irvine Health clinics. TREATMENT TYPE DESC is Basic Science. AGE DESCRIPTION is Adults. MODIFIED DATE is 2021-02-12T11:45:58. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Melanoma, Skin.
4. TITLE is Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 /CDK Pathway Mutations. SHORT TITLE is Ph II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas w/ SMO/ AKT/ NF2 Mutations. INVESTIGATOR NAME is Daniela Bota. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria: 
- Histologically proven intracranial meningioma as documented by 
central pathology review
- Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN 
mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 
copy number gain in tumor sample as documented specifically by the central laboratory
- Male or female who are not pregnant and not nursing

Exclusion Criteria:
- Patients who have active bacterial infection
- Patients who have history of heart diseases as described by the study protocol
- Patients who have uncontrolled hypertension. DESCRIPTION is This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-06-17T16:20:02. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Alliance, NRG Oncology , SWOG. DISEASE SITES is Brain and Nervous System.
5. TITLE is A Phase I/II, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). SHORT TITLE is Ph I/II Study of TPX-0005 for ALK/ROS1/NTRK1-3 Rearrangements in Adv Solid Tumors (TRIDENT-1). INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you 
&#8226;	Are a male or female subject, 18 years of age or older 
&#8226;	Are able to adhere to the study visit schedule and other protocol requirements
&#8226;	Have a confirmed diagnosis of locally advanced or metastatic solid tumor that has a specific gene rearrangement

Exclusion Requirements 
You cannot participate in this study if you
&#8226;	Are pregnant or breastfeeding, or intending to become pregnant during the study 
&#8226;	Are currently participating in another therapeutic clinical trial
&#8226;	Have a known active infection (bacterial, fungal, or viral, including human immunodeficiency virus positivity).. DESCRIPTION is This study has 2 parts (Phase 1 and Phase 2): 
&#8226;	Phase 1: Phase 1 of this research study is currently ongoing. It was the first time that the study drug, reprotrectinib, was given to humans.
o	The purpose of Phase 1 was to determine the dose of repotrectinib to use in Phase 2 of the study.  Phase 1 look at the side effects and response of tumors to different doses of repotrectinib. Phase 1 also looked at how different foods affect how repotrectinib gets into the body. Phase 1 includes the following sub-studies:
&#61607;	Phase 1a, where the study drug is given under fasting conditions. You will need to fast 1 hour before and 2 hours after study drug administration. As of November 5th 2018, this part of the study is completed and will not enroll any new subjects
&#61607;	Phase 1b is a Food Effect Sub-Study (a study within a study). You may be asked to participate in the Food Effect Sub-Study. The purpose of the Food Effect Sub-Study is to determine the effect of high-fat, high-calorie food on a single dose of repotrectinib (how much and how fast repotrectinib gets into the body after a meal). As of November 5th 2018, this part of the study is completed and will not enroll any new subjects.
&#61607;	Phase 1 also includes a study of repotrectinib when administered continuously with food, where you will take every dose of the study drug with a standard meal, called Phase 1c. 
&#8226;	Phase 2: You are being asked to participate in Phase 2 of this study (not Phase 1). The purpose of Phase 2 is to determine, more specifically, whether repotrectinib works, especially in groups of subjects who have the various tumor gene rearrangements mentioned above. Phase 2 will also continue to look at the side effects as well as how repotrectinib is absorbed into the body.
The Phase 2 portion of the study will evaluate the anti-cancer activity of repotrectinib at the dose listed below:
&#8226;	160 mg once a day for 14 days that may increase to 160 mg twice a day based on the drug&#8217;s tolerability 
The study doctor will assess and decide if your dose should be increased or decreased.
 No study procedures related to this study will be performed until you have signed this Informed Consent Form. A copy of the signed Informed Consent Form will be given to you to keep.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-02-08T16:27:33. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Turning Point Therapeutics, INC Research, Inc. (Raleigh, North Carolina). DISEASE SITES is Brain and Nervous System, Breast, Colon, Thyroid, Rectum, Other Digestive Organ, Lip, Oral Cavity and Pharynx, Melanoma, Skin, Other Skin, Lung, Urinary Bladder, Kidney.
6. TITLE is Phase II, Single Arm Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent WHO Grade III Malignant Astrocytoma. SHORT TITLE is Ph II Study of Optune in Bevacizumab-Na√Øve Subjects w/ Recurrent WHO Grade III Malignant Astrocytoma. INVESTIGATOR NAME is Daniela Bota. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults 21 years of age and older. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.
 
Inclusion Requirements
You can participate in this study if you:
1.	Are greater than 21 years of age
2.	Have been diagnosed with brain tumors Anaplastic Astrocytoma (AA)
3.	Have not been treated with Bevacizumab or any anti-angiogenesis drug prior to treatment.

Exclusion Requirements 
You cannot participate in this study if you:
1.	Are pregnant or breastfeeding
2.	Have had chemotherapy within 4 weeks of starting this study
3.	Have any condition the study doctor feels increase the risk to you by participating on this study.. DESCRIPTION is This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second line treatment and who have not previously received any BEV (Bevacizumab) or any experimental agents.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-02-12T13:18:01. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NovoCure Ltd., UCI. DISEASE SITES is Brain and Nervous System.
7. TITLE is  Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma. SHORT TITLE is Ph III Trial of Observation Vs Irradiation for a Gross Totally Resected Grade II Meningioma. INVESTIGATOR NAME is Xiao-Tang Kong. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria: 
- The patient must have a newly diagnosed unifocal intracranial meningioma, gross totally resected, and histologically confirmed as WHO grade II based upon pathology findings at the enrolling institution; WHO grade will be assigned according to WHO 2016 criteria
- Gross total resection (GTR) will be interpreted as modified Simpson grade 1-3 without gross residual dural-based or extradural tumor; GTR must be confirmed both by modified Simpson grade and by post-operative magnetic resonance imaging (MRI) findings
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry

Exclusion Criteria: 
- Definitive evidence of metastatic meningioma
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (carcinoma in situ of the breast, oral cavity, cervix, melanoma in situ, or other non-invasive malignancies are permissible)
- Previous radiotherapy to the scalp, cranium, brain, or skull base and radiation-induced meningiomas. DESCRIPTION is This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-05-26T13:28:34. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Brain and Nervous System.
8. TITLE is Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas. SHORT TITLE is Ph II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas. INVESTIGATOR NAME is Yoon Jae Choi. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria: 
- Pre-registration: Patients must have local diagnosis of papillary craniopharyngioma and have tissue slides available for submission to central pathology review; central pathology review will include immunohistochemistry (IHC) testing for BRAF V600E mutation (VE1 clone) and beta-catenin IHC (membranous, non-nuclear pattern) if needed to confirm diagnosis of papillary craniopharyngioma
- Histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC
- Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required

. DESCRIPTION is This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-05-26T13:45:24. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Alliance. DISEASE SITES is Brain and Nervous System.
9. TITLE is A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001).. SHORT TITLE is Ph I/II LOXO-292 for RET Fusion+ Solid Tumors, Medullary Thyroid Ca & Other Tumors w/RET Activation. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Key Inclusion Criteria:

For Phase 1:

Participants with a locally advanced or metastatic solid tumor that:
Has progressed on or is intolerant to standard therapy, or
For which no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or
Decline standard therapy
Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed
A RET gene alteration is not required initially. Once adequate PK exposure is achieved, evidence of RET gene alteration in tumor and/or blood is required as identified through molecular assays, as performed for clinical evaluation
Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate to tumor type
Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 or Lansky Performance Score (LPS) greater than or equal to (&#8805;) 40 percent (%) (age less than [<] 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment
Adequate hematologic, hepatic and renal function
Life expectancy of at least 3 months
For Phase 2: As for phase 1 with the following modifications:

For Cohort 1: Participants must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinical benefit from appropriate standard of care therapy
Cohorts 1 and 2:

Enrollment will be restricted to participants with evidence of a RET gene alteration in tumor
At least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated
Cohorts 3 and 4: Enrollment closed
Cohort 5:

Without measurable disease but otherwise meet criteria for Cohorts 1 and 2;
MTC syndrome spectrum cancers (e.g., MTC, pheochromocytoma), cancers with neuroendocrine features/differentiation, or poorly differentiated thyroid cancers with other RET alteration/activation may be allowed with prior Sponsor approval;
cfDNA positive for a RET gene alteration not known to be present in a tumor sample
Cohort 6: Participants who otherwise are eligible for Cohorts 1, 2 or 5 who discontinued another RET inhibitor due to intolerance may be eligible with prior Sponsor approval
Cohort 7: Participants must have a histologically confirmed stage IB-IIIA NSCLC by AJCC (The American Joint Committee on Cancer) version 8. The tumor must have been deemed resectable by a thoracic surgeon, the participant must be determined to be medically operable based on the determination of a thoracic surgeon, and the participant must not have received prior systemic therapy, including prior radiation therapy, for NSCLC.

Key Exclusion Criteria (Phase 1 and Phase 2):

Phase 2 Cohorts 1 and 2: an additional known oncogenic driver
Cohorts 3 and 4: Enrollment closed
Cohorts 1, 2 and 5: prior treatment with a selective RET inhibitor Notes: Participants otherwise eligible for Cohorts 1, 2, and 5 who discontinued another selective RET inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval
Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292 (selpercatinib). In addition, no concurrent investigational anti-cancer therapy is permitted Note: Potential exception for this exclusion criterion will require a valid scientific justification and approval from the Sponsor
Major surgery (excluding placement of vascular access) within 4 weeks prior to planned start of LOXO-292 (selpercatinib). DESCRIPTION is This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-01-05T21:24:26. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Loxo Oncology, Inc.. DISEASE SITES is Rectum, Anus, Liver, Other Respiratory and Intrathoracic Organs, Other Skin, Kaposi's Sarcoma, Pancreas, Other Male Genital, Kidney, Brain and Nervous System, Stomach, Colon, Other Digestive Organ, Bones and Joints, Ovary, Eye and Orbit, Lip, Oral Cavity and Pharynx, Esophagus, Mycosis Fungoides, Other Female Genital, Other Endocrine System, Melanoma, Skin, Breast, Larynx, Lung, Soft Tissue, Thyroid, Ill-Defined Sites, Corpus Uteri, Prostate, Unknown Sites, Cervix Uteri, Bladder, Small Intestine, Other Urinary.
10. TITLE is An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors. SHORT TITLE is Phase I/II Study of RP1 as a Single Agent & in Combo W/ PD1 Blockade in Pts W/ Solid Tumors. INVESTIGATOR NAME is John P Fruehauf. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult
. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.


Inclusion Requirements 
You can participate in this study if you 
-At least one measurable and injectable lesion
-Have provided a former tumor pathology specimen or be willing to supply a new tumor sample from a biopsy
-Have a predicted life expectancy of &#8805; 3 months
-Subjects with NMSC: has diagnosis of locally advanced or metastatic NMSC that are not considered treatable by surgery including basal cell carcinoma, cutaneous squamous cell carcinoma, basosquamous carcinoma, Merkel cell carcinoma and other non-melanoma skin cancers (per protocol) for whom anti-PD1/PD-L1 therapy is indicated, or have refused, become intolerant to or have no further therapy options available
-Subjects with anti-PD1 failed cutaneous melanoma: has confirmed progressive disease while on anti-PD1 treatment for at least 8 weeks and documented BRAF mutation status
-Subjects with anti-PD1 failed NSCLC: has confirmed progressive disease after no more than two prior systemic treatments including anti-PD1/PD-L1 treatment

Exclusion Requirements 
You cannot participate in this study if you 
-Prior treatment with an oncolytic therapy
-History of viral infections according to the protocol
-Prior complications with herpes infections
-Chronic use of anti-virals
-Uncontrolled/untreated brain metastasis
-History of interstitial lung disease
-History of non-infectious pneumonitis
-History of clinically significant cardiovascular disease. DESCRIPTION is RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T13:37:44. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Replimune Inc.. DISEASE SITES is Other Digestive Organ, Corpus Uteri, Brain and Nervous System, Thyroid, Colon, Soft Tissue, Eye and Orbit, Ill-Defined Sites, Pancreas, Prostate, Urinary Bladder, Melanoma, Skin, Lip, Oral Cavity and Pharynx, Larynx, Multiple Myeloma, Small Intestine, Lung, Other Respiratory and Intrathoracic Organs, Other Skin, Cervix Uteri, Breast, Anus, Liver, Mycosis Fungoides, Other Endocrine System, Stomach, Bones and Joints, Ovary, Other Male Genital, Other Urinary, Esophagus, Rectum, Other Female Genital, Kidney, Bladder.
11. TITLE is A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation. SHORT TITLE is Ph I/II Study of MRTX849 in Pts w/ Adv Solid Tumors w/ KRAS G12C Mutation. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
Unresectable or metastatic disease
Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
Adequate organ function

Exclusion Criteria:

History of intestinal disease or major gastric surgery or inability to swallow oral medications
Other active cancer. DESCRIPTION is This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-01-05T21:20:47. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Mirati Therapeutics, Inc.. DISEASE SITES is Stomach, Small Intestine, Rectum, Other Endocrine System, Non-Hodgkin's Lymphoma, Anus, Myeloid and Monocytic Leukemia, Kaposi's Sarcoma, Melanoma, Skin, Other Digestive Organ, Lymphoid Leukemia, Lung, Breast, Colon, Pancreas, Hodgkin's Lymphoma, Leukemia, other.
12. TITLE is A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of Adjuvant Avelumab (anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases. SHORT TITLE is Ph III Trial of Adjuvant Avelumab in Merkel Cell Ca Pts W/ Clinically Detected Lymph Node Metastases. INVESTIGATOR NAME is Ling Gao. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is -Medical records or confirmed diagnosis of Merkel Cell Carcinoma metastases in regional lymph node(s)
-Life expectancy of more than 3 years
-Must start study treatment no more than 120 days from date of therapy
-Women of childbearing potential must have a negative serum or urine pregnancy test at screening
-Both male and female subjects must be willing to use highly effective contraception
-Ability to provide informed consent and follow study procedures. DETAILED ELIGIBILITY is -Confirmation of the MCC diagnosis in the regional lymph node(s) is mandatory for trial participation
-Estimated life expectancy greater than 3 years
-Must start the study treatment no more than 120 days from the start date of definitive therapy
-Women of childbearing potential must have a negative serum or urine pregnancy test at screening
-Both male and female subjects must be willing to use highly effective contraception
-Must have an ability to understand and the willingness to sign a written informed consent document
. DESCRIPTION is This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-02-09T16:29:22. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is University of Washington. DISEASE SITES is Other Skin.
13. TITLE is Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients with Acute Myelogenous Leukemia with MDS Related Changes or Therapy-Related Acute Myeloid Leukemia. SHORT TITLE is PhII Study: Combo Glasdegib&Vyxeos in Pts w/ Ac Myelogeous Leuk w/ MDS or Ac Myeloid Leuk out of MDS. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria:
- Have previously untreated AML with MDS-related changes or therapy-related AML
- Are 18 years of age or older
- Do not have any unstable heart conditions such as having a heart attack within the past 6
months, uncontrolled heart failure, or uncontrolled irregular heartbeat

Exclusion Requirements
You cannot participate in this study if you satisfy the following criteria:
- Previous treatment with either CPX-351 or Glasdegib
- Any active infection or other cancers
- Are pregnant or breastfeeding. DESCRIPTION is This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-02-12T12:49:37. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI, Jazz Pharmaceuticals, Inc., Pfizer Pharmaceutical Inc., UC Hematologic Malignancies Consortium. DISEASE SITES is Leukemia, other, Myeloid and Monocytic Leukemia.
14. TITLE is A Phase I Open-Label, Dose Escalation Study of Pitavastatin in Combination with Venetoclax in Patients with Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia. SHORT TITLE is A Phase I Study of Pitavastatin in Combination with Venetoclax for CLL or AML. INVESTIGATOR NAME is Elizabeth A Brem. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined;the study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria: 
- At least 18 years of age
- Confirmed diagnosis of CLL or AML
- You are starting treatment with a regimen that includes VEN and are on a stable dose of VEN

Exclusion Requirements 
You cannot participate in this study if you have any of the following criteria:
- Are pregnant or nursing
- Unable to swallow pills 
- Have received any investigational agents during the previous 30 days or will be receiving any other investigational agents at any time during the study.

. DESCRIPTION is This is a phase I, dose-escalation, open-label clinical trial determining the safety and tolerability of adding Pitavastatin to Venetoclax (VEN) in subjects with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). These are subjects who are newly diagnosed subjects with AML who are ineligible for intensive induction chemotherapy, relapsed/refractory CLL or newly diagnosed CLL.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-28T15:49:11. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI, Department of Defense. DISEASE SITES is Lymphoid Leukemia, Leukemia, other.
15. TITLE is Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer. SHORT TITLE is Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of
study criteria to help you better understand how your eligibility in the study will be determined; your study
team will go through the study eligibility criteria with you to verify if you qualify for participation in this
study.

You can participate in this study if you:
- Are female
- Over the age of 18
- Ability to understand and the willingness to sign a written informed consent document
- Consent to be in the study, signed and dated an approved consent form, which conforms to federal and institutional guidelines.
- For cancer patients, you must have either Stage I, Stage II, Stage III or Stage IV Breast cancer
- For cancer patients, you must have either hormone Receptor +, Her-2 receptor positive, triple
positive or triple negative breast cancer

Exclusion Requirements
You cannot participate in this study if you
- Are physically or mentally incapable to give verbal or written consent
- For cancer patients: have other active cancers expect for cured skin and in situ cervical cancer
- For non-cancer participants: history of cancer diagnosis or prior exposure to chemotherapy
agents. DESCRIPTION is Scientists and clinicians at this institution are working together to discover new ways to monitor cancer
and find tests that could detect recurrence early on. The purpose of this research study is to determine
a group of particles in the blood called exosomes that may be associated with response to treatment
or could predict recurrence and side effects.. TREATMENT TYPE DESC is Basic Science. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-12-01T13:51:12. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI, Hitachi Chemical Research Center. DISEASE SITES is Breast.
16. TITLE is Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma. SHORT TITLE is Ph III: Radio w/ Concom & Adj TMZ vs. Radio w/ Adj PCV Chemo in Pts w/ 1p/19q Anapl. or Low-g Glioma. INVESTIGATOR NAME is Xiao-Tang Kong. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:

- Histological evidence of WHO grade III anaplastic glioma or WHO grade II low grade glioma 
- Surgery (partial or gross total resection or biopsy) must be performed more than 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery.
- Willingness and ability to personally complete neurocognitive testing (without assistance) and willingness to complete the QOL testing, (either personally or with assistance)

Exclusion Criteria: 

- Pregnant and/or nursing women
- Subjects of childbearing potential who are unwilling to employ adequate contraceptive method during treatment and 6 months after chemotherapy treatments
- Immunocompromised patients or HIV Positive Patients Receiving Retroviral Medications. DESCRIPTION is Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-05-25T13:31:12. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Alliance. DISEASE SITES is Brain and Nervous System.
17. TITLE is Phase II Study of Cabozantinib Combined with Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC) Who are not Candidates for Curative Intent Treatment. SHORT TITLE is Ph II of Cabo. w/ Ipi./Nivo. and TACE in Pts w/ HCC (not candidates for Curative Tx). INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy following criteria:
- At least 18 years of age
- Biopsy proven or imaging based diagnosis of hepatocellular carcinoma ("primary liver cancer")
- Not a candidate for surgery or curative treatment based on your doctor's assessment

Exclusion Requirements
You cannot participate in this study if you have any of the following criteria:
- Previous treatment with cabozantinib or immunotherapy
- Any active infection (except for controlled Hepatitis B or C) or other cancers
- Pregnant or nursing. DESCRIPTION is This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-12-07T17:16:04. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI, Exelixis, Inc. , Anti Cancer Challenge Grant. DISEASE SITES is Liver.
18. TITLE is A Non-Interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Solid Tumors Including Gastric and Gastroesophageal Junction Adenocarcinoma. SHORT TITLE is A Non-Interventional Biomarker Study on the Molecular Evaluation of Tumor Tissue in Pts w/ GastricCa. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

- Patients with histologically or cytologically confirmed locally advanced or metastatic gastric adenocarcinoma or GEJ adenocarcinoma at the time of enrollment.
- Patients who have available archival tumor tissue sample from biopsy or tumor resection not older than 20 years and adequate for central laboratory testing of MUC17 and CLDN18.2, with corresponding pathology report. 

Exclusion Criteria:

- There are no exclusion criteria for this study as long as the subject meets all inclusion criteria.. DESCRIPTION is The purpose of this research study is to study previously collected tumor tissue that will help in identifying potential patients with MUC17 and/or CLDN18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.. The results of this study may be used later for the identification of subjects who may be referred to interventional studies at UCI with investigational drugs, AMG 199 or AMG 910. . TREATMENT TYPE DESC is Screening. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-12-07T08:37:35. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Amgen Inc.. DISEASE SITES is Lip, Oral Cavity and Pharynx, Anus, Lung, Other Respiratory and Intrathoracic Organs, Bones and Joints, Brain and Nervous System, Thyroid, Liver, Other Skin, Other Urinary, Melanoma, Skin, Small Intestine, Other Digestive Organ, Ovary, Other Male Genital, Corpus Uteri, Other Female Genital, Unknown Sites, Breast, Stomach, Rectum, Larynx, Kidney, Mycosis Fungoides, Eye and Orbit, Ill-Defined Sites, Esophagus, Soft Tissue, Cervix, Prostate, Urinary Bladder, Colon, Pancreas, Other Endocrine System, Kaposi's Sarcoma.
19. TITLE is Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer. SHORT TITLE is Ph III Trial of Concurrent Chemoradiation w/ or w/o Atezolizumab for Localized MIBC. INVESTIGATOR NAME is Ramy Yaacoub. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

- Histologically proven urothelial carcinoma of the bladder within 120 days prior to the start of  the study
- No prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor
- No clinically significant liver disease, including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, or inherited liver disease.

Exclusion Criteria:

- Major surgical procedure within 28 days prior to the start of the study
- Patients who have received a live, attenuated vaccine (such as a flu shot) within 4 weeks prior to participation
- Patients with active infection requiring oral or IV antibiotics within 14 days prior to participation
. DESCRIPTION is This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.
. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-02-22T10:48:09. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Urinary Bladder.
20. TITLE is A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors. SHORT TITLE is Ph I/II Study of MCLA-128, IgG1 Bispecific Antibody Targeting HER2 & HER3, in Pts w/ Solid Tumors. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

At least one measurable lesion according to RECIST v1.1 OR evaluable disease for a limited number of patients (up to 10) in Group H;
Performance status of ECOG 0 or 1;
Estimated life expectancy of at least 12 weeks;
Toxicities incurred as a result of previous anti-cancer therapy resolved to &#8804;Grade 1;
Treatment with anti-cancer medication or investigational drugs within the following intervals before the first dose of MCLA-128:

>14 days or >5 half-lives prior to study entry, whichever is shorter.
>14 days for radiotherapy.
Recovery from major surgery or other complication to &#8804; Grade 2 or baseline ;
Absolute neutrophil count &#8805;1.5 x 109/L without colony stimulating factor support;
Platelets &#8805;100 x 109/L;
Hemoglobin &#8805;8 g/dL or &#8805;2.2 mmol/L;
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) &#8804;3 x upper limit of normal (ULN) and total bilirubin &#8804;1.5 x ULN; in cases of metastatic liver involvement, ALT/AST &#8804;5 x ULN and total bilirubin &#8804;2 x ULN will be allowed; in cases of antecedents of Gilbert's syndrome when total bilirubin &#8804;3.0 x ULN or direct bilirubin &#8804;1.5 x ULN will be allowed;
Estimated glomerular filtration rate (GFR) of >30 mL/min
Able to provide a tumor biopsy sample (fresh strongly preferred or else archival);
Not pregnant or nursing

Exclusion Criteria:

Pregnant or lactating;
Presence of an active uncontrolled infection or an unexplained fever;
Known hypersensitivity to any of the components of MCLA-128;
Known HIV, active Hepatitis B or Hepatitis C; patients treated for Hepatitis C and have undetectable viral loads are eligible
Known symptomatic or unstable brain metastases;
Patients with leptomeningeal metastases
Presence of congestive heart failure or Left Ventricular Ejection Fraction<50% or history of significant cardiac disease, unstable angina, myocardial infarction or ventricular arrhythmia requiring medication.
Previous or concurrent malignancy (excluding non-basal cell carcinoma of skin or carcinoma in situ of the uterine cervix) unless the tumor was treated with curative intent more than 2 years prior to study entry;
Presence of any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate or participate in the study, or interfere with the interpretation of the results.
. DESCRIPTION is This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T20:48:16. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Merus N.V. . DISEASE SITES is Liver, Other Respiratory and Intrathoracic Organs, Other Urinary, Breast, Stomach, Mycosis Fungoides, Brain and Nervous System, Rectum, Ovary, Colon, Other Digestive Organ, Larynx, Other Female Genital, Unknown Sites, Lip, Oral Cavity and Pharynx, Pancreas, Bones and Joints, Other Skin, Eye and Orbit, Thyroid, Melanoma, Skin, Esophagus, Soft Tissue, Prostate, Other Male Genital, Kidney, Cervix, Urinary Bladder, Other Endocrine System, Kaposi's Sarcoma, Small Intestine, Anus, Lung, Ill-Defined Sites.
21. TITLE is A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation. SHORT TITLE is Ph I/II, Study of DZD9008 in Pts w/ Adv Non-Small Cell Lung Cancer (NSCLC) w/ EGFR or HER2 Mutation. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Aged at least 18 years old (&#8805; 20 if in Japan), be able to provide a signed and dated, written informed consent.
With documented histological or cytological confirmed locally advanced or metastatic NSCLC with EGFR or HER2 mutations.
(ECOG) performance status 0-1.
Predicted life expectancy &#8805; 12 weeks
Patient must have measurable disease according to RECIST 1.1.
Patients with brain metastasis (BM) can be enrolled under the condition that BM is stable, neurologically asymptomatic and does not require corticosteroid treatment.
Adequate organ system function.
Exclusion Criteria:

For part B: Patients who have received prior treatment with Poziotinib or TAK788 or other EGFR/HER2 exon20 insertion inhibitors should be excluded. Prior treatment with currently approved EGFR TKIs for sensitizing or T790M resistance mutations, such as gefitinib, erlotinib, osimertinib, afatinib and dacomitinb, are allowed.
Treatment with EGFR or HER2 antibodies, major surgery (excluding placement of vascular access), or onco-immunotherapy (e.g. immune checkpoint inhibitors PD-1, PD-L1, CTLA-4) within 4 weeks before screening.
Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days before screening.
Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose or with a wide field of radiation which must be completed within 4 weeks before screening.
Receiving (or unable to stop using) medications or herbal supplements known to be potent inhibitors or inducers of CYP3A within 2-3 weeks before screening.
Grapefruit, grapefruit juice, and orange marmalade (made with Seville oranges) within 1 week before screening.
Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting DZD9008 with the exception of alopecia and grade 2 prior platinum-therapy related neuropathy.
Spinal cord compression or leptomeningeal metastasis.
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
Any of the following cardiac criteria: (1) Mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs); (2) Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec. (3) Any factors that increase the risk of QTcF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of DZD9008
History of hypersensitivity to active or inactive excipients of DZD9008 or drugs with a similar chemical structure or class to DZD9008. DESCRIPTION is This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T20:42:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Dizal (Jiangsu) Pharmaceutical Co., Ltd. DISEASE SITES is Lung.
22. TITLE is Genetic Testing in Guiding Treatment for Patients with Brain Metastases. SHORT TITLE is Genetic Testing in Guiding Treatment for Patients with Brain Metastases. INVESTIGATOR NAME is Yoon Jae Choi. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Pre-registration Eligibility:

- Tissue available for biomarker testing (any brain metastasis tissue and extracranial site from any prior resection or biopsy)

Registration Eligibility:

- Participants must have histologically confirmed parenchymal metastatic disease to the brain from any solid tumor
- Female participants must not be pregnant or breastfeeding
- Ability to obtain MRIs with contrast
. DESCRIPTION is This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-04-21T09:36:35. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Alliance, Alliance for Clinical Trials in Oncology. DISEASE SITES is Melanoma, Skin, Brain and Nervous System, Breast, Lung.
23. TITLE is Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage. SHORT TITLE is Ph III Study DFP-10917 vs. Non-Intensive or Intensive Reinduction for AML Pts in 2nd or 3rd Salvage. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements

You can participate in this study if you
-  must be able to sign the informed consent prior to the start of any study specific procedures.

Exclusion Requirements

You cannot participate in this study if you
-  pregnant or lactating woman.
-  have  known human immunodeficiency virus (HIV), active Hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection

. DESCRIPTION is Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with Acute myeloid leukemia (AML) relapsed/refractory after 2, 3, or 4 prior induction regimens:

Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m¬≤/day followed by a 14-day resting period per 28-day cycles.

Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-01T08:59:34. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Delta-Fly Pharma, Inc. . DISEASE SITES is Myeloid and Monocytic Leukemia.
24. TITLE is Phase II, Open-Labeled, Single-Armed Combination Treatment with Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer . SHORT TITLE is Ph II Trial of Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer . INVESTIGATOR NAME is Rita Mehta. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult, Older Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
&#61623; Are at least 18 years of age
&#61623; Have a diagnosis of hormone receptor positive (HR+) breast cancer
&#61623; Are able to swallow oral medications

Exclusion Requirements
You cannot participate in this study if you
&#61623; Are pregnant or nursing
&#61623; Are receiving an investigational drug in other clinical trials
&#61623; Have an active bacterial or fungal infection. DESCRIPTION is This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast cancer or subjects who have progressed following treatment free interval of more than 12 months following adjuvant or neoadjuvant treatment.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-09-01T14:47:56. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Breast.
25. TITLE is Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) . SHORT TITLE is Phase II/III, Circulating Tumor DNA as Predictive Biomarker in Adj Chemo in Pts w/Stage IIA Colon Ca. INVESTIGATOR NAME is Jason Zell. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
You must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically/pathologically confirmed stage IIA adenocarcinoma of the colon (T3, N0, M0) with at least 12 lymph nodes examined at the time of surgical resection.
Appropriate for active surveillance (i.e., no adjuvant chemotherapy) at the discretion of and as documented by the evaluating oncologist based on current practice patterns.
The distal extent of the tumor must be >= 12 cm from the anal verge on pre-surgical endoscopy (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation). If the patient did not undergo a pre-surgical endoscopy, then the distal extent of the tumor must be >= 12 cm from the anal verge as determined by surgical examination or pre-operative imaging.
You must have had an en bloc complete gross resection of tumor (curative resection) as definitive surgical cancer treatment within 14 to 60 days of study randomization. Patients who have had a two-stage surgical procedure to first provide a decompressive colostomy and then, in a later procedure, to have the definitive surgical resection, are eligible.
Availability and provision of adequate surgical tumor tissue for molecular diagnostics and confirmatory profiling.

Exclusion Criteria:
Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma, sarcoma, lymphoma, squamous cell carcinoma, etc.).
Pathologic, clinical, or radiologic evidence of overt metastatic disease. This includes isolated, distant, or non-contiguous intra-abdominal metastases, even if resected (including the presence of satellite nodules constituting N1c disease in the absence of lymph node involvement).
Tumor-related bowel perforation.
History of prior invasive colon malignancy, regardless of disease-free interval.
History of organ transplantation.
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer (e.g., primary rectal adenocarcinomas for which treatment with neoadjuvant chemoradiation is warranted are not permitted).
Other invasive malignancy within 5 years before randomization. Exceptions are colonic polyps, non-melanoma skin cancer or carcinoma-in-situ including those of the cervix and breast (DCIS).
Synchronous primary rectal and/or colon cancers.
Antineoplastic therapy (e.g., chemotherapy, targeted therapy, or immunotherapy) within 5 years before randomization. (For the purposes of this study, hormonal therapy is not considered chemotherapy.).. DESCRIPTION is This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T10:25:13. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Colon.
26. TITLE is A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE). SHORT TITLE is Ph II Study De-Intensified ChemoRadiation Early-Stage Anal Squamous Cell Carcinoma . INVESTIGATOR NAME is Jason Zell. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Eligibility Criteria:

- Patient must have diagnosed anal cancer with tumors measuring less than or equal to 4 cm within 4 weeks prior to registration. 
- Patient's tumor size must be documented on physical examination including digital rectal exam and/or anoscopy/proctoscopy within 4 weeks prior to Step 0 pre-registration.
- Patient must have no history of prior radiation or chemotherapy for carcinoma of the anus.
- Patient must not have had prior potentially curative surgery (i.e. abdominal-perineal resection) for carcinoma of the anus.. DESCRIPTION is This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-05-11T15:56:51. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ECOG-ACRIN. DISEASE SITES is Anus.
27. TITLE is A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <=75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma. SHORT TITLE is PhIII Rituxima Cyclophosphamid Doxorubicin Vincristin Prednison v inComb w/Acalabrutini NonGermDLBCL. INVESTIGATOR NAME is Elizabeth A Brem. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note, this is not a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- are between the ages &#8805;18 and &#8804;75 years at the time of screening
- are male or female

Exclusion Requirements
You cannot participate in this study if you
- are a female  who is currently pregnant (confirmed with positive pregnancy test) or breastfeeding . DESCRIPTION is Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects &#8804;75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-22T14:27:44. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Acerta Pharma BV. DISEASE SITES is Non-Hodgkin's Lymphoma.
28. TITLE is A Phase IV, Multi-Center Open-Label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects with Minimal Residual Disease (MRD) of B-Precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission. SHORT TITLE is Ph IV Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects w/ MRD of B-precursor ALL. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult subjects. DETAILED ELIGIBILITY is 	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note, this is not a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- age &#61619; 18 years in age
- must have negative pregnancy test of you are  women of childbearing potential.


Exclusion Requirements
You cannot participate in this study if you
- are currently receiving treatment with an investigational device or drug study or less than 30 days 
since ending treatment on an investigational device or drug study(ies)
- have no cellular service at home. DESCRIPTION is The purpose of this study is to determine the safety and feasibility of outpatient blinatumomab administration for subjects with Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia.. PHASE DESC is IV. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-05-14T11:33:57. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Amgen Inc.. DISEASE SITES is Lymphoid Leukemia.
29. TITLE is Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas. SHORT TITLE is Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help subjects better understand how their eligibility in the study will be determined; the study team will go through the study eligibility criteria with the subject to verify if they qualify for participation in this study.

Inclusion Requirements
Subjects can participate in this study if they satisfy the following criteria:
- At least 18 years of age
- Confirmed diagnosis of adenocarcinoma (cancer) of the colon
- Positive ctDNA assay (test)

Exclusion Requirements
Subjects cannot participate in this study if they have any of the following criteria:
- Previous treatment with either irinotecan or TAS-102
- Any active infection or other cancers
- Pregnant or nursing. DESCRIPTION is This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-05-24T12:28:07. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI, Taiho Pharmaceuticals, Natera, Inc.. DISEASE SITES is Colon.
30. TITLE is A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ¬± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients. SHORT TITLE is Ph I IO-202 inCombo w/ Azacitidine in Relap/Ref AML w/ Monocytic Differentiation & in Relap/Ref CMML. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements

You can participate in this study if you
-  must be &#8805;18 years old.
-  must be able to understand and willing to sign an informed consent.

Exclusion Requirements

You cannot participate in this study if you
-  must not be pregnant or breast feeding.
-  must not have Active bacterial, viral, and/or fungal infection including hepatitis B (HB), hepatitis C, human immunodeficiency virus (HIV), 
   SARS-CoV-2, or acquired immunodeficiency syndrome (AIDS)-related illness.. DESCRIPTION is To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D) and dose schedule as monotherapy.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-01T09:02:01. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Immune-Onc Therapeutics, Inc.. DISEASE SITES is Myeloid and Monocytic Leukemia.
31. TITLE is A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications. SHORT TITLE is Ph I/II DF1001 in Pts w/ Locally Adv or Metastatic Solid Tumors, & Expansion in Selected Indications. INVESTIGATOR NAME is Jennifer Brooke Valerin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Eligibility Criteria:

Inclusion Criteria:
- Male or female patients at least 18 years of age
- Patients must have histologically or cytologically proven locally advanced or metastatic solid tumors with documented HER2 expression.

Exclusion Criteria:
- Patients must not have had receipt of any organ transplantation including autologous or allogeneic stem-cell transplantation.
- Significant acute or chronic infections (including positive test for HIV), or active or latent hepatitis B or active hepatitis C.
- Serious cardiac illness or medical conditions.. DESCRIPTION is This is a Phase I/II study to see whether the study drug DF1101, is safe and tolerable for patients with locally advanced or metastatic solid tumors. Patients will be enrolled into 1 of 2 parts: Dose Escalation or Efficacy Expansion. 

Dose Escalation: The main purpose of this part is to test different doses of the study drug, starting with the lowest dose and up to the highest dose. If the dose is considered safe, another group of patients will join the study to receive the study drug at a higher dose.

Efficacy Expansion: The main purose of this part is to further test the selected dose of the study drug in subjects with bladder cancer, breast cancer, or cancers that have high levels of a protein called HER2. Patients in this part of the study will receive the study drug DF1001 alone.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-08-25T12:27:09. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Dragonfly Therapeutics, Inc.. DISEASE SITES is Mycosis Fungoides, Other Skin, Ovary, Other Male Genital, Urinary Bladder, Stomach, Lung, Soft Tissue, Other Endocrine System, Hodgkin's Lymphoma, Multiple Myeloma, Cervix, Prostate, Other Digestive Organ, Eye and Orbit, Breast, Esophagus, Liver, Other Respiratory and Intrathoracic Organs, Bones and Joints, Ill-Defined Sites, Small Intestine, Colon, Rectum, Anus, Corpus Uteri, Brain and Nervous System, Pancreas, Larynx, Kidney, Other Urinary, Thyroid, Melanoma, Skin, Kaposi's Sarcoma, Lip, Oral Cavity and Pharynx, Other Female Genital, Non-Hodgkin's Lymphoma, Unknown Sites.
32. TITLE is University of California COVID-19 and Cancer Registry and Outcomes Project. SHORT TITLE is University of California COVID-19 and Cancer Registry and Outcomes Project. INVESTIGATOR NAME is Warren A Chow. STATUS is OPEN TO ACCRUAL. TREATMENT TYPE DESC is Other. AGE DESCRIPTION is Both. SCOPE DESC is National. MODIFIED DATE is 2021-02-23T16:15:01. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UC San Francisco . DISEASE SITES is Stomach, Mycosis Fungoides, Other Urinary, Lip, Oral Cavity and Pharynx, Rectum, Larynx, Urinary Bladder, Other Endocrine System, Non-Hodgkin's Lymphoma, Ill-Defined Sites, Melanoma, Skin, Small Intestine, Pancreas, Prostate, Brain and Nervous System, Lymphoid Leukemia, Liver, Other Respiratory and Intrathoracic Organs, Soft Tissue, Corpus Uteri, Multiple Myeloma, Unknown Sites, Lung, Other Male Genital, Myeloid and Monocytic Leukemia, Kaposi's Sarcoma, Colon, Ovary, Other Hematopoietic, Esophagus, Other Skin, Other Female Genital, Eye and Orbit, Leukemia, other, Breast, Anus, Other Digestive Organ, Bones and Joints, Cervix, Kidney, Thyroid, Hodgkin's Lymphoma.
33. TITLE is A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus Liver). SHORT TITLE is Ph Ib/II Study Evaluating Immuno-based Tx Combin in Pt w/ Adv Liver Ca. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

- Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically
- Disease that is not amendable to curative surgical and/or locoregional therapy
- No prior systemic treatment (including systemic investigational drugs) for HCC

Exclusion Criteria:

- Treatment with locoregional therapy to liver (e.g., radiofrequency ablation,
percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused
ultrasound, transarterial chemoembolization, transarterial embolization, etc.) within
28 days prior to initiation of study treatment, or non-recovery from side effects of any
such procedure
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to initiation of study treatment; or abdominal surgery, abdominal interventions
or significant abdominal traumatic injury within 60 days prior to initiation of study
treatment; or anticipation of need for major surgical procedure during the course of
the study or non-recovery from side effects of any such procedure
- Radiotherapy within 28 days or abdominal/pelvic radiotherapy within 60 days prior to
initiation of study treatment with the exception of palliative radiotherapy to bone
lesions within 7 days prior to initiation of study treatment. DESCRIPTION is This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.

Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-02-09T17:17:27. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is F. Hoffmann-La Roche Ltd. DISEASE SITES is Liver.
34. TITLE is Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis.. SHORT TITLE is Ph II Trial of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Cancer . INVESTIGATOR NAME is Maheswari Senthil. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Eligibility Criteria:

Inclusion Criteria:
- Patients must have confirmed primary gastric or gastroesophageal cancer and have received a minimum of 3 months of first line treatment without visceral (liver, lung, brain) metastases. 
- Patients must have peritoneal cytology positive disease or peritoneal carcinomatosis.


Exclusion Criteria:
- Patients must not have had systemic treatment for unresectable or metastatic disease for more than 3 months prior to enrollment.
- Patients must not have any evidence of distant, solid organ metastes (visceral (liver, lung, brain), bone, extra-abdominal).
- Patients must not have any evidence of small or large bowel obstruction with the exception of gastric outlet obstruction due to primary malignancy.
. DESCRIPTION is The purpose of this research study is to see if sequential intravenous chemotherapy followed by intraperitoneal chemotherapy with paclitaxel combination is safe and will improve cancer control in patients who have gastric cancer that is spread in the abdominal lining ( peritoneum) called peritoneal carcinomatosis (PC). Currently, patients with gastric cancer who have cancer spread to the abdominal lining are only treated with intravenous chemotherapy, which is chemotherapy administered through the vein into the body. We are proposing to add intraperitoneal chemotherapy (chemotherapy infused into the abdominal cavity through a small access device implanted into the abdominal fat tissue) to the usually used intravenous chemotherapy, to study if this combination improves survival in patients.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. MODIFIED DATE is 2021-03-30T15:18:06. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Stomach, Esophagus.
35. TITLE is Prospective Study to Assess the Role of Plasma Exosomal Gene Signature and PD-L1 Expression to Predict Response to Treatment in Solid Organ Malignancies. SHORT TITLE is PD-L1 to Predict Response to Immune Checkpoint Inhibition in Melanoma & Solid Organ Malignancies. INVESTIGATOR NAME is Maheswari Senthil. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is -Male and Female Adults ages 18 and above
-Able to provide consent and follow procedures
-Medical records confirming diagnosis of melanoma, malignant solid tumors. DETAILED ELIGIBILITY is Inclusion Criteria:
-Ability to understand and the willingness to sign a written informed consent
-Patients must have immunotherapy na√Øve histologically, radiologically, or cytologically confirmed cancer (
Melanoma, HCC, colorectal, appendix or gastric cancer).
-Must have measurable disease at the time of enrollment
-Life expectancy of greater than 6 months
-Adequate organ and marrow function per lab results / values

Exclusion Criteria
-Patient who have received immunotherapy prior to enrollment
-Known active secondary malignancy except for basal cell carcinoma, low grade ( Gleason <6) prostate cancer
and cervical carcinoma in-situ
-Inability to comply with study and follow-up procedures as judged by the Investigator
. DESCRIPTION is This is a phase 2 prospective study to to evaluate a blood test from patients with solid organ malignancies to predict
response to treatment.. TREATMENT TYPE DESC is Basic Science. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2021-02-23T14:56:31. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Melanoma, Skin, Rectum, Lung, Stomach, Colon, Kidney, Liver.
36. TITLE is A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors. SHORT TITLE is Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors. INVESTIGATOR NAME is Arash Rezazadeh Kalebasty. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

- Pathologically or serologically confirmed diagnosis of a Germ Cell Tumor
- Patients mush have initial imaging, laboratory, and other clinical evaluations performed within 42 days prior to registration
- Risk of relapse assessment determined by the investigator prior to registration

Exclusion Criteria:

- Registration outside of the 42-day window after diagnosis
- Patients who do not agree to submit required specimens for defined translational medicine studies
- Patients who do not have beta-human chorionic gonadotropin, alpha-fetoprotein, and lactate dehydrogenase assessments within 42 days prior to registration.. DESCRIPTION is This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.. TREATMENT TYPE DESC is Basic Science. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T09:35:49. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Other Male Genital.
37. TITLE is An Open-Label Phase I/Ib Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations with JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non-Small Cell Lung Cancer. SHORT TITLE is Ph I/Ib JNJ-73841937 (Lazertinib) Monotherapy or in Combo w/ JNJ-61186372 Pts w/ Advanced NSCLC. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Phase 1 and Phase 1b lazertinib+Amivantamab combination cohorts: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with previously epidermal growth factor receptor (EGFR) mutation (identified locally in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory [or equivalent]) that is metastatic or unresectable, and have progressed after standard of care front-line therapy, and exhausted available options with targeted therapy. A participant who has refused all other currently available therapeutic options is allowed to enroll
For the Phase 1b Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP) combination cohort: histologically or cytologically confirmed advanced or metastatic EGFR-mutated NSCLC who have progressed on or after an EGFR-TKI as the most recent line of treatment with a maximum of 3 prior lines of therapy in the metastatic setting allowed
For all expansion cohorts, the EGFR mutation must have been previously histologically or cytologically characterized, as performed by a CLIA-certified (US sites) or an accredited (outside of US) local laboratory, with a copy of the mutation analysis being submitted during screening (Phase 1b expansion Cohort B, C and D)

Exclusion Criteria:

Participant has an uncontrolled illness, including but not limited uncontrolled diabetes, ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics week prior to study treatment] or diagnosed or suspected viral infection); active bleeding diathesis; Impaired oxygenation requiring continuous oxygen supplementation; Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of study treatment; or psychiatric illness or any other circumstances including (social circumstances) that would limit compliance with study requirements. Any ophthalmologic condition that is either clinically unstable or requires treatment
Prior treatment with antiPD-1 or anti Programmed death-ligand 1 (PD-L1) antibody within 6 weeks of planned first dose of study intervention
Untreated brain or other central nervous system (CNS) metastases whether symptomatic or asymptomatic. Participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment may be eligible for Phase 1b expansion cohorts. If brain metastases are diagnosed on Screening imaging, the participant may be enrolled, or rescreened for eligibility, after definitive treatment if above criteria are met. DESCRIPTION is The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B and C), to estimate the antitumor activity of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B and C), to identify the recommended Phase 2 dose (RP2ChD) of Lazertinib when combined with Amivantamab and standard of care chemotherapy and to determine the tolerability of the Lazertinib, Amivantamab, and platinum-doublet chemotherapy (LACP) combination (Phase 1b LACP combination cohort) and to characterize the safety and tolerability of Lazertinib at the RP2ChD and Amivantamab and standard of care chemotherapy in participants with advanced or metastatic EGFR-mutated NSCLC (Phase 1b LACP combination cohort), to assess 2 potential biomarker strategies to identify participants at increased, or decreased, probability of tumor response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T20:31:42. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Janssen Research & Development, LLC. DISEASE SITES is Lung.
38. TITLE is An Open-Label, Randomized, Phase III Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy. SHORT TITLE is Ph III MK-6482 in Combo w/ Lenvatinib vs Cabozantinib in Pts w/ Adv Renal Cell Carcinoma . INVESTIGATOR NAME is Arash Rezazadeh Kalebasty. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:

- Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).
- Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment with progression on or within 6 months of last dose.
- Received no more than 2 prior systemic regimens.

Exclusion Criteria:

- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Clinically significant cardiac disease within 6 months of first dose of study intervention.
- Currently participating in a study of an investigational agent or using an investigational device.
- History of human immunodeficiency virus (HIV) infection.
- History of hepatitis B or known active hepatitis C infection.. DESCRIPTION is This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-03-23T10:17:34. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Merck Sharp & Dohme Corp.. DISEASE SITES is Kidney.
39. TITLE is A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER). SHORT TITLE is Ph I CB-010 CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Ptsw/ R/R Non-Hodgkin Lymphoma . INVESTIGATOR NAME is Susan O'Brien. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note, this is not a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
&#61623; Are at least 18 years old
&#61623; Understand and are willing to sign informed consent.

Exclusion Requirements  
You cannot participate in this study if you
&#61623; Are pregnant or breastfeeding
&#61623; Have history of infection with human immunodeficiency virus (HIV)
&#61623; Have active hepatitis B or C virus infection
. DESCRIPTION is CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-03-24T10:16:52. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Caribou Biosciences, Inc. . DISEASE SITES is Non-Hodgkin's Lymphoma.
40. TITLE is A Phase III Randomized Placebo controlled Double-Blind Study of Romiplostim for the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer. SHORT TITLE is Ph III, Romiplostim for the Tx of Chemo-Induced Thrombocytopenia in Pts Receiving FOLFOX-Based Chemo. INVESTIGATOR NAME is Zahra Pakbaz. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is adult. DETAILED ELIGIBILITY is 	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female 18 years of age at signing of the informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant . DESCRIPTION is Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-08-17T18:26:39. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Amgen Inc.. DISEASE SITES is Other Hematopoietic.
41. TITLE is Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities. SHORT TITLE is Ph I/II Selective RET Inhibitor TAS0953/HM06 in Pts w/ Adv Solid Tumors with RET Gene Abnormalities. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Phase I - Common inclusion criteria for Dose-Escalation / Dose-Expansion:

Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
Available RET-gene abnormalities determined on tissue or liquid biopsy
Documented progression of disease following existing therapies deemed by the Investigator to have demonstrated clinical benefit or unable to receive such therapies.
Adequate hematopoietic, hepatic and renal function
Phase I Dose-Escalation - Specific inclusion criteria:

Advanced solid tumors
Measurable and/or non-measurable disease as determined by RECIST 1.1
If patient has brain and/or leptomeningeal metastases, (s)he should be asymptomatic.
Phase I Dose-Expansion - Specific inclusion criteria:

Locally advanced or metastatic non small cell lung cancer (NSCLC) patients with primary RET gene fusion and prior exposure to RET selective inhibitors
Measurable disease as determined by RECIST 1.1
If patient has brain and/or leptomeningeal metastases,(s)he should have:

asymptomatic untreated brain/leptomeningeal metastases off steroids and anticonvulsant for at least 7 days or
asymptomatic brain metastases already treated with local therapy and be clinically stable on steroids and anticonvulsant for at least 7 days before study drug administration.
Phase II :

Available RET-gene abnormalities determined on tissue or liquid biopsy
Locally advanced or metastatic:

NSCLC patients with primary RET gene fusion and prior exposure to RET selective inhibitors;
NSCLC patients with RET gene fusion and without prior exposure to RET selective inhibitors
patients with advanced solid tumors that harbour RET gene abnormalities (other than NSCLC patients with primary RET gene fusions) and has failed all the available therapeutic options
Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
Measurable disease as determined by RECIST 1.1
If patient has brain and/or leptomeningeal metastases,(s)he should have:

asymptomatic untreated brain/leptomeningeal metastases off steroids and anticonvulsant for at least 7 days or
asymptomatic brain metastases already treated with local therapy and be clinically stable on steroids and anticonvulsant for at least 7 days before study drug administration.
Adequate hematopoietic, hepatic and renal function
Exclusion Criteria:

Common exclusion criteria for Phase 1 and Phase 2

Investigational agents or anticancer therapy within 5 half-lives prior to the first dose of study drug
Major surgery (excluding placement of vascular access) within 4 weeks prior to the first dose of study drug or planned major surgery during the course of study treatment.
Whole Brain Radiotherapy within 14 days or other palliative radiotherapy within 7 days prior to the first dose of study drug, or persisting side effects of such therapy, in the opinion of the Investigator.
Clinically significant, uncontrolled, cardiovascular disease including myocardial infarction within 3 months prior to Day 1 of Cycle 1, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial hypertension, according to the Investigator's opinion.
QT interval corrected using Fridericia's formula (QTcF) >470 msec; personal or family history of prolonged QT syndrome or history of Torsades de pointes (TdP). History of risk factors for TdP
Treatment with strong CYP3A4 inhibitors within 1 week prior to the first dose of study drug or strong CYP3A4 inducers within 3 weeks prior to the first dose of study drug.
Phase I Dose-Expansion - and Phase II specific exclusion criteria:

Presence of known EGFR, KRAS, ALK, HER2, ROS1, BRAF and METex14 activating mutations.. DESCRIPTION is Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-09-27T09:17:09. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Taiho Pharmaceuticals, Helsinn Healthcare SA. DISEASE SITES is Lip, Oral Cavity and Pharynx, Esophagus, Urinary Bladder, Colon, Prostate, Other Male Genital, Kaposi's Sarcoma, Small Intestine, Rectum, Other Digestive Organ, Other Skin, Cervix, Brain and Nervous System, Other Respiratory and Intrathoracic Organs, Larynx, Lung, Bones and Joints, Soft Tissue, Kidney, Other Urinary, Other Endocrine System, Ill-Defined Sites, Other Female Genital, Breast, Liver, Mycosis Fungoides, Corpus Uteri, Ovary, Thyroid, Melanoma, Skin, Stomach, Anus, Pancreas, Eye and Orbit, Unknown Sites.
42. TITLE is A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors. SHORT TITLE is Ph II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab Skin Tumors. INVESTIGATOR NAME is Maki Yamamoto. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults, Older Adults
. DETAILED ELIGIBILITY is -18 Yrs old and over
-Ability to understand and the willingness to sign a written informed consent document.
-Must histologic or cytologic diagnosis of non-melanoma skin cancer (NMSC) or lymphomas other than B-cell lymphomas
-Untreated central nervous system (CNS) involvement; patients with known brain metastases are eligible
-Must be able and willing to undergo serial biopsies of injected lesion(s)
-Women of child-bearing potential (WOCBP) and must agree to use adequate contraception. DESCRIPTION is This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T09:34:03. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ETCTN. DISEASE SITES is Melanoma, Skin, Other Skin.
43. TITLE is The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. SHORT TITLE is Ph II Study of Olaparib in Isocitrate Dehydrogenase Mutant R/R AML and Myelodysplastic Syndrome. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
- Diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) per World Health Organization 2016 classification. AML may be de novo, or following a prior hematologic disorder, including MDS or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related.
- Patients must have a documented IDH1 or IDH2 mutation within 30 days of inclusion
based on mutational testing. Only specific mutations that lead to a neomorphic
phenotype will be eligible for enrollment
- Patients with AML or MDS should have disease that has relapsed after, or is refractory
to, first-line therapy, with or without subsequent additional therapy.

Exclusion Criteria:
- Patients with acute promyelocytic leukemia.
- Patients with active central nervous system (CNS) leukemia or requiring maintenance
intrathecal chemotherapy.
- Patients receiving concurrent chemotherapy, radiation therapy, or immunotherapy for
AML/MDS.
- Patients actively receiving any other investigational agents.. DESCRIPTION is This phase II trial studies how well olaparib works in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or myelodysplastic syndrome. Patients must also have a change in the gene called the IDH gene (IDH mutation). Olaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to see if olaparib is better or worse in treating acute myeloid leukemia or myelodysplastic syndrome compared to the standard chemotherapy drugs.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2020-11-16T17:50:01. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ETCTN. DISEASE SITES is Myeloid and Monocytic Leukemia.
44. TITLE is Randomized Phase II Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer. SHORT TITLE is Ph II Nab-Paclitaxel+Durvalumab+Tremelimumab + Neoantigen Vaccine in Pts w/ Met Triple Neg Breast Ca. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria: 
- Patients must have a histologically confirmed diagnosis of metastatic invasive triple negative breast cancer.
- Must have a life expectancy of at least 12 weeks.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria: 
- Patients who are not considered to be candidates for carboplatin + gemcitabine for first line therapy of their metastatic triple negative breast cancer are not eligible.
- Patients who have had chemotherapy, radiotherapy (to more than 30% of the bone marrow), or biologic therapy within 30 days (42 days for nitrosoureas or mitomycin C) prior to entering the study.
- Patients who have received prior immunotherapy for metastatic disease.. DESCRIPTION is This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-03-24T11:21:55. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ETCTN. DISEASE SITES is Breast.
45. TITLE is Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer. SHORT TITLE is Ph II Radium-223 Dichloride in Combination w/ Paclitaxel in Patients w/ Bone Metastatic Breast Ca. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-Women or men with metastatic breast cancer with two or more bone metastases identified by technetium Tc-99m (99mTc) bone scintigraphy and/or computed tomography (CT), at least one of these bone lesions must not have been treated with prior radiation therapy
-A diagnosis of breast cancer must have been histologically or cytologically confirmed at any time point

Exclusion Criteria:
-Patients with peripheral neuropathy > grade 1
-Patients who have not recovered from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
-Prior therapy with radionuclides (e.g., strontium, samarium, rhenium, radium)

. DESCRIPTION is This phase II trial studies how well radium-223 dichloride and paclitaxel work in treating patients with advanced breast cancer that has spread to the bones. Radium-223 dichloride is a radioactive drug that behaves in a similar way to calcium and collects in cancer that has spread to the bones (bone metastases). The radioactive particles in radium-223 dichloride act on bone metastases, killing the tumor cells and reducing the pain that they can cause. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radium-223 dichloride and paclitaxel may work better in treating patients with metastatic breast cancer compared to paclitaxel alone. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-07-09T17:45:49. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ETCTN. DISEASE SITES is Breast.
46. TITLE is A Phase I/II Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma. SHORT TITLE is  Ph I/II Peposertib in Combo w/Hypofractionated Radiotherapy for Tx of Adv Pancreatic Adenocarcinoma. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

- Patients must have pathologically confirmed pancreatic adenocarcinoma.
- Patients must have received 4-6 months of induction chemotherapy with either FOLFIRINOX or gemcitabine/abraxane, as per standard of care.
- Patients must have locally advanced pancreatic cancer according to NCCN Guidelines on CT scan performed within 21 days of registration.

Exclusion Criteria:

- Patients who have completed induction chemotherapy less than 2 weeks or more than 8 weeks prior to study enrollment.
- Patients who are participating in other clinical trials and receiving any other investigational treatment.
- Patients who have evidence of distant metastatic disease.
- Patients who have had more than 1 line of chemotherapy for the treatment of localized pancreatic cancer.. DESCRIPTION is This phase I/II trial studies the side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that cannot be removed by surgery and has not spread to other parts of the body (localized). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may work better than radiation therapy alone in the treatment of patients with localized pancreatic cancer.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-30T13:50:49. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ETCTN. DISEASE SITES is Pancreas.
47. TITLE is A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and In Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors with a KRAS G12c Mutation. SHORT TITLE is Ph I GDC-6036 in Patients with Advanced Solid Tumors with a KRAS G12C Mutation. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.
Men who are not surgically sterile must agree to remain abstinent or use contraception, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.
Exclusion Criteria:

Active brain metastases.
Malabsorption or other condition that interferes with enteral absorption.
Clinically significant cardiovascular dysfunction or liver disease.. DESCRIPTION is This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T20:21:08. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Genentech, Inc.. DISEASE SITES is Colon, Rectum.
48. TITLE is A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects. SHORT TITLE is Ph II Olaparib in Patients w/ Metastatic/Advanced Urothelial Carcinoma w/ DNA-Repair Defects. INVESTIGATOR NAME is Arash Rezazadeh Kalebasty. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria: 
- Patients must have a histologically confirmed diagnosis of urothelial carcinoma (cancer) of the urothelial tract/bladder cancer.
- Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of olaparib.
- Patients must provide tumor sample for mutation analysis or be willing to undergo mandatory screening biopsy.

Exclusion Criteria: 
- Patients who have had prior treatment with olaparib or any other PARPi
- Patients who are receiving any other investigational agents. Patients may be on other clinical trials or treatment during screening to determine eligibility.
- Patients with known active hepatitis (i.e., Heptatitis B or C) due to risk of transmitting the infection through blood or other body fluids.. DESCRIPTION is This phase II trial studies how well olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-01-08T10:18:37. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ETCTN. DISEASE SITES is Urinary Bladder.
49. TITLE is A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Tafasitamab plus Lenalidomide in Addition to Rituximab versus Lenalidomide in Addition to Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3A or R/R Marginal Zone Lymphoma (MZL). SHORT TITLE is Ph III Tafasitamab+Lenalidomide & Rituximab in Pts w/ R/R Follicular Lymphoma or R/R MZ Lymphoma . INVESTIGATOR NAME is Elizabeth A Brem. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are ? 18 years of age

Exclusion Requirements.
You cannot participate in this study if you are pregnant or breastfeeding.. DESCRIPTION is This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-10-19T16:18:03. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Incyte Corporation. DISEASE SITES is Non-Hodgkin's Lymphoma.
50. TITLE is Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers. SHORT TITLE is Ph II Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers. INVESTIGATOR NAME is Daniela Bota. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of
study criteria to help you better understand how your eligibility in the study will be determined; your study
team will go through the study eligibility criteria with you to verify if you qualify for participation in this
study.

Inclusion Requirements
You can participate in this study if you
- have clinically confirmed recurrence of rare Central Nervous System (brain or spine) tumors
- are at least 18 years of age or older
- must be able to provide informed consent prior to study entry

Exclusion Requirements
You cannot participate in this study if you.
- are currently receiving other experimental drugs
- are pregnant or breastfeeding. DESCRIPTION is More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an effective treatment for people with rare CNS tumors.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-03-19T09:56:19. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Bristol-Myers Squibb, NCI. DISEASE SITES is Brain and Nervous System.
51. TITLE is A Randomized Phase II Study of Gemcitabine and NabPaclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Na√Øve Metastatic Pancreatic Cancer (GIANT). SHORT TITLE is PhII dFdC & ABI-007 Compared w/5-FU, Leucovorin & MM-398 in Older Pts w/Tx Na√Øve Met Pancreatic Ca. INVESTIGATOR NAME is Jennifer Brooke Valerin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Eligibility Criteria:

- Patients must have newly diagnosed untreated biopsy-proven, metastatic pancreatic cancer. Previous surgery, adjuvant chemotherapy, and/or radiation therapy is allowed, provided radiation therapy is completed at least 2 weeks prior to registration and adjuvant therapy was administered more than 6 months prior to registration. Patients with the following histology are excluded: Acinar cell; Adenosquamous carcinoma.
- Patients must be at least 70 years of age or older.
- Patient must agree not to take any medications or substances that are strong inhibitors or inducers of CYP3A4 (important enzyme in the body, mainly found in the liver and in the intestine). Those who are randomized to liposomal irinotecan treatment arm should avoid drugs that are UGT1A1 (enzyme found in the liver) inhibitors.. DESCRIPTION is The purpose of this study is to find out if two treatment combinations: Gemcitabine and Nab-paclitaxel or 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan, is more effective at lengthening the lives of "vulnerable" patients over the age of 70 with metastatic pancreatic cancer. Currently, there is no known best practice for this type of patient. . PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-03-24T13:06:17. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ECOG-ACRIN. DISEASE SITES is Pancreas.
52. TITLE is Screening to Improve Survival in AL Amyloidosis. SHORT TITLE is Screening to Improve Survival in AL Amyloidosis. INVESTIGATOR NAME is Lisa Xingguang Lee. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 60 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

- Patients 60 years of age and older
- Diagnosed with &#955; LC MGUS or &#955; LC SMM
- dFLC greater than 23 mg/L and &#954;::&#955; free LC ratio below normal

If the patient has an eGFR less than 50 mL/min/1.73m2, the &#954;::&#955; free LC ratio is inconsequential. The patient only needs to meet the age, dFLC, and &#955; LC MGUS or &#955; LC SMM diagnosis criteria in this case 

Exclusion Criteria:

- Patients with &#954; LC MGUS or &#954; LC SMM
- Amyloid in the bone marrow or in other biopsies will not be included. DESCRIPTION is The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.. TREATMENT TYPE DESC is Screening. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-08-24T16:21:10. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Tufts Medical Center. DISEASE SITES is Multiple Myeloma.
53. TITLE is A Phase IB, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients with NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy
. SHORT TITLE is PhIB HM95573 as SingleAgentCombo w/Cotellic or Cotellic+Tecentriq in Pts w/NRAS-Mutant Adv Melanoma . INVESTIGATOR NAME is John P Fruehauf. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and over; Ability to comply with the study requirements; Life expectancy of more than or equal to 12 weeks; Confirmed diagnosis or medical records of Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma; Adequate organ functions defined by the laboratory test results; For women of child bearing potential - (refrain from heterosexual intercourse) or use a contraception; For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.. DETAILED ELIGIBILITY is Signed Informed Consent Form ;Age = or >  18 years; Ability to comply with the study protocol; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Life expectancy > or = 12 weeks; Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma, previously treated with one or two lines of systemic anti-cancer therapy that included anti-PD-1 or anti PD-L1 therapy; Documentation of NRAS mutation-positive status in melanoma tumor tissue (archival or newly obtained), as determined by the local laboratory within 5 years prior to screening; Adequate hematologic and end-organ function, defined by the following laboratory test results; For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraception; For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:. DESCRIPTION is The purpose of this study is to test the safety of an experimental drug called belvarafenib given alone (by itself) or in combination with cobimetinib or in combination with both cobimetinib and atezolizumab.  We want to find out what dose of belvarafenib plus cobimetinib should be used in people with melanoma (skin cancer).  In addition, we also want to find out what effects, good and/or bad, the study drug(s) have on you and your cancer, and to understand the way your body processes the study drug(s).. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-02-01T15:09:34. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Genentech, Inc.. DISEASE SITES is Melanoma, Skin.
54. TITLE is A Phase I/IB First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients with Advanced Solid Tumors
. SHORT TITLE is Ph I/IB First-in-Human Study of the SHP2 Inhibitor BBP-398 in Pts w/Adv Solid Tumors. INVESTIGATOR NAME is Arash Rezazadeh Kalebasty. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Key Inclusion Criteria: 
- Male and non-pregnant females >18 years old.
- Patients must have adequate organ function.
- Patients must be willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other specified study procedures.

Key Exclusion Criteria: 
- Patients with known active Hepatitis B, Hepatitis C infection, or HIV infection.
- Patients with clinically significant cardiac disease.
- Patients with a known additional malignancy that is progressing or requires active treatment.
- Patients on dialysis.. DESCRIPTION is A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.. PHASE DESC is Early Phase I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-01T11:39:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Navire Pharma Inc. . DISEASE SITES is Other Digestive Organ, Lung, Stomach, Liver, Other Respiratory and Intrathoracic Organs, Mycosis Fungoides, Other Skin, Other Endocrine System, Breast, Colon, Bones and Joints, Soft Tissue, Urinary Bladder, Small Intestine, Anus, Pancreas, Other Male Genital, Eye and Orbit, Lip, Oral Cavity and Pharynx, Esophagus, Cervix, Other Female Genital, Thyroid, Rectum, Corpus Uteri, Brain and Nervous System, Ovary, Prostate, Kidney, Unknown Sites, Ill-Defined Sites, Kaposi's Sarcoma, Larynx, Other Urinary, Melanoma, Skin.
55. TITLE is Assessment of Chimerism and Relapse Post Bone marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test (ACROBAT). SHORT TITLE is Assessment of Chimerism & Relapse Post Bone Marrow/HCT Using AlloHeme Test (ACROBAT). INVESTIGATOR NAME is Stefan Octavian Ciurea. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

-Male or female, aged 18 years or above.
-The patient must have one of the following diseases: Adult acute myeloid leukemia (AML), Acute lymphocytic leukemia
(ALL) or Myelodysplastic syndromes (MDS)
-Eligible for allogeneic hematopoietic stem cell transplant

Exclusion Criteria:
-Pregnancy. DESCRIPTION is AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA. Before transplant, patient and donor peripheral blood sample will be collected to identify informative marker for routine chimerism testing and baseline establishment for AlloHeme. Post-transplant blood or bone marrow samples are obtained and compared to the baseline sample profiles to calculate % chimerism of recipient cells in the blood and/or bone marrow samples. Cell selection from blood and bone marrow samples is applied to evaluate chimerism in specific cell subtypes that are relevant to AML and MDS diseases (CD3+ T lymphocytes, CD33+ Myeloid cells and CD15+ Granulocyte cell subtypes from blood and CD34+ hematopoietic stem cells from bone marrow).. TREATMENT TYPE DESC is Diagnostic. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-08-04T10:14:56. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is CareDx, Inc.. DISEASE SITES is Non-Hodgkin's Lymphoma, Other Hematopoietic, Multiple Myeloma, Lymphoid Leukemia, Leukemia, other, Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia.
56. TITLE is A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults. SHORT TITLE is PhIII Steroids+Tyrosine KI Induction w/Chemo or Blinatumomab for New Diagnose BCR-ABL+ ALL in Adults. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- are must be &#8805; 18 and &#8804; 75 years of age.



Exclusion Requirements.
You cannot participate in this study if you 
- are pregnant or breast-feeding. DESCRIPTION is This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-16T18:16:48. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ECOG-ACRIN. DISEASE SITES is Lymphoid Leukemia.
57. TITLE is Phase I/II Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-C-MET Bispecific Antibody, in Patients with Advanced NSCLC and Other Solid Tumors
. SHORT TITLE is PhI/II Study of MCLA-129 in Pts w/Adv NSCLC & Other Solid Tumors. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Histologically or cytologically confirmed solid tumors with evidence of metastatic or locally advanced unresected disease that is incurable.
Patients with NSCLC or other solid tumors who have failed prior standard first-line treatment. Patients must have progressed on or be intolerant to therapies that are known to provide clinical benefit. There is no limit to the number of prior treatment regimens.
Availability of archival or a fresh tumor tissue sample.
Measurable disease as defined by RECIST version 1.1 by radiologic methods.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy &#8805; 12 weeks, as per Investigator.

Exclusion Criteria:

Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy (> 10 mg prednisone or equivalent) to control symptoms within 14 days of study entry.
Known leptomeningeal involvement.
Participation in another clinical study or treatment with any investigational drug within 4 weeks prior to study entry.
Prior treatment with a bispecific EGFR-c-MET antibody.
Systemic anticancer therapy or immunotherapy within 4 weeks or 5 half-lives, whichever is shorter, of the first dose of study drug. For cytotoxic agents that have major delayed toxicity (e.g., mitomycin C, nitrosoureas), a washout period of 6 weeks is required.
Major surgery or radiotherapy within 3 weeks of the first dose of study drug.
Persistent grade >1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy &#8804; grade 2 NCI-CTCAE v5.0 and hypothyroidism &#8804; grade 2 which is stable on hormone replacement are allowed.
History of hypersensitivity reaction or any toxicity attributed to human proteins or any of the excipients that warranted permanent cessation of these agents.. DESCRIPTION is A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 as monotherapy in patients with NSCLC, or HNSCC or other solid tumors and who have progressed after receiving prior therapy for advanced/metastatic disease.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T20:10:55. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Merus N.V. . DISEASE SITES is Liver, Larynx, Mycosis Fungoides, Cervix, Leukemia, other, Breast, Kaposi's Sarcoma, Lip, Oral Cavity and Pharynx, Stomach, Rectum, Other Digestive Organ, Corpus Uteri, Ill-Defined Sites, Esophagus, Other Male Genital, Urinary Bladder, Colon, Anus, Other Respiratory and Intrathoracic Organs, Soft Tissue, Eye and Orbit, Other Endocrine System, Small Intestine, Bones and Joints, Prostate, Kidney, Brain and Nervous System, Other Female Genital, Other Urinary, Unknown Sites, Pancreas, Lung, Other Skin, Ovary, Thyroid, Myeloid and Monocytic Leukemia, Melanoma, Skin.
58. TITLE is A Multi-Center, Open-Label, Phase I/II Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non Hodgkin Lymphoma of B-Cell Origin. SHORT TITLE is PhI/II AB-101 Monotherapy & AB-101 + Rituximab in Pts w/ Relapse/Refrac NHL of B-Cell Origin. INVESTIGATOR NAME is Lauren C Pinter-Brown. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is 	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding. DESCRIPTION is AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells.

This clinical trial is conducted in two phases. The primary objective of Phase 1 is to test the safety of AB-101 given alone or in combination with rituximab. The primary objective of Phase 2 is to determine if AB-101 in combination with rituximab has activity in patients with relapsed/refractory Non-Hodgkin lymphoma of B-cell origin.

Patients will receive eight weekly doses of AB-101 followed by scheduled assessments of overall health and tumor response.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-05-02T14:29:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Artiva . DISEASE SITES is Non-Hodgkin's Lymphoma.
59. TITLE is A Phase I, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies. SHORT TITLE is PhI NX-2127, a BTK Degrader, in Adults w/ Relapse/Refract B-cell Malignancies. INVESTIGATOR NAME is Susan O'Brien. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are  &#8805; 18 years of age

Exclusion Requirements.
You cannot participate in this study if you are unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug
. DESCRIPTION is This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-08-09T17:23:44. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Nurix Therapeutics, Inc.. DISEASE SITES is Non-Hodgkin's Lymphoma.
60. TITLE is Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study. SHORT TITLE is PhIII Early Intervene w/Venetoclax&Obinutuzumab vsDelay w/Venetoclax&Obinutuzumab in Pts w/CLL/SLL. INVESTIGATOR NAME is Catherine Coombs. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study. 

Inclusion Criteria:

-Patients must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients must have been diagnosed within 12 months prior to registration.
-Patients must not have received or be currently receiving any prior CLL-directed therapy, including non-protocol-related therapy, anti-cancer immunotherapy, experimental therapy, or radiotherapy
-Patients must be >= 18 years of age
-Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-Patients may not have had major surgery within 30 days prior registration or minor surgery within 7 days prior to registration. 
-Patients must not have known bleeding disorders (e.g., von Willebrand's disease or hemophilia).
-Patients must not be pregnant or nursing. DESCRIPTION is This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-06-11T11:24:38. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Lymphoid Leukemia.
61. TITLE is A Pilot Study of Immunotherapy Combined with Stereotactic Ablative Radiotherapy for Patients with Advanced or Metastatic Sarcoma
. SHORT TITLE is A Pilot immunotherapy Combined w/Stereotactic Ablative Radiotherapy for Pts w/Adv or Met Sarcoma. INVESTIGATOR NAME is Jeremy Harris. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria:
- are at least 18 years of age or older
- have been diagnosed with soft tissue sarcoma
- are not a candidate for surgery based on your doctor&#8217;s assessment

Exclusion Requirements
You cannot participate in this study if you satisfy the following criteria:
- are pregnant or nursing
- are receiving any other investigational agents. DESCRIPTION is The purpose of this research study is to test if a combination of two treatments, immunotherapy and stereotactic ablative radiotherapy (SBRT), can delay tumor growth in patients with cancers that develop in their soft tissues (sarcomas).. PHASE DESC is Early Phase I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2023-05-08T12:47:51. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Bones and Joints, Kaposi's Sarcoma, Soft Tissue. THERAPY NAMES is 
      .
62. TITLE is An Open-Label, Phase II Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas ("NAVAL-1"). SHORT TITLE is Ph II Trial of Nanatinostat in Combo w/Valganciclovir in Subj w/EBV+ R/R Lymph ("NAVAL-1"). INVESTIGATOR NAME is Elizabeth A Brem. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are  &#8805; 18 years of age

Exclusion Requirements.
You cannot participate in this study if you are pregnant or breastfeeding.. DESCRIPTION is A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-10-18T09:15:04. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Viracta Therapeutics, Inc.. DISEASE SITES is Lymphoid Leukemia, Hodgkin's Lymphoma, Other Hematopoietic, Non-Hodgkin's Lymphoma.
63. TITLE is The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
. SHORT TITLE is COMPASSHER2 RD Ph III Trial of T-DM1 & Placebo Compared w/ T-DM1 & Tucatinib. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-HER2-positive status will be based on pretreatment biopsy material and defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) according to current American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines. Central testing is not required
* Known hormone receptor (HR) status as defined by ASCO/CAP guidelines (based on pretreatment biopsy material). Hormone receptor positive status can be determined by either known positive estrogen receptor (ER) or known positive progesterone receptor (PR) status; hormone receptor negative status must be determined by both known negative ER and known negative PR
-Patients with clinical stage T1-4, N0-3 disease at presentation and residual invasive disease postoperatively as defined above are eligible. (Note: Patients with T1a/bN0 tumors are not eligible at initial breast cancer diagnosis are not eligible)
-Patients with residual HR-negative, HER2 positive (+) disease in the breast and/or lymph nodes per the surgical pathology report are eligible; however, patients with HR+ HER2+ cancers must have node-positive residual disease per the surgical pathology report in order to qualify for the study. The presence of residual invasive disease in the breast is not mandatory for these patients
-Patients with weakly ER-positive (1-10%) breast cancer (based on the pretreatment core biopsy) are eligible even if they have node-negative disease per the surgical pathology report
-The residual disease tissue (breast and/or lymph nodes) is not required to be HER2-positive, as eligibility for NCI-2020-03770 (A011801) is based on a positive HER2 status at the time of the initial breast cancer diagnosis
* Note: The presence of micrometastases in lymph nodes after preoperative therapy counts as residual disease, whereas the presence of isolated tumor cells does not

Exclusion Criteria:
-No adjuvant treatment with any anti-cancer investigational drug within 28 days prior to registration
-Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative serum pregnancy test done =< 7 days prior to registration is required
-Patients with known active and/or untreated hepatitis B or hepatitis C or chronic liver disease are ineligible. Patients with a diagnosis of hepatitis B or C that has been treated and cleared and normal liver function are eligible to participate in the study if the other eligibility parameters are met. DESCRIPTION is This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-12-07T17:32:51. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Alliance. DISEASE SITES is Breast.
64. TITLE is A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA). SHORT TITLE is PhIIIDurvalumab w/Tremelimumab&Enfortumab Vedotin orDurva w/EnfortumabVedotin forIneligCisplat MIBC. INVESTIGATOR NAME is Arash Rezazadeh Kalebasty. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

- Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage T2-T4aN0/1M0 with transitional and mixed transitional cell histology;
- Medically fit for cystectomy and able to receive neoadjuvant therapy;
- Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC;
- Must have a life expectancy of at least 12 weeks at randomization.

Exclusion criteria:

- Evidence of lymph node (N2+) or metastatic TCC/UC disease at the time of screening.
- Active infection
- Uncontrolled intercurrent illness
- Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG])
- Current or prior use of immunosuppressive medication within 14 days before the first dose of IPs.. DESCRIPTION is This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-03-28T14:24:07. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is AstraZeneca. DISEASE SITES is Urinary Bladder.
65. TITLE is A Multicenter, OpenLabel Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy. SHORT TITLE is Berubicin in Adult Pts w/ Recur GBM (WHO Grade IV) After Failure of Standard 1st Line Therapy. INVESTIGATOR NAME is Daniela Bota. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Inclusion Criteria:

- Confirmed Glioblastoma Multiforme (GBM) diagnosis based on local review of tumor tissue from the initial biopsy, surgery, re-resection, or a formal pathology report confirming GBM.
- No more than 1 prior line of cancer treatment (for example, surgery followed by radiation with concomitant chemotherapy, followed by adjuvant chemotherapy is considered as 1 line of treatment).
- Patients with prior malignancies must be disease-free for &#8805;5 years. However curatively
treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix,
breast, or bladder; or prostate cancer curatively treated at the time of screening is allowed.

Exclusion criteria:

- Known to be positive for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV), human immunodeficiency virus (HIV), COVID-19 (currently positive at time of screening), or any other acute viral, bacterial, or fungal infection (testing not required unless symptomatic or suspected disease).
- Patients with any other uncontrolled intercurrent medical conditions, including but not limited to diabetes mellitus or chronic obstructive pulmonary disease that have not been well controlled by medical management over the prior 3 months are ineligible unless approved by the sponsor.
- Prior treatment with bevacizumab and/or lomustine.. DESCRIPTION is This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria.

A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-12-08T15:34:09. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is CNS Pharmaceuticals. DISEASE SITES is Brain and Nervous System.
66. TITLE is A Phase I Dose-Escalation and Dose Expansion Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors. SHORT TITLE is PhI Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:

- Patients with confirmed advanced or metastatic solid tumor whose disease has progressed beyond standard therapy or not a candidate for current treatment options. 
- Willingness and ability to consent for self to participate in study and the ability comply with scheduled visits, treatment plan, lab tests, and other study procedures.
- Male and female patients agreeable to use two forms of effective contraception methods while participating on study until 12 weeks after the last dose of study treatment. 

Exclusion Criteria:

- Patients are not eligible if they have had prior exposure to CLDN18.2-targeted therapy (therapy targeted to the CLDN 18.2 protein expressed in cancers). 
- Known active or chronic Hepatitis B, Hepatitis C, or HIV.
- Female patients in pregnancy, breastfeeding, or having a positive pregnancy test within 7 days prior to study treatment.. DESCRIPTION is The purpose of this study is to test the safety of a study drug called TJ033721. The study will test different dose levels to find out what effects, both good and/or bad, the study treatment has on you and your solid tumor.  The study drug, TJ033721, is investigational and has been tested in animals, but not yet in people. This means it has not been approved for commercial use by the United States Food and Drug Administration (FDA).. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-02-17T09:45:02. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is I-MAB Biopharma. DISEASE SITES is Colon, Other Digestive Organ, Other Respiratory and Intrathoracic Organs, Mycosis Fungoides, Other Female Genital, Urinary Bladder, Ill-Defined Sites, Melanoma, Skin, Soft Tissue, Kaposi's Sarcoma, Larynx, Other Endocrine System, Lip, Oral Cavity and Pharynx, Esophagus, Small Intestine, Anus, Pancreas, Cervix, Corpus Uteri, Ovary, Prostate, Eye and Orbit, Breast, Liver, Thyroid, Stomach, Kidney, Other Urinary, Brain and Nervous System, Unknown Sites, Rectum, Lung, Other Skin, Bones and Joints, Other Male Genital.
67. TITLE is A Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors
. SHORT TITLE is A Phase I/IB Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-Participants (male or female);18 years of age
-Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type

Exclusion Criteria:
-Known or suspected leptomeningeal or brain metastases or spinal cord compression
-Primary central nervous system (CNS) tumors. DESCRIPTION is This is an open-label, multicenter, Phase 1/1b study of RMC-5552 monotherapy in participants with advanced relapsed or refractory solid tumors. The study will include 2 components: 1) a Dose-Escalation Component for participants with relapsed or refractory solid tumors and 2) a Dose-Expansion Component for participants with relapsed or refractory solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of the mTOR pathway. Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T16:10:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Revolution Medicines. DISEASE SITES is Anus, Soft Tissue, Urinary Bladder, Lip, Oral Cavity and Pharynx, Prostate, Other Digestive Organ, Bones and Joints, Cervix, Ovary, Brain and Nervous System, Unknown Sites, Ill-Defined Sites, Melanoma, Skin, Colon, Liver, Other Urinary, Other Endocrine System, Small Intestine, Larynx, Other Respiratory and Intrathoracic Organs, Thyroid, Stomach, Rectum, Mycosis Fungoides, Other Skin, Other Male Genital, Kidney, Eye and Orbit, Kaposi's Sarcoma, Corpus Uteri, Other Female Genital, Esophagus, Pancreas, Lung, Breast.
68. TITLE is Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression. SHORT TITLE is Phase I/II Study of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- Written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling or analyses
- At least 18 years-of-age at the time of signature of the informed consent form
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Acceptable renal, hepatic, hematologic and coagulation functions
- Negative pregnancy test for women of childbearing potential
- Male participants with female partners of childbearing potential and female participants of childbearing potential are required to follow highly effective contraception
- All patients must have tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers. In the absence of available tumor tissue, patients must be willing to undergo a biopsy to provide fresh tumor samples
- Life expectancy greater than 12 weeks after the start of BT5528 treatment according to the Investigator's judgment.
- Must be willing and able to comply with the protocol and study procedures.

Additional inclusion criteria for Phase I (dose escalation phase, with BT5528 alone or in combination with nivolumab):

- Metastatic recurrent histologically confirmed malignant solid tumors historically known for high EphA2 tumor expression. Confirmation of EphA2 expression prior to enrollment is not required for participants with ovarian cancer and specific other individual tumor types.
- Exhausted all appropriate treatment options per local guidelines


Additional inclusion criteria for Phase II (dose expansion phase, with BT5528 alone):

- Participants with metastatic recurrent disease histologically confirmed to be non-small cell lung cancer, ovarian cancer, triple-negative breast cancer (TNBC), gastric/upper gastrointestinal (GI) cancer, head and neck (H&N) cancer, urothelial cancer are eligible and must have failed or are ineligible for all appropriate treatment options per local guidelines and must have evidence of radiographic progression on the most recent line of therapy
- Patients with urothelial cancer who have previously received treatment with enfortumab vedotin (EV) are eligible to the study. Patients who received EV and showed disease progression within 6 months of treatment start are planned for less than 50% of total patients enrolled in the cohort

Exclusion Requirements
You cannot participate in this study if you
- Chemotherapy treatments within 14 days prior to first dose of study treatment, other anticancer treatments, treatment within 28 days or 5 half-lives, whichever is the shorter
- Experimental treatments within 4 weeks of first dose of BT5528
- Prior toxicities must have resolved to Grade 1 per Common Terminology Criteria for Adverse - - Events (CTCAE) v 5.0 (except alopecia which can be Grade 2)
- Current treatment with strong inhibitors or inducers of CYP3A4 or strong inhibitors of P-gp
Known sensitivity to any of the ingredients of the investigational product or monomethyl auristatin E (MMAE)
- Any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or is not in the best interest of the patient to participate in the opinion of the investigator including but not limited to specific cardiovascular criteria
- Major surgery (excluding placement of vascular access) within 4 weeks of first dose of BT5528 study . DESCRIPTION is Brief Summary:
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to:

- Find the recommended dose of BT5528 that can be given safely to participants alone and in combination with nivolumab
- Learn more about the side effects of BT5528
- Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer.
- Learn more about BT5528 therapy alone and in combination with nivolumab.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T14:22:13. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Bicycle Tx Limited. DISEASE SITES is Lung.
69. TITLE is Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL. SHORT TITLE is Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL. INVESTIGATOR NAME is Susan O'Brien. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Requirements
You can participate in this study if you 
&#8226;	Are 18 years of age or older
&#8226;	Have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) 
&#8226;	Are willing and able to participate in all required evaluations and procedures in this study 


Exclusion Requirements 
You cannot participate in this study if you 
&#8226;	Have prior SARS-CoV-2/COVID19 infection 
. DESCRIPTION is The purpose of this research study is to find out how your blood immune markers change before and after a vaccination. We will use samples and data to better understand how your body&#8217;s immune system reacts to the COVID-19 vaccine.. TREATMENT TYPE DESC is Other. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-06-11T11:30:52. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is University of Washington. DISEASE SITES is Lymphoid Leukemia.
70. TITLE is A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk Myelodysplastic Syndrome. SHORT TITLE is PhIII SY-1425 + Azacitidine vsPlacebo +Azacitidine in New Diagnosed RARA+ Adult Pts w/HigherRisk MS. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult, Older Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Key Inclusion Criteria:
1. Participants must be at least 18 years old at the time of signing of an informed consent.
2. Participants must be newly diagnosed with Higher Risk-MDS 

Key Exclusion Criteria:
1. Participants are suitable for and agree to undergo allogeneic HSCT at the time of Screening.
2. Participants who received prior treatment for MDS with any hypomethylating agent, chemotherapy or allogeneic HSCT.
3. Patients have an active, life-threatening, or clinically-significant, uncontrolled systemic infection requiring hospitalization.
4. Patients have a known malabsorption syndrome or other condition that may impair absorption of study medication (e.g., gastrectomy).
5. Pregnant females, breastfeeding females, and males not willing to comply with contraceptive requirements or females of childbearing potential not willing to comply with contraceptive requirements.. DESCRIPTION is This study compares the efficacy of SY-1425 in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-12-06T23:02:56. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Syros. DISEASE SITES is Myeloid and Monocytic Leukemia.
71. TITLE is A Phase I/II, Open-Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NonHodgkin s Lymphoma or Chronic Lymphocytic Leukemia. SHORT TITLE is PhI/II MB-106 in Pts w/ Relapse or Refra CD20+ B-Cell Non-Hodgkin s Lymph or CLL. INVESTIGATOR NAME is Susan O'Brien. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding. DESCRIPTION is Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL
. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-07-11T12:26:10. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Mustang. DISEASE SITES is Lymphoid Leukemia, Non-Hodgkin's Lymphoma.
72. TITLE is Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma. SHORT TITLE is PhII/IIINivolumab+Ipilimumab+Sargramostim vsNivolumab+Ipilimumab inPts w/UnresecStg IIIorIV Melanoma. INVESTIGATOR NAME is Warren A Chow. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult, Older Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
-Patients must have known BRAF mutational status of tumor; wild-type (WT) or mutated, prior to randomization
-Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for at least one week prior to the start of the research study, and continuing for 5 months for women of childbearing potential and 7 months for sexually active males after the last dose of the study drugs
-Patients must have unresectable stage III or stage IV melanoma; patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive
-Adequate organ functions based on lab values
-Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible

Exclusion Criteria:
-Women must not be pregnant or breast-feeding due to use of cytotoxic immunotherapy and risk of teratogenic side effects; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-Patients may not have had any prior ipilimumab and/or anti-PD-1/PD-L1 agent in the metastatic setting
-Patients must not receive any other investigational agents while on study or within four weeks prior to randomization
-Patients must not have any serious or unstable pre-existing medical conditions
-Patients with human immunodeficiency virus (HIV) infection are ineligible;
-Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible; patients with cleared HBV and HCV (0 viral load) infection will be allowed
-Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis); other CNS autoimmune disease (e.g., multiple sclerosis)
-Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
-Patients must not have other significant medical, surgical, or psychiatric conditions or require any medication or treatment. DESCRIPTION is This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T09:33:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ECOG-ACRIN. DISEASE SITES is Melanoma, Skin.
73. TITLE is A Phase I/II Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer. SHORT TITLE is Ph I/II Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant NSCLC. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is &#8805;18 years of age at the time of signing the informed consent.
Pathologically confirmed, definitively diagnosed, metastatic NSCLC harboring an activating EGFR mutation.
Previously received at least 1 prior EGFR-targeted TKI. For patients enrolled to expansion Group 2, prior treatment must include an approved EGFR-targeted TKI with activity against the T790M mutation, such as osimertinib.
EGFR mutation profile determined locally via a Sponsor-approved testing methodology, using either tumor tissue (ideally from a progressing lesion) and/or ctDNA in plasma. It is preferable that samples used for analysis be obtained during or after disease progression on the last EGFR-targeted TKI received.

Dose escalation: At each dose level, slots may be reserved for patients with the mutations of interest.
Expansion Groups: Patients must have NSCLC harboring EGFR T790M and C797S mutation (Group 1); EGFR T790M but not C797S (Group 2); or EGFR C797S but not T790M (Group 3).
Pretreatment tumor sample (either an archival sample or a sample obtained by pretreatment biopsy) submitted for central analysis. It is preferable that pretreatment tumor samples be obtained from a progression lesion, during or after disease progression on the last EGFR-targeted TKI received.

Patients without archival tissue available, where biopsy is not considered safe and/or medically feasible, may be discussed with the study medical monitor and may be approved for enrollment on a case-by-case basis.

Phase 2 Expansion Groups: Patient has at least 1 measurable target lesion evaluable by RECIST 1.1 as assessed by the investigator.
Eastern Cooperative Oncology Group (ECOG) performance status is 0-2.
Agrees to use contraception consistent with local regulations. DESCRIPTION is This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-06-08T15:09:31. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Blueprint Medicines. DISEASE SITES is Lung.
74. TITLE is Outcomes of Cutaneous Melanoma Patients Clinically Tested DecisionDx - Melanoma (CONNECTION). SHORT TITLE is Outcomes of Cutaneous Melanoma Patients Clinically Tested DecisionDx -Melanoma . INVESTIGATOR NAME is James Jakowatz. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is 1. Patient diagnosed with biopsy confirmed Stage I, Stage II or Stage III (at time of diagnosis) cutaneous melanoma (CM).
2. Patient is greater than or equal to 18 years of age at the time of diagnosis.
3. Patient who received successful DecisionDx¬Æ-Melanoma test results whose test was ordered between January 1, 2013 and December 31, 2017.
** Patient who has more than one invasive CM lesion tested, must be enrolled only once, using the highest-risk lesion (per DecisionDx¬Æ-Melanoma) as the lesion under study.
Patients who have not experienced a metastatic event must meet the additional following criteria:
4. Patient must have a minimum of 3 years documented clinical follow up demonstrating they have not experienced a metastatic event (this includes regional and distant metastatic events).
Patients who have experienced a metastatic event must meet the following additional criteria:
5. Patient must have documentation of melanoma metastasis and/or melanoma-specific death but is not required to have a full three years documented clinical follow up.
Exclusion
1. No exclusions except not meeting inclusion criteria above.. TREATMENT TYPE DESC is Diagnostic. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-12-03T10:21:03. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Castle Biosciences Inc. DISEASE SITES is Melanoma, Skin.
75. TITLE is S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC. SHORT TITLE is PhIII Atezolizumab Plus SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC. INVESTIGATOR NAME is Jeremy Harris. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Patient must have histologically or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC), without radiographic evidence of nodal or distant involvement (N0M0). Patient may have T3 disease with the exclusion of multifocal tumors and pericardial involvement
Disease must have one or more of the following high-risk features:

Tumor diameter >= 2 cm as assessed by diagnostic computed tomography (CT)
Tumor standard uptake value (SUV) max >= 6.2 as assessed by fludeoxyglucose F-18 (FDG) positron emission tomography (PET)/CT
Moderately differentiated, poorly differentiated, or undifferentiated histology
Patient must have undergone diagnostic chest CT with contrast (unless medically contraindicated) within 42 days prior to randomization. PET-CT may be used if the CT portion is of identical diagnostic quality to a stand-alone CT. All disease must be assessed within 42 days prior to randomization
Patient must have undergone FDG PET/CT of chest within 90 days prior to randomization
Patient must not have evidence of hilar or mediastinal nodal involvement. Any patient with radiographically suspicious hilar or mediastinal nodes (including features such as non-calcified nodes with a short axis diameter > 1 cm, abnormal morphology, and/or elevated FDG avidity) must undergo cytologic sampling of suspicious nodes to rule out involvement prior to randomization. Mediastinal nodal sampling for other patients is optional
Patient must have undergone history and physical examination within 28 days prior to randomization
Patient must be medically or surgically inoperable as documented by a board certified thoracic surgeon or multi-disciplinary tumor board consensus OR patient's unwillingness to undergo surgical resection must be clearly documented
Patient must not have received any prior treatment for the current NSCLC diagnosis
Patient must not have undergone prior radiation to overlapping regions of the chest that, in the opinion of the treatment physician, will interfere with protocol treatment
Patient must not have received treatment with systemic immunostimulatory or immunosuppressive agents, including corticosteroids, within 14 days prior to randomization
Patient must be >= 18 years old
Patient must have Zubrod performance status of 0-2
Patient must have adequate liver function defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper level of normal (IULN) within 28 days prior to randomization
Patient must have adequate renal function defined as calculated creatinine clearance >= 30 mL/min using the following formula. The serum creatinine value used in the calculation must have been collected within 28 days prior to randomization
Patient must have absolute neutrophil count (ANC), platelets, and hemoglobin measured within 28 days prior to randomization. The purpose of these tests is to collect baseline values to compare with on-treatment values
Patient must have thyroid-stimulating hormone (TSH) measured within 28 days prior to randomization. The purpose of this test is to collect baseline values to compare with on-treatment values
Patient must not have significant cardiovascular disease (New York Heart Association [NYHA] class II or greater)
Patient must not have myocardial infarction within 90 days prior to randomization
Patient must not have unstable arrhythmias or unstable angina
Patient must not have known left ventricular ejection fraction < 40% within 28 days prior to randomization. DESCRIPTION is This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-06T22:37:35. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Lung.
76. TITLE is An Open Label, First in Human (FIH), Phase I Trial of LVGN6051 as Single Agent and in Combination with Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy. SHORT TITLE is Ph I LVGN6051 as Single Agent & in Combo w/ Keytruda (Pembrolizumab) in Adv or Met Malignancy. INVESTIGATOR NAME is Warren A Chow. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult, Older Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
- Males or females aged &#8805; 18 years.
- Ability to understand and willingness to sign a written informed consent document.
- Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy.

Exclusion Criteria: 
- Receipt of systemic anticancer therapy including investigational agents or devices within 5 half-lives of the first dose of study treatment.
- Previous radiotherapy within 14 days of the first dose of study treatment.
- Has received a live-virus vaccine within 30 days.. DESCRIPTION is LVGN6051 is a humanized monoclonal antibody that specifically binds to CD137, and acts as an agonist against CD137.

This first in human study of LVGN6051 is designed to establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN6051, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Pembrolizumab/MK-3475) in the treatment of advanced or metastatic malignancy.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-28T16:25:38. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Lyvgen BioPharma Holdings Limited. DISEASE SITES is Other Respiratory and Intrathoracic Organs, Other Male Genital, Urinary Bladder, Brain and Nervous System, Breast, Kidney, Leukemia, other, Unknown Sites, Lip, Oral Cavity and Pharynx, Small Intestine, Other Female Genital, Prostate, Ill-Defined Sites, Other Skin, Thyroid, Hodgkin's Lymphoma, Multiple Myeloma, Myeloid and Monocytic Leukemia, Anus, Lung, Bones and Joints, Other Urinary, Eye and Orbit, Lymphoid Leukemia, Other Hematopoietic, Stomach, Colon, Soft Tissue, Cervix, Other Endocrine System, Esophagus, Liver, Other Digestive Organ, Mycosis Fungoides, Corpus Uteri, Non-Hodgkin's Lymphoma, Melanoma, Skin, Kaposi's Sarcoma, Rectum, Pancreas, Larynx, Ovary.
77. TITLE is An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer with a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab. SHORT TITLE is PhII Tx of Liver Met Colorectal Ca & NSCLC w/ a Combo of TATE & Pembrolizumab. INVESTIGATOR NAME is Nadine Abi-Jaoudeh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
mCRC progressed on at least two lines of standard chemotherapy; or
NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
Measurable disease
ECOG 0-1
At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
Adequate organ function

Exclusion Criteria:
Prior organ transplantation
Liver metastasis more than 50%
Oxygen saturation less than 92% in room air
Prior autoimmune disorder
CNS metastasis
Major GI bleeding in the last 2 months. DESCRIPTION is Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T09:42:21. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Teclison Limited. DISEASE SITES is Colon, Rectum, Lung.
78. TITLE is A Phase I/II, First-in-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications  . SHORT TITLE is PhI/IIDF6002 as Mono &Combo w/Nivolumab in Pts w/Local Adv or Met Solid Tumors & Expan in Select Ind. INVESTIGATOR NAME is Jennifer Brooke Valerin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Male or female patients aged 18 years and over. DETAILED ELIGIBILITY is General Inclusion and Exclusion Criteria 
- Male or Female patients ages 18 years and over
-Histologically or cytologically proven locally advanced or metastatic solid tumors, for which no standard therapy exists or standard therapy has failed among the following tumor types: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate.
-Clinical or radiological evidence of disease
-Adequate hematological, hepatic and renal function
-Effective contraception for women of child-bearing potential as defined by World Health Organization guidelines for 1 "highly effective" method or 2 "effective" methods
Additional Phase 1 Monotherapy and Phase 1b Combination With Nivolumab Expansion Inclusion Criteria:
-Has one of the following tumor types: melanoma, non-small cell lung cancer, or triple negative breast cancer
-Agrees to undergo a pre-treatment biopsy and another biopsy while on treatment
Expansion Inclusion Criteria specific to Melanoma:
-Histologically confirmed, unresectable Stage III or Stage IV melanoma, as specified in the American Joint Committee on Cancer staging system.
-Participants with ocular or uveal melanoma are ineligible.
-Must have documented progressive or recurrent disease on or after discontinuation of anti-PD-(L)1 therapy
Additional Inclusion Criteria for Phase 2 (Advanced Melanoma Patients)
-Participants who received anti-PD-(L)1 in the advanced/metastatic setting, must have documented progressive or recurrent disease on or within 3 months of discontinuation of anti-PD-(L)1 therapy
-Participants who received anti-PD-(L)1 in the adjuvant setting must have documented progressive or recurrent disease on or within 6 months of discontinuation of anti-PD-(L)1 therapy
-Disease progression was confirmed at least 4 weeks after the initial diagnosis of disease progression while receiving an anti PD-1 antibody.
-Participants with ocular or uveal melanoma are ineligible.
-Confirmation of radiographic progression on prior anti-PD-(L)1 therapy is required
Exclusion Criteria for All Patients (All Phases)
-Prior treatment with rhIL2 or any recombinant long acting drug containing an IL2 moiety.
-Concurrent anticancer treatment (with the exception of palliative bone directed radiotherapy), immune therapy, or cytokine therapy (except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of study treatment.
-Previous malignant disease other than the current target malignancy within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin, localized prostate cancer or cervical carcinoma in situ.
-Rapidly progressive disease.
-Any Grade 2 and higher neurological or pulmonary toxicity during a treatment with an anti-PD-1 or PD-L1 agent administered as a monotherapy.
-Active or history of central nervous system (CNS) metastases.
-Receipt of any organ transplantation, autologous or allogeneic stem-cell transplantation.
-Significant acute or chronic infections, or active or latent hepatitis B or active hepatitis C.
-Preexisting autoimmune disease needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years, clinically relevant immunodeficiencies, or fever within 7 days of Day 1.
-Known severe hypersensitivity reactions to monoclonal antibodies and any history of anaphylaxis, or uncontrolled asthma
-Serious cardiac illness or medical conditions.
History of life-threatening toxicity related to prior immune therapy except those that are unlikely to re-occur with standard countermeasures.
Contacts and Locations. DESCRIPTION is This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with nivolumab.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-05-13T16:44:00. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Bristol-Myers Squibb, Dragonfly Therapeutics, Inc.. DISEASE SITES is Stomach, Mycosis Fungoides, Other Female Genital, Prostate, Ill-Defined Sites, Melanoma, Skin, Anus, Larynx, Lung, Cervix, Kaposi's Sarcoma, Other Respiratory and Intrathoracic Organs, Soft Tissue, Urinary Bladder, Corpus Uteri, Eye and Orbit, Brain and Nervous System, Unknown Sites, Breast, Esophagus, Liver, Bones and Joints, Other Skin, Lip, Oral Cavity and Pharynx, Small Intestine, Colon, Other Digestive Organ, Other Endocrine System, Rectum, Pancreas, Ovary, Other Male Genital, Kidney, Other Urinary, Thyroid.
79. TITLE is A Phase I/II Study of the Highly Selective ROS1 Inhibitor NUV=520 in Patients with Advanced NSCLC and Other Solid Tumors. SHORT TITLE is Ph I/II Highly Selective ROS1 Inhibitor NUV=520 in Pts w/ Adv NSCLC & Other Solid Tumors. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Age &#8805;18 years (Cohort 2e only: Age &#8805;12 years and weighing>40 kg).
Phase 1:

Histologically or cytologically confirmed metastatic solid tumor with documented ROS1 rearrangement.
Cohorts 2a, 2b, 2c and 2d: Histologically or cytologically confirmed metastatic NSCLC with ROS1 rearrangement.
Cohort 2e: Histologically or cytologically confirmed metastatic solid tumor (other than NSCLC) with ROS1 rearrangement.
Prior anticancer treatment (except cohort 2a).
Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1. Phase 2: Must have measurable disease according to RECIST 1.1.
Adequate baseline organ function and bone marrow reserve.. DESCRIPTION is Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors.

Phase 1 will determine the RP2D and/or maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors.

Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T16:01:21. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Nuvalent, Inc.. DISEASE SITES is Esophagus, Larynx, Prostate, Colon, Liver, Other Skin, Other Female Genital, Kaposi's Sarcoma, Small Intestine, Other Digestive Organ, Lung, Bones and Joints, Eye and Orbit, Ill-Defined Sites, Breast, Lip, Oral Cavity and Pharynx, Stomach, Anus, Other Male Genital, Other Urinary, Brain and Nervous System, Other Endocrine System, Rectum, Soft Tissue, Mycosis Fungoides, Cervix, Corpus Uteri, Kidney, Thyroid, Unknown Sites, Other Respiratory and Intrathoracic Organs, Ovary, Urinary Bladder, Melanoma, Skin, Pancreas.
80. TITLE is A Phase Ia/Ib Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors . SHORT TITLE is A Phase Ia/Ib Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors . INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Patients have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).
Participants must have a histological or a cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and meet cohort-specific criteria.
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Have adequate organ function.
Have discontinued all previous treatments for cancer with resolution of any significant ongoing adverse events (AEs).
Must be able to swallow capsule/tablet.
Agree and adhere to contraceptive use, if applicable.. DESCRIPTION is This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability, and preliminary efficacy of oral LY3537982 in patients with KRAS G12C-mutant solid tumors.

This study will be conducted in 2 parts, Part 1a is a dose escalation and Part 1b is a dose expansion. Part 1a will establish a recommended Phase 2 dose. Part 1b will have multiple arms of either monotherapy or in combination with other drugs.

KRAS G12C mutations will be identified through standard of care testing.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-01-05T15:56:19. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Loxo Oncology, Inc.. DISEASE SITES is Larynx, Ill-Defined Sites, Mycosis Fungoides, Corpus Uteri, Other Female Genital, Urinary Bladder, Thyroid, Colon, Liver, Soft Tissue, Cervix, Ovary, Other Male Genital, Eye and Orbit, Brain and Nervous System, Lip, Oral Cavity and Pharynx, Esophagus, Other Skin, Stomach, Anus, Other Digestive Organ, Lung, Bones and Joints, Prostate, Rectum, Other Respiratory and Intrathoracic Organs, Other Urinary, Unknown Sites, Breast, Small Intestine, Kidney, Other Endocrine System, Melanoma, Skin, Kaposi's Sarcoma, Pancreas.
81. TITLE is A Phase Ib/II, Two-Part, Open-Label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination with ALX148 in Advanced HER2-Expressing Cancer. SHORT TITLE is Ph Ib/II Zanidatamab in Combo w/ALX148 in Adv HER2-Expressing Ca. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria: 
- Locally advanced (inoperable) and/or metastatic HER2-expressing cancer based on local or central laboratory test results
- Progression after or during the most recent systemic regimen of treatment for advanced cancer.
- The subject is willing and able to comply with study procedures.

Eligibility Criteria
- Previous allogeneic stem cell transplant.
- Had major surgery within 4 weeks of the first dose of zanidatamab/ALX148.
- Poorly-controlled seizures.. DESCRIPTION is This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced [inoperable] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-12-14T08:41:46. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Zymeworks. DISEASE SITES is Breast.
82. TITLE is Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
. SHORT TITLE is PhI/II BGB-A425 in Combo w/ Tislelizumab in Pts w/ Adv Solid Tumors. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Criteria
Key Inclusion Criteria:

Phase 1: Patients with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors who have previously received standard systemic therapy or for which treatment is not available, not tolerated or refused.
Has Eastern Cooperative Oncology Group (ECOG) Performance Status &#8804;1.
Phase 2: Patients with one of the following histologically or cytologically confirmed solid tumors:
Cohort 1 (HNSCC, PD-L1 positive):

Recurrent/metastatic head and neck squamous cell cancer of the oral cavity, oropharynx, hypopharynx, and/or larynx whose tumor is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy

Cohort 2 (NSCLC, PD-L1 positive):

Locally recurrent Stage IIIB, stage IIIC or Stage IV squamous or non-squamous non-small cell lung cancer

Cohort 3 (RCC):

Locally advanced unresectable or metastatic and histologically confirmed renal cell carcinoma with a clear cell histology

Key Exclusion Criteria:

Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
Active autoimmune diseases or history of autoimmune diseases that may relapse.
With infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal, or antiviral therapy &#8804; 14 days prior to the first dose of study drug(s), or a requirement for chronic prophylactic treatment with antibiotics.
Concurrent participation in another therapeutic clinical trial. 6. Received prior therapies targeting TIM-3.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.. DESCRIPTION is BGB-A425 is a humanized, immunoglobulin gamma-1 (IgG1)-variant monoclonal antibody against TIM-3. Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-06-30T15:18:01. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is BeiGene, Ltd.. DISEASE SITES is Lip, Oral Cavity and Pharynx, Other Male Genital, Other Urinary, Esophagus, Rectum, Anus, Kidney, Colon, Bones and Joints, Small Intestine, Other Respiratory and Intrathoracic Organs, Mycosis Fungoides, Other Skin, Breast, Other Digestive Organ, Larynx, Corpus Uteri, Other Female Genital, Eye and Orbit, Other Endocrine System, Pancreas, Lung, Unknown Sites, Melanoma, Skin, Liver, Soft Tissue, Prostate, Brain and Nervous System, Thyroid, Ill-Defined Sites, Stomach, Cervix, Ovary, Urinary Bladder, Kaposi's Sarcoma.
83. TITLE is An Open-Label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinectics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL). SHORT TITLE is PhII Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma . INVESTIGATOR NAME is Daniela Bota. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
- Pathologically diagnosed with Primary Central Nervous System Lymphoma
- Life expectancy of at least 3 months (part A) or at least 6 months (part B)
- Adequate bone marrow, renal, and hepatic function as described by the study protocol

Exclusion Criteria:
- Patient who is intolerant of contrast-enhanced MRI due to allergic reactions to contrast agents
- Patient with systemic presence of lymphoma
- Prior radiotherapy within 14 days before starting tirabrutinib (study drug) treatment. DESCRIPTION is This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment na√Øve PCNSL (Part B). PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-06-17T16:13:53. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ONO Pharmaceutical Co., Ltd.. DISEASE SITES is Brain and Nervous System.
84. TITLE is Phase III Randomized, Controlled Study of Blinatumomab Alternating with Low-Intensity Chemotherapy Versus Standard of Care for Older Adults with Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia with Safety Run-In . SHORT TITLE is PhIIIBlinatumomab Alter w/LI Chemo vsSOC for OldAdults w/ND Phil(-) BCell Precur ALL w/SafeRunIn. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is 	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female ages &#8805; 55 years at the time of informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant. DESCRIPTION is The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-07T20:35:12. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Amgen Inc.. DISEASE SITES is Lymphoid Leukemia.
85. TITLE is An Open-Label, Multi-Center, Non Randomized Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma . SHORT TITLE is PhI of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma. INVESTIGATOR NAME is Lauren C Pinter-Brown. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding. DESCRIPTION is This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-04-12T16:36:57. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ONO Pharmaceutical Co., Ltd.. DISEASE SITES is Lymphoid Leukemia.
86. TITLE is A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases. SHORT TITLE is Ph II of Sacituzumab Govitecan for Patients w/ HER2-Negative Breast Ca & Brain Met. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-Participants must have histologically confirmed HER2-negative (per 2018 American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] joint guideline) invasive breast cancer that has metastasized to the brain. NOTE: Pathology report must confirm HER2-negative invasive breast cancer. Brain metastases must be confirmed by radiology report
- Participants must have an magnetic resonance imaging (MRI) of the brain within 28 days prior to registration and must have central nervous system metastases with at least one measurable brain metastasis >= 1.0 cm in size (per RANO-BM) that has not been irradiated, or has progressed despite prior radiation therapy (in the opinion of the treating physician). In the rare case that a previously irradiated brain metastasis is the sole target lesion and if there is concern about possible radiation necrosis, patient is eligible only if there is clear progression in the previously radiated lesion. Computed tomography (CT) of the head cannot substitute for brain MRI. All central nervous system (CNS) disease must be assessed and documented on the S2007 Brain Metastases Baseline Tumor Assessment Form

Exclusion Criteria:
-Participants must not have had more than 2 seizures within 28 days prior to registration
-Participants must not have received systemic therapy (including small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (e.g., tamoxifen) within 7 days prior to registration
-Participants must not have received anti-cancer biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to registration. DESCRIPTION is This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-08-06T17:05:50. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Breast, Brain and Nervous System.
87. TITLE is A Phase I/II Study of REGN5093-M114 (METXMET Antibody-Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer. SHORT TITLE is PhI/II REGN5093-M114 in Patients with MET Overexpressing Advanced Cancer. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- Histologically confirmed NSCLC that is at advanced stage for which there are no approved therapies available expected to confer clinical benefit as defined in the protocol
- Willing to provide tumor tissue from newly obtained biopsy from tumor site. Newly obtained biopsies at tissue screening are required. An archival sample can be accepted only after discussion with the medical monitor and if the sample is not more than 6 months old and obtained after completion of the last therapy. The enrollment of patients will be based on an immunohistochemistry (IHC)-based assay using freshly obtained tumor biopsies or an archival biopsy as described above. Only patients with MET overexpressing tumors by central IHC analysis will be enrolled. For expansion cohorts only: tumor site for biopsy must not have been irradiated previously and must not be the only measurable lesion.
- Tumor must overexpress MET protein as defined in the protocol by central IHC analysis
- For expansion only: At least one lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ and bone marrow function as defined in the protocol

Exclusion Requirements
You cannot participate in this study if you
- Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks or 5 half-lives of the prior treatment, whichever is shorter with a minimum of 7 days from the first dose of study therapy
- Has not yet recovered (ie, grade &#8804;1 or baseline) from any acute toxicities resulting from prior therapy except as described in the protocol
- Has received radiation therapy or major surgery within 14 days of first administration of study drug or has not recovered from adverse events as defined in the protocol
- Another malignancy that is progressing or requires active treatment except as noted in the protocol
- Untreated or active primary brain tumor, central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Encephalitis, meningitis, organic brain disease (eg Parkinson's disease) or uncontrolled seizures in the year prior to first dose of study therapy
- Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency as defined in the protocol. DESCRIPTION is Brief Summary:
The primary objective of the dose escalation (phase 1) part of the study is:

To assess the safety, tolerability and pharmacokinetics (PK) of the antibody drug conjugate (ADC) REGN5093-M114 in order to determine a maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) of REGN5093-M114 in patients with mesenchymal epithelial transition factor (MET) overexpressing non-small cell lung cancer (NSCLC).

The primary objective of the dose expansion (phase 2) part of the study is:

To assess preliminary anti-tumor activity of REGN5093-M114 in MET-overexpressed NSCLC as measured by the objective response rate (ORR)

The secondary objective of the dose escalation (phase 1) part of the study is:

To assess preliminary anti-tumor activity of REGN5093-M114 as measured by the ORR

The secondary objective of the dose expansion (phase 2) part of the study is:

To assess the safety, tolerability profile, and PK of REGN5093-M114 ADC and total antibody in each expansion cohort

The secondary objectives of both phases of the study are:

To evaluate other measures of preliminary anti-tumor activity
To assess immunogenicity to REGN5093-M114. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T14:09:05. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Regeneron Pharmaceuticals, Inc. DISEASE SITES is Lung.
88. TITLE is A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors. SHORT TITLE is Ph II Taletrectinib in Pts w/ Adv or Met ROS1 Positive NSCLC & Other Solid Tumors. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 years and older . DETAILED ELIGIBILITY is Eligibilities:
- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC or other solid tumors.
- Evidence of ROS1 fusion in tumor tissue determined by molecular assays as performed in Clinical Laboratory Improvement Amendments (CLIA)-certified or locally equivalent laboratories.
- Patients with central nervous system (CNS) involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously treated and controlled, are allowed; the use of seizure prophylaxis is allowed as long as patients are taking non enzyme inducing anti-epileptic drugs (non-EIAEDs). If corticosteroid treatment is required, it should be on stable or decreasing dose of &#8804;10 mg prednisone or equivalent. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment at least 14 days before enrollment and be clinically stable.
- The patient is either ROS1 TKI treatment na√Øve, or treated with prior ROS1 TKI(s).
Exclusion:
- Investigational agent or anticancer therapy within 2 weeks (or 5 half-lives of the compound, whichever is longer) prior to study enrollment. In addition, no concurrent anticancer therapy is permitted.
- Previously treated with immuno-oncology (IO) including immune checkpoint inhibitors within 12 weeks before enrollment.
- Major surgery within 4 weeks prior to enrollment.
- Radiation therapy with a limited field for palliation within 1 week of the first dose of study treatment.
- Toxicities due to prior therapy are unresolved to &#8804; CTCAE 5.0 Grade 1 except for AEs not constituting a safety risk to the patient based on the judgment of investigators.. DESCRIPTION is This is a global Phase 2, multicenter, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene.

119 patients will be enrolled and divided into 4 cohorts, depending on past history of ROS1 TKI treatment.

Taletrectinib will be administered 600mg once daily in 21-day cycles. Patients will continue with the study treatment until progression of disease as determined by the investigator.

The tumor response evaluation will be conducted on a regular basis until progression of disease. Long-term survival follow up will be conducted as well.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-06-01T13:12:58. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is AnHeart Therapeutics. DISEASE SITES is Lung.
89. TITLE is Phase Ib/II Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3). SHORT TITLE is Ph Ib/II Agents Targeting Mitogen-Activated Protein Kinase Pathway in Pts w/Adv Gastro Malignancies . INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
1. Have histologically or cytologically confirmed metastatic colorectal cancer (CRC) harboring applicable mutation(s) (e.g., BRAF V600E; KRAS or NRAS mutations) based on an analytically validated assay performed on tumor tissue in a certified testing laboratory
2. Willing to comply with all protocol-required visits, assessments, and procedures
3. Able to swallow oral medication

Exclusion Criteria:
1. Symptomatic brain metastasis or leptomeningeal disease.
2. Major surgery within 28 days of enrollment, or anticipation of major surgery during study treatment.
3. Pregnant or breastfeeding women
. DESCRIPTION is This study is being done to test ERAS-007 in combination with other drugs for the treatment of advanced or metastatic colorectal cancer.  The study is divided into sub-studies based on mutation status and number of prior therapies.  You are being asked to take part in this portion of the research study because you have been diagnosed with a type of advanced or metastatic colorectal cancer with a specific change (or mutation) in the BRAF gene (BRAF V600E).  This change leads to the uncontrolled growth and spread of the affected colon cells into colon cancer.  ERAS-007 in combination with other therapies is designed to target these mutations.  ERAS-007 is an investigational drug that has shown anti-cancer activity in animals and humans by blocking a cell pathway that contributes to cancer formation and progression.  Investigational means that the drug has not been approved by health authorities, such as the United States Food and Drug Administration (US FDA), for the treatment of people with your medical condition.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-03-23T10:29:40. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Erasca. DISEASE SITES is Colon, Pancreas, Rectum.
90. TITLE is Pilot Trial Comparing Circulating Tumor DNA (ctDNA) From Immediate Draining Vein vs. Standard Peripheral Vein Sample in Patients Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers. SHORT TITLE is Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hep & Pancreatic Ca. INVESTIGATOR NAME is Nadine Abi-Jaoudeh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of
study criteria to help you better understand how your eligibility in the study will be determined; your study
team will go through the study eligibility criteria with you to verify if you qualify for participation in this
study.

Inclusion Requirements
You can participate in this study if you
- Are 18 years of age or older
- Have or are undergoing work-up for hepatobiliary and/or pancreatic cancer
- Are scheduled for an image-guided percutaneous or trans-jugular biopsy of a lesion

Exclusion Requirements
You cannot participate in this study if you
- Have a gross body weight over 375 pounds
- Have moderate to severe ascites (abdominal swelling caused by accumulation of fluid)
and unable to undergo trans-jugular biopsy or sufficient drainage
- Cannot have a peripheral blood draw for ctDNA. DESCRIPTION is This is a, prospective single center pilot study to investigate whether ctDNA detection can be improved by sampling the cancer draining vein vs. a peripheral vein (current practice). As a secondary endpoint, both ctDNA results will be compared with percutaneous biopsy (standard of care).. TREATMENT TYPE DESC is Diagnostic. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-09-07T11:29:17. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Pancreas, Liver, Other Digestive Organ.
91. TITLE is A Phase I, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignances with Isocitrate Dehydrogenase (IDH) Mutations. SHORT TITLE is Ph I HMPL-306 in Adv Hematological Malignances w/ Isocitrate Dehydrogenase (IDH) Mutations. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is 	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding. DESCRIPTION is An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-07T13:10:56. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Hutchison MediPharma Limited. DISEASE SITES is Non-Hodgkin's Lymphoma, Leukemia, other, Other Hematopoietic, Hodgkin's Lymphoma, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia.
92. TITLE is A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer. SHORT TITLE is PhIIIDeEscalate of BreastRad for Tx of StgI, Horm Sensitive HER2- Onco Recur Score >/= to 18BreastCa. INVESTIGATOR NAME is Rita Mehta. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults, Older Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.
- The patient must be >= 50 years and < 70 years of age.
- The patient must have an ECOG performance status of 0 or 1.
- The trial is open to female and male patients.
- The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for LCIS are eligible without additional resection.)
- The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.

Exclusion Criteria: 
- Patient had a mastectomy.
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study therapy or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
- Use of any investigational product within 30 days prior to study entry.. DESCRIPTION is This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-02-24T20:31:05. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Breast.
93. TITLE is An Open-Label, Multi-Center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors. SHORT TITLE is Ph I/II MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria: 
- Understands and provides written informed consent and willing to follow the requirements specified in protocol.
- A negative serum pregnancy test (if female and aged between 18-55 years old). Women who are pregnant or breast feeding are not to be included.
- Must have histologically or cytologically confirmed unresectable or metastatic cancer with documented disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types&#8211; Part A and Part B 

Exclusion Criteria: 
- Concurrent malignancy within 5 years prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer, thyroid cancer not requiring treatment, ductal carcinoma in situ of the breast, or <T1 urothelial carcinoma
- Major surgery within 4 weeks of the first dose of study treatment and not fully recovered. Minor surgery within 2 weeks prior to study treatment.
- Any severe and/or uncontrolled systemic disease that at the discretion of investigator and sponsor makes it undesirable for the patient to participate in this study.. DESCRIPTION is The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-05-03T17:27:51. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Shanghai Miracogen Inc.. DISEASE SITES is Pancreas, Corpus Uteri, Breast, Urinary Bladder, Cervix.
94. TITLE is A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZDO171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors. SHORT TITLE is PhII AZDO171 in Combo w/Durvalumab &Chemo in Pts w/Local Adv orMet Solid Tumors. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 130 Years . DETAILED ELIGIBILITY is Inclusion Criteria:
You must have an Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment
You must have a Gustave Roussy Immune Score of 0 or 1
You must be diagnosed with histologically confirmed metastatic pancreatic adenocarcinoma
You must have at least 1 measurable lesion to be called a target lesion according to RECIST v1.1
You must consent to providing sufficient archival specimen taken during metastatic stage or fresh tumour specimens for tumoural CD8+ T cell testing for enrolment
You must have normal organ and bone marrow function measured within 28 days prior to first dose of study intervention
Your body weight must be greater than or equal to 35 kg. DESCRIPTION is The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-08-25T08:26:39. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is AstraZeneca. DISEASE SITES is Colon, Liver, Soft Tissue, Corpus Uteri, Kidney, Brain and Nervous System, Other Endocrine System, Ill-Defined Sites, Rectum, Pancreas, Bones and Joints, Cervix, Stomach, Eye and Orbit, Other Hematopoietic, Breast, Other Digestive Organ, Mycosis Fungoides, Other Skin, Thyroid, Kaposi's Sarcoma, Lip, Oral Cavity and Pharynx, Esophagus, Lung, Other Respiratory and Intrathoracic Organs, Anus, Ovary, Other Urinary, Unknown Sites, Small Intestine, Larynx, Other Female Genital, Prostate, Urinary Bladder, Melanoma, Skin.
95. TITLE is A Phase I/II Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors. SHORT TITLE is Ph I/II Study of Ozuriftamab Vedotin (BA3021) Alone & in Combo w/Nivolumab in Pts w/Adv Solid Tumors. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.
-For the dose expansion phase: Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS)
-Life expectancy of at least three months.

Exclusion Criteria:
-Patients must not have clinically significant cardiac disease. 
-Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
-Patients must not be women who are pregnant or breast feeding.. DESCRIPTION is This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active biologic (CAB) ROR2-targeted antibody drug conjugate (CAB-ROR2-ADC) BA3021 in patients with advanced solid tumors.

This study will consist of a dose escalation phase and a dose expansion phase with BA3021 in Phase 1. Phase 2 will study BA3021 alone or in combination with a PD-1 inhibitor.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-21T14:14:54. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Bioatla. DISEASE SITES is Lung.
96. TITLE is Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial. SHORT TITLE is Ph II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC. INVESTIGATOR NAME is Jeremy Harris. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria
- Pathologically proven diagnosis of extensive stage small cell lung cancer
- Patients with bone metastases are eligible 
- For women of childbearing potential, a negative serum or urine pregnancy test within 14 days prior to registration

Exclusion Criteria
-Metastatic disease invading the liver (>3 metastases), heart or >10 metastatic sites detectable after induction systemic therapy
-Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 5 years prior to randomization
-History of autoimmune disease
-Severe, active co-morbidity 
-Pregnancy or women who are breastfeeding and unwilling to discontinue.
-History of allogeneic organ transplant.
-Patients who have had immunotherapy-induced  pneumonitis.. DESCRIPTION is This study is being done to know if we extend the time without extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer (an immunotherapy drug called atezolizumab). As well to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for extensive stage small cell lung cancer.. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-05-24T15:28:00. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Lung. THERAPY NAMES is 
      .
97. TITLE is A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na√Øve Metastatic Anal Cancer Patients. SHORT TITLE is Ph III Immune Checkpoint Inhibition w/Chemo in Tx-Na√Øve Met Anal Ca Pts. INVESTIGATOR NAME is Jennifer Brooke Valerin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Eligibility Criteria:

You are eligible to participate if:

- You have inoperable, recurrent, or metastatic disease.
- You have confirmed anal cancer (includes basaloid and cloacogenic lesions).
- You are a woman and currently not pregnant or breast-feeding.
- You have not had prior immunotherapy. 
. DESCRIPTION is This study is being done to answer the following question: Will adding an immune checkpoint inhibitor to the usual combination of chemotherapy drugs help prevent your cancer from getting worse?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your anal canal cancer. The usual approach is defined as care most people get for na√Øve metastatic anal cancer. These treatments may reduce symptoms and may stop the tumor from growing for a few months or longer.
. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2021-12-14T09:39:02. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ECOG-ACRIN. DISEASE SITES is Anus.
98. TITLE is Gronigen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial. SHORT TITLE is Gronigen International Study on Sentinel Nodes in Vulvar Cancer: A Prospective Phase II . INVESTIGATOR NAME is Krishnansu Tewari. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Sexes Eligible for Study:	Female
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Histological confirmed primary SCC of the vulva
-T1 tumor, not encroaching urethra/vagina/anus
-Depth of invasion > 1mm
-Tumor diameter < 4cm
-Unifocal tumor
-No enlarged (>1.5cm) or suspicious inguinofemoral lymph nodes at imaging (CT/MRI/ultrasound)
-Possibility to obtain informed consent
-Metastatic sentinel lymph node; size of metastasis > 2mm and / or extracapsular extension, or
-Metastatic sentinel lymph node: more than 1 SN with metastasis greater than or equal to 2mm
-Patients are able to understand requirements of study, provide written informed consent and comply with the study and follow-up procedures
-Adequate bone marrow, renal and liver function:
-Absolute neutrophil count greater than or equal to  1.5 x 109 /L
-Platelet count greater than or equal t 100 x 109 /L
-Creatinine clearancegreater than or equal to  40 ml/min measured by the Cockroft Gault formula
-Total bilirubin < 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) greater than or equal to 2.5 x ULN
-Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A)
-Age 18 years or older
-Life expectancy of greater than or equal to12 weeks
-Written informed consent

Exclusion Criteria:

-Inoperable tumors and tumors > 4cm
-Multifocal tumors
-Tumors with other pathology than squamous cell carcinoma
-Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine needle aspiration cytology
-No other carcinomas, other than basal cell carcinomas, within last 5 years
-History of pelvic radiotherapy
-History of any infection requiring hospitalization or antibiotics within 2 weeks before enrollment
-Pregnant female or nursing mother
-Desire to become pregnant
-Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids
-Unstable angina, myocardial infarction, cerebrovascular accident, > Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment. DESCRIPTION is Vulvar cancer patients with SN-metastasis > 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-06-03T11:12:49. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Other Female Genital.
99. TITLE is A Multicenter, Open-Label, Phase II Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors. SHORT TITLE is Ph II  MK-7684A w/ or w/o Other Anticancer Therapies in Participants w/ Selected Solid Tumors. INVESTIGATOR NAME is Krishnansu Tewari. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is -18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

One of the following histologically or cytologically confirmed, advanced (locally recurrent unresectable or metastatic) solid tumors:

-Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
-Endometrial cancer
-Head and neck swuamous cell carcinoma (HNSCC)
-Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
-Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
-Triple-negative breast cancer (TNBC)
-Hepatocellular carcinoma (HCC)
-Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.
-Adequately controlled blood pressure (BP) with or without antihypertensive medications.
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).
-Male participants must agree to follow contraceptive guidance.
-Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.
-Adequate organ function.

Exclusion Criteria:

-History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
-Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
-Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
-Active autoimmune disease that has required systemic treatment in past 2 years.
-Active infection requiring systemic therapy.
-Concurrent active hepatitis B and hepatitis C virus infection.
-History of allogenic tissue/solid organ transplant.
-Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
-History of congestive heart failure or myocardial infarction within 6 months of treatment (for participants who will receive paclitaxel in their assigned allocation arm).. DESCRIPTION is The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-04-29T16:36:45. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Merck Sharp & Dohme Corp.. DISEASE SITES is Mycosis Fungoides, Corpus Uteri, Kaposi's Sarcoma, Lip, Oral Cavity and Pharynx, Esophagus, Colon, Larynx, Other Respiratory and Intrathoracic Organs, Cervix, Thyroid, Unknown Sites, Stomach, Pancreas, Other Skin, Prostate, Kidney, Other Urinary, Rectum, Other Endocrine System, Bones and Joints, Soft Tissue, Other Male Genital, Eye and Orbit, Brain and Nervous System, Melanoma, Skin, Liver, Other Digestive Organ, Lung, Ovary, Other Female Genital, Ill-Defined Sites, Small Intestine, Anus, Urinary Bladder, Other Hematopoietic, Breast.
100. TITLE is A Phase IB/III Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Cancer with FGFR2b Overexpression. SHORT TITLE is PhI/IIIBemarituzumab + Chemo &Nivo vsChemo & Nivo in Subj w/Prev Untreat Adv Gastric & GEC w/FGFR2b . INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
Adult with unresectable, locally advanced or metastatic (not amenable to curative therapy) histologically documented gastric or gastroesophageal junction adenocarcinoma.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Measurable disease or non-measurable, but evaluable disease, according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1)
You must have no contraindications to mFOLFOX6 chemotherapy or nivolumab

Exclusion Criteria:
Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway
Known positive human epidermal growth factor receptor 2 (HER2) status
Untreated or symptomatic central nervous system disease metastases and leptomeningeal disease
Peripheral sensory neuropathy grade 2 or higher
Clinically significant cardiac disease
Other malignancy within the last 2 years (exceptions for definitively treated disease)
Chronic or systemic ophthalmologic disorders
Major surgery or other investigational study within 28 days prior to randomization
Palliative radiotherapy within 14 days prior to randomization
Abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer
Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study. DESCRIPTION is The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab.

The main objective Part 2 is to compare efficacy of bemarituzumab plus mFOLFOX6 and nivolumab to placebo plus mFOLFOX6 and nivolumab as assessed by overall survival.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T08:48:04. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Amgen Inc.. DISEASE SITES is Esophagus, Stomach.
101. TITLE is A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies. SHORT TITLE is A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies. INVESTIGATOR NAME is Susan O'Brien. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- you or your legal representative can sign the informed consent


. DESCRIPTION is This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.
. PHASE DESC is I. TREATMENT TYPE DESC is Other. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-07-25T17:37:43. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Caribou Biosciences, Inc. . DISEASE SITES is Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Other Hematopoietic, Leukemia, other.
102. TITLE is A Phase IIa, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV). SHORT TITLE is PhIIa of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV). INVESTIGATOR NAME is Angela G Fleischman. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding. DESCRIPTION is The main purpose of this study is to evaluate the efficacy of IONIS-TMPRSS6-LRx in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-07-11T12:27:29. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Ionis Pharmaceuticals. DISEASE SITES is Other Hematopoietic.
103. TITLE is A Randomized Phase III Trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma. SHORT TITLE is PhIII Nivolumab in Combo w/ Chemo for the Tx of Newly Diagnosed Primary Mediastinal B-cell Lymphoma. INVESTIGATOR NAME is Elizabeth A Brem. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- are must be &#8805; 2 years of age



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding. DESCRIPTION is This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Both. SCOPE DESC is National. MODIFIED DATE is 2022-02-07T11:37:52. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is CHILDREN¬íS ONCOLOGY GROUP. DISEASE SITES is Non-Hodgkin's Lymphoma.
104. TITLE is Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk And Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (Predict-Rt*). SHORT TITLE is Parallel Ph III for High Risk Prostate Ca Evaluating De-Intensification & Intensification of Tx. INVESTIGATOR NAME is Steven Neema Seyedin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
- Pathologically proven diagnosis of adenocarcinoma of prostate cancer within 180 days prior to registration
- The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug

Exclusion Criteria: 
- Prior systemic chemotherapy within =< 3 years prior to registration; note that prior chemotherapy for a different cancer is allowed (completed > 3 years prior to registration)
- Prior radical prostatectomy
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. DESCRIPTION is This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-05-11T11:33:32. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Prostate. THERAPY NAMES is 
      .
105. TITLE is A Prospective, Multicenter, Open-Label Single Arm Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres Y-90 Resin Microspheres on Duration of Response (DoR) and Objective Response Rate (ORR) in Unresectable Hepatocellular Carcinoma (HCC) Patients (DOORwaY90 Study). SHORT TITLE is SIRT Using SIR-Spheres Y-90 Resin Microspheres on DoR & ORr in Unresectable HCC Patients . INVESTIGATOR NAME is Nadine Abi-Jaoudeh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
- Participants must be 18 or older at the time of consent.
-Participants must be willing, able, and mentally competent to provide written informed consent
- Participants must have a negative serum pregnancy test at baseline


Exclusion Criteria:
- Participants who have prior systemic anti-cancer therapy (including immunotherapy and/or targeted therapy), radiotherapy or use of other investigational agents for the treatment of HCC
-Participants who have planned localized cancer treatment to the liver, other than the study treatment, throughout the duration of the study
- Participants with prior liver resections and/or liver transplant. DESCRIPTION is The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C.

SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90 (Y-90), with a size between 20 and 60 microns in diameter. Y-90 is a high-energy pure beta-emitting isotope with no primary gamma emission.

SIR-Spheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1 and B2, maximal single lesion size of 8 cm, no macrovascular invasion, well-compensated liver function and good performance status. It is also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of Floxuridine (FUDR).. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-04-06T12:40:00. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Sirtex Medical Inc.. DISEASE SITES is Liver.
106. TITLE is AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEWLY DIAGNOSED CANCERS. SHORT TITLE is Ph I Study of IGM-8444 as a Single Agent & in Combo in Subjects w/ Relapsed &/or Refr Solid Cancers. INVESTIGATOR NAME is Warren A Chow. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is You can participate in this study if you are at least 18 years of age or older; have been clinically diagnosed with of locally advanced or metastatic cancer. You cannot participate in this study if you are pregnant or breast feeding; if you are using medication well known to cause liver toxicity.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-10-17T12:12:22. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is IGM Biosciences, Inc. DISEASE SITES is Small Intestine, Anus, Lung, Corpus Uteri, Kidney, Eye and Orbit, Stomach, Other Urinary, Other Endocrine System, Esophagus, Liver, Mycosis Fungoides, Ovary, Urinary Bladder, Breast, Kaposi's Sarcoma, Prostate, Melanoma, Skin, Pancreas, Other Skin, Other Male Genital, Unknown Sites, Colon, Bones and Joints, Cervix, Other Female Genital, Ill-Defined Sites, Lip, Oral Cavity and Pharynx, Larynx, Other Respiratory and Intrathoracic Organs, Soft Tissue, Thyroid, Rectum, Other Digestive Organ, Brain and Nervous System.
107. TITLE is A Randomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1. SHORT TITLE is Ph III Study of Sacituzumab Govitecan + Pembro v. Dr. Choice + Pembro in Pts w/ Trip-Neg Breast Ca. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria
-Participants must be at least 18 years of age
-Participants must have locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.
-Male and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.

Exclusion Criteria
-Participants who are pregnant or lactating
-Participants who have received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.
-Participants who have active serious infection requiring antibiotics.. DESCRIPTION is The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-27T11:05:02. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Gilead Sciences, Inc.. DISEASE SITES is Breast.
108. TITLE is A Phase III Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. SHORT TITLE is PhIII Pirtobrutinib + Venetoclax & Rituximab vs Venetoclax & Rituximab in PrevTreated CLL/SLL. INVESTIGATOR NAME is Catherine Coombs. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is You have been diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and have previously received at least one treatment that may include a BTK inhibitor for your disease and:
did not respond to that treatment, or
initially responded but your CLL/CLL later progressed on that treatment, or; 
experienced side effects that made it difficult to continue that treatment or
the decision to stop that treatment was made by you and your study doctor. DESCRIPTION is The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-09-28T13:07:37. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Loxo Oncology, Inc.. DISEASE SITES is Lymphoid Leukemia.
109. TITLE is Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors. SHORT TITLE is PhII Postop Adj Capecitabine & Temozolomide vs Obs in High-Risk Pancreatic Neuroendocrine Tumors. INVESTIGATOR NAME is Jennifer Brooke Valerin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older. DETAILED ELIGIBILITY is Inclusion Criteria:
Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 90 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam
Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report
Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be >= 3% and =< 55%. If more than one Ki-67 is reported (e.g., primary tumor versus lymph node or metastatic site), the highest one should be considered for the study eligibility criteria
Participants with localized resected pNETS must have a Zaidi score of >= 3 derived by the following factors and points:
1 point; symptomatic tumor defined as one of the following:
Gastrointestinal bleed
Jaundice
Gastrointestinal obstruction
Pain from primary tumor prior to surgical resection
Pancreatitis
2 points; primary pancreas tumor size > 2 cm
1 point; Ki-67 3% to 20%
1 point; lymph node positivity = 1
6 points; Ki-67 21% to 55%
Participants may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of well-differentiated pNET resection
Participants must have recovered from effects of surgery as determined by the treating investigator
Participants must be >= 18 years old
Participants must have Zubrod performance status of 0-2
Participants must have a complete medical history and physical exam within 28 days prior to registration
Leukocytes >= 3 x 10^3/uL (within 28 days prior to registration)
Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to registration)
Platelets >= 100 x 10^3/uL (within 28 days prior to registration)
Total bilirubin =< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN (within 28 days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional ULN (within 28 days prior to registration)
Serum creatinine =< 1.5 x institutional ULN (within 28 days prior to registration)
Calculated creatinine clearance >= 50 ml/min (within 28 days prior to registration)
Participants must be able to swallow pills
Participants must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol
No other active malignancy or history of prior malignancy is allowed, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Exclusion Criteria:
Participants must not have unresected or unablated metastatic disease
Participants must not have clinically apparent central nervous system metastases or carcinomatous meningitis
Participants must not have received prior neoadjuvant therapy for treatment of pancreatic neuroendocrine tumor. Use of somatostatin analogs prior to surgery is permitted. DESCRIPTION is This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-07-07T09:10:39. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Pancreas.
110. TITLE is A Phase IB Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination with Docetaxel in Subjects with Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201). SHORT TITLE is PhIB of Bemarituzumab Monotherapy & Combo w/ Docetaxel in Subjects w/ Squamous-Cell NSCLC. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Inclusion Criteria:

Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures
Age &#8805; 18 years old (or legal adult within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed
Pathologically confirmed squamous cell lung carcinoma
Disease that is unresectable, locally advanced or metastatic (not amenable to curative therapy)
Participant must have progressed on, or recurred after at least 1 prior systemic therapy (Part 1 and 2 only) or at least 2 prior systemic therapies (Part 3 only) for locally advanced and unresectable or metastatic disease. Prior treatment must include a platinum-based doublet chemotherapy and checkpoint inhibitor for advanced or metastatic disease, either given as one line of therapy or as individual lines of therapy, unless the participant has a medical contraindication to one of the required therapies (which must be documented in the electronic case report form [eCRF]). Additionally, if the participant's tumor was previously identified as having a driver mutation (according to local standard of care or guidelines, e.g., Kirsten rat sarcoma [KRAS] G12C, neurotrophic tyrosine receptor kinase [NTRK]), which has an approved therapy for which the participant is eligible and available, the participant must have received the approved therapy in a prior line of treatment.
For Part 4, participants may not have received prior systemic therapy for their locally advanced and unresectable or metastatic disease. For Part 4, participants who received peri-operative systemic therapy are eligible if that adjuvant/neoadjuvant therapy was completed at least 12 months prior to diagnosis of locally advanced and unresectable or metastatic disease.
Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ function as determined per protocol
Part 2, 3 and 4 only: FGFR2b overexpression as determined by centrally performed immunohistochemistry (IHC) testing. DESCRIPTION is 18 Years to 99 Years   (Adult, Older Adult). PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-28T20:31:09. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Amgen Inc.. DISEASE SITES is Lung.
111. TITLE is An Open-Label, Multicenter, Phase II Study of Sacituzumab Govitecan Combinations in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations. SHORT TITLE is PhIISacituzumab Govitecan Combos in 1st-Line Tx of Pts w/Adv or Met NSCLC w/oActionable Genome Alter. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is If you decide to take part in this study, there are some rules you must follow.  Some of the rules are listed below.  There could be other rules that your study doctor will review with you.

1. You must not get pregnant or get someone pregnant during this study.
2. It is very important that you tell your study doctor all of the information you know about your health and medications you are taking now or start taking while in the study.  If you do not tell the study doctor everything you know, you may be putting your health at risk.
3. You are not allowed to take certain medications while in the study treatment phase of this study. Please consult with your study doctor to see what medications you may not take.
4. You must follow all instructions given to you while you are taking part in this study.  If you do not, you may no longer be able to take part in the study.  If you are unsure about what you are supposed to do, ask your study doctor.
. DESCRIPTION is The primary objectives of the study are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of SG in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin) in participants with advanced or metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-08-15T17:26:55. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Gilead Sciences, Inc.. DISEASE SITES is Lung.
112. TITLE is A Novel Method for Treating Lung Metastases with the Combination of Electrical Fields and Radiation Therapy: A Single-Arm Pilot Study . SHORT TITLE is A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm . INVESTIGATOR NAME is Jeremy Harris. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria:
-18 years of age or older 
- Patients must have histologically or cytologically confirmed metastatic cancer of any histology and have at least one lung tumor
Patients must have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.

Exclusion Requirements
You cannot participate in this study if you satisfy the following criteria:
- Pregnant or nursing
- Receiving any other investigational agents. DESCRIPTION is This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.. PHASE DESC is Early Phase I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2023-01-06T12:12:35. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Lung. THERAPY NAMES is 
      .
113. TITLE is A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinectics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors. SHORT TITLE is PhI KT-333 in Adult Patients w/ R/R Lymphomas, Large Granular Lymphocytic Leukemia, & Solid Tumors. INVESTIGATOR NAME is Lauren C Pinter-Brown. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding. DESCRIPTION is This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), and solid tumors.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-21T10:02:14. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Kymera Therapeutics. DISEASE SITES is Colon, Rectum, Other Digestive Organ, Other Respiratory and Intrathoracic Organs, Soft Tissue, Mycosis Fungoides, Other Male Genital, Eye and Orbit, Lip, Oral Cavity and Pharynx, Other Skin, Thyroid, Melanoma, Skin, Larynx, Lung, Urinary Bladder, Ill-Defined Sites, Esophagus, Stomach, Liver, Prostate, Non-Hodgkin's Lymphoma, Unknown Sites, Bones and Joints, Ovary, Kidney, Brain and Nervous System, Other Endocrine System, Lymphoid Leukemia, Kaposi's Sarcoma, Small Intestine, Anus, Pancreas, Cervix, Hodgkin's Lymphoma, Breast, Corpus Uteri, Other Female Genital, Other Urinary.
114. TITLE is A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinectics of Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients with Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma. SHORT TITLE is PhIBGlofitamab Combo w/Rituximab+Ifosfamide CarboplatinEtoposidePhosphate in Pts w/R/R TransEligDBCL. INVESTIGATOR NAME is Lauren C Pinter-Brown. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female 18 years of age at signing of the informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant. DESCRIPTION is The purpose of this study is to evaluate the preliminary efficacy, safety, and pharmacokinetics of glofitamab (glofit) in combination with rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have failed one prior line of therapy incorporating an anti-cluster of differentiation (CD) 20 antibody (i.e., rituximab) and an anthracycline, and who are transplant or chimeric antigen receptor T-cell (CAR-T) therapy eligible, defined as being medically eligible for intensive platinum-based salvage therapy followed by autologous stem cell transplantation (ASCT) or for CAR-T therapy.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-16T09:11:58. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is F. Hoffmann-La Roche Ltd. DISEASE SITES is Non-Hodgkin's Lymphoma.
115. TITLE is Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations. SHORT TITLE is PhII Olaparib + Pembrolizumab vs. Olaparib in Met Pancreatic Ca Pts w /Germline BRCA1 or BRCA2 Mut. INVESTIGATOR NAME is Jennifer Brooke Valerin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Eligibility Criteria:

- Patient must have histological or cytological diagnosis of pancreatic adenocarinoma.
- Patient must have one of the following mutations: germline mutation in BRCA 1 or 2 from a CLIA certified lab defined as positive and/or deleterious (pathogenic or likely pathogenic variant).
- Patient must have metastatic disease and received first line platinum-based chemotherapy (i.e. FOLFIRINOX, FOLOFX, gemcitabine + nab-paclitaxel + cisplatin or gemcitabine + cisplatin). . DESCRIPTION is The purpose of this study is to compare the usual treatment (olaparib) alone to using pembrolizumab plus the usual treatment.  The addition of pembrolizumab to the usual treatment could help to shrink your cancer   but, it could also cause side effects. This study will help the study doctors find out if this different approach is  better, the same, or worse than the usual approach.  To decide if it is better, the study doctors will be looking to see if the study drug pembrolizumab increases the time it takes for the cancer to grow  by 5 months or more compared to the usual approach.  

Olaparib alone has been approved as maintenance therapy for patients with germline BRCA1 or BRCA2 mutated pancreatic cancer. . PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-02-23T12:07:43. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Pancreas.
116. TITLE is Phase I, Open-Label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients with Advanced Solid Tumor. SHORT TITLE is Ph I, Preliminary Efficacy Modified Salmonella Typhimurium SGN1 Pts Adv Solid Tumor. INVESTIGATOR NAME is Warren A Chow. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
1. Age 18-75 years inclusive of end value, regardless of gender.
2. Part 1: Patients with advanced stage (unresectable or metastatic) cancer including but not limited to small cell lung cancer, non-small cell lung cancer (adeno- and squamous), Hodgkin's lymphoma or non-Hodgkin's lymphoma, sarcoma, cervical carcinoma, melanoma, head and neck cancer, breast cancer, ovarian cancer, pseudomyxoma peritoneum (Pseudomyxoma peritonei, PMP) and hepatocellular carcinoma characterized by failure of standard treatment (disease progression or intolerance, such as chemotherapy, targeted therapy, and other immunotherapies) or patients who have no standard treatment or patients who are unable to receive standard treatment.

Part 3: Patients who meet all the standards above and should be the selected tumor type according to part1&2.

3. Patients must be able to follow up after the treatment.

Exclusion Criteria: 
1. Currently using antibiotic.
2. Tumors in hollow organs (Stomach, esophagus, intestine, urinary tract etc.).
3. Vaccination within 28 days of the first trial treatment, except for administration of inactivated vaccines and RNA vaccines (e.g., inactivated influenza vaccines and COVID-19 RNA vaccines). DESCRIPTION is To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1, a genetically modified strain of Salmonella enterica, serotype typhimurium that expresses L-Methioninase,in participants with refractory solid tumors. 

The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. 

The treatment populations shall be patients presenting with histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy and for which no other conventional therapy exists.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-28T16:15:43. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Guangzhou Sinogen Pharmaceutical Co., Ltd.. DISEASE SITES is Mycosis Fungoides, Other Skin, Melanoma, Skin, Kaposi's Sarcoma, Soft Tissue.
117. TITLE is An Open-Label, Phase IB Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndrome (LR MDS) Who are Refractory/Resistant to Prior Therapies . SHORT TITLE is Ph IB Study of R289 in Pts w/ LR MDS Who are Refractory/Resistant to Prior Therapies. INVESTIGATOR NAME is Piyanuch Kongtim. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is If you decide to participate in the study, some tests will be done to see if you are eligible. If the test results show that you meet the study requirements, then you will be able to start the study. If the test results show that you do not meet the study requirements, you will not be able to participate. . DESCRIPTION is The study will be an open-label, Phase 1b study of R289 to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed, refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), thrombopoietin (TPO), luspatercept, or hypomethylating agents (HMAs) for MDS.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-01T13:33:57. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Rigel Pharmaceuticals, Inc.. DISEASE SITES is Myeloid and Monocytic Leukemia.
118. TITLE is A Phase I/II Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1). SHORT TITLE is Ph I/II Study of NVL-655 Patients with Advanced NSCLC and Other Solid Tumors. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Criteria:

1. Age = or > 18 years
2. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.
3. Phase 2
a. Cohorts 2a, 2b, and 2c: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement
b. Cohort 2d: histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation
4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1
5. Adequate organ function and bone marrow reserve

Exclusion criteria:
1. Patient's cancer has a known oncogenic driver alteration other than ALK.
2. Known allergy/hypersensitivity to excipients of NVL-655.
3. Major surgery within 4 weeks of the study entry
4. Ongoing or anticancer therapy
5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.. DESCRIPTION is Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.

Phase 1 will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors.

Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-09-09T16:40:25. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Nuvalent, Inc.. DISEASE SITES is Small Intestine, Other Respiratory and Intrathoracic Organs, Soft Tissue, Mycosis Fungoides, Ovary, Colon, Larynx, Lung, Other Female Genital, Lip, Oral Cavity and Pharynx, Pancreas, Urinary Bladder, Brain and Nervous System, Breast, Rectum, Anus, Prostate, Kidney, Melanoma, Skin, Kaposi's Sarcoma, Esophagus, Thyroid, Unknown Sites, Stomach, Other Digestive Organ, Bones and Joints, Cervix, Corpus Uteri, Other Urinary, Liver, Other Skin, Other Male Genital, Eye and Orbit, Other Endocrine System, Ill-Defined Sites.
119. TITLE is A First-in-Human, Multicenter, Open-Label, Phase I Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies Including Lymphoma. SHORT TITLE is Ph I study of TAB004 as Monotherapy &in Combo w/ Toripalimab in Pts w/Adv Solid Tumors inc. Lymphoma. INVESTIGATOR NAME is Warren A Chow. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults with advanced unresectable or metastatic solid tumors or relapsed/refractory lymphoma.
. DETAILED ELIGIBILITY is Inclusion
- Male or female; 18 years or older
- Patients with histologically or cytologically confirmed advanced unresectable or metastatic solid tumors or lymphoma that have progressed following prior treatment.
- Adequate organ and marrow function. 
- Willingness to provide an archival tumor sample obtained within the past 2 years or agreement to undergo a pre-treatment biopsy from safely accessible lesions to provide a tumor sample if such an archival specimen cannot be provided. For patients who cannot provide a fresh pre-treatment biopsy, and a recent sample from the past 2 years is not available, the most recent accessible archival specimen will be required. 
- Females of childbearing potential who are sexually active with a non-sterilized male partner must use effective contraception from time of screening, and must agree to continue using such precautions for 90 days after the final dose of TAB004 or toripalimab; cessation of birth control after this point should be discussed with a responsible physician.
- Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as at least 12 months with no menses confirmed by follicle-stimulating hormone [FSH] levels.
- Patients must use effective contraception. 
- Non-sterilized males who are sexually active with a female partner of childbearing potential must use effective contraception from Day 1 and for 90 days after the receipt of the final dose of TAB004 or toripalimab.

Exclusion 
- Pregnant or breastfeeding women. 
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study. 
- Any concurrent anti-cancer therapy, such as but not limited to chemotherapy, targeted therapy, radiotherapy, immunotherapy, or biologic therapy. 
- Receipt of any investigational anticancer therapy within 28 days prior to the first dose of TAB004.
- Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of TAB004. 
- Prior exposure to anti-BTLA or anti-HVEM antibodies.
- Prior allogeneic bone marrow transplantation or prior solid organ transplantation. 
- Patients with another malignancy that has not been curatively treated.
- Major surgery within 28 days prior to first dose of TAB004.
- Unresolved toxicities from prior anticancer therapy. 
- Active or prior documented autoimmune disease. 
- Clinically significant (intracranial, gastrointestinal) bleeding within 2 weeks prior to screening. 
- Known history of tuberculosis. 
- History of or current drug-induced interstitial lung disease or pneumonitis. 
- Subjects who have discontinued prior immune therapy due to immune mediated adverse reaction(s). 
- Known to be human immunodeficiency virus (HIV) positive. 
- Evidence of hepatitis B or C virus infection.
- Active or prior documented inflammatory bowel disease (e.g., Crohn&#8217;s disease, ulcerative colitis).
- History of anaphylaxis or eczema that cannot be controlled with topical corticosteroids. 
- Adult asthma that is moderate or severe, or asthma.
- Uncontrolled intercurrent illness.
- Untreated central nervous system (CNS) and leptomeningeal metastases or requiring ongoing treatment for these metastases, including corticosteroids. 
- Receipt of live attenuated vaccination within 28 days prior to study entry or within 30 days of receiving TAB004. . PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-07-15T13:18:37. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is TopAlliance Biosciences, Inc.. DISEASE SITES is Rectum, Liver, Ovary, Other Urinary, Lymphoid Leukemia, Breast, Other Digestive Organ, Prostate, Other Endocrine System, Stomach, Bones and Joints, Corpus Uteri, Kaposi's Sarcoma, Esophagus, Lung, Lip, Oral Cavity and Pharynx, Colon, Cervix, Melanoma, Skin, Small Intestine, Anus, Larynx, Other Respiratory and Intrathoracic Organs, Mycosis Fungoides, Other Skin, Brain and Nervous System, Unknown Sites, Pancreas, Other Female Genital, Other Male Genital, Urinary Bladder, Eye and Orbit, Thyroid, Non-Hodgkin's Lymphoma, Soft Tissue, Kidney, Hodgkin's Lymphoma, Ill-Defined Sites.
120. TITLE is A Phase II Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor. SHORT TITLE is BA3011 Alone & in Combinationw/Nivolumab in Adult Patientsw/Met on a PD-1/L1, EGFR, or ALK Inhibitor. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is You need to have the following exams, tests or procedures to find out if you can be in the study:

- You will be asked about your health history including any surgeries you've had and the treatments you've received for your cancer. 
- Complete physical exam 
- Performance status assessment, to see how able you are to perform your daily activities. 
- Measurement of your height and weight
- Vital sign measurements, including blood pressure, heart rate, breathing (respiratory) rate, and body temperature.
- Routine blood tests [about 13 mL or 2 ¬Ω teaspoons of blood (in total)] to test your:

- blood counts (white blood cells, red blood cells, etc.),
- liver, kidney, and thyroid function,
- cholesterol while fasting (no food within 6 hours),
- blood clotting ability.

- Blood test [about 1.5 mL or ¬º teaspoon of blood] for specific viruses, including hepatitis B and hepatitis C, and HIV. If you have positive test results for HIV or Hepatitis B or C, we will notify you. We are required to notify state health authorities of positive results.
- Routine urine testing
- Blood or urine test for pregnancy, if you are a woman who is capable of childbearing (unless you have had a hysterectomy or your tubes tied, or you are in menopause and your last menstrual period was at least 1 year ago). 
 
- Evaluation of the location and size of your cancer will be performed. 

- Your doctor may use different types of imaging, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), clinical exam or some combination of these tests.

- Electrocardiogram (ECG): a test that measures the electrical activity of your heart by using electrodes placed on your body. This assessment is not invasive which means that it does not involve the introduction of instruments or other objects into the body or body cavities.
-You will be asked about all medications (including over-the-counter and herbal remedies) you are taking and have taken in the past month.
- You will be asked to describe any symptoms you are currently experiencing.. DESCRIPTION is The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-09-08T16:37:50. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Bioatla. DISEASE SITES is Lung.
121. TITLE is An Open-label, Randomized, Multicenter, Phase III Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04). SHORT TITLE is Trastuzumab Deruxtecan, NSCLC Harboring HER2 Exon 19 or 20 Mutations. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults . DETAILED ELIGIBILITY is Inclusion Criteria:
-Participants at least 18 years of age
-Locally advanced not amenable to curative therapy, or metastatic disease
-Histologically documented non-squamous NSCLC with HER2 mutation in exons 19 or 20 by tissue NGS or ctDNA
-Treatment-na√Øve for palliative intent systemic therapy for locally advanced or metastatic disease
-Left ventricular ejection fraction (LVEF) &#8805; 50%
-Measurable disease assessed by Investigator based on RECIST 1.1
-Protocol-defined adequate organ function including cardiac, renal, hepatic function
-ECOG 0-1
-Having tumour tissue available for central testing

Exclusion Criteria:

-Tumors with targetable alterations to EGFR (or other targetable mutations including but not limited to ALK, if routinely tested as a targetable alteration with approved available therapy)
-Any clinically active brain metastases; previously treated brain metastases allowed
-Active autoimmune or inflammatory disorders
-Medical history of myocardial infarction within 6 months prior to randomization
-History of non-infectious pneumonitis/ILD, current or suspected ILD
-Lung-specific intercurrent clinical significant severe illness
-Contraindication to platinum-based doublet chemotherapy or pembrolizumab. DESCRIPTION is Eligible participants will be those diagnosed with unresectable, locally advanced or metastatic histologically documented non-squamous NSCLC with HER2 exons 19 or 20 mutations and who are treatment-na√Øve for palliative intent systemic therapy for locally advanced or metastatic disease.

The study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) as compared with Standard of Care treatment (Investigator's choice of cisplatin or carboplatin + pembrolizumab + pemetrexed). This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse or simply to live longer, compared to patients receiving standard of care treatment. This study is also looking to see how the treatment and the cancer affects patients' quality of life.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-10-21T12:43:16. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is AstraZeneca. DISEASE SITES is Lung.
122. TITLE is A Phase III Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma. SHORT TITLE is PhIII of Axicabtagene Ciloleucel vs SOC Therapy in Subj w/ Relapsed/Refractory Follicular Lymphoma. INVESTIGATOR NAME is Elizabeth A Brem. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female 18 years of age at signing of the informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant. DESCRIPTION is The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-04-03T14:51:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Kite Pharma. DISEASE SITES is Non-Hodgkin's Lymphoma.
123. TITLE is A Phase Ib/II Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma. SHORT TITLE is BXQ-350 in Combination w/mFOLFOX7 & Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma. INVESTIGATOR NAME is Fa Chyi Lee. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older. DETAILED ELIGIBILITY is Inclusion Criteria:
8 years of age at the time of signing the informed consent.
You have newly diagnosed Stage IV metastatic adenocarcinoma of the colon / rectum.
You have a life expectancy > 3 months.
You have acceptable liver function defined as:
Total serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for the study site; in participants with known Gilbert Syndrome, total bilirubin less than or equal to; 3 x ULN, with direct bilirubin less than or equal to; 1.5 x ULN).
Aspartate transaminase (AST), serum glutamic oxaloacetic transaminase (SGOT), alanine transaminase (ALT), serum glutamic pyruvic transaminase (SGPT) less than or equal to; 3 x ULN (if liver metastases are present, then less than or equal to; 5 x ULN is allowed).
Serum albumin greater than or equal to; 3 g/ dL.
You have acceptable renal function defined as:
Creatinine clearance greater than or equal to; 50 mL/minute calculated using the Cockcroft-Gault formula (Cockcroft 1976): CCr = {((140 - age) x weight kg) / (72 x SCr)} x 0.85 (if female).
Urine dipstick protein < 1 + (30 - 70 mg/dL), urine protein/creatinine ratio of < 1, OR 24 hour urine protein < 1g/24 hours.
You have acceptable bone marrow function defined as:
Absolute neutrophil count greater than or equal to 1,500 cells / mm3.
Platelet count greater than or equal to 100,000 cells / mm3 (unsupported, no transfusion within 7 days of enrollment).
Hemoglobin > 9.0 g/dL (unsupported, no transfusion within 7 days of enrollment).
You have acceptable coagulation parameters (anti-coagulation allowed) defined as:
International normalized ratio less than or equal to 2 x ULN unless on anticoagulation or prothrombin time within normal limits.
Activated partial thromboplastin time within normal limits.
You have a negative serum pregnancy test result at screening (females of childbearing potential [FCBP] only). Not applicable to participants who are surgically sterile (i.e., bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or who are post-menopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. FCBP whose partner(s) are non-sterilized males and non-sterilized male participants whose sexual partner(s) are FCBP must abstain from heterosexual activity or agree to use an acceptable method of contraception according to the following guidelines:
The reliability of sexual abstinence for male and/or female enrollment eligibility needs to be evaluated in relation to the duration of the entire period of risk associated with study interventions and the preferred and usual lifestyle of the participant. Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post ovulation methods), the rhythm method, and withdrawal are not acceptable methods of contraception.
Non-sterilized Male Participants:
Must use an acceptable method of contraception such as male condom plus spermicide during the entire period of risk associated with study interventions which includes the total duration of the study and the drug washout period (6 months after the last dose of study intervention) and refrain from sperm donation or banking throughout this period.. DESCRIPTION is The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-07-22T10:22:36. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Bexion Pharmaceuticals, Inc.. DISEASE SITES is Colon, Rectum.
124. TITLE is A Phase II/III, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer. SHORT TITLE is GRT-C901/GRT-R902, A Neoantigen Vaccine, for Pts W/Metastatic Colorectal Ca. INVESTIGATOR NAME is Fa Chyi Lee. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
You have histologically confirmed metastatic colorectal cancer (CRC) who are planned for, or have received <30 days of first-line treatment in the metastatic setting with FOLFOX/bev, CAPEOX/bev, FOLFOXIRI/bev, or CAPOXIRI/bev per SOC
Measurable and unresectable metastatic disease according to RECIST v1.1
Availability of formalin-fixed paraffin-embedded (FFPE) tumor specimens.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You have adequate organ function per defined criteria
If you are of childbearing potential (WCBP), you must be willing to undergo pregnancy testing and agrees to the use at least 1 highly effective contraceptive method during the study treatment period and for 150 days after last investigational study treatment.

Exclusion Criteria:
Patients with deficient mismatch repair (dMMR) or microsatellite instability (MSI-H) phenotype
Patient has a known tumor mutation burden <1 non-synonymous mutations/megabase
Known DNA Polymerase Epsilon mutations
Patients with known BRAFV600E mutations
Bleeding disorder or history of significant bruising or bleeding following IM injections or blood draws
Immunosuppression anticipated at time of study treatment
History of allogeneic tissue/solid organ transplant
Active or history of autoimmune disease or immune deficiency
Patient with symptomatic or actively progressing central nervous system (CNS) metastases, carcinomatous meningitis, or has been treated with whole brain radiation
History of other cancer within 2 years with the exception of neoplasm that has undergone potentially curative therapy
Any severe concurrent non-cancer disease that, in the judgment of the Investigator, would make the patient inappropriate for the current study
Active tuberculosis or recent (<2 weeks) clinically significant infection, evidence of active hepatitis B or hepatitis C, or known history of positive test for HIV
History of pneumonitis requiring systemic steroids for treatment (with the exception of prior resolved in-field radiation pneumonitis)
Myocardial infarction within previous 3 months, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure
Pregnant, planning to become pregnant, or nursing.. DESCRIPTION is The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.
. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Both. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T09:54:52. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Gritstone bio, inc.. DISEASE SITES is Colon, Rectum.
125. TITLE is A Phase I First-in-Human Dose-Escalation and Dose-Escalation and Dose-Expansion Study of BMF-219, an Oral, Covalent, Menin Inhibitor, in Adult Patients with Acute Leukemia (AL), Diffuse Large B-Cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL). SHORT TITLE is PhI BMF-219 in Adult Patients w/ AL, DLBCL, & MM . INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female ages &#8805; 55 years at the time of informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant. DESCRIPTION is A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia, acute lymphocytic leukemia with KMT2A/ MLL1r, NPM1 and other mutations.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-07T20:36:20. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Biomea Fusion, Inc.. DISEASE SITES is Multiple Myeloma, Leukemia, other, Non-Hodgkin's Lymphoma.
126. TITLE is Open-Label, Multicenter, Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase, in Subjects with Advanced Solid Tumors. SHORT TITLE is Ph I Study of CB-03-10 with in Subjects with Advanced Solid Tumors. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older. DETAILED ELIGIBILITY is INCLUSION CRITERIA:

Signed informed consent For Part 1 (Dose Escalation): Histologically or cytologically confirmed relapsed or refractory locally advanced or metastatic solid tumor, not amenable to standard therapy For Part 2 (Dose Expansion): Histologically or cytologically confirmed relapsed or refractory locally advanced or metastatic solid tumor limited to a specific tumor subtype as determined by the SRC Age >18 years Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 For Part 1 (Dose Escalation): Measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria For Part 2 (Dose Expansion): Measurable disease as per RECIST v1.1 criteria. Adequate renal, hepatic and bone marrow function as defined by Screening labs Negative pregnancy test for females of childbearing potential at the Screening Visit and use of appropriate method of birth control.

EXCLUSION CRITERIA:

Pregnant or breastfeeding women Known central nervous system (CNS) metastases or spinal cord compression Known second cancer of other primary origin (excluding Stage I non-melanoma skin cancer and prostate cancer controlled with hormonal therapy) within the prior 5 years Active autoimmune disease Significant cardiac disease Uncontrolled hypertension Major surgery or irradiation within 28 days prior to start of study treatment Fewer than 28 days (or fewer than 5 half-lives, whichever is shorter) from prior anticancer therapy Requirement for chronic corticosteroids or other immunosuppressant drugs Known infection with hepatitis B or C virus Known infection with HIV and CD4+ T-cell counts < 350 cells/uL Patients with an opportunistic infection within the past 12 months.. DESCRIPTION is Subjects will undergo baseline evaluation and an assessment of extent of disease.

Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a modified Fibonacci schema using a standard oncology 3+3 study design to define an MTD and a RP2D. Plasma PK samples will be collected at predetermined timepoints for all subjects.

Subjects in Part 2 (Dose Expansion) of the study will receive CB-03-10 at the RP2D determined in the Part 1 of the study. The indications included in each group will be determined at the completion of Part 1 of the study by Safety Review Committee (SRC).

Subjects will be evaluated weekly initially (for 2 cycles in Part 1 and for 1 cycle in Part 2) and every 2 weeks thereafter. Reassessment of disease will be conducted at Week 8 and every 8 weeks thereafter. Subjects with evidence of response (partial or complete) will be re-evaluated at least 4 weeks later for confirmation.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-09-30T10:32:23. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Cosmo Technologies, Ltd.. DISEASE SITES is Soft Tissue, Prostate, Lip, Oral Cavity and Pharynx, Esophagus, Lung, Other Respiratory and Intrathoracic Organs, Bones and Joints, Cervix, Other Female Genital, Brain and Nervous System, Ill-Defined Sites, Breast, Kaposi's Sarcoma, Rectum, Corpus Uteri, Ovary, Urinary Bladder, Anus, Liver, Pancreas, Other Digestive Organ, Larynx, Thyroid, Other Skin, Eye and Orbit, Small Intestine, Colon, Other Male Genital, Kidney, Stomach, Unknown Sites, Mycosis Fungoides, Other Urinary, Other Endocrine System, Melanoma, Skin.
127. TITLE is A Phase Ib/II, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301). SHORT TITLE is A Phase Ib/II Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression . INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria
-Participants must be at least 18 years of age
-Participants must have a disease that is unresectable, locally advanced or metastatic

Exclusion Criteria
-Participants who have an active infection requiring systemic treatment or any uncontrolled infection within 14 days prior to first dose of study treatment
-Participants who are unwilling to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment
- Participants who are breastfeeding, plan to breastfeed or become pregnant while on study through 90 days after the last dose of bemarituzumab. DESCRIPTION is The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.. PHASE DESC is I/II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-27T09:47:19. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Amgen Inc.. DISEASE SITES is Corpus Uteri, Colon, Cervix, Rectum, Ovary, Esophagus, Anus, Small Intestine, Larynx, Breast, Stomach, Other Digestive Organ, Other Female Genital, Eye and Orbit.
128. TITLE is A Phase Ib, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors. SHORT TITLE is Phase Ib Study of XMT-1660 in Solid Tumors Likely to Express B7-H4. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria
-Participants must be at least 18 years of age
-Participant has proven recurrent or advanced solid tumor and has disease progression
after treatment with available anti-cancer therapies known to confer benefit or is
intolerant to treatment
-Participant must be willing to undergo a minimally invasive tumor biopsy to obtain tumor
tissue for local testing, if medically feasible, prior to C1D1.

Exclusion Criteria
-Participant has received prior treatment with another ADC containing an auristatin or
maytansinoid payload (e.g., mirvetuxuximab)
-Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy within 14 days of starting study treatment.
-Participants with human immunodeficiency virus (HIV) infection are excluded from
study entry. An HIV test is required during Screening. DESCRIPTION is A Study of XMT-1660 in Solid Tumors. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-12-28T14:28:44. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Mersana Therapeutics, Inc.. DISEASE SITES is Lip, Oral Cavity and Pharynx, Colon, Pancreas, Larynx, Soft Tissue, Corpus Uteri, Stomach, Lung, Rectum, Anus, Other Digestive Organ, Ovary, Brain and Nervous System, Other Respiratory and Intrathoracic Organs, Other Urinary, Bones and Joints, Other Male Genital, Thyroid, Unknown Sites, Ill-Defined Sites, Melanoma, Skin, Liver, Other Skin, Kidney, Breast, Esophagus, Small Intestine, Cervix, Other Female Genital, Prostate, Urinary Bladder, Eye and Orbit, Other Endocrine System.
129. TITLE is A Phase II Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
. SHORT TITLE is Ph II Disitamab Vedotin Alone & Comb w/Pembrolizumab in Adv Unresect or Metastat Urothelial Ca HER2. INVESTIGATOR NAME is Nataliya Mar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
- Expected survival >=12 weeks
- Histologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra

Exclusion Criteria:
- Known hypersensitivity to disitamab vedotin, pembrolizumab (in Cohort C), or any of their components
- Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study
- Major surgery that has not fully recovered within 4 weeks prior to dose administration. DESCRIPTION is This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-08T09:01:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Seagen Inc. DISEASE SITES is Urinary Bladder.
130. TITLE is Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer. SHORT TITLE is Tailor RT: Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer. INVESTIGATOR NAME is Erin Heather Healy. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults 35 years and older. DETAILED ELIGIBILITY is The study population consists of women with newly diagnosed biomarker low risk node positive and T3N0 breast cancer with no evidence of metastases that have been treated by mastectomy or BCS.

Inclusion Criteria: 
- Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care.
- Patient must consent to provision of, and investigator(s) must agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted.
- Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted.

Exclusion Criteria: 
- Patients who are pregnant
- Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator&#8217;s decision).. DESCRIPTION is The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-05-03T13:59:28. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Canadian Cancer Trials Group (CCTG). DISEASE SITES is Breast.
131. TITLE is A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma. SHORT TITLE is PhII Immune Checkpoint Combos w/Axitinib in Pts w/Prev Untreated Local AdvUnresec or Metastatic RCC. INVESTIGATOR NAME is Nataliya Mar. STATUS is RRI SIGNOFF. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
- Measurable disease with at least one measurable lesion
- Negative for HIV, hepatitis B, or hepatitis C virus (HCV)

Exclusion Criteria:
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 90 days after the final dose of tiragolumab, 4 months after the final dose of RO7247669 and pembrolizumab, or for 1 week after the final dose of axitinib, whichever occurs last
- Inability to swallow a tablet or malabsorption syndrome
- Uncontrolled tumor-related pain
- Uncontrolled hypertension
- Significant cardiovascular/cerebrovascular disease within 3 months prior to randomization. DESCRIPTION is This study will evaluate the efficacy, safety, and pharmacokinetics of RO7247669 (PD1-LAG3) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-06-02T14:41:02. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is F. Hoffmann-La Roche Ltd. DISEASE SITES is Kidney.
132. TITLE is MAGNETISMM-17 ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY. SHORT TITLE is Elranatamab Tx Pts w/R/R MM Ref 1 Protea Inhibit, Immuno Drug &AntiCD38 & No Access OtherTherapy. INVESTIGATOR NAME is Lisa Xingguang Lee. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult Male or female participants age &#8805;18 years. DETAILED ELIGIBILITY is -Prior diagnosis of Multiple Myeloma 
-Participants who are ineligible for participation in any ongoing clinical trial of elranatamab, including lack of access due to geographical limitations, and who have exhausted all other treatment options.. DESCRIPTION is Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.

This expanded access protocol will provide access to elranatamab until it becomes commercially available to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-12-13T11:37:29. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Pfizer Pharmaceutical Inc.. DISEASE SITES is Multiple Myeloma.
133. TITLE is Phase III, Double-Blind, Randomized, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Patients with EGFR Mutation-Positive Stage IA2-IA3 Non-Small Cell Lung Cancer, Following Complete Tumour Resection (ADAURA2). SHORT TITLE is PhIII Osimertinib vs Placebo in Pts w/EGFR Mut+ Stage IA2-IA3 NSCLC Following Complete Tumour Resec. INVESTIGATOR NAME is Misako Nagasaka. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Male or female, at least &#8805; 18 years.
NSCLC, of non-squamous histology.
Stage IA2 or IA3 disease, based on TNM8 classification.
Complete surgical resection (R0) of the primary NSCLC by lobectomy, segmentectomy or sleeve resection.
Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.
World Health Organization performance status of 0 or 1.
Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.
A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas¬Æ EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne¬Æ test.
Minimum life expectancy of > 6 months.
Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.. DESCRIPTION is 18 Years and older   (Adult, Older Adult). PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-28T20:11:44. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is AstraZeneca. DISEASE SITES is Lung.
134. TITLE is Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
. SHORT TITLE is Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US). INVESTIGATOR NAME is Jason Zell. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older. DETAILED ELIGIBILITY is Inclusion Criteria:
You must have an ECOG performance status of 0 or 1.
You must have histologically/pathologically confirmed colon adenocarcinoma (T1-3, N1/N1c) with R0 resection accordingly to AJCC 8th edition criteria. NOTE: Patients with pathologic stages II or IIIC colon adenocarcinoma with R0 resection who have a commercially obtained Signatera&#8482; ctDNA+ve assay result post-operatively meeting all timelines and eligibility requirements otherwise, are eligible for enrollment and inclusion in Cohort B.
You must have no radiographic evidence of overt metastatic disease within 28 days prior to study entry (CT with IV contrast or MRI imaging is acceptable and must include chest, abdomen, and pelvis).
The distal extent of the tumor must be greater than or equal to 12 cm from the anal verge on colonoscopy or above the peritoneal reflection as documented during surgery or on pathology specimen (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation).
You must have had an en bloc complete gross resection of tumor (curative resection). Patients who have had a two-stage surgical procedure, to first provide a decompressive colostomy and then in a later procedure to have the definitive surgical resection, are eligible.

Exclusion Criteria:
Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma, sarcoma, lymphoma, squamous cell carcinoma, etc.).
Pathologic, clinical, or radiologic overt evidence of metastatic disease. This includes isolated, distant, or non-contiguous intra-abdominal metastases, even if resected.
Tumor-related bowel perforation.
History of prior invasive colon malignancy, regardless of disease-free interval.
History of bone marrow or solid organ transplantation (regardless of current immunosuppressive therapy needs). Bone grafts, skin grafts, corneal transplants and organ/tissue donation are not exclusionary.
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer (e.g., primary colon adenocarcinomas for which treatment with neoadjuvant chemotherapy and/or radiation is warranted are not permitted).
Other invasive malignancy within 5 years before study entry. Exceptions are colonic polyps, non-melanoma skin cancer or any carcinoma-in-situ.
Synchronous primary rectal and/ or colon cancers.. DESCRIPTION is This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-08-10T14:24:20. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Colon, Rectum.
135. TITLE is A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors. SHORT TITLE is A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors. INVESTIGATOR NAME is Krishnansu Tewari. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-Adequate bone marrow and organ function at baseline
-Life expectancy of >12 weeks
-Histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumors who meet one of the following criteria (dose escalation only):
a. Relapsed or progressed through standard therapy
b. Have a disease for which no standard effective therapy exists
c.Not a candidate for standard effective therapy

Exclusion Criteria:
-Grade 2 or greater toxicity, except alopecia related to any prior treatment (ie, chemotherapy, targeted therapy, radiation, or surgery)
-Prior anticancer treatment including:

a. Chemotherapy or small molecule-targeted therapy < 2 weeks prior to first dose of study treatment
b. Any antibody therapy < 5 half-lives from first dose of study treatment (or 4 weeks since last therapy, whichever is the shortest)
c. PD-1 (anti-programmed death 1) or PD-L1 (anti-programmed death ligand 1) therapy < 4 weeks from first dose of study treatment
d. Invasive surgery requiring general anesthesia < 30 days from first dose of study treatment
e. Chemotherapy with nitrosoureas or mitomycin C, < 45 days from first dose of study treatment
f. Radiation therapy (including radiofrequency ablation) < 4 weeks prior to initiation of study treatment
. DESCRIPTION is This is a Phase 1 study to assess the safety and clinical activity of KSQ-4279 alone and in combination in patients with advanced solid tumors. This is a Phase 1 study consisting of 2 parts: Dose Escalation and Expansion to evaluate the safety, tolerability, clinical activity, and pharmacokinetics (PK) Study of KSQ-4279 as a Monotherapy or in Combination in Patients with Advanced Solid Tumors.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-23T09:00:18. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is KSQ Therapeutics, Inc.. DISEASE SITES is Stomach, Ovary, Thyroid, Unknown Sites, Breast, Bones and Joints, Other Male Genital, Kidney, Esophagus, Other Skin, Cervix, Corpus Uteri, Urinary Bladder, Other Endocrine System, Multiple Myeloma, Melanoma, Skin, Rectum, Pancreas, Lung, Soft Tissue, Lip, Oral Cavity and Pharynx, Small Intestine, Anus, Liver, Other Digestive Organ, Larynx, Other Respiratory and Intrathoracic Organs, Prostate, Brain and Nervous System, Colon, Other Urinary, Eye and Orbit.
136. TITLE is A Randomized, Double-Blind, Placebo-Controlled, Phase IIA Study of Topical Pirenzepine or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel. SHORT TITLE is Topical Pirenzepine Prevention of Limiting Chemo Peripheral Neuropathy Carboplatin and Paclitaxel. INVESTIGATOR NAME is Jill Tseng. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:

- Males and females, ages > 18 years and older
- Ability to sign informed consent and understand the nature of a placebo-controlled trial
-If diabetic, be on stable antidiabetic treatment (> 2 months prior to screening) (oral or injectable antidiabetic therapy and/or lifestyle) that is not anticipated to change during the course of the study, except if medically required.

Exclusion Criteria:

-Pre-existing history (with or without current symptoms) in medical history of any type of peripheral neuropathy due to any cause other than prior chemotherapy (diabetes, alcohol, toxins, neurotoxic treatments, hereditary, autoimmune, etc.).
- Head or neck cancers
-Scheduled to undergo radiation therapy while on study. DESCRIPTION is A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study Of Topical Pirenzepine (WST-057) Or Placebo For The Prevention Of Dose Limiting Chemotherapy Induced Peripheral Neuropathy In Oncology Patients Administered Carboplatin And Paclitaxel. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-05-10T14:36:54. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Winsantor, Inc. DISEASE SITES is Cervix, Other Female Genital, Corpus Uteri.
137. TITLE is Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial. SHORT TITLE is Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III . INVESTIGATOR NAME is Zeljka Jutric. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Eligibility Criteria:

-Patients must be 18 years of age or older
-Patients must have confirmed T2 or T3 gallbladder cancer discovered incidentally at the time of or following routine cholecystectomy for presumed benign disease.
-Patients must have undergone initial cholecystectomy within 12 weeks. DESCRIPTION is This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-09-14T08:53:21. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ECOG-ACRIN. DISEASE SITES is Liver.
138. TITLE is A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN). SHORT TITLE is PhII of Prostate Oligomet Radiotherapy w/ or w/o ADT in Oligomet Prostate Ca. INVESTIGATOR NAME is Steven Neema Seyedin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration
- The patient must agree to use a highly effective contraception (even men with vasectomies) if he is having sex with a woman of childbearing potential or with a woman who is pregnant while on study drug and for 2 weeks following the last dose of study drug

Exclusion Criteria:
- Currently on androgen deprivation or anti-androgen therapy
- Prior metastatic or non-metastatic, invasive malignancy (except non metastatic, non-melanomatous skin cancer) unless continuously disease free for >= 3 years
- Prior chemotherapy for prostate cancer or bilateral orchiectomy. DESCRIPTION is This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing or spreading.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-09-12T16:48:29. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Prostate.
139. TITLE is Phase I/IB, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors. SHORT TITLE is PhI/IB of RMC-6291 Monotherapy in Subj w/ Advanced KRASG12C Mutant Solid Tumors. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements 
You can participate in this study if you :
- must be > or = 18 years of age.
- must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor types, is intolerant to, or is considered ineligible for standard-of-care anticancer treatments.
- ECOG performance status 0 or 1
- Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation
- Adequate organ function

Exclusion Requirements 
You cannot participate in this study if you:
- Have primary central nervous system (CNS) tumors
- Have active brain metastases
- Have known impairment of GI function that would alter the absorption
- Have major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
- Have prior therapy with KRASG12C (ON) inhibitor
Other inclusion/exclusion criteria may apply.. DESCRIPTION is The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-12-19T16:56:01. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Revolution Medicines. DISEASE SITES is Colon, Eye and Orbit, Melanoma, Skin, Esophagus, Rectum, Bones and Joints, Other Skin, Ovary, Urinary Bladder, Other Respiratory and Intrathoracic Organs, Soft Tissue, Stomach, Anus, Larynx, Other Male Genital, Brain and Nervous System, Thyroid, Breast, Kaposi's Sarcoma, Small Intestine, Lung, Other Female Genital, Kidney, Other Digestive Organ, Lip, Oral Cavity and Pharynx, Liver, Pancreas, Mycosis Fungoides, Cervix, Unknown Sites, Corpus Uteri, Prostate, Other Urinary, Other Endocrine System, Ill-Defined Sites.
140. TITLE is Phase I/IB Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS. SHORT TITLE is PhI/IB of RMC-6236 in Subj w/ Adv Solid Tumors Harboring Specific Mutations in KRAS. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is IRB INITIAL APPROVAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is If you are eligible for this study and decide to take part, you will be required to do the following:

- Keep all your study appointments/visits and complete the study assessments
- Let the study staff/study doctor know about any changes in your health or medications
- Agree to using highly effective methods of birth control during this study and for at least 3 months after the last dose of the study drug if you are male and at least 1 month after the last dose of the study drug if you are female. Your study doctor will discuss what highly effective methods of contraception are with you.
- Let the study staff/study doctor know if you think you are pregnant (women) or if your partner is pregnant (men)
- Agree not to take part in another research drug study
- Let the study staff/study doctor know if you change your mind about taking part in the study
- Consider letting your regular (primary) doctor know or allowing the study doctor to notify your (primary) doctor that you are taking part in this research study, your permission will be sought at the end of this document.
- Agree to not eat grapefruit, including products containing grapefruit for 7 days before Cycle 1 Day 1 and while receiving RMC-6236.
- Agree not to use certain medications or foods that may interact with the study drug within 7 days of study drug administration on Cycle 1 Day 1. Your study doctor will let you know which medications are not allowed. Let your study doctor know if you need to start taking any new medications.
. DESCRIPTION is Evaluate the safety and tolerability of RMC-6236 in adults with KRAS p.G12 mutant advanced solid tumors, KRAS p.G12C excluded.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-03T18:41:27. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Revolution Medicines. DISEASE SITES is Small Intestine, Mycosis Fungoides, Ovary, Kidney, Unknown Sites, Breast, Pancreas, Other Digestive Organ, Lung, Other Skin, Stomach, Rectum, Prostate, Urinary Bladder, Thyroid, Other Endocrine System, Esophagus, Other Respiratory and Intrathoracic Organs, Other Male Genital, Colon, Soft Tissue, Other Urinary, Melanoma, Skin, Lip, Oral Cavity and Pharynx, Anus, Liver, Larynx, Other Female Genital, Eye and Orbit, Brain and Nervous System, Ill-Defined Sites, Bones and Joints, Cervix, Corpus Uteri, Kaposi's Sarcoma.
141. TITLE is A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive Ovarian Cancer (UP-NEXT). SHORT TITLE is Ph III Placebo St Upifitamab Rilsodotin Post-Platinum Ther Platinum-Sensitive Recurrent Ovarian Ca. INVESTIGATOR NAME is Jill Tseng. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-Participant must have a histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube and primary peritoneal cancer, that is metastatic or recurrent.
-Participant must have platinum-sensitive recurrent disease, defined as having achieved either a partial or complete response to 4 or more cycles in their penultimate platinum- containing regimen and their disease progressing more than 6 months after completion of the last dose of platinum containing therapy in the penultimate regimen.
-Participant must have had as their best response to last line of treatment one of the following: No Evidence of Disease (NED); Complete Response (CR); Partial Response (PR); OR Stable Disease (SD)

Exclusion Criteria:
-Participant has history of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver disease. Testing beyond laboratory studies otherwise defined in the eligibility criteria, to diagnose potentially clinically significant liver disease based on risk factors such as hepatic steatosis or history of excessive alcohol intake, will be based on clinical judgement of the investigator.
-Participant has history of or suspected pneumonitis or interstitial lung disease.
-Participant has untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis, or carcinomatous meningitis.
. DESCRIPTION is UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.
. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-23T11:04:58. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is GOG Partners, Mersana Therapeutics, Inc.. DISEASE SITES is Ovary.
142. TITLE is Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis. SHORT TITLE is Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis. INVESTIGATOR NAME is Maheswari Senthil. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study. 

Inclusion Requirements You can participate in this study if you
- At least 18 years of age
- Able to provide written informed consent
- Have a planned surgical procedure at UCI for your peritoneal carcinomatosis from your gastric cancer

Exclusion Requirements You cannot participate in this study if you
- Do not have peritoneal carcinomatosis from a non-gastric tumor.. DESCRIPTION is This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.. TREATMENT TYPE DESC is Basic Science. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2023-05-04T11:04:37. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Stomach.
143. TITLE is A Phase III, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-Dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-Dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma. SHORT TITLE is PhIII Subcutaneous Nivolumab+Relatlimab Fixeddose Comb vsIntravenous Nivolumab+Relatlimab Melanoma. INVESTIGATOR NAME is Warren A Chow. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements 
You can participate in this study if
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of < 1/Lansky Performance Score, > 80% for adolescents 12 to 18 years of age).
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the American Joint Committee for Cancer (AJCC) staging system.
- Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the AJCC staging system (8th edition).

Exclusion Requirements 
- Participants must not have ocular melanoma.
- Participants must not have a history of myocarditis, regardless of etiology.
- Participants must not have a condition requiring systemic treatment with either corticosteroids (>10 milligrams [mg] daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.. DESCRIPTION is The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Children. SCOPE DESC is National. MODIFIED DATE is 2023-04-24T14:57:25. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Bristol-Myers Squibb. DISEASE SITES is Melanoma, Skin.
144. TITLE is A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy. SHORT TITLE is Doubledummy EfficacyPalonosetron HCl Buccal Film IV Palonosetron0.25mg PrevenNausea Emetogenic Chemo. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 years and older. DETAILED ELIGIBILITY is To participate in this study, you must meet the following criteria:
Be at least 18 years of age 
Have a diagnosis of solid tumor cancer 
Be scheduled to receive chemotherapy that is known to cause nausea and vomiting
You must be able to read, understand, and follow the study procedures 
Be able to complete a subject diary on your own
Your assessed Karnofsky performance status should be not less than 50
If you have a seizure disorder that is unstable and require anticonvulsant medication, you  cannot participate in this study
If your cardiovascular system, kidney or liver is impaired, you may participate only at the discretion of the study doctor
You cannot participate if you experienced moderate to severe nausea following any previous chemotherapy unless enrolled at the discretion of the study doctor
You cannot be in the study if you have any ongoing vomiting from any organic etiology, or if you have experienced any vomiting, retching, or National Cancer Institute (NCI) common Toxicity Criteria grade 2 or 3 or nausea in the 24 hours preceding chemotherapy
If you have symptomatic primary or metastatic CNS malignancy, you cannot participate. 
You cannot participate if you will be receiving moderately-emetogenic chemotherapy or radiotherapy during Study Day 2-5 or highly-emetogenic chemotherapy or radiotherapy during Study Day 1-6 or will be receiving radiotherapy of the upper abdomen or cranium during Study Day 2
If you will be receiving bone marrow or stem cell transplant during the study, you cannot  participate. DESCRIPTION is The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.. PHASE DESC is III. TREATMENT TYPE DESC is Prevention. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-10-03T14:07:07. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Xiamen LP Pharmaceutical Co., Ltd.. DISEASE SITES is Esophagus, Stomach, Small Intestine, Other Digestive Organ, Rectum, Colon, Anus.
145. TITLE is A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with Exemestane Plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. SHORT TITLE is PhIII StudyEvaluating Giredestrant+Everolimust Compare w/Exemestane+Everolimus Pts ER+HER2-Breast Ca. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria
- Patients at least 18 years old at the time of signing informed consent form
- Patients with advanced unresectable or metastatic adenocarcinoma of the breast
- Patients willing and able to use an electronic device for PRO data collection

Exclusion Criteria
- Patients with prior chemotherapy for locally advanced unresectable or metastatic disease
- Patients with any investigationaly therapy within 28 days prior to initiation of study treatment
- Patients with major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 14 days prior to randomization. DESCRIPTION is This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-06-01T15:42:30. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Genentech, Inc.. DISEASE SITES is Breast.
146. TITLE is S2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma. SHORT TITLE is PhIII MultiCentreMulti-NationalControl Tria Inves1cmv2cm WideExcision Margins Primary Cutaneous Mela. INVESTIGATOR NAME is Maki Yamamoto. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Patients must have a stage II primary invasive cutaneous melanoma . DESCRIPTION is Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-30T13:38:46. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Melanoma, Skin.
147. TITLE is OPtimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC) . SHORT TITLE is OPtimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC) . INVESTIGATOR NAME is Nataliya Mar. STATUS is IRB INITIAL APPROVAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria:
- Male or female >= 18 years of age at the time of informed consent
- Patient can comprehend and sign the study informed consent form
- No prior systemic therapy for renal cell carcinoma (RCC) in the neoadjuvant, adjuvant or metastatic setting

Exclusion Criteria:
- Active infection requiring infusional treatment
- Major surgery requiring general anesthesia =< 14 days before first dose of protocol-indicated treatment
- Inadequately controlled hypertension (systolic blood pressure [SBP] > 160/90 mmHg). DESCRIPTION is This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenous infusions into a vein. The other combination is one immunotherapy drug (nivolumab infusion) plus an oral pill taken by mouth (cabozantinib). Nivolumab and ipilimumab are "immunotherapies" which release the brakes of the immune system, thus allowing the patient's own immune system to better kill cancer cells. Cabozantinib is a "targeted therapy" specifically designed to block certain biological mechanisms needed for growth of cancer cells. In kidney cancer, cabozantinib blocks a tumor's blood supply. The genetic (DNA) makeup of the tumor may affect how well it responds to therapy. Testing the makeup (genes) of the tumor, may help match a treatment (from one of the above two treatment options) to the specific cancer and increase the chance that the disease will respond to treatment. The purpose of this study is to learn if genetic testing of tumor tissue may help doctors select the optimal treatment regimen to which advanced kidney cancer is more likely to respond.. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-06-02T14:55:09. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Vanderbilt University Medical Center. DISEASE SITES is Kidney.
148. TITLE is De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx. SHORT TITLE is Observational Study De-escalated Radiation Human PapillomavirusPos Squamous Carcinoma Oropharynx. INVESTIGATOR NAME is Allen Min Chen. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. 
Inclusion Requirements
You can participate in this study if you 
&#8226;	Are 18 years of age or older 
&#8226;	Able to provide written informed consent 
&#8226;	Are diagnosed with HPV-Positive squamous cell cancer of the oropharynx

Exclusion Requirements 
You cannot participate in this study if you
&#8226;	Received prior radiotherapy
&#8226;	Received prior chemotherapy for the study cancer
. DESCRIPTION is This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2023-01-06T11:58:38. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is UCI. DISEASE SITES is Larynx, Lip, Oral Cavity and Pharynx.
149. TITLE is Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer. SHORT TITLE is Ph II Trial Encorafenib Cetuximab w/or w/out Nivolumab Pts PreviouslyTreated MicrosatelliteBRAFV600E. INVESTIGATOR NAME is Jennifer Brooke Valerin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
You must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum. The date of diagnosis will be determined according to the pathologic date of diagnosis
You must have measurable disease according to RECIST1.1 criteria. Computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within 28 days prior to registration. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form
You must have documented unresectable and/or metastatic disease on CT or MRI imaging. All disease must be assessed and documented on the Baseline Tumor Assessment Form
You must have BRAF^V600E mutated colorectal cancer as tested in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory
You must have proficient mismatch repair (pMMR) or microsatellite stable (MSS) status as tested in a CLIA-certified laboratory and documented by the treating clinician. Proficient mismatch repair status can be determined by intact expression by immunohistochemistry of all 4 mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2). Microsatellite instability can be determined by polymerase chain reaction (PCR)

Exclusion Criteria:
You must not have a known positive serology for human immunodeficiency virus (HIV). Encorafenib is contraindicated with concomitant use of non-nucleoside analog reverse transcriptase inhibitors like efavirenz and etravirine. In addition, it is recommended in the investigator brochure of encorafenib to avoid using encorafenib with protease inhibitors. Therefore, because all participants on this study would receive encorafenib for either randomized arm of treatment, participants with HIV who receive these components of highly active antiretroviral therapy (HAART) would be at high risk for complications of drug-drug interaction
You must not have had prior treatment with a BRAF inhibitor (including, but not limited to, encorafenib, dabrafenib, or vemurafenib), MEK inhibitor (including, but not limited to, trametinib, selumetinib, or binimetinib), or ERK inhibitor (of note, regorafenib is not considered a BRAF inhibitor for the context of eligibility criteria)
You must not have had prior treatment with anti-EGFR therapies
You must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways. DESCRIPTION is This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
. PHASE DESC is II. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-03T10:08:20. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is SWOG. DISEASE SITES is Rectum, Colon.
150. TITLE is A Phase III, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy. SHORT TITLE is Ph3StudyGedatolisib Combw/Palbociclib&Fulvestrant toTherapiesw/HR+ HER2+AdvBeastCa PrevTreatw/CDK4/6. INVESTIGATOR NAME is Ritesh Parajuli. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Key Inclusion Criteria
-Patients must be at least 18 years of age.
-Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment.
-Patients must have histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer.

Key Exclusion Criteria
-Patients with prior treatment with chemotherapy and antibody drug conjugates (e.g., Enhertu) for advanced disease 
-Patients with bone only disease that is only blastic with no soft tissue component
-Patients with type 1 diabetes or uncontrolled type 2 diabetes. DESCRIPTION is This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-04-28T13:35:18. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Celcuity Inc. DISEASE SITES is Breast.
151. TITLE is Lorlatinib (PF-06463922) Continuation Protocol: An Open-Label, Single-Arm Continuation Study for Participants with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Continuing From Pfizer Sponsored Lorlatinib Clinical Studies. SHORT TITLE is Lorlatinib Contin Protocol: Study Participants w/ALK+orROS1+NonSmall LungCa Pfizer Spon Lorlatinib. INVESTIGATOR NAME is Sai-Hong Ignatius Ou. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements 
You can participate in this study if you:
1  - are any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study.
2 - are a participant that must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function

Exclusion Requirements 
You cannot participate in this study if you:
1  - are a female participant who is pregnant or breastfeeding.
 2 - have any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.. DESCRIPTION is The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention.. PHASE DESC is IV. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-12-19T17:40:26. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Pfizer Pharmaceutical Inc.. DISEASE SITES is Lung.
152. TITLE is A Phase I, Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-Tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High-Risk Myelodysplastic Syndrome (MDS). SHORT TITLE is PhI of LYT-200 in Pts w/ R/R AML or w/ R/R, High/Very High Risk MDS. INVESTIGATOR NAME is Deepa Jeyakumar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is You have had at least one line of therapy for AML or MDS and your cancer relapsed or 
was refractory (resistant) to treatment and there are no standard treatment options 
available that are known to be effective to treat your cancer or you have refused to 
receive treatment with standard of care treatments. 

You are up and about and are able to visit the study center frequently.
You have satisfactory blood test results and medical examination.
You are able to conceive a child, you are not pregnant and you agree to use two forms 
of birth control (one of which must be a barrier method) starting at screening and for 
90 days after receiving the final study drug administration.
You and your partner who could conceive a child agree to use two forms of birth 
control (one of which must be a barrier method) starting at screening.
You have agreed not to donate your reproductive material (ova) or breastfeed for the 
period of the study and for 90 days after receiving the final study drug administration.
You have not taken any anticancer medications in at least the last 2 weeks or in the 
amount of time needed for the previous anticancer medication to clear from your body 
(otherwise known as half-life of the drug), which can be shorter than 2 weeks, and your 
doctor will know.
You have not had major surgery or radiation therapy within 4 weeks prior to the first 
study dose.
You have not received any live vaccine within 30 days prior to the first study dose.. DESCRIPTION is Why are we doing this study and why have you been asked to take part?

We are asking you to join this study because you are suffering from cancer of the blood and bone 
marrow. In this study, we are looking at a new investigational drug called LYT-200 that is 
intended to inhibit (hinder) galectin-9. Galectin-9 is a protein which suppresses immune function
and disables immune-mediated attack on the cancer cells through multiple pathways. At present, 
there are no approved therapies targeting galectin-9 for any disease. Early studies conducted in 
animals suggest LYT-200 might be a good treatment for patients with blood and bone marrow 
cancer.
This study is among the first research studies of LYT-200 in people and its main purpose is to 
test its safety and tolerability in patients suffering from two types of blood and bone marrow 
cancer: acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In this study we 
shall also examine how the drug is changed by and removed from the body and will look for 
signs that the drug may be effective against AML or MDS. LYT-200 will be tested at several 
different doses.
. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-07T14:41:39. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is PureTech Health, LLC. DISEASE SITES is Myeloid and Monocytic Leukemia, Other Hematopoietic.
153. TITLE is A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma. SHORT TITLE is PhIIILomustineTemozolomide Comb TherapyVSStandard Temozolomide Ptsw/Methylated MGMT PromoterGlioblas. INVESTIGATOR NAME is Xiao-Tang Kong. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Inclusion Criteria:
-Neurologic function assessment within 28 days prior to Step 2 registration
-Contrast-enhanced brain MRI within 4 days after surgery
-The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria:
-Current or planned treatment with any other investigational agents for the study cancer
-Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-History of pulmonary fibrosis. DESCRIPTION is This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-11-22T10:20:37. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is NRG Oncology . DISEASE SITES is Brain and Nervous System. THERAPY NAMES is 
      .
154. TITLE is Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response. SHORT TITLE is Prospective Study Comparing Brand and Generic Immunosuppression. INVESTIGATOR NAME is Uttam G Reddy. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult, Older Adult who have had Renal Transplant Rejection.. DETAILED ELIGIBILITY is Inclusion Criteria

1.  Signed informed consent and or/assent
2.  Between the ages of 18 and 70 years, inclusive
3.  Current or future kidney transplant recipients, no more than 14 days after transplant and prior to hospital discharge. Inclusion of future kidney transplant recipients cannot exceed 30-days pre-transplant.
4.  Able to swallow tablets and capsules at the time of randomization
5.  Subjects must be receiving a primary or secondary kidney allograft from a deceased donor or from a non- HLA identical living donor
6.  Negative cross match test, and compatible (A, B, AB or O) blood type
7.  Subjects must have no known contraindications to tacrolimus
8.  Women of childbearing potential (WOCBP) must have a negative pregnancy test and be willing to use 2 methods of contraception during the study and for 6 weeks after stopping the study drug.

-  WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea &#8805; 12 consecutive months; or women on hormone replacement therapy with documented serum follicle stimulating hormone level > 35 mIU/cc). Women who are using oral, implanted, or injectable contraceptive hormones (intrauterine device), mechanical products or barrier methods (diaphragm, condoms, spermicides), are practicing abstinence, or have a sterile partner (e.g., vasectomy), will be considered of child bearing potential.

-  In addition, WOCBP who are taking MMF must use methods of birth control as stipulated in the package insert, namely:

-  Either intrauterine device, or partner with vasectomy, or one hormone (oral contraceptive pill, transdermal patch, vaginal ring, or progesterone injection or implant) and one barrier method (diaphragm or cervical cap with spermicide, contraceptive sponge, or male or female condom), or two barrier methods as described above.

-  WOCBP must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at the time of transplant.

Exclusion Criteria

1.  Those who receive simultaneous combined organ transplants
2.   Subjects with clinically significant active infections (for example, those requiring hospitalization, or as judged by the Investigator) or malignancies
3.  Recipients who are concurrently receiving belatacept or anticipate to receive belatacept as part of their immunosuppressive regimen
4.  Subjects currently enrolled in another investigational device or drug study
5.  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for 6 weeks after stopping the study drug
6.  Women who are breast-feeding or pregnant with a positive pregnancy test on enrollment or prior to study drug administration
7.  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
8.  Any psychiatric or medical condition that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.. DESCRIPTION is A prospective, randomized, open-label, multicenter, parallel, observational study to assess safety and efficacy of 200 kidney transplant recipients comparing brand tacrolimus to generic tacrolimus over a one year follow up period. All subjects will receive other immunosuppressive medications including induction therapy (thymoglobulin, basiliximab, or no induction) and maintenance including mycophenolate mofetil and corticosteroid therapy as directed by standard-of-care at each center. Their medication information will be recorded in their study files.

The study population includes recipients of kidney allografts in the first 14 days after transplantation.

The totals of 7 visits over 12 months period are planned as follows. The blood samples specified below are for the translational research study labs. Subjects will continue to receive routine labs as part of their standard of care from their treating physician. These safety labs are done as part of their stand of care from their treating physician.

If the subject needs more study drug medication before his or her next study visit the subject will come in to the clinic to get a new supply.. PHASE DESC is IV. TREATMENT TYPE DESC is OBS - Registry. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:43:10. DEPARTMENT NAME is SOM/Medicine. SPONSOR NAMES is U.S. Food and Drug, Tacrolimus. DISEASE SITES is Kidney - Nephrology, Kidney Transplant.
155. TITLE is Neuroimaging in the Oldest Old. SHORT TITLE is Neuroimaging in the Oldest Old. INVESTIGATOR NAME is Claudia Kawas. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Older Adult, Age 90+ years old with cerebral amyloid burden. DESCRIPTION is This study is designed to prospectively investigate cerebral amyloid burden (PET scans) and white matter disease, vascular disease, and atrophy (MRI scans) in relation to subsequent cognitive performance in 90+ year olds.. TREATMENT TYPE DESC is INT - Procedure/Surgery. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:40:28. DEPARTMENT NAME is SOM/Neurology. SPONSOR NAMES is National Institute on Aging. DISEASE SITES is Aging, Brain - Neurologic/ Psychologic.
156. TITLE is Preclinical Studies in Inherited and Acquired Myopathies. SHORT TITLE is Preclinical Studies in Inherited and Acquired Myopathies. INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 1. Have no muscle condition
2. Are age 3 years or older
. DETAILED ELIGIBILITY is Eligibility Criteria

Partnership 1: 
1.	Adult patients (above the age of 40 years old) of either gender, who fulfill the ENMC 2011 criteria for IBM with either clinical definite or clinical probable IBM.
2.	Adult patients between the ages of 18-65 years with a diagnosis of dermatomyositis according the Bohan-Peter criteria
3.	Willing to provide verbal consent and follow research procedures. 
4.	Not have any other muscle condition or significant heart disease.
5.	Not have any history of a systemic malignancy

Partnership 2a:
1.	Patients with Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy type 2B (LGMD2B), Facioscapulohumeral Muscular Dystrophy (FSHD), Dermatomyositis (DM) and Inclusion Body Myositis (IBM)
2.	DMD patients ages 3 years &#8211;24 years
3.	IBM patients ages 45 years &#8211;85 years
4.	FSHD patients ages 18 years &#8211;70 years
5.	LMGD2B and DM patients age 18 years &#8211;65 years 
6.	Willing to provide verbal consent and follow research procedures. 
7.	Not have any other muscle condition or significant heart disease.
8.	Not have any history of a systemic malignancy

Partnership 2b:
1.	Patients with Duchenne Muscular Dystrophy (DMD) (anticipated ages of 3 years &#8211;24 years)
2.	Healthy control patients are age-matched with DMD population of 3 years &#8211;24 years
3.	Willing to provide verbal consent and follow research procedures. 
4.	Not have any other muscle condition or significant heart disease

Partnership 3: 
1.	Patients with genetically proven GNE myopathy and unaffected relatives
2.	Symptomatic patients with positive family history of GNE myopathy and unaffected relatives
3.	Age above 18 years of age
4.	Willing to provide verbal consent and follow research procedures. 
5.	No history of coagulation disorder

. DESCRIPTION is This is an interventional study where biomarkers will be studied as a surrogate marker of disease progression or treatment response.  Any drugs identified as potentially engaging drug-gable targets will be studied initially.. TREATMENT TYPE DESC is INT - Procedure/Surgery. AGE DESCRIPTION is Both. MODIFIED DATE is 2023-02-07T13:28:05. DEPARTMENT NAME is SOM/Neurology. SPONSOR NAMES is Department of Neurology. DISEASE SITES is Myopathy, Dermatomyositis, Facioscapulohumeral Muscular Dystrophy, Brain - Neurologic/ Psychologic, Muscular Dystrophy, Myositis.
157. TITLE is TOPAZ Study, Trial of Parkinson's and Zoledronic Acid A
Randomized Placebo-controlled Trial of Zoledronic Acid for Prevention of Fractures in Patients with Parkinson s Disease
. SHORT TITLE is Topaz. INVESTIGATOR NAME is Nicolas Phielipp. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 60 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Current Parkinson's Disease diagnosis or neurodegenerative parkinsonism diagnosis (including progressive supranuclear palsy, multiple system atrophy, cortical basal degeneration, vascular parkinsonism, dementia with Lewy bodies or another form of neurodegenerative parkinsonism) based on an expert assessment (neurologist diagnosis via medical records confirmation or Telemedicine Screening Assessment)
2.  Willing and able to continue in follow-up for at least 2 years
3.  Willing and able to provide informed consent

Exclusion Criteria:
1.  History of hip fracture
2.  Any use of a bisphosphonate drug within the last 12 months
3.  Use of any other osteoporosis treatment (such as SERMs and denosumab) within the last 6 months
4.  Tooth extraction or invasive dental procedures within the past 30 days or planned/scheduled extraction/procedure in the next 12 months
Non-ambulatory, i.e., unable to walk without assistance of another person.
5.  Undergoing kidney dialysis
6.  A diagnosis of multiple myeloma or Paget's disease
7.  Unable to speak or read English sufficiently to complete informed consent
8.  Any other criteria, which would make the patient unsuitable to participate in this study as determined by the study staff (e.g., an uncontrolled drug and/or alcohol addiction). DESCRIPTION is This home-based randomized clinical trial is designed to test the efficacy of ZA-5 mg in Parkinson's disease (PD) and parkinsonism patients. This trial will also address barriers to treatment of patients with PD and parkinsonism by providing rigorous evidence about whether ZA reduces fracture risk in patients with PD and parkinsonism, simplifying treatment by giving ZA at home without extra medical visits and BMD testing, and overcoming poor persistence with oral therapies because one infusion may prevent bone loss for at least 2 years. The outcome of this trial will demonstrate how a home-based fracture prevention can reach older PD patients who would not otherwise receive treatment to reduce their high risk of fractures.

Patients with PD will be recruited throughout the US by participating neurologists and health networks as well as the Parkinson's Foundation. Patients may also self-refer to the study. Interested patients can access study information on a study website (topaz.eurekaplatform.org) as well as through the Parkinson's Foundation Helpline. Patients who wish to enroll will be directed to an interactive electronic consent (eConsent). Following eConsent, participants complete a screening questionnaire (to confirm eligibility), followed by a baseline questionnaire. If a participant is determined to be eligible following these steps, they may be scheduled for a Telemedicine assessment to further confirm the PD or parkinsonism diagnosis, unless they have been referred directly from a participating neurologist. If confirmed, the participant will be mailed a supply of vitamin D3 800-1000 IU and instructed to take one vitamin D tablet every day for 2 months. Lastly, a Nurse Home Visit will be scheduled and conducted to confirm final eligibility, randomization, and administration of the study drug, if appropriate. Participants who are randomized will be contacted every 4 months for at least 2 years to determine if they have had any fractures.. PHASE DESC is IV. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2022-01-07T15:42:39. DEPARTMENT NAME is SOM/Neurology. SPONSOR NAMES is National Institute on Aging. DISEASE SITES is Parkinson Disease, Brain - Neurologic/ Psychologic.
158. TITLE is A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte s Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients with Life or Limb-threatening Vascular Trauma. SHORT TITLE is  Humacyte s Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients with Life . INVESTIGATOR NAME is Roy Fujitani. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is Inclusion Criteria:
1. Patients with life or limb threatening traumatic injury to an arterial vessel in the limb or torso, other than the heart, which requires replacement or reconstruction
2. Preoperative imaging or clinical examination indicates the damaged vessel has a defect length of &#8804; 38cm and is appropriately size matched to the 6mm Human Acellular Vessel (HAV) per the judgment of the treating surgeon taking into account vasoconstriction and situational inflow and outflow considerations.
3. Autologous vein graft is either not feasible in the judgment of the treating surgeon (e.g. because of lack of availability of suitable conduit, presence of severe venous insufficiency) or is not desirable because of the urgency of revascularization
4. Aged 18 to 85 years old, inclusive
5. Able to communicate meaningfully with investigative staff, and able to comply with entire study procedures. If the patient is unconscious, then information from a reliable witness indicates that the patient would normally be able to comply with study procedures
6. Patient or relative is able, willing and competent to give informed consent
7. Life expectancy of at least 1 year
. PHASE DESC is II. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-05-04T17:26:55. DEPARTMENT NAME is SOM/Surgery. SPONSOR NAMES is Humacyte Inc., ARG. DISEASE SITES is Trauma, Blood - Hematologic.
159. TITLE is Dexmedetomidine for Acute Pain Control in Patients with Multiple Rib Fractures: A Randomized Controlled Trial.. SHORT TITLE is Dexmedetomidine for Acute Pain Control in Patients with Multiple Rib Fractures. INVESTIGATOR NAME is Jeffry Nahmias. STATUS is OPEN TO ACCRUAL. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2023-02-07T13:30:20. DEPARTMENT NAME is SOM/Surgery. SPONSOR NAMES is UCI. DISEASE SITES is Trauma, Muscles and Bones - Musculoskeletal, Rib Fractures.
160. TITLE is A Phase III, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676). SHORT TITLE is Ph III, MK-3475 in Combo w/BCG in Participants w/NMIBC that is Persistent or Recurrent Following BCG. INVESTIGATOR NAME is Edward Uchio. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is persistent or recurrent following adequate BCG induction. The primary hypothesis is that the combination of pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central pathology review compared to BCG in participants with carcinoma in situ (CIS).. DETAILED ELIGIBILITY is Inclusion Criteria:

Has histologically-confirmed diagnosis of non-muscle invasive (T1, high grade Ta and/or CIS) transitional cell carcinoma (TCC) of the bladder
Has been treated with one adequate course of BCG induction therapy for the treatment of HR NMIBC
Following adequate BCG induction therapy, must have persistent or recurrent HR NMIBC
Has undergone cystoscopy/ transurethral resection of bladder tumor (TURBT) to remove all resectable disease
Has provided tissue for biomarker analysis
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Has adequate organ function
Male participants must agree to use approved contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period
Female participants who are not pregnant, not breastfeeding, and either not a woman of child bearing potential (WOCBP) or are a WOCBP who agrees to use approved contraception during the treatment period and for at least 120 days after the last dose of study treatment

Exclusion Criteria:

Has persistent T1 disease following an induction course of BCG
Has a history of or concurrent muscle invasive (i.e., T2, T3, T4), locally advanced non-resectable or metastatic UC
Has concurrent extra-vesical (i.e., urethra, ureter, renal pelvis) non-muscle invasive TCC of the urothelium, concurrent upper tract involvement, or invasive prostatic TCC including T1 or greater disease, or ductal invasion
WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization
Has received prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks of start of study treatment
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks of start of study treatment
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days of start of study treatment
Has a known additional malignancy that is progressing or requires active treatment within the past 3 years
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Has one or more of the following contraindications to BCG: prior BCG sepsis or systemic infection, total bladder incontinence, or an adverse experience to a previous BCG instillation that resulted in treatment discontinuation and precludes retreating with BCG
Has an active infection requiring systemic therapy
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has current active tuberculosis
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment
Has had an allogenic-tissue/solid organ transplant. DESCRIPTION is This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is persistent or recurrent following adequate BCG induction. The primary hypothesis is that the combination of pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central pathology review compared to BCG in participants with carcinoma in situ (CIS).. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:31:43. DEPARTMENT NAME is SOM/Urology. SPONSOR NAMES is Merck Sharp & Dohme Corp.. DISEASE SITES is Bladder Cancer, Cancer - Oncologic, Urology. THERAPY NAMES is 
      .
161. TITLE is A Phase III of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG). SHORT TITLE is PhIII of CG0070 in Pts w/NMIBC Unresponsive to BCG. INVESTIGATOR NAME is Edward Uchio. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adults. DETAILED ELIGIBILITY is Key Inclusion Criteria:
- Ineligible for radical cystectomy or refusal of radical cystectomy
- Adequate organ function

Key Exclusion Criteria: 
- Muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer
- Has known upper tract or prostatic urethra malignancy
- Immuno-deficient due to chronic steroid or other immunosuppressant use, HIV, or prior organ transplant
- Clinically significant or active cardiac disease
- Active autoimmune disease. DESCRIPTION is To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:34:24. DEPARTMENT NAME is SOM/Urology. SPONSOR NAMES is CG Oncology Inc.. DISEASE SITES is Cancer - Oncologic, Bladder Cancer.
162. TITLE is AUTOLOGOUS T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED TO B-CELL MATURATION ANTIGEN (BCMA) IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (MG). SHORT TITLE is BCMA IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (MG). INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is Inclusion Criteria:
Patient must be at least 18 years of age.
Patient must have Generalized Myasthenia Gravis at the time of screening.
Concomitant immunosuppressive drugs must be deemed necessary by the investigator.

Exclusion Criteria:
Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
Patient is pregnant or lactating.. PHASE DESC is I/II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T15:01:57. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is Cartesian Therapeutics. DISEASE SITES is Myasthenia Gravis, Brain - Neurologic/ Psychologic.
163. TITLE is FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Disease. SHORT TITLE is Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Pompe Diseas. INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is Key Inclusion Criteria:

Subject is aged &#8805; 18 years (ambulatory or nonambulatory).
Subject has a documented clinical diagnosis of Pompe disease by genetic testing.
Subject has received enzyme replacement therapy (ERT) with rhGAA for the previous &#8805; 2 years.
Subject has been on a stable standard dose (at least 20 mg/kg every 2 weeks) of ERT with rhGAA for at least the previous 6 months.
Subject has upright FVC &#8805; 30% of predicted normal value.
Subject or legally authorized representative(s) (LAR) (if applicable) provides written informed consent.
Subject must agree to use appropriate contraception following consent through 6 months post AT845 administration.
Note: There are additional inclusion criteria. The study center will determine if you meet all of the criteria.

Key Exclusion Criteria:

Subject is currently participating in an interventional study or has received gene or cell therapy.
Subject tests positive for AAV8 neutralizing antibodies with titers above protocol specified threshold.
Subject has received immune-modulating agents within 90 days before dosing (use of inhaled corticosteroids is allowed).
Subject tests positive for GAA total antibodies with titers above protocol specified threshold.
Subject has a high risk for a severe allergic reaction to rhGAA (ie, previous moderate to severe anaphylactic reaction to alglucosidase alfa or and/or a history of sustained high immunoglobulin G [IgG] antibody titers to alglucosidase alfa that in the opinion of the Investigator suggests a high risk for an allergic reaction to ERT).
Subject has an active viral infection based on clinical observation.
Subject has a history of, or currently has, a clinically important cardiac condition, such as an echocardiogram (ECHO) with ejection fraction below 40%, or has symptoms or signs of cardiomyopathy that in the opinion of the Investigator precludes enrollment.
Subject has a clinically significant underlying liver disease.
Subject has a contraindication to study drug or ingredients or to corticosteroids.
Note: There are additional exclusion criteria. The study center will determine if you meet all of the criteria.. DESCRIPTION is This study (FORTIS) will evaluate the safety and efficacy of an investigational gene replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose of AT845 delivered via intravenous (IV) infusion.

Up to 2 nominal dose levels of AT845 are planned to be evaluated in FORTIS. A single AT845 administration via IV infusion is planned for each subject. The initial dosing cohort will receive a single dose at 3x10^13 vg/kg of AT845. The second dose cohort will receive a single dose at 6x10^13 vg/kg of AT845.

The core observation period will be completed by Week 48 for each subject. Subjects will be followed for a total of 5 years after administration of AT845.. PHASE DESC is I/II. TREATMENT TYPE DESC is INT - Biological/vaccine. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:38:54. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is Audentes Therapeutics, Inc. DISEASE SITES is Brain - Neurologic/ Psychologic, Pompe Disease (late onset).
164. TITLE is Electroacupuncture for the Management of Symptom Clusters in Cancer Patients and Survivors (EAST): A Feasibility Study. SHORT TITLE is Electroacupuncture for the Management of Symptoms Clusters in Cancer Patients and Survivors. INVESTIGATOR NAME is Alexandre Chan. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

- Patients diagnosed with cancer that have received anti-cancer treatment within the past one year
- Greater than or equal to 18 years of age
- Life expectancy greater than or equal to 6 months
- Complaints of two or more of the following symptoms (fulfilling the definition of a symptom cluster): memory impairment/attention deficit, fatigue, insomnia, depression, or anxiety over the past 7 days
- Able to provide informed consent to participate in the study.



Exclusion Criteria:

- Presence of metastasis
- Severe needle phobia
- Psychiatric or medical disorders which would affect cognitive assessments, such as, dementia, Alzheimer's disease, a history of any neurological condition, traumatic brain injury, stroke, and the use of psychotropic medication
- Known bleeding disorder (e.g. hemophilia, Von Willebrand's disease, thrombocytopenia)
- Has pacemaker or other electronic metal implants
- Epilepsy
- Already receiving acupuncture therapy or received acupuncture treatment in the past 3 months.
- Breastfeeding, pregnant or are planning get pregnant during the study period. DESCRIPTION is The purpose of this study is to investigate the efficacy, safety, and feasibility of offering electroacupuncture as an intervention to improve cancer-related symptoms (cognitive impairment, fatigue, psychological distress and insomnia) and quality of life among cancer patients and survivors receiving care at UCI Health. In addition, changes in biomarkers (plasma BDNF, pro-inflammatory cytokines and mitochondrial DNA) known to be associated with cancer-related symptoms. We hypothesize that EA is an effective, safe, and feasible intervention for cancer patients and survivors.

Our specific aims are as follows:

To compare the efficacy of EA versus sham-EA control in reducing cognitive toxicity, fatigue, psychological distress, insomnia and quality of life.

To evaluate the impact of EA versus sham-EA control on biomarkers, including circulating BDNF, pro-inflammatory cytokines (IL-1&#946;, IL-4, IL-6, IL-8, IL-10, TNF-alpha), mitochondrial DNA (oxidative stress indicator), and safety.

To assess the feasibility of administering EA to manage symptom clusters in cancer patients.. TREATMENT TYPE DESC is Supportive Care. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2022-05-03T11:28:25. DEPARTMENT NAME is PHS/Pharmaceutical Sciences. SPONSOR NAMES is UCI. DISEASE SITES is Rectum, Prostate, Lip, Oral Cavity and Pharynx, Esophagus, Small Intestine, Anus, Bones and Joints, Stomach, Larynx, Thyroid, Breast, Kaposi's Sarcoma, Liver, Other Female Genital, Colon, Pancreas, Other Digestive Organ, Lung, Unknown Sites, Other Respiratory and Intrathoracic Organs, Other Skin, Cervix, Corpus Uteri, Ovary, Other Male Genital, Kidney, Other Urinary, Eye and Orbit, Mycosis Fungoides, Urinary Bladder, Other Endocrine System, Melanoma, Skin, Soft Tissue, Ill-Defined Sites.
165. TITLE is Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort A CHDI Foundation Project. SHORT TITLE is A Prospective Registry Study in a Global Huntington's Disease Cohort A CHDI Foundation Project. INVESTIGATOR NAME is Anna E Morenkova. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Huntington's Disease. DETAILED ELIGIBILITY is Study Population:
Patients with HD and their family members are recruited from specialty clinics (Human Genetics, Neurology, Psychiatry) that advise and treat people affected by HD. In addition, in some areas community clinics and neurologists who see HD patients recruit participants for this study. Participants also receive information about the study through websites, clinical practices, support groups, advocacy newsletters, etc. and place a direct request to be considered for participation in the study. Community controls are identified by study site staff (using advertisements, flyers and newsletters) with the support of the Enroll-HD operational staff.

Inclusion Criteria:
1.  Carriers: This group comprises the primary study population and consists of individuals who carry the HD gene expansion mutation.
2.  Controls: This group comprises the comparator study population and consists of individuals who do not carry the HD expansion mutation.
3.  These two major categories can be further subdivided into six different subgroups of eligible individuals:
4.  Manifest/Motor-manifest HD: Carriers with clinical features that are regarded in the opinion of the investigator as diagnostic of HD.
5.  Pre-Manifest/-Motor-manifest HD: Carriers without clinical features regarded as diagnostic of HD.
6.  Genotype Unknown: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has not undergone predictive testing for HD and therefore has an undetermined carrier status.
7.  Genotype Negative: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has undergone predictive testing for HD and is known not to carry the HD expansion mutation.
8.  Family Control: Family members or individuals not related by blood to carriers (e.g., spouses, partners, caregivers).
9.  Community Controls: Individuals unrelated to HD carriers who did not grow up in a family affected by HD. Data collected from community controls will be used for generation of normative data for sub-studies.
10.  Participant status will be captured in the study database using 2 variables: 1) Investigator Determined Status: this will be based on clinical signs and symptoms and genotyping performed as part of medical care, and will be updated at every visit; and 2) Research Genotyping Status: this will be based on genotyping conducted as part of Enroll-HD study procedures. Based on research genotyping, participants will be reclassified under this variable from Genotype Unknown to 'Carriers' or 'Controls'. Investigators and participants will be blinded to this reclassification.

Exclusion Criteria:
1.  Individuals who do not meet inclusion criteria,
2.  Individuals with choreic movement disorders in the context of a negative test for the HD gene mutation.
3.  For Community Controls: those individuals with a major central nervous system disorder will be excluded (e.g. stroke, Parkinson's disease, multiple sclerosis, etc.).
4.  Participants under 18 may be eligible to participate (if they have juvenile-onset HD).. DESCRIPTION is The primary objective of Enroll-HD is to develop a comprehensive repository of prospective and systematically collected clinical research data (demography, clinical features, family history, genetic characteristics) and biological specimens (blood) from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g., spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation). Enroll-HD is conceived as a broad-based and long-term project to maximize the efficiencies of non-clinical research and participation in clinical research. With 158 active clinical sites in 19 countries, Enroll-HD is now the largest HD database available and is accessible to any interested researcher - visit https://urldefense.com/v3/__http://www.enroll-hd.org/for-researchers/access-data/__;!!OLgoXmg!X3XOGgZgxwQ0K5eZ2_3uHMJxiHOHF6nDLh67FE-4yWEWh58WXLkKNQATvFxoVAfJhn6EhlagWE7pmXRWFFQ$  to learn more.. TREATMENT TYPE DESC is OBS - Registry. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:38:24. DEPARTMENT NAME is CCR. SPONSOR NAMES is CHDI Foundation . DISEASE SITES is Brain - Neurologic/ Psychologic, Huntington's Disease.
166. TITLE is Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial. SHORT TITLE is CREST-2. INVESTIGATOR NAME is Shuichi Suzuki. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 35 Years to 100 Years   (Adult, Older Adult)
Carotid Stenosis. DETAILED ELIGIBILITY is General Inclusion Criteria:

1. Carotid stenosis defined as:
2. Stenosis greater than or equal to 70% by catheter angiography (NASCET Criteria); OR
by DUS with greater than or equal to 70% stenosis defined by a peak systolic velocity of at least 230 cm/s plus at least one of the following: an end diastolic velocity greater than or equal to 100 cm/s, or internal carotid/common carotid artery peak systolic velocity ratio greater than or equal to4.0, or CTA with greater than equal to 70% stenosis, or MRA with greater than or equal to 70% stenosis.
3. No medical history of stroke or TIA ipsilateral to the stenosis within 180 days of randomization. Life-long asymptomatic patients will be defined as having no medical history of stroke or transient ischemic attack and negative responses to all of the symptom items on the Questionnaire for Verifying Stroke-free Status (QVSS).18
4. Patients must have a modified Rankin Scale score of 0 or 1 at the time of informed consent.
5. Women must not be of childbearing potential or, if of childbearing potential, have a negative pregnancy test prior to randomization.
6. Patients must agree to comply with all protocol-specified follow-up appointments.
7. Patients must sign a consent form that has been approved by the local governing Institutional Review Board (IRB)/Medical Ethics Committee (MEC) of the respective clinical site.
8. Randomization to treatment group will apply to only one carotid artery for patients with bilateral carotid stenosis. Management of the non-randomized stenosis may be done in accordance with local PI recommendation. Treatment of the non-study internal carotid artery must take place at least 30 days prior to randomization, or greater than 44 days after randomization and 30 days after the study procedure is completed (whichever is longer).
9. Carotid stenosis must be treatable with CEA, CAS, or either procedure.

. DESCRIPTION is Prevention of stroke involves managing and treating risk factors. Most strokes are caused when blood flow to a portion of the brain is blocked. One place this often happens is in the carotid artery. This blockage is called atherosclerosis or hardening of the arteries.

The purpose of this trial is to determine the best way to prevent strokes in people who have a high amount of blockage of their carotid artery but no stroke symptoms related to that blockage. Each eligible participant will be evaluated to determine which procedure(s) is best for him/her. All participants will receive intensive medical treatment. In addition, participants will be randomized to receive the selected procedure or not.

The trial will be conducted in the United States and Canada by physicians carefully selected on their ability to perform the procedures at low risk. Another key component of the trial is that important stroke risk factors, including hypertension, diabetes, high cholesterol, cigarette smoking, physical activity, and diet will be managed intensively. Participants will remain in the study for 4 years.. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-29T12:53:30. DEPARTMENT NAME is CCR. SPONSOR NAMES is National Institute of Neurological Disorders and Stroke, Mayo Clinic Jacksonville. DISEASE SITES is Brain - Neurologic/ Psychologic.
167. TITLE is CorEvitas Inflammatory Bowel Disease (IBD) Drug Safety and Effectiveness Registry. SHORT TITLE is CorEvitas Inflammatory Bowel Disease (IBD) Drug Safety and Effectiveness Registry. INVESTIGATOR NAME is Nimisha Parekh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Inflammatory Bowel Diseases
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is ** ELIGIBILITY CRITERIA&#8727; To be eligible for enrollment into the Corrona IBD Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below.**

Inclusion Criteria:
1.  At least 18 years of age or older.
2.  Willing and able to provide written consent for participation in the IBD Registry.
3.  Willing and able to provide Personally Identifiable Information (PII) which includes the following types of personal information at a minimum: full name, date of birth, sex, and home address zip code.
4.  Diagnosis of one of the following by a gastroenterologist: Crohn's disease, Ulcerative colitis.
5.  Prevalent users or new /incident users of an approved biologic drug or JAK inhibitor (Tofacitinib) for the treatment of UC or Crohn's disease.

Exclusion Criteria:

**Participating in or planning to participate in a clinical trial (Phase I - III) or a post-marketing study or registry (i.e. phase IV).**

Eligible Medications Grouped by Drug Class:  

ANTI-TNF AGENTS AND BIOSIMILARS - Adalimumab (HUMIRA), Adalimumab-atto (AMJEVITA), Certolizumab pegol (CIMZIA), Golimumab (SIMPONI), Infliximab (REMICADE), Infliximab-dyyb (INFLECTRA)

INTEGRIN RECEPTOR ANTAGONISTS - Natalizumab (TYSABRI), Vedolizumab (ENTYVIO)

INTERLEUKIN ANTAGONIST (IL-12 AND IL-23), Ustekinumab (STELARA),

JAK INHIBITOR - Tofacitinib (XELJANZ)

1.  Once clinical trial participation has ended, a patient is permitted to enroll in the registry if they satisfy the eligibility requirements.

2.  These criteria are subject to change with the needs of the registry at the sole discretion of the Sponsor (Corrona).. DESCRIPTION is The objective of the Corrona Inflammatory Bowel Diseases (IBD) Registry is to create a national cohort of patients with IBD. The diseases under study include Crohn's Disease (CD) and Ulcerative Colitis (UC). Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of IBD. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the prevalence and incidence of comorbidities and adverse events, medication utilization patterns, and patient productivity measures.

The design is a prospective, non-interventional registry for patients with IBD under the care of a certified gastroenterologist. Longitudinal follow-up data is collected from both patients and their treating gastroenterologist during routine clinical encounters using Corrona registry questionnaires. These questionnaires collect data on patient demographics, disease duration, medical history (including all prior and current treatments for IBD), smoking status, alcohol use, disease activity and severity, pain, as well as other clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes.

After the enrollment visit, IBD patients and physicians will complete the follow-up questionnaires during regularly scheduled clinical encounters. The goal is to collect data from patients and providers at six month intervals, not to exceed 2 visits in any 12 month period.

Adverse events may be volunteered spontaneously by the subject, or be discovered as a result of general questioning by the Investigator. During all Corrona related visits with the Investigator, subjects will be questioned regarding the occurrence of adverse events.. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T15:00:06. DEPARTMENT NAME is CCR. SPONSOR NAMES is Corevitas (Previously Corrona), Corrona. DISEASE SITES is Inflammatory Bowel Disease (IBD), Digestive - Gastrointestinal.
168. TITLE is Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies. SHORT TITLE is Registry: Generalized Myasthenia Gravis Treatment With Complement C5 Inhibition Therapies. INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Study Population:
Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, or have ever been treated with Alexion C5IT prior to enrollment, and meet the inclusion criteria and exclusion criteria are eligible for registry participation.

Inclusion Criteria:
1.  Participants with gMG who have received treatment with Alexion C5IT.
2.  Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions.
3.  Participants must have myasthenia gravis historical data available to be enrolled in the Registry.

Exclusion Criteria:
1.  Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.. DESCRIPTION is At the time of enrollment in the Registry, participant records will be queried for retrospective information about the participants' medical history and gMG disease treatment history. Following enrollment, prospective data collection will be performed using data obtained as part of the routine clinical care and through patient-reported outcome methods in use. Data will be collected using an electronic data capture system. The duration of data collection for the Registry will be up to 5 years from the first participant enrolled.. TREATMENT TYPE DESC is OBS - Registry. AGE DESCRIPTION is Adults. MODIFIED DATE is 2021-12-21T11:43:43. DEPARTMENT NAME is CCR. SPONSOR NAMES is Syneos Health, Alexion Pharmaceuticals, Inc.. DISEASE SITES is Brain - Neurologic/ Psychologic, Myasthenia Gravis.
169. TITLE is Sleep for Stroke Management And Recovery Trial (Sleep SMART). SHORT TITLE is Sleep for Stroke Management And Recovery Trial (Sleep SMART). INVESTIGATOR NAME is Masaki Nagamine. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1. TIA with ABCD2 greater than or equal to 4 or ischemic stroke, within the prior 14 days.

Exclusion Criteria:
1.  Pre-event inability to perform all of own basic ADLs.
2.  Unable to obtain informed consent from subject or legally authorized representative
incarcerated.
3.  Known pregnancy.
4.  Current mechanical ventilation (can enroll later if this resolves) or tracheostomy
current use of positive airway pressure, or use within one month prior to stroke
anatomical or dermatologic anomaly that makes use of CPAP interface unfeasible
severe bullous lung disease.
5.  History of prior spontaneous pneumothorax or current pneumothorax.
6.  Hypotension requiring current treatment with pressors (can enroll later if this resolves)
other specific medical circumstances that conceivably, in the opinion of the site PI, could render the patient at risk of harm from use of CPAP.
7.  Massive epistaxis or previous history of massive epistaxis.
8.  Cranial surgery or head trauma within the past 6 months, with known or possible CSF leak or pneumocephalus.
9.  Recent hemicraniectomy or suboccipital craniectomy (i.e. those whose bone has not yet been replaced), or any other recent bone removal procedure for relief of intracranial pressure.
10.  Current receipt of oxygen supplementation >4 liters per minute
11.  Current contact, droplet, respiratory/airborne precautions. DESCRIPTION is Sleep SMART has a prospective, randomized, open-label, blinded-endpoint (PROBE) design. It is a multi-site, parallel-group superiority trial that compares 6 months of OSA treatment to usual care. The study includes two trials: a prevention study with an embedded recovery trial. 3062 subjects will be randomized over 5 years at 110 sites within the NINDS-funded StrokeNet clinical trials network.

Experimental: Intervention Arm: CPAP with Usual Care (6 months of CPAP plus usual medical therapy).

vs.

No Intervention: Control Arm: Usual Care (6 months of usual medical therapy alone).. PHASE DESC is III. TREATMENT TYPE DESC is INT - Behavioral. AGE DESCRIPTION is Adults. MODIFIED DATE is 2021-12-21T12:06:12. DEPARTMENT NAME is CCR. SPONSOR NAMES is National Coordinating Center (NCC) - University of Cincinnati, NIH. DISEASE SITES is Stroke, Brain - Neurologic/ Psychologic.
170. TITLE is Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE). SHORT TITLE is Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery. INVESTIGATOR NAME is Wengui Yu. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1. Age at least 18 years
2. Intracerebral hemorrhage (ICH) (including primary intraventricular hemorrhage) confirmed by brain CT or MRI
3. Can be randomized within 14-120 days after ICH onset
5. Non-valvular AF (defined as atrial fibrillation or atrial flutter), documented by electrocardiography or a physician-confirmed history of prior AF
6. CHA2DS2-VASc score >/= 2
7. Provision of signed and dated informed consent form by patient or legally authorized representative
8. Able to comply with all study procedures and available for duration of the study
9. For females of reproductive potential: use of highly effective contraception

Exclusion Criteria:

1. History of ICH before index event
2. Active infective endocarditis
3. Lobar ICH with cerebral amyloid angiopathy
4. Clear indication for anticoagulant drugs (e.g., requires anticoagulation for deep vein thrombosis or pulmonary embolism) or antiplatelet drugs (e.g., requires aspirin or clopidogrel for recent MI).
5. Previous or planned left atrial appendage closure
6. Clinically significant bleeding diathesis
7. Serum creatinine >/= 2.5 mg/dL
8. Active hepatitis or hepatic insufficiency with Child-Pugh score B or C
9. Anemia (hemoglobin <8 g/dL) or thrombocytopenia (<100 x 109/L) that is chronic in the judgment of the investigator
10. Life expectancy <1 year
11. Pregnant or breastfeeding
12. Known allergy to aspirin or apixaban
13. Concomitant participation in a competing therapeutic trial
14. Considered by the investigator to have a condition that precludes safe participation in the trial
15. Unwilling to discontinue prohibited medications. DESCRIPTION is ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent Intracerebral hemmorhage (ICH)  and high-risk non-valvular atrial fibrillation (AF) (CHA2DS2-VASc score >/= 2). Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T15:35:11. DEPARTMENT NAME is CCR. SPONSOR NAMES is NIH, National Coordinating Center (NCC) - University of Cincinnati. DISEASE SITES is Brain - Neurologic/ Psychologic, Stroke.
171. TITLE is Use of NexoBrid for Treatment of Acute deep partial and full thickness Burn Injuries. SHORT TITLE is Use of NexoBrid for Treatment of Acute deep partial and full thickness Burn Injuries. INVESTIGATOR NAME is Victor Joe. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Thermal Burn
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria patient level:
1.  Thermal burns caused by fire/flame, scalds or contact,
2.  Patient total burns area greater than or equal to 1% DPT and / or FT with eschar that should be removed in SOC,
3.  Patient total burns area to be treated should be less than or equal to 30% TBSA; SPT, DPT and/or FT in depth,
4.  Informed consent can be obtained within 84h of the burn injury,

All planned TWs should meet the following criteria:
1.  SPT areas that cannot be demarcated from DPT and FT areas should be less than 50% of the % TBSA of the TW, with eschar that should be removed in SOC,
2.  Wound's blisters can be removed/ unroofed, as judged by the investigator.

Exclusion Criteria patient level:
1.  Modified Baux index greater than equal to 80,
2.  Patients with burned, charred fingers, 3rd degree in depth and possibly devoid of circulation,
3.  Patients with abraded wound/s that cannot be treated by an enzymatic debrider application (NexoBrid),
4.  Patients with pre enrolment escharotomy,
5.  Patients with electrical or chemical burns,
6.  The following pre-enrollment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),
7.   Patients with pre-enrolment wounds which are covered by eschar heavily saturated with Silver, Iodine or by SSD pseudoeschar (pseudoeschar as a result of > 12 hrs SSD treatment),
8.  Patients with diagnosed infections as described in the protocol,
9.  Diagnosis of smoke inhalation injury [12],
10.  Pregnant women (serum positive pregnancy test) or nursing mothers,
11.  Poorly controlled diabetes mellitus (HbA1c>11%) in patients with known diabetes as captured in the medical history,
12.  BMI greater than 39.0 kg/m2 in patients with burns area of up to 15% TBSA or BMI greater than 34.0 kg/m2 in patients with burns area of more than 15% %TBSA,
13.  American Society of Anesthesiologists (ASA) physical status classification system greater than 2
14.  Cardio-pulmonary disease (MI within 6 months prior to injury, severe or unstable Ischemic Heart Disease, severe or unstable heart failure, severe pulmonary hypertension, severe COPD or pre-existing oxygen-dependent pulmonary diseases, severe broncho-pneumonia within 1 month prior to injury, steroid dependent asthma or uncontrolled asthma),
15.  Pre-existing diseases which interfere with circulation (severe peripheral vascular disease, severe circulatory edema and/or lymphedema, regional lymph nodes dissection, significant varicose veins),
16.  Any conditions that would preclude safe treatment or adding further risk to the basic acute burn trauma (such as severe immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, severe cardiovascular disorder, significant pulmonary disorder, significant liver disorder including post alcoholic abuse impaired function or neoplastic disease, blast injury),
17.  Chronic systemic steroid intake,
18.  History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or papain.
19.  Enrollment in any investigational drug trial within 4 weeks prior to screening.. DESCRIPTION is This is an Expanded Access (treatment) protocol to allow ongoing treatment of burn patients with NexoBrid following completion of the enrollment stage of protocol MW2010-03-02 (DETECT study).

This protocol is also designed to collect and evaluate the safety and clinical performance of NexoBrid in patients suffering from DPT and FT thermal burns.

Following the enrollment of a patient to the protocol, physicians will identify one or more target wounds (TWs) per patient according to the TW definition. All patient's DPT and FT burns that comply with the specified entrance criteria will be treated with NexoBrid and, therefore, must be designated as TWs. This will further allow an evaluation of the patient's systemic safety by allowing treatment of the patient's entire deep burns.

Prior to initiation of eschar removal treatment, patients will be medicated with appropriate analgesia and undergo wound cleansing and dressing of all wounds with antibacterial solutions according to product instruction for use in order to ensure clean and moist eschar covered wound bed for NexoBrid application. Vital signs (Blood Pressure, Heart Rate and temperature) measurements and pain assessment will be performed within 24 hrs before start of treatment as well as haematology, biochemistry blood tests & PTT/INR. Pressure measurements for circumferential extremity wounds will be performed 1 hour before start of treatment and will be closely monitored during treatment. Following wound cleansing and soaking treatments, patients will undergo the eschar removal process. TWs of up to 15% total body surface area (TBSA) will be treated with a single application of NexoBrid for 4 hours. Patients with TWs >15% TBSA and up to 30% TBSA will be treated with 2 consecutive applications of 4 hours each. NexoBrid should not be applied to more than 15% TBSA in one session. PK samples will be taken from sub-set of patients with TWs area >15% TBSA. Pressure measurements for circumferential extremity wounds will be performed after the removal of NexoBrid.

Post eschar removal completion, patients will undergo daily vital signs (Blood Pressure, Heart Rate and temperature measurements) and pain assessments for 1 week, starting on the morning following start of eschar removal. Blood tests (haematology and biochemistry) will be performed 24 ¬± 6 hrs post eschar removal as well as PTT/INR. Weekly assessments of wound healing progress including the dressings used until complete wound closure will be performed.

Cosmesis (scar quality) evaluation (using MVSS) will be performed at 3 and 12 months post wound closure confirmation visit.. TREATMENT TYPE DESC is INT - Biological/vaccine. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:01:11. DEPARTMENT NAME is CCR. SPONSOR NAMES is MediWound, Ltd. DISEASE SITES is Skin - Dermatologic, Burn Injuries.
172. TITLE is A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by an Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis. SHORT TITLE is Evaluate MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in ALS. INVESTIGATOR NAME is Namita Goyal. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 80 Years   (Adult, Older Adult)
. DETAILED ELIGIBILITY is Major Inclusion Criteria:
- Male or female subjects age 18 - 80 years, inclusive;
- Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000) research diagnostic criteria for ALS [clinically definite, clinically probable, probable-laboratory-supported];
- ALS onset of &#8804;18 months from first clinical signs of weakness prior to screening;
- If currently using riluzole, subject must be on a stable dose for at least 30 days prior to initiation of study drug;
- If currently using edaravone, subject should have completed at least 14 days of their initial treatment cycle prior to initiation of study drug;
- Last documented pulmonary function test result (i.e., slow vital capacity or forced vital capacity) must be greater than or equal to 70% predicted;;
- Able to swallow study medication capsules;
- No known allergies to the study drug or its excipients;
- Received pneumococcal vaccine within 6 years prior to starting clinical trial.

Major Exclusion Criteria:
- ALSFRS-R score of &#8804;1 on more than one item in the assessment's individual components;
- Currently diagnosed with a clinically significant psychiatric disorder or dementia that would preclude evaluation of symptoms;
- Currently use or treated with parenteral (intramuscular or intravenous) high dose (>25 mg/week) Vitamin B12 within 30 days prior to study drug administration;
- Poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator;
- Currently participating, or has participated in a study with an investigational or marketed compound or device within 30 days or 5 half-lives, whichever is shorter, prior to signing the informed consent;
- Use of tracheostomy or >22/24-hour ventilatory support.. DESCRIPTION is This is a Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 followed by an open-label extension phase compared to matching placebo in subjects diagnosed with ALS.

The study will consist of a screening phase (up to 30 days) followed by a double-blind phase (12 months). Following the screening phase, subjects who continue to meet entry criteria will be randomly assigned to one of two treatment groups: MN-166 or matching placebo in a 1:1 ratio. Upon completion of the double-blind phase, subjects will be given the option to continue to the Open-label Extension Phase for a period of six months.. PHASE DESC is II/III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T14:56:06. DEPARTMENT NAME is CCR. SPONSOR NAMES is MediciNova, Inc. . DISEASE SITES is Brain - Neurologic/ Psychologic, Amyotrophic Lateral Sclerosis (ALS).
173. TITLE is Statins Use in intRacereberal hemorrhage patieNts (SATURN). SHORT TITLE is Statins Use in intRacereberal hemorrhage patieNts (SATURN). INVESTIGATOR NAME is Mohammad Shafie. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 50 Years and older   (Adult, Older Adult)
Intracerebral Hemorrhage. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Age greater than or equal to 50 years.
2.  Spontaneous lobar ICH confirmed by CT or MRI scan
3.  Patient was taking a statin drug at the onset of the qualifying/index ICH.
4.  Randomization can be carried out within 7 days of the onset of the qualifying ICH.
5.  Patient or legally authorized representative, after consultation with physicians, agrees to be randomized to statin continuation (restart) vs. discontinuation.

Exclusion Criteria:
1.  Suspected secondary cause for the qualifying ICH, such as an underlying vascular abnormality or tumor, trauma, venous infarction, or hemorrhagic transformation of an ischemic infarct.
2.  History of recent myocardial infarction (attributed to coronary artery disease) or unstable angina within the previous 3 months.
3.  Diabetic patients with history of myocardial infarction or coronary revascularization.
4.  History of familial hypercholesterolemia.
5.  Patients receiving proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors.
6.  Known diagnosis of severe dementia.
7.  Inability to obtain informed consent.
8.  Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, or other obvious reasons for noncompliance, such as unable to adhere to the protocol specified visits/assessments.
9.  Life expectancy of less than 24 months due to co-morbid terminal conditions.
Pre-morbid mRS >3.
10.  ICH score >3 upon presentation.
11.  Contraindications to continuation/resumption of statin therapy, such as significant elevations of serum creatinine kinase and/or liver transaminases, and rhabdomyolysis.
12.  Woman of childbearing potential.
13.  Concurrent participation in another research protocol for investigation of experimental therapy.
14.  Indication that withdrawal of care will be implemented for the qualifying ICH.. DESCRIPTION is SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset). Participating subjects will undergo baseline testing for APOE genotype and will be followed for 24 months to assess for the occurrence of recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events (MACCE) during the follow-up period.

Recruitment will take place at ~ 140 sites coordinated through the NIH/NINDS StrokeNet and the Canadian Stroke Consortium.. PHASE DESC is III. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T15:37:26. DEPARTMENT NAME is CCR. SPONSOR NAMES is National Coordinating Center (NCC) - University of Cincinnati, National Institute of Neurological Disorders and Stroke. DISEASE SITES is Brain - Neurologic/ Psychologic, Stroke.
174. TITLE is A Multicenter Case-Control Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck, versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett s Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma. SHORT TITLE is EsoGuard efficacy on Samples Collected Using EsoCheck, versus Esophagogastroduodenoscopy. INVESTIGATOR NAME is Jason Samarasena. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 22 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

All Patients:
1.  Men aged 50 years and above
2.  Greater than or equal to &#8805; years either of Gastroesophageal Reflux Disease (GERD) symptoms,
GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or any combination of treated and untreated periods, as long the cumulative total is at least 5 years.
3.  No solid foods eaten for at least 2 hours prior to EsoCheck procedure
4.  One or more of the following:  Caucasian race, Current or past history of chronic smoking, Body mass index (BMI) of at least 30 kg/m2, First-degree relative with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC)

Cases:
1.  Previous diagnosis of non-dysplastic Barrett's Esophagus (NDBE), low grade dysplasia (LGD), high grade dysplasia (HGD), and/or intramucosal adenocarcinoma (IMC).
2.  Diagnosis by esophagogastroduodenoscopy (EGD) (with exception of NDBE) was within 4 months prior to study enrollment.
3.  Indicated for surveillance EGD or for therapeutic EGD.
4.  Able to provide, by day of study EGD, the original glass slide(s) of biopsy specimens from most recent prior EGD.

Exclusion Criteria:
1.  Inability to provide written informed consent
2.  On anti-coagulant drug(s) that cannot be temporarily discontinued
3.  Known history of esophageal varices or esophageal stricture
4.  Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula, and/or esophageal ulceration
5.  History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
6.  Oropharyngeal tumor
7.  History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure
8.  History of myocardial infarction or cerebrovascular accident within past 6 months
9.  Any known lesion which, in the opinion of the endoscopist, obstructs greater than 25% of the esophageal lumen
10.  Prior participation in PR-0139/EG-CL-101 (Lucid BE Screening Study)
11.  Prior EGD during which a therapeutic procedure such as, but not limited to, ablation, cryotherapy or endoscopic mucosal resection, was performed for the treatment of BE and/or EAC.
. DESCRIPTION is This is a two phase multicenter study to assess the operating characteristics of the EsoGuard diagnostic assay panel performed on esophageal mucosal cells collected using the EsoCheck cell collection device in known "Cases" of disease (i.e., patients with a history of Barrett's Esophagus (BE) with and without varying degrees of dysplasia or intramucosal adenocarcinoma [IMC]) and in patients with no known history of these conditions. . TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-04-12T13:14:53. DEPARTMENT NAME is CCR. SPONSOR NAMES is Lucid Diagnostics, Inc.. DISEASE SITES is Digestive - Gastrointestinal, Barrett's Esophagus.
175. TITLE is Advarra Reliance #26: Neuromuscular Observational Research (MOVR) Data Hub Protocol  Pro00034893   . SHORT TITLE is Advarra Reliance #26: Neuromuscular Observational Research (MOVR) Data Hub Protocol  Pro00034893   . INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. TREATMENT TYPE DESC is OBS - Biorepository. AGE DESCRIPTION is Both. MODIFIED DATE is 2021-12-21T11:40:49. DEPARTMENT NAME is CCR. SPONSOR NAMES is Muscular Dystrophy Association. DISEASE SITES is Brain - Neurologic/ Psychologic.
176. TITLE is GRASP-LGMD RESEARCH PROTOCOL; Project 1a Defining Clinical Endpoints in LGMD. SHORT TITLE is GRASP-LGMD RESEARCH PROTOCOL; Project 1a Defining Clinical Endpoints in LGMD. INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 4 Years to 65 Years   (Child, Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Age between 4-65 at enrollment
2.  Clinically affected (defined as weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity)
3.  A genetically or functionally confirmed mutation in ANO5, CAPN3, DYSF, DNAJB6 or SGCA-G.
Ambulatory

Exclusion Criteria:
1.  Non-ambulatory at the time of enrollment.
2.  Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator.. DESCRIPTION is The genetic heterogeneity has been a barrier to broad natural history efforts, with prior investigations often limited to single gene mutations. Much attention is paid to the variability within individual mutations (e.g. distal presentations), as opposed to defining the best strategy for measuring change in overall LGMD disease burden. This presents a major dilemma for LGMD rare disease research: how to balance diverse genes leading to overlapping phenotypes, versus variants in the same gene leading to divergent phenotypes. What is clear, is as a group, LGMDs are chronic and progressive leading to significant lifetime morbidity and represent a large unmet clinical need.

Recent developments in the investigator's genetic understanding of LGMD and molecular approaches to therapy have led to proposed gene replacement therapies for at least three of the LGMD mutations. Several of these gene replacement therapies are currently in pre-clinical/phase 1 testing, leading to an urgent need for natural history data. In addition, non-specific therapies which target muscle mass or function are being tested in other muscular dystrophies and may prove beneficial for LGMD.. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. MODIFIED DATE is 2021-12-21T11:42:14. DEPARTMENT NAME is CCR. SPONSOR NAMES is Virginia Commonwealth University, Muscular Dystrophy Association. DISEASE SITES is Brain - Neurologic/ Psychologic, Limb Girdle Muscular Dystrophy, Muscular Dystrophy.
177. TITLE is A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure. SHORT TITLE is Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failur. INVESTIGATOR NAME is Dawn Lombardo. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older  (Adult, Older Adult)
Acute Heart Failure
. DETAILED ELIGIBILITY is Inclusion Criteria
1. Age >= 18 years (male or female)
2. Currently hospitalized for AHF defined as meeting all the following criteria:
a. Presentation with worsening symptoms of heart failure (e.g., worsening dyspnea or dyspnea at rest, progressive fatigue, rapid weight gain, worsening edema/abdominal distention/anasarca)
b. Objective signs or diagnostic testing consistent with volume overload (e.g., jugular venous distension, pulmonary basilar crackles, S3 gallop, ascites, hepatomegaly, peripheral edema, radiological evidence of pulmonary congestion, noninvasive or invasive hemodynamic evidence of elevated filling pressures)
c. Intensification of AHF therapy during admission defined as at least one of the following:
i. Augmentation of oral diuretic therapy [e.g., >= 2x outpatient regimen dose, addition of a second diuretic agent, or new initiation of diuretic therapy in a previously na√Øve patient] ii. Initiation of intravenous diuretic therapy iii. Initiation of intravenous vasoactive agent (e.g., inotrope or vasodilator)

The majority of enrolled patients should have an established history of heart failure (defined as present for >= 2 months and for which the patient is on treatment). Trial leadership will monitor this proportion and may cap enrollment of patients without an established history of heart failure (i.e., patients presenting with de novo heart failure).

3. Left ventricular ejection fraction (LVEF) measured within the past 12 months (including during the current hospitalization)
4. Elevated NT-proBNP or BNP during current hospitalization:
a. For patients with LVEF <= 40%: NT-proBNP >= 1600 pg/mL or BNP >= 400 pg/mL (NT-proBNP >= 2400 pg/mL or BNP >= 600 pg/mL if patient in atrial fibrillation or atrial flutter)
b. For patients with LVEF >40%: NT-proBNP >= 1200 pg/mL or BNP >= 300 pg/mL (NT-proBNP >= 1800 pg/mL or BNP >= 450 pg/mL if patient in atrial fibrillation or atrial flutter)

5. Eligible patients will be randomized no earlier than 24 hours and up to 14 days after presentation while still hospitalized once they have been stabilized, as defined by:
a. No increase (i.e., intensification) in the dose of intravenous diuretics during the 12 hours prior to randomization
b. No use of intravenous vasodilators or inotropes during the 24 hours prior to randomization

Patients across the spectrum of LVEF are eligible for participation in the trial. Trial leadership will monitor the proportion of patients with various LVEFs and may cap enrollment of certain subgroups to ensure a broad population.

In addition, patients with and without type 2 diabetes are eligible for participation in the trial. Trial leadership will monitor the proportion of patients with and without type 2 diabetes and may cap enrollment of one subgroup to ensure adequate representation of the other.

. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:46:13. DEPARTMENT NAME is CCR. SPONSOR NAMES is AstraZeneca, TIMI Study Group. DISEASE SITES is Heart - Cardiovascular/ Circulatory, Heart Failure.
178. TITLE is A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury.. SHORT TITLE is MT-3921. INVESTIGATOR NAME is Jefferson W Chen. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Spinal Cord Injury
18 Years to 75 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Provide written informed consent prior to beginning any study procedures
2.  Cervical spinal cord injury that meet all of the following criteria: a) Classified as AIS A, AIS B or AIS C, b) ISNCSCI neurological level of injury between C4 and C7 (for C4, the subject must have at least 1 point of motor activity between C5 to C7), and c)UEMS &#8804;28 at Screening
3.  Body mass index (BMI) <40

Exclusion Criteria:

1.  Any concomitant injury that interferes with the procedures and examinations required by study protocol, including performance, interpretation or validity of neurological examinations
2.  Poly-traumatic Injury as defined by Injury Severity Score (ISS) values > 25
3.  Penetrating spinal cord injuries
4.  Complete transection of the spinal cord
5.  Any other significant pre-existing medical conditions prior to spinal cord injury or current conditions that, in the judgement of the iInvestigator, may increase the risks associated with study participation
6.  History of anaphylaxis or clinically significant allergic reactions to any medication
7.  History or presence of malignancy within the last 3 years prior to screening
8.  Subjects with current SARS-CoV-2 infection (COVID-19)
9.  Subjects with hereditary fructose intolerance
10.  Psychoactive substance use disorder
11.  Participation in any clinical trial of a new chemical entity within 12 weeks prior to Screening
12.  Female subjects who are pregnant or lactating

Additional screening criteria check may apply for qualification:
. DESCRIPTION is The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury.

Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:47:10. DEPARTMENT NAME is CCR. SPONSOR NAMES is Mitsubishi Tanabe Pharma America, Inc.. DISEASE SITES is Spinal Cord Diseases, Brain - Neurologic/ Psychologic.
179. TITLE is Patient Observational Pain and Activity Survey (POPAS) Study using RS-4i Sequential Stimulator with Intersperse Technology in Axial Spine and Peripheral Joint Pain. SHORT TITLE is POPAS. INVESTIGATOR NAME is David Majors. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Osteoarthritis
18 Years to 89 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Study Population:
Subjects will be current adult patients of the UCI PM&R or Orthopedic Department

Criteria:
Inclusion Criteria:
1.  chronic and persistent MSK lumbar back pain for greater than 12 weeks as documented in patient records
2.  Age 18 to 89
3.  Willingness to comply with study protocol
4.  Signed Patient Consent on file
5.  Verified patient usage collected from RS-4i Plus via patient data adapter

Exclusion Criteria:
1.  Pregnancy
2.  Any contraindications, as indicated in the RS-4i Plus prescribing information
3.  Substantial allergy to adhesives
4.  Skin infection or irritation of skin where electrodes are to be placed
5.  Pacemaker/ICD
6.  Abnormal skin sensation
7.  Serious psychological disorder
8.  End-stage cardiac, peripheral arterial or pulmonary disease
9.  h/o recent vertebral fracture
10.  Severe degenerative or traumatic neuromuscular disease
11.  Non-English speaking
12.  Uncontrolled diabetes meelitus (Hb A1c> 8.5%)
13.  ESRD or ESHD
14.  Active cancer. DESCRIPTION is Spine pain and joint pain are among the most common worldwide ailments and directly contributes to disability as well as increased duration of care. Spine and joint pain affect work sick leave, production and increased financial costs to healthcare. Non-invasive treatments for spine and joint pain can vary widely from lifestyle changes, physical therapy, oral medication, and select medical devices, that can improve pain level and help improve the quality of life of individuals. Thus, the general population suffers from an ailment that has multiple conservative treatment options with variable outcomes.

. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:23:30. DEPARTMENT NAME is CCR. SPONSOR NAMES is RS Medical. DISEASE SITES is Muscles and Bones - Musculoskeletal, Osteoarthritis.
180. TITLE is Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI). SHORT TITLE is Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial. INVESTIGATOR NAME is Anand Ganesan. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 75 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1. Participant must be able to understand and provide informed consent
2. A clinical diagnosis of active or stable vitiligo made by a dermatologist
3. Facial Vitiligo Area Scoring Index (F-VASI) greater than or equal to 0.25
4. Total Body Vitiligo Area Scoring Index (T- VASI) greater than or equal to 3
5. Willingness to Undergo narrow band ultraviolet B (nbUVB) phototherapy
and Stop all other treatments for vitiligo from screening through the final follow up visit at week 48

Exclusion Criteria:
1. Inability or unwillingness of a participant to give written informed consent or comply with the study protocol
2. Diagnosis of segmental vitiligo
3. Contraindication to narrow band ultraviolet B (nbUVB) phototherapy
4. More than 33% leukotrichia on the face or on the total body
5. Use of biologic, investigational, or experimental therapy or procedure within 12 weeks or 5 half-lives prior to Visit 0 (whichever is longer)
6. Use of laser or light-based treatment (phototherapy), including tanning beds within 8 weeks prior to Visit 0
7. Use of non-biologic systemic or topical immunosuppressive or immunomodulatory agents within 4 weeks prior to Visit 0
8. History of melanocyte-keratinocyte transplantation procedure (MKTP) or other surgical treatment for vitiligo
9. Current or past use of the depigmenting agent monobenzyl ether of hydroquinone, including Benoquin¬Æ (Monobenzone);
10. Presence of skin conditions or lesions that would confound the vitiligo assessments
11. Spontaneous repigmentation within 6 months prior to Visit 0 (e.g., repigmentation without any treatment, and significant in amount as determined by the investigator)
12. Uncontrolled thyroid function at screening as determined by the investigator:
--Note: If the participant has a history of thyroid disease and is on treatment, the participant must be on a stable thyroid regimen for at least three months prior to Visit 0
13. Greater than 3 adequately treated nonmetastatic basal cell carcinomas (BCC) or squamous cell carcinomas (SCC) within 12 months prior to Visit 0, or a previous history of multiple BCC or SCC which may pose additional risks from participation in the study, in the opinion of the investigator;
14. Previous or current diagnosis of other cancer, with the exception of adequately treated cervical carcinoma in situ
15. Acute or chronic infection
16. Evidence of infection, including Human immunodeficiency virus (HIV), Current or prior infection with hepatitis B (HBV), as indicated by positive HBsAg or positive HBcAb, or 
Current or prior hepatitis C (HCV), unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 12 weeks after cessation of therapy), or
Positive QuantiFERON-tuberculosis (TB) Gold or QuantiFERON-TB Gold Plus test 
---Note: Purified protein derivative (PPD) skin test may be substituted for Quantiferon-TB Gold or Quantiferon-TB Gold Plus test.
17. Laboratory abnormalities
18. Women of child-bearing potential who are unwilling to use a medically acceptable form of contraception until study.  Women who are pregnant or lactating
20. Vaccination with a live attenuated vaccine within 30 days prior to Visit 0
21. Known drug allergy or reaction to any component of AMG 714 or proteins derived from mammalian cell lines
22. Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may: pose additional risks from participation in the study,
may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study, or
23. Current, diagnosed mental illness (e.g. severe depression for example) or current, diagnosed or self- reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.. DESCRIPTION is Phase 2a, double blind, placebo-controlled, multi-center, proof of concept trial of AMG 714 for the treatment of vitiligo. Participants will be randomized 2:1 to receive AMG 714 or placebo for AMG714. Random assignment will be stratified by active versus stable vitiligo.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:48:45. DEPARTMENT NAME is CCR. SPONSOR NAMES is National Institute of Allergy and Infectious Diseases , Virginia Mason Medical Center/Benaroya Research Institute . DISEASE SITES is Skin - Dermatologic, Vitiligo.
181. TITLE is Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial. SHORT TITLE is Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial. INVESTIGATOR NAME is Jay Shah. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 80 Years   (Adult, Older Adult)
Intracerebral Hemorrhage. DETAILED ELIGIBILITY is Inclusion Criteria:

- Patients aged 18-80 years, inclusive
- Patients with spontaneous ICH
- Able to treat with study medication (rFVIIa/placebo) within 120 minutes of stroke onset or last known well
- Efforts to obtain informed consent per EFIC guidelines (U.S.) or adherence to country-specific emergency research informed consent regulations (Canada, Germany, Spain, U.K., Japan)
Exclusion Criteria:

- Score of 3 to 7 on the Glasgow Coma Scale
- Secondary ICH related to known causes (e.g., trauma, aneurysm, arteriovenous malformation (AVM), oral anticoagulant use (vitamin K antagonists or novel oral anticoagulants) within the past 7 days, coagulopathy, etc.)
- ICH volume < 2 cc or &#8805; 60 cc
- IVH score > 7
- Pre-existing disability (mRS > 2)
- Symptomatic thrombotic or vaso-occlusive disease in past 90 days (e.g., cerebral infarction, myocardial infarction, pulmonary embolus, deep vein thrombosis, or unstable angina)
- Clinical or EKG evidence of ST elevation consistent with acute myocardial ischemia
- Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)
- Refusal to participate in study by patient, legal representative, or family member
- Known or suspected thrombocytopenia (unless current platelet count documented above 50,000/&#956;L)
- Unfractionated heparin use with abnormal PTT
- Low-molecular weight heparin use within the previous 24 hours
- Recent (within 90 days) carotid endarterectomy or coronary or cerebrovascular angioplasty or stenting
- Advanced or terminal illness or any other condition the investigator feels would pose a significant hazard to the patient if rFVIIa were administered
- Recent (within 30 days) participation in any investigational drug or device trial or earlier participation in any investigational drug or device trial for which the duration of effect is expected to persist until to the time of FASTEST enrollment
- Planned withdrawal of care or comfort care measures
- Patient known or suspected of not being able to comply with trial protocol (e.g., due to alcoholism, drug dependency, or psychological disorder)
- Known or suspected allergy to trial medication(s), excipients, or related products
- Contraindications to study medication
- Previous participation in this trial (previously randomized)
- Females of childbearing potential who are known to be pregnant or within 12 weeks post-partum and/or lactating at time of enrollment. DESCRIPTION is The investigators will perform a global, Phase III, randomized, double-blind controlled trial of rFVIIa plus best standard therapy vs. placebo and best standard therapy alone. The investigators will include participants with a volume of ICH &#8805; 2 and < 60 cc, no more than a small volume of intraventricular hemorrhage (IVH) (IVH score &#8804; 7), age &#8805; 18 and &#8804; 80, Glasgow Coma Scale of &#8805; 8, and treated within 120 minutes from stroke onset. To minimize time-to-treatment, the study will use emergency research informed consent procedures (including exception from informed consent (EFIC) in the United States) and mobile stroke units (MSUs), with a goal of ¬Ω of participants treated within 90 minutes, as accomplished in the NINDS t-PA trials. The FASTEST Trial will include approximately 100 hospital sites and at least 15 MSUs in the NINDS-funded StrokeNet and key global institutions with large volumes of ICH patients and the ability to treat them within 120 minutes of stroke onset. Recruitment of 860 participants over 3¬Ω years is planned. Countries participating in the trial include the United States, Canada, Japan, Germany, Spain, and the United Kingdom.

Participants will be randomized in a double-blinded fashion to rFVIIa 80 ¬µg/kg dose (maximum 10 mg dose) or placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg. The primary outcome (ordinal mRS with the following categories: 0-2, 3, and 4-6) will be determined at 180 days, but participants will be followed by remote assessment at 30 days and 90 days. To measure growth of ICH, all participants will have a standard of care baseline non-contrast CT of the head and a repeat scan at 24 hours. Centralized volumetric measurements of ICH, IVH, and edema will be performed for both time points.

Novo Nordisk A/S will manufacture and supply rFVIIa as a research medication for use in the FASTEST Trial. Novo Nordisk A/S will also manufacture and supply matching placebo that is identical to rFVIIa in appearance and administration.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T15:53:13. DEPARTMENT NAME is CCR. SPONSOR NAMES is National Institute of Neurological Disorders and Stroke. DISEASE SITES is Brain - Neurologic/ Psychologic.
182. TITLE is An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Patients with Sickle Cell Disease. SHORT TITLE is Study of Oral FT-4202, a Pyruvate Kinase Agonist in Patients with Sickle Cell Disease (Hibiscus). INVESTIGATOR NAME is Zahra Pakbaz. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Sickle Cell Disease
12 Years to 65 Years   (Child, Adult, Older Adult). DETAILED ELIGIBILITY is Key Inclusion Criteria:
1.  Provision of consent
2.  Patient has a confirmed diagnosis of sickle cell disease
3.  At least 2 episodes of vaso-occlusive crises in the past 12 months
4.  Hemoglobin greater than or equal to 5.5 and less than or equal to 10.5 g/dL (>/= 55 and </=105 g/L) during screening
5.  Patients taking hydroxyurea, must demonstrate a stable dose for at least 90 days prior to start of study treatment
6.  Patients on crizanlizumab or L-glutamine treatment at the time of consent must be on a stable dose for &#8805; 12 months and must be &#8805; 80% compliant with the planned regimen at the time of consent and meet the VOC eligibility criteria
7.  Female patients of childbearing potential must use highly effective methods of contraception, male patients are willing to use barrier methods of contraception


Key Exclusion Criteria:
1.  More than 10 vaso-occlusive crises within the past 12 months
2.  Female who is breastfeeding or pregnant
3.  Hepatic dysfunction characterized by: Alanine aminotransferase (ALT) > 4.0 √ó upper limit of normal (ULN) and  Direct bilirubin > 3.0 √ó ULN
4.  Known HIV positivity
5.  Active hepatitis B or hepatitis C infection
6.  Severe renal dysfunction or on chronic dialysis
7.  History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following: Unstable angina pectoris or myocardial infarction or elective coronary intervention, Congestive heart failure requiring hospitalization, Uncontrolled clinically significant arrhythmias
Symptomatic pulmonary hypertension, History of overt clinical stroke within previous 2 years or any history of an intracranial hemorrhage, and/or History of deep venous thrombosis requiring systemic anti-coagulation therapy for >/= 6 weeks, occurring within 6 months prior to Day 1 of study treatment.

Prior/Concomitant Therapy
1.  Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion)
2.  Receiving or use of concomitant medications that are strong inducers of CYP3A4/5 within 2 weeks of starting study treatment or anticipated need for such agents during the study
3.  Use of voxelotor within 28 days prior to starting study treatment or anticipated need for this agent during the study
4.  Use of an experimental selectin antagonist (eg, monoclonal antibody or small molecule) within 28 days of starting study treatment or anticipated need for such agents during the study
5.  Use of erythropoietin or other hematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study
6.  Receipt of prior cellular-based therapy (eg, hematopoietic cell transplant, gene modification therapy). DESCRIPTION is Etavopivat is designed to activate PKR and thereby modulate RBC metabolism by impacting two critical pathways in RBCs. The etavopivat clinical development program will investigate whether decreasing 2,3-DPG may help oxygen bind to hemoglobin (i.e. increasing oxygen affinity), and thereby increase ATP and impact RBC function. This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients age 12 to 65 years (inclusive), with sickle cell disease. There are two planned interim analyses in this study design. Initially, patients will be randomized at 1:1:1 to one of two dose levels of etavopivat or placebo. At the first interim analysis, one of the two etavopivat dose levels will be selected for the Phase 3 portion of the study, in which patients will be randomized at 1:1 to the selected etavopivat dose or placebo. Efficacy on hemoglobin will be evaluated at the second interim analysis, and then will be tested along with evaluation of efficacy on vaso-occlusive crises at the final analysis. Following completion of 52 weeks of double-blind treatment, patients may enter a 52-week etavopivat open-label extension period.. PHASE DESC is II/III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Both. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T15:43:56. DEPARTMENT NAME is CCR. SPONSOR NAMES is FORMA Therapeutics, Inc.. DISEASE SITES is Blood - Hematologic, Sickle Cell Disease (SCD).
183. TITLE is Multicenter Single-blind Randomized Controlled Trial Of Laparoscopic Paraesophageal Hiatal Hernia Repair Combined With Transoral Incisionless Fundoplication Versus Laparoscopic Nissen Fundoplication For Treatment Of Gastroesophageal Reflux Disease In Patients Requiring Hiatal Hernia Repair
. SHORT TITLE is Laparoscopic Paraesophageal Hiatal Hernia Repair Combined With Transoral Incisionless Fundoplication. INVESTIGATOR NAME is Kenneth Chang. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Hiatal Hernia
22 Years to 80 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  22-80 years of age
2.  Subjects have GERD with hiatal hernia < 5 cm (defined as maximum ,axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at time of surgery) and Hill grade III or IV
3.  Pathologic reflux while off PPI based on Lyon criteria by either of the following:

3.1. Conclusive evidence for pathologic reflux defined as acid exposure time (AET) > 6% (worst day) or LA grade C or D esophagitis.

3.2. Borderline evidence of pathologic reflux defined as presence of one of the following parameters: AET 4-6%, LA grade A or B.

4.  Commitment to long-term study
5.  Ability to give consent individually or by a legally authorized representative


Exclusion Criteria:
1.  Hiatal hernia > 5 cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at time of surgery)
2.  Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator
3.  Pregnancy (in females) at time of procedure
4.  Previous anti-reflux procedure
5.  Subjects requiring mesh treatment at time of procedure
6.  At the discretion of the site PI for subject safety
7.  BMI > 35 at time of surgery.
8.  Prior gastric surgery that may affect ability to perform either procedure or affect normal gastric function (e.g. gastrectomy, gastric bypass, sleeve gastrectomy, pyloroplasty.
9.  Severe gastroparesis. DESCRIPTION is Measures will be taken to minimize or avoid bias in the study "masking/blinding procedures." Neither treatment groups will be advised as to which procedure (TIF or LNF) they will be receiving. Randomization assignment will be recorded in the EDC and subject tracking, but will not be recorded within the EMR to reduce clinical team exposure to their randomized status for follow-up care. Research teams will not be blinded to the randomization results.. TREATMENT TYPE DESC is INT - Procedure/Surgery. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:54:23. DEPARTMENT NAME is CCR. SPONSOR NAMES is EndoGastric Solutions, Inc.. DISEASE SITES is Gastroesophageal Reflux Disease (GERD), Digestive - Gastrointestinal.
184. TITLE is A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study with Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults with Myasthenia Gravis. SHORT TITLE is Myasthenia Gravis Inebilizumab Trial. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Diagnosis of MG with anti-AChR or anti-MuSK antibody.
2.  MGFA Clinical Classification Class II, III, or IV.
3.  MG-ADL score of 6 or greater at screening and at randomization with > 50% of this score attributed to non-ocular items.
4.  QMG score of 11 or greater.
5.  Subjects must be on:

a.  Corticosteroids only, with no dose increase within 4 weeks prior to randomization, or
b.  One allowed non-steroidal IST, with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization, or
c.  Combination of (1) corticosteroids with no dose increase within 4 weeks prior to randomization and (2) one allowed non-steroidal IST with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization.
d.  Allowed ISTs, alone or in combination with corticosteroids, are azathioprine, mycophenolate mofetil, and mycophenolic acid.

Exclusion Criteria:
1.  Receipt within the 4 weeks prior to Day 1:  Cyclosporine (except eye drops), Tacrolimus (except topical), and Methotrexate
2,  Current use of:  Prednisone > 40 mg/day or > 80 mg over a 2-day period (or equivalent dose of other corticosteroids). DESCRIPTION is This study is a phase 3, randomized, double-blind, placebo-controlled study, to be conducted at approximately 100 study sites. Approximately 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. Patients with MG who are positive for anti-AChR or anti-MuSK antibodies will be enrolled and analyzed separately as 2 populations: (1) AChR-Ab+ and (2) MuSK-Ab+. Patients who do not have anti-AChR or anti-MuSK antibodies will not be enrolled. Patients with MGFA classification II, III, or IV disease, MG-ADL score &#8805; 6, QMG score &#8805; 11, and use of a corticosteroid and/or non-steroidal immunosuppressant will be included in the study.

All subjects who complete the randomized controlled period will have the option to enroll in a 1.5-year open-label period.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2021-12-21T11:34:18. DEPARTMENT NAME is CCR. SPONSOR NAMES is Medpace, Inc., Viela Bio. DISEASE SITES is Myasthenia Gravis, Brain - Neurologic/ Psychologic.
185. TITLE is Evaluation of pancreatic cystic lesions via EUS-guided fine needle aspiration with and without micro forceps biopsies: A randomized controlled study. SHORT TITLE is Eval of pancreatic cystic lesions via EUS-guided fine needle aspiration w/ and w/o micro forceps. INVESTIGATOR NAME is Jason Samarasena. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 89 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Adult patients >18 years old
2.  Cysts > 20 mm in size deemed appropriate for FNA by the endoscopist, based on clinical presentation, radiologic imaging features, associated solid mass or nodules, and patient anxiety about the diagnosis

Exclusion Criteria:
1.  Age <18 years
2.  Inability to provide informed consent
3.  Thrombocytopenia (Platelets < 50,000) or coagulopathy (INR > 1.8)
4.  Pregnancy
5.  Post-surgical anatomy where the cyst is not accessible for FNA
6.  EUS findings suggesting that cyst FNA would be unsafe (e.g. intervening blood vessels)
7.  EUS appearance suggesting FNA is not indicated (e.g. cyst smaller than prior radiologic imaging, cyst not seen, EUS suggestive of serous cystadenoma). DESCRIPTION is Pancreatic cystic lesions (PCLs) are a common incidental finding in cross sectional imaging (up to 27% on CT scan and 41% on MRI) and pose a management challenge to physicians. According to society guidelines, PCLs with specific features should prompt additional workup with endoscopic ultrasound (EUS) for cyst characterization as well as cyst sampling. This can help determine if the cyst is mucinous or non-mucinous which has implications for its malignant potential. Cyst fluid has traditionally been sampled using EUS with FNA (Fine-Needle Aspiration) and sent for fluid analysis (CEA and amylase) and cytology. However, despite use of a cyst fluid carcinoembryonic antigen (CEA) level cutoff of 192 ng/mL and cytology, accuracy of diagnosis for PCLs is poor. As the spectrum ranges from benign to high risk for neoplasm, precise diagnosis is critical. More recently, the adjunctive use of the Moray¬Æ through the needle microforceps biopsy (EUS-MFB) has shown promise for diagnosis of PCLs. This technology utilizes a microforceps through a 19-guage needle to biopsy the cyst wall for histology, in addition to collecting cyst fluid for CEA level and cytology. Only a few small retrospective reports have been published regarding the use of MFB. Pancreatic cysts continue to pose a management dilemma for practicing clinicians, especially with the increased use of radiologic imaging modalities identifying incidental pancreatic cystic lesions with higher frequency. This leads to patient anxiety and increased costs due to radiologic surveillance and even surgery. The results of this study will hopefully help increase diagnostic yield by obtaining a histopathologic diagnosis of these PCLs, and potentially affect practice patterns of gastroenterologists and the endoscopic community, specifically those physicians who perform EUS in these patients. Furthermore, the results will help determine whether there is reason to continue this line of research to obtain a definite histologic tissue diagnosis of PCLs.. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-15T09:43:38. DEPARTMENT NAME is CCR. SPONSOR NAMES is University of Colorado Denver, US Endoscopy. DISEASE SITES is Pancreatic Cyst, Digestive - Gastrointestinal.
186. TITLE is A Phase 2, multicenter, open label, proof-of-concept study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). SHORT TITLE is BIVV020 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Documented definite or probable diagnosis of CIDP (typical CIDP, pure motor CIDP, or Lewis-Sumner Syndrome) according to the European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS) Task Force first revision.
2.  Belonging to one of the following three groups: standard-of-care (SOC)-Treated, SOC-Refractory or SOC-Na√Øve
3.  Clinically meaningful deterioration
4.  Documented vaccinations against encapsulated bacterial pathogens given within 5 years of enrollment or initiated a minimum of 14 days prior to first dose
5.  A female participant must use a double contraception method including a highly effective method of birth control from inclusion and up to 52 weeks plus 30 days after the last study dose and agree not to donate eggs, ova or oocytes during this period.
6.  A female participant must have a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours before the first dose of study intervention.
7.  Male participants, whose partners are of childbearing potential must accept to use, during sexual intercourse, a double contraceptive method according to the following: condom plus an additional highly effective contraception
8.  Male participants must have agreed not to donate sperm during the intervention and up to 52 weeks after the last dose.
9.  Capable of giving signed informed consent.. DESCRIPTION is The duration of the study for a participant will include:

Part A Screening period: up to 6 weeks. Treatment period: once successfully screened, enrolled participants will receive study intervention for 24 weeks.

Safety follow-up visit: participants who do not enroll (rollover) into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24, ie, approximately at Week 46.

Part B Treatment period (extension): for all groups, this period will consist of 52 weeks of treatment with BIVV020 (Weeks 24 to 76; Part A and B total treatment period of 76 weeks).

Safety follow-up visit: At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last BIVV020 dose (Week 98).. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:20:56. DEPARTMENT NAME is CCR. SPONSOR NAMES is Sanofi US Services Inc (Sanofi). DISEASE SITES is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Brain - Neurologic/ Psychologic.
187. TITLE is An  Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis . SHORT TITLE is Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis . INVESTIGATOR NAME is Sandra Sunhee Park. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 16 Years to 80 Years   (Child, Adult, Older Adult)
Ulcerative Colitis. DETAILED ELIGIBILITY is Inclusion Criteria:

- Must have met the eligibility criteria and have been enrolled in the qualified Phase 2 or 3 parent studies and meet the following additional criteria:

1. Participants previously enrolled in Study APD334-301 (NCT03945188) or APD334-210 (NCT04607837) must have completed the Week 12 visit and have been assessed to have active UC that has not improved or has worsened from baseline or completed the Week 52 visit
2. Participants previously enrolled in APD334-302 (NCT03996369) must have completed the Week 12 visit
Exclusion Criteria:

- If Investigator considers the participant to be unsuitable for any reason to participate in the Open-Label Extension study
- Experienced an adverse event that led to discontinuation from parent study. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:37:34. DEPARTMENT NAME is CCR. SPONSOR NAMES is IQVIA, Arena Pharmaceuticals, Inc. DISEASE SITES is Ulcerative Colitis, Digestive - Gastrointestinal.
188. TITLE is A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS). SHORT TITLE is Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS). INVESTIGATOR NAME is Ramy Hanna. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 12 Years and older   (Child, Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Body weight >= 40 kg at screening.
2.  Vaccination against Neisseria meningitidis.
3.  For participants receiving other therapies (e.g., immunosuppressants, corticosteroids, mTORi, or calcineurin inhibitors: stable dose for 28 days.
4.  For female participants of childbearing potential: an agreement to remain abstinent or use contraception.
5.  Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
6.  Evidence of TMA (for Naive Cohort only).
7.  Onset of TMA =<28 days prior to first crovalimab administration (for Naive Cohort only).
8.  Documented treatment with a C5 inhibitor (for Switch Cohort only).
9.  Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
10.  Known C5 polymorphism (for C5 SNP Cohort only).
11.  Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP Cohort only).

Exclusion Criteria:
1.  TMA associated with non-aHUS related renal disease.
2.  Positive direct Coombs test.
3.  Chronic dialysis and/or end stage renal disease.
4.  Identified drug exposure-related TMA.
5.  Presence or history of a condition that could trigger TMA, such as malignancy, organ transplant (other than kidney transplant) or autoimmune disease.
6.  History of a kidney disease, other than aHUS.
7.  History of Neisseria meningitidis infection within 6 months.
8.  Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
9.  Positive HIV test.
10.  Multi-system organ dysfunction or failure.
11.  Recent IVIg treatment.
12.  Pregnant or breastfeeding or intending to become pregnant.
13.  Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
14.  Recent use of tranexamic acid.
15.  Current or previous treatment with a complement inhibitor (for Na√Øve Cohort only).
16.  Positive for Active Hepatitis B and C infection (HBV/HCV) (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
17.  Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
18.  Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to 19.  Diacylglycerol kinase &#949; (DGKE) nephropathy.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T15:21:59. DEPARTMENT NAME is CCR. SPONSOR NAMES is Genentech, Inc., Roche Diagnostics, F. Hoffmann-La Roche Ltd. DISEASE SITES is Atypical Hemolytic Uremic Syndrome (aHUS), Kidney - Nephrology.
189. TITLE is Evaluation of a Closed Incision Negative Pressure Dressing (PREVENA) To Prevent Lower Extremity Amputation Wound Complications. SHORT TITLE is PREVENA. INVESTIGATOR NAME is Nii-Kabu Kabutey. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Male or female adults 18 years or older
2.  Patients undergoing above-knee amputation (includes the revision of emergency guillotine amputations)
3.  Patients undergoing below-knee amputation (includes the revision of emergency guillotine amputations)
4.  Informed Consent signed by patient

Exclusion Criteria:

1.  Minors under 18 years
2.  Women who are pregnant or breastfeeding
3.  Patients undergoing emergent or guillotine amputation
4.  Patients having BOTH legs amputated
5.  Patients with sensitivity to silver
6.  Unwilling or unable to provide informed consent
7.  Inability to comply with planned study procedures. DESCRIPTION is This is a prospective, multi-center, two-arm, unblinded, randomized controlled trial to evaluate the impact of a closed incision negative pressure dressing (PREVENA&#8482; PEEL & PLACE&#8482; Dressing Kit) on incidence of post-operative wound complications in patients undergoing above-the-knee (AKA) or below-the-knee (BKA) amputation. Up to 440 subjects at approximately five (5) participating sites will be randomized to receive either the Prevena dressing or a standard care dressing. The incision will be assessed for complications at post-op day 5 or day 6 and at approximately 30 days after discharge. The primary outcome of this study is reported wound complications, including dehiscence (opening of the incision), seroma, lymph leak, infection (deep or superficial), hematoma (blood clots), ischemia (decreased blood supply), and necrosis (tissue death) A major complication is defined as any wound complication requiring intravenous or oral antibiotics, reoperation and/or hospital readmission. All data (demographics, medical history, and clinical outcomes) will be collected via medical record review. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:26:00. DEPARTMENT NAME is CCR. SPONSOR NAMES is Thomas Jefferson University, Kinetic Concepts Inc. . DISEASE SITES is Muscles and Bones - Musculoskeletal, Amputation, Other, Traumatic Wounds.
190. TITLE is Dietary Sodium Intake and Blood pressure in Living Kidney Donors: A Pilot Single-Center Crossover Single-Blind Randomized Controlled Trial (SPLID Trial). SHORT TITLE is Dietary Sodium Intake and Blood pressure in Living Kidney Donors (SPLID Trial). INVESTIGATOR NAME is Ekamol Tantisattamo. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Hypertension
Living Kidney Donor
Dietary Sodium Intake. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Living kidney donors who underwent a living kidney donation at least 5 months ago but not more than 12 months
2.  Age >/= 18 years old
3.  Agree to perform the procedure as per study protocol (Table 1)
4.  Living kidney donors with an average sitting SBP <160 mmHg at 5-month post-donation measured by automatic office blood pressure (AOBP)
5.  Able to sign informed consent
6.  Able to attend all research visits
7.  Woman using birth control methods other than hormonal contraception

Exclusion Criteria:
1.  History of previous cardiovascular (CV) events including acute MI, HF, and stroke
2.  Symptomatic heart failure within 5 months after living kidney donation or left ventricular ejection fraction (by any method) <35%
3.  CV event or procedure or hospitalization for hypertensive-related disorders within 5 months after living kidney donation
4.  Diagnosed with HTN or on antihypertensive medication(s) before living kidney donation
5.  Patients who are supposed to take BP lowering medications for reasons other than BP control but do not take those medications or take them with in appropriate doses
6.  Arm circumference is too small or large to allow accurate BP measurement with available 24-h ABPM machines.
7.  An average standing SBP &#8805;160 mmHg at 5-month post-donation measured by automatic office blood pressure (AOBP)
8.  Albuminuria that equals or is equivalent to 1 g per day by using spot urinary albumin per urine creatinine ratio (UACR) or 24-hour urinary albumin excretion rate by a 24-hour urine collection within 5 months post-donation
9.  Advanced kidney function defined by estimated glomerular filtration rate (eGFR) by using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation22 of <20 ml/min/1.73m2 or requiring dialysis after living kidney donation
10.  Drink coffee > two 8-ounce (237 mL) cup a day or equivalence
11.  Drinks alcohol >3 drinks/day or >30 ml/day
12.  Smoking cigarette >/=10 cigarettes/day
13.  Take Nonsteroidal anti-inflammatory drugs (NSAIDS)
14.  Use hormone replacement therapy or oral contraceptives
15.  Pregnancy, currently trying to become pregnant
16.  Using birth control pills
17.  A medical condition likely to limit survival to less than 2 years
18.  Any factors that are likely to limit adherence to interventions. . DESCRIPTION is This is a pilot study to determine the feasibility of the study design and examine the main outcome whether low dietary sodium intake <2.3 g/day (<100 mmol/day) is superior to high dietary sodium intake >/= 4 - <6 g/day (>/= 174 - <261 mmo/day) in controlling blood pressure (BP) to be within normotensive range, lowering systolic and diastolic blood pressures (SBP and DBP) from the baseline blood pressures, and decreasing the risk of hypertension, worsening kidney function, and proteinuria in living kidney donors between 5 and 12 months after living kidney donation.. PHASE DESC is Pilot. TREATMENT TYPE DESC is INT - Behavioral. AGE DESCRIPTION is Adults. SCOPE DESC is Local. MODIFIED DATE is 2023-05-04T17:35:53. DEPARTMENT NAME is CCR. SPONSOR NAMES is UCI. DISEASE SITES is Kidney Donor, Kidney - Nephrology.
191. TITLE is A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Adult Patients With Relapsing Multiple Sclerosis. SHORT TITLE is Fenebrutinib Compared With Teriflunomide In Adult Patients With Relapsing Multiple Sclerosis. INVESTIGATOR NAME is Michael Sy. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 55 Years   (Adult)
Relapsing Multiple Sclerosis. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening.
2.  A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria.
3.  Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in < 240 seconds.
4.  Ability to perform the Timed 25-Foot Walk Test (T25FWT).
5.  For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs.
6.  For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm.

Exclusion Criteria:
1.  Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening < 2.0.
2.  Female participants who are pregnant or breastfeeding, or intending to become pregnant.
3.  Male participants who intend to father a child during the study.
4.  A diagnosis of PPMS or non-active SPMS.
5.  Any known or suspected active infection at screening, including but not limited to a positive screening tests for Hepatitis B and C, an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML).
6.  History of cancer including hematologic malignancy and solid tumors within 10 years of screening.
7.  Known presence of other neurological disorders, clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal disease.
8.  Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
9.  Hypoproteinemia.
10.  Participants with severe renal or hepatic disease impairment.
11.  Participants with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia.
12.  Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study.
13.  History of alcohol or other drug abuse within 12 months prior to screening.
14.  History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of HIV infection.
15.  Inability to complete an MRI scan.
16.  Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening.
17.  Receipt of a live-attenuated vaccine within 6 weeks prior to randomization.
18.  Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period.

OLE Inclusion Criteria:
1.  Completed the Double-Blind Treatment (DBT) phase of the study (remaining on study treatment; no other Disease-Modifying Therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib.
2.  Participants randomized to the teriflunomide treatment arm during the DBT phase must undergo the ATEP prior to the first administration of open-label fenebrutinib.
F4.  or female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs.
5.  For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:33:57. DEPARTMENT NAME is CCR. SPONSOR NAMES is F. Hoffmann-La Roche Ltd, Syneos Health, Genentech, Inc.. DISEASE SITES is Brain - Neurologic/ Psychologic, Multiple Sclerosis (MS).
192. TITLE is A prospective multicenter study to validate a serum-based biomarkers panel to detect mucosal healing in moderate-to-severe UC patients treated with anti-TNFa. . SHORT TITLE is study to validate a serum-based biomarkers panel to detect mucosal healing in moderate-to-severe UC . INVESTIGATOR NAME is Nimisha Parekh. STATUS is OPEN TO ACCRUAL. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. MODIFIED DATE is 2022-03-09T16:23:29. DEPARTMENT NAME is CCR. SPONSOR NAMES is Glycominds. DISEASE SITES is Digestive - Gastrointestinal, Ulcerative Colitis.
193. TITLE is A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Dapirolizumab Pegol In Study Participants With Moderately To Severely Active Systemic Lupus Erythematosus. SHORT TITLE is Dapirolizumab Pegol In Study Participants With Moderately To Severely Active Systemic Lupus Erythema. INVESTIGATOR NAME is Sheetal Desai. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 16 Years and older   (Child, Adult, Older Adult)
Systemic Lupus Erythematosus. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Rescreening will be allowed once during the study in case there is new evidence for an inclusion criterion that was not fulfilled at the first screening or in case a study participant no longer meets an exclusion criterion or screening period exceeded the maximum duration due to delays in screening processes
2.  Study participant must be &#8805;16 years of age, unless restricted by local regulation, at the time of signing the Informed Consent form (ICF)
3.  Study participants who have moderate to severe disease activity due to either persisting active SLE or due to an acute worsening of SLE in the scope of frequent flaring/relapsing-remitting systemic lupus erythematosus (SLE) despite stable standard of care (SOC) medication.
4.  British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in greater than or equal to 2 organ systems and/or a BILAG 2004 Grade A in greater than or equal to 1 organ systems at Screening and Baseline Visit AND
5.  Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) greater than or equal to 6 at Screening Visit AND
6.  SLEDAI-2K without labs greater than or equal to 4 at Baseline Visit e. Receiving the following standard of care (SOC) mediation at stable dose.

Exclusion Critiera:
1  Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life threatening condition
2.  Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies
3.  Study participant has a history of malignancy, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma
4.  Study participant has an increased risk for thromboembolic events due to an ongoing heart disease or due to a medical device, including but not limited to vascular graft, valvular heart disease, atrial fibrillation, or a heart rhythm disorder
5.  Study participant has evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection
6.  Study participant had a reactivated latent infection (example, cytomegalovirus, herpes simplex virus, or herpes zoster infection) or opportunistic infection (including but not limited to, pneumocystis, cytomegalovirus, or severe herpes zoster infection) within 12 weeks prior to the first study medication infusion (Visit 2), or is currently receiving suppressive therapy for an opportunistic infection
7.  Study participants who have received live/live attenuated vaccines within 6 weeks prior to the first study medication infusion
8.  Study participant has clinically significant active or latent infection
9.  Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE
10.  Study participant takes any protocol defined prohibited concomitant medication
11.  Study participant has previously been randomized within this study or participant has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP
12.  Study participant has participated in another study of an IMP within the previous 12 weeks or 5 half-lives of the investigational medicinal product (IMP) whatever is longer or is currently participating in another study of an IMP
13.  Study participant has chronic kidney failure stage 4, manifested by estimated glomerular filtration rate <30 mL/min/1.73m2, or serum creatinine >2.5 mg/dL, or participant has proteinuria >3 g/day, or protein: creatinine ratio >340 mg/mmol at the Screening Visit. DESCRIPTION is Experimental: Dapirolizumab pegol - Subjects will receive dapriolizumab pegol througout the Treatment Period.

Vs

Placebo Comparator - Subjects will receive placebo througout the Treatment Period.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Both. MODIFIED DATE is 2023-05-04T17:34:39. DEPARTMENT NAME is CCR. SPONSOR NAMES is PAREXEL (sponsor CRA), UCB Biopharma SPRL. DISEASE SITES is Muscles and Bones - Musculoskeletal, Lupus Erythematosus, Rheumatology.
194. TITLE is A Prospective, Multicenter Study Evaluating the Safety and Performance of Posterior Fixation in Trauma, Reconstructive, and Tumor Surgery of the Occipito-cervico-thoracic Spine. SHORT TITLE is Posterior Cervical Study. INVESTIGATOR NAME is Michael Oh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Craniocervical Injuries
Cervical Radiculopathy
Cervical Disc Disease
Cervical Fusion
Cervical Spine Disease
Cervical Myelopathy
Cervical Instabilities Spine
Thoracic Injury. DETAILED ELIGIBILITY is Inclusion Criteria:
1. Patients who are >= 18 years of age at the time of consent
2. Have planned craniocervical, cervical (C1 to C7), and/or upper thoracic (T1-T3) spine surgery using posterior fixation planned for treatment of any of the following conditions:
a. traumatic spinal fractures and/or traumatic dislocations
b. instability or deformity
c. failed previous fusions (e.g., pseudoarthrosis)
d. tumors involving the cervical spine
e. degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability

3. Using one of the following posterior occipito-cervico-thoracic fixation systems (NuVasive, Inc, San Diego, CA):
a. Vuepoint II OCT
b. Reline-C

4. Able to undergo surgery based on physical exam, medical history, and surgeon judgment
5. Understands the conditions of enrollment and is willing to sign an informed consent form to participate in the study

Exclusion Criteria:
1. Patient is involved in active litigation relating to the spine (workers' compensation claim is allowed if it is not contested)
2. Use of bone growth stimulators postoperatively
3. Active smoking within 6 weeks of surgery
4. Patient has known sensitivity to materials implanted
5. Systemic or local infection (latent or active) or signs of local inflammation
6. Patient has inadequate bone stock or quality, or a physical or medical condition that would prohibit beneficial surgical outcome based on surgeon judgment
7. Pregnant, or plans to become pregnant
8. Patient is a prisoner
9. Patient is participating in another clinical study that would confound study data. DESCRIPTION is This study is a prospective, uncontrolled, multicenter study to evaluate the safety and performance of select occipito-cervico-thoracic posterior fixation systems in patients who undergo posterior fixation fusion surgery. Consecutive patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. These patients will present with traumatic, reconstructive, and/or tumor conditions in the craniocervical, cervical, and/or upper thoracic spine that are amenable to surgical treatment and will be screened prior to study enrollment. Once enrolled in the study, subjects will undergo posterior occipito-cervico-thoracic fixation surgery using one of the NuVasive posterior fixation systems (Vuepoint II OCT or Reline-C) based on the surgeon's standard of care. At least 150 subjects (a minimum of 75 in each implant arm) will be enrolled and will be followed for 24 months after the surgery.. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:43:02. DEPARTMENT NAME is CCR. SPONSOR NAMES is NuVasive Inc.. DISEASE SITES is Degenerative Disc Disease, Muscles and Bones - Musculoskeletal.
195. TITLE is PLS Natural History Study (PNHS). SHORT TITLE is PNHS. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:44:30. DEPARTMENT NAME is CCR. SPONSOR NAMES is Columbia University Medical Center, ALS Association, Mitsubishi Tanabe Pharma America, Inc., Spastic Paraplegia Foundation (SPF). DISEASE SITES is Brain - Neurologic/ Psychologic.
196. TITLE is A Phase 3, Open-Label, Multicenter, Extension Study To Evaluate The Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration. SHORT TITLE is Study To Evaluate The Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atr. INVESTIGATOR NAME is Baruch Kuppermann. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 60 Years and older   (Adult, Older Adult)
Geographic Atrophy Secondary to Age-related Macular Degeneration. DETAILED ELIGIBILITY is Inclusion Criteria - Participants are eligible to be included in the study only if all of the following criteria apply:

- Ocular-specific inclusion criteria apply to the study eye only

-  Subjects must have participated in APL2-103 (NCT03777332) or completed the treatment at Month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600).

-  For subjects who participated in either the 303 or 304 studies, the condition listed below must also be met for participating in this study.  Subjects who did not fully stop study drug treatment, but missed the visit at Month 24, can also participate in the study. However, to participate, subjects must be seen within 60 days from the last day of the period allowed for the 24 months visit in the previous study.

-  The eyes of subjects must have transparency to permit visualization of parts inside the eye such as the retina and subjects must be able to look steadily at a provided target allowing the doctor to get good quality pictures from the eye.

-  Female subjects must be:  Women that cannot have children, or  Women who can have children must have a negative result of a blood pregnancy test on the first day of the study visit and agree to use ways to avoid pregnancy during the study and 90 days after the last dose of the study medication.

-  Males with female partners who can get pregnant must also agree to use ways to avoid pregnancy and agree not to donate sperm while in the study or until 90 days after administering the last dose of the study medication.

-  Agree to participate in the study by signing the consent document providing information about the study; and take part in all tests and assessments as required.

Exclusion Criteria - Subjects cannot take part in the study if the eye that will be treated during the study currently meets any of the following conditions:

-  Participants in APL2 303/304 studies who fully stopped study drug treatment before the visit in month 24 but remain in the study to observe the study medication's safety. Those subjects who temporarily paused study drug treatment are still eligible to participate.

-  If, according to your doctor you currently have any disease affecting your eyes that could interfere with your vision, including diseases that affect your retina or macula (the center of the back of your eyes). And, if according to your doctor, the disease in your eyes is benign and does not interfere with the study (e.g. diseases that affects the periphery of the retina), you are also eligible to take part in the study.

-  If, according to your doctor you currently have any inflammation/infection in or around your eyes that could prohibit you from receiving an injection inside your eyes.

-  If, according to your doctor, any current disease that could directly interfere in your participation in the study or that could make it difficult for you to come to the scheduled visits during the next three yearsover the next 36 months.

-  If you have known allergies to fluorescein sodium, a solution that is injected into your body for eye testing; or to pegcetacoplan (the study drug) or any inactive substances in pegcetacoplan solution.

-  If you currently are pregnant, breastfeed or have a positive pregnancy test.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T15:57:27. DEPARTMENT NAME is CCR. SPONSOR NAMES is Apellis Pharmaceuticals, Inc., Labcorp Drug Development, Inc. DISEASE SITES is Eye - Ophthalmologic, Geographic Atrophy, Macular Degeneration.
197. TITLE is A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis. SHORT TITLE is A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
. DETAILED ELIGIBILITY is Inclusion Criteria:
.  Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study

Exclusion Criteria:

.  With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted). DESCRIPTION is Primary Outcome Measures: Record number of participants with adverse events. 

Secondary Outcome Measures  :
1. The MG-ADL profile provides an assessment of MG symptom severity and measures 8 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the ADL score. The ADL score can range from 0 (least severe) to 24 (most severe).

2. The QMG test is a standardized quantitative strength scoring system and measures 13 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the QMG score. The QMG score can range from 0 (least severe) to 39 (most severe).. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T16:11:32. DEPARTMENT NAME is CCR. SPONSOR NAMES is F. Hoffmann-La Roche Ltd, Syneos Health, Genentech, Inc.. DISEASE SITES is Myasthenia Gravis, Brain - Neurologic/ Psychologic.
198. TITLE is RiOciguAt UseRs Registry - The ROAR Registry. SHORT TITLE is The ROAR Registry. INVESTIGATOR NAME is Bassam Yaghmour. STATUS is OPEN TO ACCRUAL. PHASE DESC is IV. TREATMENT TYPE DESC is OBS - Registry. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-03-09T16:45:09. DEPARTMENT NAME is CCR. SPONSOR NAMES is Bayer Healthcare Pharmaceuticals . DISEASE SITES is Lung - Pulmonary.
199. TITLE is A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis. SHORT TITLE is Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopath. INVESTIGATOR NAME is Ramy Hanna. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 12 Years and older   (Child, Adult, Older Adult)
C3G
IC-MPGN
C3 Glomerulopathy
C3 Glomerulonephritis
Complement 3 Glomerulopathy
Complement 3 Glomerulopathy (C3G)
Complement 3 Glomerulonephritis
Dense Deposit Disease
DDD
Membranoproliferative Glomerulonephritis
Membranoproliferative Glomerulonephritis (MPGN)
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN). DETAILED ELIGIBILITY is Inclusion Criteria:

- Aged at least 18 years; where approved, adolescents (aged 12-17 years) weighing at least 30 kg may also be enrolled.
- A diagnosis of primary C3G or IC-MPGN (with or without previous renal transplant).
- Evidence of active renal disease, based on one or more of the following:

1. In adults or adolescents with a baseline renal biopsy, at least 2+ staining for C3c on the baseline renal biopsy collected during screening, per the central pathology laboratory.
2. In adolescents not providing a baseline renal biopsy, at least one of the following:
- Serum C5b-9 level above the upper limit of normal (ULN) during screening.
- Serum C3 below the LLN during screening.
- Presence of an active urine sediment during screening, as evidenced by hematuria with at least 5 red blood cells (RBCs) per high-power field (HPF) and/or red blood cell casts on local or central microscopic analysis of urine.
- Presence of C3 nephritic factor within 6 months of screening, based on central lab results or medical history.
- No more than 50% global glomerulosclerosis or interstitial fibrosis on the baseline biopsy, for adult subjects or adolescent subjects providing a baseline biopsy.
- At least 1 g/day of proteinuria on a screening 24-hour urine collection, and a uPCR of at least 1000 mg/g on at least 2 first-morning urine samples collected during screening.
- eGFR &#8805;30 mL/min/1.73 m2 calculated by the Chronic Kidney Disease-Epidemiology Collaboration creatinine equation for adults, or the Bedside Schwartz equation for adolescents.
- Stable regimen for C3G/IC-MPGN treatment, as described below:

1. Stable and optimized angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) therapy for at least 12 weeks prior to randomization, in the opinion of the investigator.
2. Stable doses of other medications that can affect proteinuria (eg, steroids, mycophenolate mofetil (MMF) and/or other allowed immunosuppressants that the patient is receiving for treatment of C3G) for at least 8 weeks prior to the baseline renal biopsy, and at least 12 weeks prior to randomization.
- Have received vaccinations against S pneumoniae, N meningitidis (types A, C, W, Y, and B), and H influenzae (type B) within 5 years prior to randomization or agree to receive vaccinations during screening.
Exclusion Criteria:

- Previous exposure to pegcetacoplan.
- C3G/IC-MPGN secondary to another condition (eg, infection, malignancy, monoclonal gammopathy, a systemic autoimmune disease such as systemic lupus erythematosus, chronic antibody-mediated rejection, or a medication), in the opinion of the investigator.
- Current or prior diagnosis of human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection or positive serology during screening that is indicative of infection with any of these viruses.
- Weight more than 100 kg at screening.
- Hypersensitivity to pegcetacoplan or to any of the excipients.
- History of meningococcal disease.
- Malignancy, except for the following:

1. Cured basal or squamous cell skin cancer
2. Curatively treated in situ disease
3. Malignancy-free and off treatment for &#8805;5 years
- An absolute neutrophil count <1000 cells/mm3 at screening.
- Use of rituximab, belimumab, or any approved or investigational anticomplement therapy other than pegcetacoplan within 5 half-lives of that product prior to the screening period.
- Female subjects who are pregnant or who are currently breastfeeding and are unwilling to discontinue for the duration of the study and for at least 90 days after the final dose of study drug.
- Presence or suspicion of severe recurrent or chronic infections that, in the opinion of the investigator, may place the subject at unacceptable risk by study participation.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T16:12:30. DEPARTMENT NAME is CCR. SPONSOR NAMES is Apellis Pharmaceuticals, Inc., Worldwide Clinical Trials, Inc.. DISEASE SITES is Kidney - Nephrology.
200. TITLE is New IDEAS: Imaging Dementia Evidence for Amyloid Scanning Study A Study to Improve Precision in Amyloid PET Coverage and Patient Care. SHORT TITLE is Study to Improve Precision in Amyloid PET Coverage and Patient Care. INVESTIGATOR NAME is Seyed Ahmad Sajjadi. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Medicare beneficiary with Medicare as primary insurance;
Meets clinical criteria for Mild Cognitive Impairment (MCI) or Dementia as defined by the 2018 National Institute on Aging - Alzheimer's Association Research Framework
Brain MRI and/or CT within 24 months prior to enrollment;
Clinical laboratory assessment (complete blood count [CBC], standard blood chemistry profile, thyroid stimulating hormone [TSH], vitamin B12) within the 12 months prior to enrollment;
Able to tolerate amyloid PET required by protocol, to be performed at a participating PET facility;
English or Spanish speaking (for the purposes of informed consent);
Willing and able to provide consent. Consent may be by proxy;
Neuropsychiatric syndrome can be classified into "clinically typical" or "clinically atypical" categories
Exclusion Criteria:

Normal cognition or subjective complaints that are not verified by cognitive testing or key informant.
Knowledge of amyloid status, in the opinion of the referring dementia expert, may cause significant psychological harm or otherwise negatively impact the patient or family.
Amyloid status already known to patient or referring clinician based on prior amyloid imaging or cerebrospinal fluid analysis.
Current or previous enrollment in an anti-amyloid therapeutic trial.
Scan is being ordered solely based on a family history of dementia, presence of apolipoprotein E (ApoE) 4, or in lieu of genotyping for suspected autosomal mutation carriers.
Scan being ordered for nonmedical purposes (e.g., legal, insurance coverage, or employment screening).
Cancer requiring active therapy (excluding non-melanoma skin cancer).
Hip/pelvic fracture within the 12 months prior to enrollment.
Body weight exceeds PET scanner weight limit.
Currently pregnant or planning to become pregnant within 90 days of registration.
Life expectancy less than 24 months based on medical co-morbidities.
Residence in a skilled nursing facility (assisted living facility is not an exclusion criterion).. DESCRIPTION is A total of 7,000 Medicare beneficiaries meeting the study's eligibility criteria will be consented and enrolled over 30 months at sites throughout the United States. To ensure diversity, the study will enroll at least 2,000 Blacks/African Americans, at least 2,000 Latinos/Hispanics, and up to 3,000 additional participants from other racial and ethnic backgrounds. Based on disease stage prior to PET, all participants will be classified as having MCI or dementia as their disease stage. Based on their clinical presentation prior to PET, all participants will be classified as having "typical" (i.e. progressive amnestic) or "atypical" clinical presentations of AD as the potential cause of dementia or MCI.

Dementia specialists will team with PET facilities that have trained radiologists/nuclear medicine physicians and access to perform amyloid PET. All participating physicians and study staff will complete comprehensive training to ensure adherence of data requirements and study timelines. Amyloid PET will be performed and interpreted at each facility with results provided to the ordering dementia specialist for support in further decision making. The dementia specialists will record their diagnosis and intended management plan based on the current clinical and diagnostic information, and assuming no future access to amyloid PET at the "Pre-PET visit." This represents a "thought experiment" documenting the management plan that would be recommended by the specialist if the participant were not enrolling in New IDEAS and thus had no access to amyloid PET. PET results will be disclosed to patients and any consequent changes in management (if any) will be recommended at the "PET disclosure visit." Patients will return 90 ¬± 30 days following PET for an in person "Post-PET visit." At this final visit, the dementia specialists will record the diagnosis and implemented management plan, incorporating amyloid PET into clinical decision making. Medicare claims data will be collected directly from CMS for 12 months prior to the PET imaging and 12 months after the PET imaging, for each participant.

Aim 1 utilizes Medicare claims data to compare 12-month claims-derived outcomes in amyloid PET-positive versus amyloid PET-negative individuals with MCI and dementia across the entire cohort. Aims 2 and 3 investigate these associations in sub-groups of study participants based on self-identified race and ethnicity (Aim 2) and clinical presentation (Aim 3). Aims 2 and 3 additionally evaluate changes in management between the pre- and post-PET visits in the relevant sub-groups, to test whether benefits in health outcomes are mediated by changes in clinical management. The investigator's over-arching hypothesis, supported by preliminary data from the first IDEAS study, is that amyloid PET results will be associated with changes in clinical management, which in turn will translate into improved health outcomes in patients with amyloid PET-positive scans in comparison with patients with amyloid PET-negative scans. We further hypothesize that these effects will be seen across patients of different ethnoracial backgrounds, clinical presentations and disease stages (MCI and dementia).

Optional components of the study include the collection and archival of participant's amyloid PET images, and blood plasma. These repositories will serve as a resource to the field, enabling the testing and validation of emerging genetic and blood biomarkers. Separate consent will be obtained for participation in these components.. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T16:21:08. DEPARTMENT NAME is CCR. SPONSOR NAMES is American College of Radiology (ACR). DISEASE SITES is Brain - Neurologic/ Psychologic, Dementia.
201. TITLE is Prospective, Open-label, Single-arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases. SHORT TITLE is NORM-01. INVESTIGATOR NAME is Sudhir Gupta. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 12 Years to 85 Years   (Child, Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Age of greater than or equal to 2 years and less than or equal to 75 years
2.  Documented and confirmed diagnosis of PID as defined by European Society of Immunodeficiencies (ESID) and the Pan American Group for Immune Deficiency (PAGID) and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PID must be recorded.
3.  At least 12 weeks of regular treatment before the screening visit (i.e., with a stable dosing interval) with any IVIG, SCIG, or fSCIG, with a stable IgG dose between 200 and 800 mg/kg/month. A stable dose is defined as one that deviates less than ¬±25% from the mean dose for all infusions within this 12-week period before screening.
4.  Trough level of IgG greater than or equal to 5 g/L at screening and documentation of an IgG trough level of greater than or equal to 5 g/L at least once within the previous 12 weeks.
5.  Freely given written informed consent from adult patients or freely given written informed consent from the patient's parent(s)/legal guardian(s) and written informed assent from paediatric or adolescent patients in accordance with the applicable regulatory requirements, before any study-specific procedure takes place.
6.  Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2022-03-09T16:21:40. DEPARTMENT NAME is CCR. SPONSOR NAMES is Octapharma. DISEASE SITES is Primary Immunodeficiency Disease, Immunologic/ Auto Immune.
202. TITLE is Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse  Bone Graft and The Capstone  Spinal System With Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine. SHORT TITLE is Transforaminal Lumbar Interbody Fusion (TLIF). INVESTIGATOR NAME is Michael Oh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Degenerative Disease of the Lumbosacral Spine. DETAILED ELIGIBILITY is Inclusion Criteria: (A subject must meet all of the following inclusion criteria to participate in this study)

1.   Has degenerative disease of the lumbosacral spine in one or two adjacent levels (L2 to S1) that results in radiculopathy secondary to nerve root compression, manifested by: History of radiating leg or buttock pain, paresthesia, numbness or weakness, or History of neurogenic claudication.
2.   Has a history of low back pain.
3.   Has radiographic evidence (e.g. CT, MRI, x-ray, etc.) of degenerative lumbosacral disease including at least one of the following:
Instability up to and including Grade 2 spondylolisthesis/retrolisthesis based on the Meyerding classification (Meyerding, HW, 1932), or lateral listhesis demonstrated by coronal plane translation (slippage) of the superior (cranial) vertebral body lateral to the inferior (caudal) vertebral body less than or equal to 3mm, or Stenosis, or narrowing, of the lumbar spinal canal and/or intervertebral foramen requiring significant decompression leading to segmental instability, or Recurrent disc herniation.
4.  Has preoperative Oswestry Disability Index score greater than or equal to 35.
Has to meet either inclusion criteria 5 or 6 to qualify for the study:
5.  Has preoperative back and leg pain scores of (back pain greater than or equal to 4 and leg pain greater than or equal to 1) based on the Preoperative Back and Leg Pain Questionnaire.
6.  Has preoperative back and leg pain scores of (back pain greater than or equal to 1 and leg pain greater than or equal to 4) based on the Preoperative Back and Leg Pain Questionnaire.
7.  Is at least 18 years of age and skeletally mature at the time of surgery.
8.  Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of six months.
9.  Is willing and able to comply with the study plan and able to understand and sign the subject Informed Consent Form.

For exclusion criteria, please refer to treating center for more information.

. DESCRIPTION is This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively.. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:08:31. DEPARTMENT NAME is CCR. SPONSOR NAMES is Medtronic, Inc.. DISEASE SITES is Spine, Degenerative Disc Disease, Muscles and Bones - Musculoskeletal.
203. TITLE is A Phase 4 Study Evaluating Real-World Use of CDPATH , a Crohn s Disease Risk Prediction Tool. SHORT TITLE is COMPASS-CD Study. INVESTIGATOR NAME is Nimisha Parekh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Crohn's Disease. DETAILED ELIGIBILITY is Inclusion Criteria:
1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
2. Has agreed to use the CDPATH&#8482; tool.
3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:
1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
2. Has had any non-CD-related abdominal surgery.
3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
4. Has previously used CDPATH&#8482; or PROSPECT results to assess CD risk for complications.. DESCRIPTION is The tool being tested in this study is called CDPATH&#8482;. CDPATH&#8482; is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH&#8482;.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH&#8482; process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.. PHASE DESC is IV. TREATMENT TYPE DESC is OBS - Registry. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:32:20. DEPARTMENT NAME is CCR. SPONSOR NAMES is Outcome Sciences,LLC, Takeda. DISEASE SITES is Crohn's Disease, Digestive - Gastrointestinal.
204. TITLE is A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients with Myotonic Dystrophy Type 1, Followed by an Open-Label Extension. SHORT TITLE is Safety & Efficacy of  HBS-101 on Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 Patients. INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 65 Years   (Adult, Older Adult)
Excessive Daytime Sleepiness. DETAILED ELIGIBILITY is Inclusion Criteria:

- Is able to provide voluntary, written informed consent.
- Has a diagnosis of DM1 confirmed by genetic testing (cytosine-thymine-guanine [CTG] repeat of &#8805;100) and patient medical records.
- Male or female patients ages 18 to 65 years at the time of enrollment.
- Has a Clinical Global Impression of Severity (CGI-S) assessment of moderate or severe for overall severity of EDS at Screening.
- Has a mean sleep latency of &#8804;25 minutes as determined by MWT score at the Baseline Visit (Visit 2).
- If on a wake-promoting treatment that could affect EDS (including stimulants, modafinil, and armodafinil):

a. Must be on a stable dose for at least 2 months prior to Screening and agree to continue the stable dose for the duration of the Double-Blind Treatment Phase of the study (dose adjustments will be permitted in the OLE Phase).
b. If not on a stable dose for 2 months prior to Screening, washout for 5 half-lives or 14 days, whichever is longer, prior to randomization and agree to remain off these treatments for the duration of the Double-Blind Treatment Phase of the study.
- Washout of cannabidiol and tetrahydrocannabinol for 28 days prior to randomization and agree to remain off for the duration of the Double-Blind Treatment Phase of the study.
- Able to walk independently with or without an assistive device (e.g., cane, walker, orthoses allowed).
- A patient who is a female of child-bearing potential (FCBP) must have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy test at the Baseline Visit and agree to remain abstinent or use an effective method of non-hormonal contraception to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug.
- In the opinion of the Investigator, the patient is capable of understanding and complying with the protocol and administration of oral study drug.
. DESCRIPTION is The study will consist of a Screening Period, an 11-week Double-Blind Treatment Phase (including a 3-week Titration Period and an 8-week Stable Dose Period), and an optional Open Label Extension (OLE) Phase. The OLE Phase will last approximately one year for each patient or until the Sponsor elects to terminate the study.

Approximately 135 patients ages 18 to 65 years who meet all eligibility criteria will be randomized at the Baseline Visit in a 1:1:1 ratio to low dose pitolisant, high dose pitolisant, or matching placebo. In the Double-Blind Treatment Phase, patients will be titrated to their randomized stable dose of study drug during the 3-week Titration Period.

After completion of the 3-week Titration Period, patients will continue to take study drug at their randomized stable dose once daily in the morning upon wakening for an additional 8 weeks of blinded treatment (Stable Dose Period). The duration of the Double-Blind Treatment Phase will be 11 weeks.

Following the 11-week Double-Blind Treatment Phase, eligible patients will be given the opportunity to participate in an optional OLE Phase. During the OLE Phase, all eligible patients will receive treatment with open-label pitolisant. Patients will first undergo a 3-week Titration Period to a maximum target dose, after which they will continue to take their dose of pitolisant once daily in the morning upon wakening until the end of the study. The patient's dose of pitolisant may be adjusted during the OLE phase.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:11:13. DEPARTMENT NAME is CCR. SPONSOR NAMES is Harmony Biosciences, LLC, Pharmaceutical Research Associates, Inc.. DISEASE SITES is Brain - Neurologic/ Psychologic, Myotonic Dystrophy.
205. TITLE is A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in subjects with IgA nephropathy. SHORT TITLE is A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy. INVESTIGATOR NAME is Ramy Hanna. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 70 Years   (Adult, Older Adult)
. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  IgA nephropathy confirmed by pathological biopsy within 8 years prior to randomization;
2.  Male or female aged greater than or equal to 18 years old and less than or equal to 70 years old;
3.  Average 24-hour urine total protein greater than or equal to 1 g/24 h
4.  Estimated GFR (using the CKD-EPI formula) > 30 mL/min per 1.73 m^2;
5.  Stabilized AEI/ARB medications, diuretics, or other antihypertensive therapy.

Exclusion Criteria:
1.  Patients with clinically significant abnormal laboratory tests at screening;
2.  Evidence of rapid eGFR decrease > 15 ml/min during screening;
3.  Renal or other organ transplantation prior to, or expected during, the study;
4.  Patients with secondary IgA nephropathy;
5.  Patients with nephrotic syndrome, crescentic nephritis minimal change nephropathy with IgA deposition, or other pathological or clinical types of renal diseases that may confound the study data interpretation;
6.  Patients with history of any severe unstable cardiovascular and cerebrovascular events within 12 weeks prior to screening;
Immunocompromised individuals.. DESCRIPTION is IgA nephropathy is a kidney disease in which IgA, a protein meant to defend the body against foreign invaders, accumulates in the kidneys and damages them. This study will seek to determine the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.

The study is composed of 2 parts: a screening period and a double-blind treatment period. Subjects with confirmed IgA nephropathy within 8 years will be enrolled and randomized 1:1:1 to Telitacicept 160 mg, Telitacicept 240 mg, or placebo (10 per arm).. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:30:39. DEPARTMENT NAME is CCR. SPONSOR NAMES is RemeGen Co., Ltd.. DISEASE SITES is Kidney - Nephrology, IgA Nephropathy.
206. TITLE is LUX-Dx Heart Failure Sensors in an Insertable Cardiac Monitor System Clinical Study. SHORT TITLE is LUX-DX TRENDS Clinical Study. INVESTIGATOR NAME is Dawn Lombardo. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Heart Failure
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Key Inclusion Criteria:
1.  Patient is currently in NYHA Class II or III.
2.  For patients with LVEF >40% measured on most recent available echocardiography within the previous 12 months:

a)  ONE (1) of the following echocardiography findings: LA width (diameter) >3.8 cm, LA length >5.0 cm, LA area >20 cm2, LA volume >55 ml, LA volume index >29 ml/m2, LVH defined by septal thickness or posterior wall thickness of >1.1 cm AND
b)  ONE (1) of the following: Elevated BNP/NT-proBNP as defined by: BNP >100 pg/ml or NT-proBNP >300 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP >300 pg/ml or NT-proBNP >900 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months

3.   For patients with LVEF <40% (for MI patients, measured no less than 30 days post-MI) on most recent available echocardiography within the previous 12 months:

a)  ONE (1) of the following: Elevated BNP/NT-proBNP as defined by BNP >150 pg/ml or NT-proBNP >600 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP >450 pg/ml or NT-proBNP >1800 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months

4.  Patient is willing to be monitored in LATITUDE Clarity and use the ICM patient mobile app.
5.  Patient is of legal age to give informed consent and is willing to participate in the trial.

Key Exclusion Criteria:
1.  Patient is currently implanted with any other active electronic medical device.
2.  Patient has undergone a heart transplant.
3.  Patient is currently enrolled in another investigational study (excluding registries) without prior written approval from Boston Scientific.
4.  Patient is known to be pregnant at the time of enrollment or plans to become pregnant during study participation.
5.  Patient is diagnosed with amyloidosis or hypertrophic cardiomyopathy.. DESCRIPTION is The primary objective of this study is to collect physiological measurement data and heart failure (HF) event data that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems. This study will not have pre-defined statistical endpoints. To support the primary objective, diagnostic sensor data will be compared to reference clinical testing data and heart failure decompensation events.. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-31T11:27:50. DEPARTMENT NAME is CCR. SPONSOR NAMES is Boston Scientific. DISEASE SITES is Heart Failure, Heart - Cardiovascular/ Circulatory.
207. TITLE is A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy. SHORT TITLE is Efgartigimod PH20 SC (ARGX-113). INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Ability to consent in the jurisdiction in which the study is taking place and capable of giving signed informed consent.
2.  A definite or probable clinical diagnosis of idiopathic inflammatory myopathy (IIM)
3.  One of the following medical histories:
-- Diagnosis of dermatomyositis (DM) or juvenile dermatomyositis (JDM), (age of disease onset <18 years of age). The diagnosis date for juvenile dermatomyositis should not be >5 years from the screening date.
-- Diagnosis of polymyositis (PM) (including antisynthetase syndrome (ASyS))
-- Diagnosis of immune-mediated necrotizing myopathy (IMNM)

4.  Diagnosed with active disease as defined by the presence of at least 1 of the following criteria:
-- Abnormal levels of at least 1 of the following enzymes: creatine kinase (CK), aldolase, lactate dehydrogenase, aspartate aminotransaminase (AST), alanine aminotransferase (ALT), based on central laboratory results
-- Electromyography demonstrating active disease within the past 3 months
-- Active dermatomyositis (DM) skin rash
-- Muscle biopsy indicative of active idiopathic inflammatory myopathy (IIM) in the past 3 months
-- Magnetic resonance imaging within the past 3 months indicative of active inflammation

5.  Muscle weakness
6.  Receiving a permitted background treatment for idiopathic inflammatory myopathy.
7.  Contraceptive use by nonsterilized male participants and women of childbearing potential will be consistent with local regulations, where available, for individuals participating in clinical studies. Women of childbearing potential must have a negative serum pregnancy test during screening and a negative urine pregnancy test at baseline to establish the nonpregnant state before receiving investigational medicinal product (IMP).

The full list of inclusion/ exclusion criteria can be found in the protocol.. PHASE DESC is II/III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-16T20:21:39. DEPARTMENT NAME is CCR. SPONSOR NAMES is argenxBVBA. DISEASE SITES is Brain - Neurologic/ Psychologic, Myopathy.
208. TITLE is Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis   A prospective evaluation (INSPIRE-IBM). SHORT TITLE is (INSPIRE-IBM). INVESTIGATOR NAME is Namita Goyal. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 40 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Ages 40 years and older
2.  Fulfills ENMC 2011 criteria of clinically definite or probable sporadic Inclusion body myositis (sIBM)
3.  Disease onset is within the past 10 years of the time of Baseline visit
4.  Able to participate and comply with study related procedures
5.  Able to provide written consent

Exclusion Criteria:
1.  Current or very recent use (within last 6 months of the Baseline visit) of immunomodulation or immunosuppression therapy.
2.  Current or very recent use (within last 90 days of the Baseline visit) of an investigational medication or therapy.
3.  Co-existing significant medical or surgical conditions that, in the opinion of the investigator, will influence study participation or alter natural history.. DESCRIPTION is his is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants with sporadic IBM, diagnosed according to established criteria. Participants will require an routine serum sample via blood draw to evaluate for NT5c1A antibody status. This testing will be performed at Washington University School of Medicine in the Neuromuscular Laboratory. Investigators will be blinded to antibody status. A subset of participants (40) will undergo a muscle biopsy at the Baseline visit.

Aim 1. To determine for the first time whether NT5c1A antibodies mediate disease progression over a two-year interval in patients with sIBM.

We will perform a prospective, non-interventional, observational study on patients with sIBM with follow up and evaluations every 6 months over a two-year time frame. Primary analyses are: 1) the rates of disease progression and severity as measured by rates of decline in IBM Functional Rating Scale (IBMFRS) score and Timed Get Up and Go (TUG); 2) the presence or absence of serum antibodies to NT5c1A; and 3) the presence and frequency of variant T-cells in the serum and skeletal muscle.

Aim 2. To perform a detailed morphological, histochemical and immunohistochemical analysis of fresh muscle biopsy specimens obtained from a subset of patients with sIBM.

Aim 3. To characterize the distribution of "immunosenescent" lymphocytes in circulating blood from patients with sIBM.

Aim 4. To quantify the decline in the respiratory function of sIBM patients.. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:13:54. DEPARTMENT NAME is CCR. SPONSOR NAMES is UCI. DISEASE SITES is Inclusion Body Myositis, Brain - Neurologic/ Psychologic.
209. TITLE is A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures. SHORT TITLE is EP0162. INVESTIGATOR NAME is Xiaoying Lu. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 12 Years and older   (Child, Adult, Older Adult)
Stereotypical Prolonged Seizures. DETAILED ELIGIBILITY is Inclusion Criteria:

- Participant must be &#8805;12 years of age at the Baseline/Randomization Visit
- Participant must have a study caregiver &#8805;18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures
- Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:

1. Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
2. Episodes of a focal seizure with a minimum duration of 3 minutes
3. Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
- Prior to the Screening Visit, participant has experienced &#8805;4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit
- Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder
- Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit
- Male and female participants:

1. A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after IMP administration and refrain from donating sperm during this period
2. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration

- Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The ICF or a specific assent form, where required, will be signed and dated by minors
- The participant's study caregiver(s) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the iPMP. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Both. MODIFIED DATE is 2023-02-07T13:15:17. DEPARTMENT NAME is CCR. SPONSOR NAMES is PAREXEL (sponsor CRA), UCB Biopharma SPRL. DISEASE SITES is Seizures, Brain - Neurologic/ Psychologic.
210. TITLE is A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of Auxora in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome. SHORT TITLE is A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS. INVESTIGATOR NAME is Jason Samarasena. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Acute Pancreatitis
Systemic Inflammatory Response Syndrome. DETAILED ELIGIBILITY is Inclusion Criteria:
All of the following must be met for a patient to be randomized into the study:
1. The diagnosis of acute pancreatitis has been established by the presence of abdominal pain consistent with acute pancreatitis together with at least 1 of the following 2 criteria:
   a. Serum lipase > 3 times the upper limit of normal (ULN);
   b. Characteristic findings of acute pancreatitis on abdominal imaging;

2. The diagnosis of SIRS has been established by the presence of at least two of the following four criteria:
   a. Temperature < 36¬∞C or > 38¬∞C;
   b. Heart rate > 90 beats/minute;
   c. Respiratory rate >20 breaths/minute or arterial carbon dioxide tension (PaCO2) <32 mmHg;
   d. White blood cell count (WBC) >12,000 mm3, or <4,000 mm3, or > 10% immature (band) 
   forms;

3. At least one of the following criteria is also present:
   a. A peripancreatic fluid collection or a pleural effusion on a contrast-enhanced computed 
   tomography (CECT) performed in the 24 hours before Consent or after Consent and before 
   Randomization;
   b. Abdominal examination documenting either abdominal guarding or rebound tenderness;
   c. Hematocrit >= for men or >= for women;

4. The patient is >= 18 years of age;
5. Lack of pancreatic necrosis, pancreatic calcifications, pancreatic pseudocysts and no evidence for previous necrosectomy or pancreatic surgery identified by CECT performed in the 24 hours before Consent or after Consent and before Randomization;
6. A female patient of childbearing potential who is sexually active with a male partner is willing to practice acceptable methods of birth control for 180 days after the last dose of study drug. A female patient must not attempt to become pregnant for 180 days;
7. A male patient who is sexually active with a female partner of childbearing potential is willing to practice acceptable methods of birth control for 180 days after the last dose of study drug. A male patient must not donate sperm for 180 days;
8. The patient is willing and able to, or has a legal authorized representative (LAR) who is willing and able to, provide informed consent to participate, and to cooperate with all aspects of the protocol.

Exclusion Criteria:
Patients with any of the following conditions or characteristics must be excluded from randomizing:
1. Expected survival <6 months;
2. Suspected presence of cholangitis in the judgment of the treating physician;
3. The patient has a known history of:
   a. Organ or hematologic transplant;
   b. HIV, hepatitis B, or hepatitis C infection;
   c. Chronic pancreatitis;

4. Current treatment with:
   a. Chemotherapy;
   b. Immunosuppressive medications or immunotherapy
   c. Pancreatic enzyme replacement therapy;
   d. Hemodialysis or Peritoneal Dialysis;

5. The patient is known to be pregnant or is nursing;
6. The patient has participated in another study of an investigational drug or therapeutic medical device in the 30 days before randomization;
7. Allergy to eggs or known hypersensitivity to any components of study drug.. DESCRIPTION is This double blind, randomized, placebo-controlled study will evaluate the efficacy, safety, and tolerability of three different dose levels of Auxora in patients with acute pancreatitis and accompanying SIRS.

Approximately 216 patients will be randomized 1:1:1:1 into one of 4 groups using a computer generated randomization scheme accessed through an interactive voice/web response system (IXRS). Randomization will be first stratified by gender (male or female) and then by risk for organ failure in the gender subgroups (higher or lower). Higher risk for organ failure is defined by the presence of both an elevated hematocrit (HCT &#8805;44% for men or &#8805;40% for women) and hypoxemia (imputed PaO2/FiO2 &#8804;360). Lower risk for organ failure is defined by the absence of either or both an elevated hematocrit and hypoxemia. The PaO2/FiO2 will be determined using an arterial blood gas or imputed using pulse oximetry.

All patients will have received a Screening CECT of the abdomen/pancreas before being randomized into the study. CECTs performed as standard of care may be used as the Screening CECT but must have been performed in the 24 hours before Consent or after Consent and before Randomization.

The Start of First Infusion of Study Drug (SFISD) should occur within 8 hours of the patient or LAR providing informed consent. Patients randomized to Group 1 will receive 2.0 mg/kg of Auxora intravenously every 24 hours (¬±1 hour) for a total of three doses. Patients randomized to Group 2 will receive 1.0 mg/kg of Auxora intravenously every 24 hours (¬±1 hour) for a total of three doses. Patients randomized to Group 3 will receive 0.5 mg/kg of Auxora intravenously every 24 hours (¬±1 hour) for a total of three doses. Patients randomized to Group 4 will receive emulsion without any active pharmaceutical ingredient. Patients in Group 4 will receive one of three randomly assigned dose volumes, 1.25 mL/kg, 0.625 mL/kg, or 0.3125 mL/kg, which will be administered intravenously every 24 hours (¬±1 hour) for a total of three doses. The dosing will be based on actual body weight obtained at the time of hospitalization or screening for the study. As described in the pharmacy manual, the upper limit of the volume of Auxora and volume of Placebo that will be administered will be 156.25 mL. The sponsor, investigators and patients will be blinded to the assigned group. In the event of a medical emergency, investigators will be able to receive the treatment assignment if required to provide optimal care of the patient.

For all 4 groups, a study physician or appropriately trained delegate will perform assessments at screening, at the baseline assessment, immediately prior to the SFISD, and then every 24 hours until 240 hours after the SFISD, or until discharge if earlier. If patients remain hospitalized at Day 12, assessments will then be performed every 48 hours starting on Day 12 until Day 28, or until discharge if earlier. Patients discharged from the hospital before Day 25 will return at Day 30 (+5 days) to perform the Day 30 assessments. If patients are discharged on Days 25-29, the Day 30 assessments may be performed prior to discharge.

Patients will receive another CECT of the abdomen/pancreas at the Day 30 (¬±5 days) visit. All CECTs performed as standard of care after randomization and before the Day 30 CECT will also be captured. A blinded central reader will read the Screening, Day 30, and any standard of care CECTs obtained between randomization and the Day 30 visit.

...(more on ClinicalTrials.gov)







. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:30:01. DEPARTMENT NAME is CCR. SPONSOR NAMES is CalciMedica, Bionical-Emas (Emas Pharma Ltd). DISEASE SITES is Digestive - Gastrointestinal, Pancreatitis.
211. TITLE is CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD). SHORT TITLE is SPHERES NMOSD-750 Study. INVESTIGATOR NAME is Michael Sy. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Neuromyelitis Optica Spectrum Disorder. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Has a diagnosis of NMOSD at the time of enrollment according to the 2015 IPND consensus diagnostic criteria for NMOSD&#8224;.
2.  Age 18 years or older at the time of enrollment.
3.  Willing to provide Personal Information.

Exclusion Criteria:
1.  Has had a clinically confirmed NMOSD neuro-episode within the 12 weeks prior to enrollment.
2.  Is participating or planning to participate in a double-blind randomized trial for an NMOSD drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed. (All serology types (APQ4 +/- and MOG +/-) are eligible to enroll in the registry given they meet the 2015 IPND diagnostic criteria.). DESCRIPTION is The objective of the registry is to create a cohort of patients with NMOSD. Data collected will be used to prospectively study the natural history of NMOSD, real-word effectiveness and safety of medications used to treat NMOSD, and drug utilization treatment patterns. Additionally, the data will be used to systematically evaluate the burden for patients with NMOSD and the impact of therapies on quality of life. This will be done through real time capture and adjudication of relapses, the standardized collection of patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Personal information is also collected from each consenting registry patient allowing for linkages to other public or private clinical and administrative databases, as well as to databases maintained by organizations focused on the care and treatment of NMOSD for the purposes of clinical, market, or outcomes research. This provides an opportunity to evaluate other aspects of the disease and its treatment including but not limited to clinical and drug cost-effectiveness, health care resource utilization, and patient adherence.

Consent for additional ad hoc surveys will be solicited which can allow evaluation of additional aspects of the disease impact such as care giver burden or impact of disease on productivity.. TREATMENT TYPE DESC is OBS - Registry. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:16:29. DEPARTMENT NAME is CCR. SPONSOR NAMES is CorEvitas, LLC. DISEASE SITES is Neuromyelitis Optica Spectrum Disorder (NMOSD), Brain - Neurologic/ Psychologic.
212. TITLE is Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke. SHORT TITLE is Multi-arm Optimization of Stroke Thrombolysis. INVESTIGATOR NAME is Mohammad Shafie. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Acute Ischemic Stroke. DETAILED ELIGIBILITY is Inclusion Criteria:
1. Acute ischemic stroke patients
2. Treated with 0.9mg/kg IV rt-PA or 0.25mg/kg IV TNK within 3 hours of stroke onset or time last known well
3. Age >= 18
4. NIHSS score >= 6 prior to IV thrombolysis
5. Able to receive assigned study drug within 60 minutes but no later than 75 minutes of initiation of IV thrombolysis

Exclusion Criteria:
1. Known allergy or hypersensitivity to argatroban or eptifibatide
2. Previous stroke in the past 90 days
3. Previous intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation
4. Clinical presentation suggested a subarachnoid hemorrhage, even if initial CT scan was normal
5. Any surgery, or biopsy of parenchymal organ in the past 30 days
6. Trauma with internal injuries or ulcerative wounds in the past 30 days
7. Severe head trauma in the past 90 days
8. Systolic blood pressure persistently >180mmHg post-IV thrombolysis despite antihypertensive intervention
9. Diastolic blood pressure persistently >105mmHg post-IV thrombolysis despite antihypertensive intervention
10. Serious systemic hemorrhage in the past 30 days
11. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR >1.5
12. Positive urine or serum pregnancy test for women of child bearing potential
13. Glucose <50 or >400 mg/dl
14. Platelets <100,000/mm3
15. Hematocrit <25 %
16. Elevated pre-thrombolysis PTT above laboratory upper limit of normal
17. Creatinine > 4 mg/dl
18. Ongoing renal dialysis, regardless of creatinine
19. Received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin, Tinzaparin) in full dose within the previous 24 hours
20. Abnormal PTT within 48 hours prior to randomization after receiving heparin or a direct thrombin inhibitor (such as bivalirudin, argatroban, dabigatran or lepirudin)
21. Received Factor Xa inhibitors (such as Fondaparinaux, apixaban or rivaroxaban) within the past 48 hours
22. Received glycoprotein IIb/IIIa inhibitors within the past 14 days
23. Pre-existing neurological or psychiatric disease which confounded the neurological or functional evaluations e.g., baseline modified Rankin score >3
24. Other serious, advanced, or terminal illness or any other condition that the investigator felt would pose a significant hazard to the patient if rt-PA, TNK, eptifibatide or argatroban therapy was initiated
   a. Example: known cirrhosis or clinically significant hepatic disease

25. Current participation in another research drug treatment or interventional device trial - 26. Subjects could not start another experimental agent until after 90 days
Informed consent from the patient or the legally authorized representative was not or could not be obtained
27. High density lesion consistent with hemorrhage of any degree
28. Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT Scan. Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:17:01. DEPARTMENT NAME is CCR. SPONSOR NAMES is National Institute of Neurological Disorders and Stroke, University of Washington, NIH. DISEASE SITES is Brain - Neurologic/ Psychologic, Stroke.
213. TITLE is A Randomized Trial to Evaluate Sequential vs Simultaneous Spectacles Plus Patching for Amblyopia in Children 3 to <13 Years Old. SHORT TITLE is A Randomized Trial to Evaluate Sequential vs Simultaneous Patching. INVESTIGATOR NAME is Donny Won Suh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 3 Years to 13 Years   (Child)
Amblyopia. DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Age 3 to <13 years at the time of randomization
2.  Amblyopia associated with anisometropia, strabismus, or both
3.  No previous treatment for amblyopia, including no more than 24 hours of spectacle wear.
4.  Investigator planning to initiate spectacle correction of refractive error meeting the following criteria based on a cycloplegic refraction that has been performed within 30 days:
5.  At enrollment, single VA measured in each eye assessed in trial frames with the spectacle correction the investigator plans to prescribe, using the investigator's routine method
6.  Investigator is willing to prescribe spectacle wear followed sequentially by patching or simultaneous spectacles and patching treatment per protocol.
7.  Parent understands the protocol and is willing to accept randomization.
8.  Parent has phone (or access to phone) and is willing to be contacted by Jaeb Center staff or other study staff.
9.  Relocation outside of area of an active PEDIG site for this study within the next 56 weeks is not anticipated.

Exclusion Criteria:
1.  Myopia greater than -6.00 D spherical equivalent in either eye.
2.  Previous intraocular or refractive surgery.
3.  Planned strabismus surgery in the next 56 weeks.
4.  Any previous treatment for amblyopia (patching, atropine, Bangerter filter, vision therapy, or binocular treatment).
5.  Previous spectacle or contact lens wear for more than 24 hours.
6.  Parent and participant willing to forego option of contact lens wear for the duration of the study.
7.  Ocular co-morbidity that may reduce VA determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above VA criteria are met).
8.  Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities or attention deficit hyperactivity disorder (ADHD) are not excluded.
9.  Known allergy to adhesive patches.
10.  Known allergy to silicone.. DESCRIPTION is At an enrollment visit, distance VA will be measured in trial frames with or without cycloplegia based on a cycloplegic refraction performed within 30 days. If still apparently eligible, children will be prescribed spectacles and will then return for a spectacle baseline visit, where they will wear their new spectacles for the first time for at least 10 minutes (but no more than 24 hours) and will be tested in those new spectacles to confirm final eligibility prior to randomization.

Participants not found to be eligible in their new spectacles will end study participation. Participants eligible for the study will be randomly allocated to one of two treatment groups: Sequential (spectacles alone) and then patching if needed (monitored by ODM), or Simultaneous (spectacles and patching monitored by ODM).

After randomization, follow-up visits will occur at 8-week intervals through 56 weeks. At each visit on or after the 8-week visit, participants will be classified as either: stable/worsening or improving; those stable/worsening are then classified as having either resolved or residual amblyopia, provided that the current and most recent previous visit were completed at least 6-weeks apart (target 8 weeks) and provided the required test and retest VA testing was completed. Participants who are stable/worsening and have residual amblyopia in the sequential group will start patching (monitored by ODM) and continue to be followed every 8 weeks. Participants in the simultaneous group, or in the sequential group after having advanced to patching, who are stable/worsening but have residual amblyopia will be released to treatment at investigator discretion.

All participants continue 8-weekly visits until 56 weeks when Study participation ends.. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Children. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:17:46. DEPARTMENT NAME is CCR. SPONSOR NAMES is Jaeb Center for Health Research. DISEASE SITES is Pediatrics, Amblyopia, Eye - Ophthalmologic.
214. TITLE is M6¬Æ-C Artificial Cervical Disc Two-Level IDE Pivotal Study. SHORT TITLE is M6-C vs. ACDF 2-Level IDE Study. INVESTIGATOR NAME is Yu-Po Lee. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 75 Years   (Adult, Older Adult)
Cervical Disc Degenerative Disorder. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Diagnosis of degenerative cervical radiculopathy with or without spinal cord compression requiring surgical treatment at two contiguous levels from C3 to C7 demonstrated by signs and/or symptoms of disc herniation and/or osteophyte formation (e.g. neck and/or arm pain, radiculopathy, etc.) and is confirmed by patient history and radiographic studies (e.g. MRI, CT, x-rays, etc.)
2.  Inadequate response to conservative medical care over a period of at least 6 weeks or have the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management
3.  Neck Disability Index score of greater than or equal to 30% (raw score of greater than or equal to 15/50).
4.  Neck or arm pain Visual Analog Scale Score &#8805; 4 on a scale of 0 to 10
5.  Willing and able to comply with the requirements of the protocol including follow-up requirements
6.  Willing and able to sign a study specific informed consent
7.  Skeletally mature and at least 18 years old but not older than 75 years old

Exclusion Criteria:
1.  More than two cervical levels requiring surgery, or two non-contiguous levels requiring surgery
2.  Previous anterior cervical spine surgery
3.  Axial neck pain as the solitary symptom
4.  Previous posterior cervical spine surgery (such as a posterior element decompression) that destabilizes the cervical spine
5.  Advanced cervical anatomical deformity (such as ankylosing spondylitis, scoliosis) at either of the operative levels or adjacent levels
6.  Symptomatic facet arthrosis
7.  Less than four degrees of motion in flexion/extension at either of the index levels
8.  Instability as evidenced by subluxation greater than 3 millimeters at either of the index or adjacent levels as indicated on flexion/extension x-rays.
9.  Advanced degenerative changes (e.g., spondylosis) at either of the index vertebral levels as evidenced by bridging osteophytes, central disc height less than 4 millimeters and/or < 50% of the adjacent normal intervertebral disc, or kyphotic deformity > 11 degrees on neutral x-rays
10.  Severe cervical myelopathy (i.e., Nurick's Classification greater than 2)
11.  Active systemic infection or infection at the operative site
12.  Co-morbid medical conditions of the spine or upper extremities that may affect the cervical spine neurological and/or pain assessment
13.  Metabolic bone disease such as osteoporosis that contradicts spinal surgery
14.  History of an osteoporotic fracture of the spine, hip or wrist
15.  History of an endocrine or metabolic disorder (e.g. Paget's disease) known to affect bone and mineral metabolism.
16.  Taking medications that may interfere with bony/soft tissue healing including chronic steroid use
17.  Known allergy to titanium, stainless steels, polyurethane, polyethylene, or ethylene oxide residuals
18.  Fibromyalgia, Rheumatoid Arthritis (or other autoimmune disease), or a systemic disorder such as HIV or acute hepatitis B or C.
19.  Insulin dependent diabetes
20.  Medical condition (e.g., unstable cardiac disease, cancer) that may result in patient death or have an effect on outcomes prior to study completion
21.  Pregnant, or intend to become pregnant, during the course of the study
22.  Severe obesity (Body Mass Index greater than 45)
23.  Physical or mental condition (e.g. psychiatric disorder, senile dementia, Alzheimer's disease, alcohol or drug addiction) that would interfere with patient self-assessment of function, pain or quality of life.
24.  Involved in current or pending spinal litigation where permanent disability benefits are being sought.
25.  Incarcerated at time of study enrollment.
26.  Current participation in other investigational study.. DESCRIPTION is Patients will be concurrently enrolled in the M6-C treatment group and the ACDF control group. Patients should have failed at least six weeks of conservative treatment or demonstrate progressive symptoms despite continued non-operative treatment. For the study, 263 patients will undergo either a two-level cervical artificial disc procedure, or an instrumented (ACDF) procedure as per site group assignment. Patients will be evaluated clinically, radiographically, and via the collection of patient-reported outcomes at 6 Weeks, 3 Months, 6 Months, 12 Months and 24 Months. The primary endpoint is Overall Success at 24 Months.. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T15:56:41. DEPARTMENT NAME is CCR. SPONSOR NAMES is Orthofix Medical Inc.. DISEASE SITES is Muscles and Bones - Musculoskeletal.
215. TITLE is A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis. SHORT TITLE is RIN-PF-301. INVESTIGATOR NAME is Bassam Yaghmour. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 40 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Subject gives voluntary informed consent to participate in the study.
2.  Subject is greater than or equal to 40 years of age, inclusive, at the time of signing informed consent.
3.  The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution computed tomography (HRCT) (performed within the previous 12 months), and if available, surgical lung biopsy.
4.  FVC greater than or equal to 45% predicted at Screening.
5.  Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for &#8805;30 days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not permitted.
6.  Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.
7.  Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
8.  In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion Criteria:
1.  Subject is pregnant or lactating.
2.  Subject has primary obstructive airway physiology: FEV1/FVC <0.70 at Screening.
3.  The subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
4.  The subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase stimulators within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours of any study-related efficacy assessments.
5.  Use of any of the following medications: azathioprine (AZA), cyclosporine, mycophenolate mofetil, tacrolimus, oral corticosteroids (OCS) >20 mg/day or the combination of OCS+AZA+N-acetylcysteine within 30 days prior to Baseline; cyclophosphamide within 60 days prior to Baseline; or rituximab within 6 months prior to Baseline.
6.  The subject is receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.

Other protocol-defined Inclusion/ Exclusion Criteria apply. DESCRIPTION is Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of inhaled treprostinil in subjects with IPF over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.

Efficacy assessments include spirometry (forced vital capacity [FVC]), time to clinical worsening, time to first acute exacerbation of IPF, overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.

Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-16T20:38:17. DEPARTMENT NAME is CCR. SPONSOR NAMES is United Therapeutics. DISEASE SITES is Lung - Pulmonary.
216. TITLE is A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients. SHORT TITLE is Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients. INVESTIGATOR NAME is Bassam Yaghmour. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

Eligible participants must meet all of the following criteria to be enrolled in the study:

1.  Age greater than or equal to 18 years
2.  Documented diagnostic right heart catheterization (RHC) within 6 months of screening documenting a minimum PVR of greater than or equal to 4 Wood units and pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of less than or equal to 15 mmHg, with the diagnosis of WHO PAH Group 1 .
3.  Symptomatic PAH classified as WHO FC II or III
4.  REVEAL Lite 2 Risk Score &#8805; 6
5.  Diagnosis of PAH within 6 months of screening and on stable doses of a double combination of background PAH therapies for at least 90 days prior to screening. A triple combination of therapies, with stable doses for 90 days, may be allowed per local standard-of-care guidelines, but is restricted to 10% of the study population.
6.  Six-minute walk distance &#8805; 150 m repeated twice at screening at least 4 hours apart, but no longer than 1 week apart, and both values are within 15% of each other (calculated from the highest value)
7.  Females of childbearing potential must meet the following criteria:  Have 2 negative urine or serum pregnancy tests as verified by the investigator prior to starting study drug administration; she must agree to ongoing urine or serum pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug; If sexually active, have used, and agree to use, highly effective contraception without interruption, for at least 28 days prior to starting the investigational product, during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment
Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
8.  Male participants must meet the following criteria: Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
9.  Ability to adhere to study visit schedule and understand and comply with all protocol requirements
10.  Ability to understand and provide written informed consent.

Consult the investigator or research personnel for additional information on exclusion criteria.
. DESCRIPTION is Study A011-13 is Phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to background PAH therapy in newly diagnosed intermediate- or high risk PAH patients.

Participants enrolled in the study will have a diagnosis within 6 months of study screening of symptomatic PAH (WHO Group 1, classified as FC II or III) and presentation of idiopathic or heritable PAH, PAH associated with connective tissue diseases (CTD), drug- or toxin- induced PAH, post shunt correction PAH, or PAH presenting at least 1 year following the correction of congenital heart defects.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T15:58:14. DEPARTMENT NAME is CCR. SPONSOR NAMES is PPD Investigator Services, LLC, Acceleron. DISEASE SITES is Pulmonary Arterial Hypertension (PAH), Lung - Pulmonary.
217. TITLE is A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF). SHORT TITLE is A Phase 2 Study of Sotatercept for Cpc-PH due to HFpEF . INVESTIGATOR NAME is Bassam Yaghmour. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Cpc-PH Due to HFpEF (Combined Post-capillary and Pre-capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction)

18 Years to 85 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Age 18 to 85 years
2.  Clinical diagnosis of HFpEF -  Left ventricular ejection fraction greater than or equal to 50%, with no history of LVEF below 45%
3.  Demonstrated Cpc-PH by all of the following:
4.  New York Heart Association FC of II or III
5.  Six-Minute Walk Distance greater than or equal to 100 m repeated twice during Screening and both values within 15% of each other, calculated from the highest value
6.  Chronic medication for HF or for any underlying condition, administered at a stable (per investigator) dose for &#8805; 30 days prior to Visit 1. Diuretics and/or anticoagulants are excepted from this rule but should not be newly started or stopped within 30 days of Visit 1, and a prescribed dose change should not occur within 7 days of Visit 1. Anticoagulation may be suspended for RHC if necessary.
7.  Women of childbearing potential must: Have a negative pregnancy test as verified by the investigator prior to starting study drug administration; she must agree to ongoing pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug, If sexually active, have used and agree to continue to use highly effective contraception without interruption for at least 28 days prior to starting the investigational product, during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study drug, Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study drug See Appendix 2 for additional contraceptive information.
8.  Male participants must: Agree to use a condom, defined as a male latex condom or non latex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy. Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study drug
9.  Ability to adhere to the study visit schedule and understand and comply with all protocol requirements
10.  Agreement to not participate in any other trials of investigational drugs/devices while enrolled in the A011-16 study
11. Ability to understand and provide written informed consent for participation.

Consult the investigator or research personnel for additional information on exclusion criteria.

. DESCRIPTION is Participants enrolled in the study will have a diagnosis of Cpc-PH due to HFpEF with New York Heart Association (NYHA) functional class (FC) II or III. Participants will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups (placebo, 0.3mg/kg sotatercept and 0.7mg/kg sotatercept) during the placebo-controlled Treatment Period. In the extension phase, sotatercept-treated participants will continue on their current dose. Placebo participants will be re-randomized in a 1:1 ratio to one of the two sotatercept treatment groups utilized in the placebo-controlled Treatment Period. Each participant will be enrolled in the study for up to 114 weeks, including a 28-day Screening Period, a 24-week, double-blind, placebo-controlled Treatment Period, an 18-month Extension Period, and an 8-week Follow-up Period.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2022-08-25T12:41:52. DEPARTMENT NAME is CCR. SPONSOR NAMES is PPD Investigator Services, LLC, Acceleron. DISEASE SITES is Lung - Pulmonary.
218. TITLE is A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared with Oral Vancomycin in Adults with Clostridioides difficile Infection. SHORT TITLE is Randomized,Double-blind Eval of CRS3123 Vs Oral Vancomycin in Adult PTs w/Clostridioides difficile. INVESTIGATOR NAME is Alpesh Amin. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
. DETAILED ELIGIBILITY is Criteria:

1.  More than or equal to 3 diarrheal stools/day in 24 hours prior to randomization and in the judgment of the investigator that C difficile is the likely causative agent for the diarrhea.
2.  Stool positive for C. difficile GDH plus Toxin A and/or B
3.  Participants with a primary episode or first recurrence of CDI are eligible
4.  In the judgement of the investigator, the expectation that the participant will survive with effective antibiotic therapy and appropriate supportive care for the anticipated duration of the study
5.  Participants may be either inpatient or outpatient. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T16:00:27. DEPARTMENT NAME is CCR. SPONSOR NAMES is Crestone, Inc., NIH. DISEASE SITES is Clostridioides Difficile, Infectious Disease.
219. TITLE is A Randomized Trial of Low-Dose Bevacizumab Versus Laser for Type 1 Retinopathy of Prematurity. SHORT TITLE is A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP. INVESTIGATOR NAME is Donny Won Suh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is up to 6 Months   (Child)
Retinopathy of Prematurity. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Birth weight < 1251 grams
2.  Newly diagnosed (within 2 days) type 1 ROP in one or both eyes; meeting the following criteria:

Zone I, any stage ROP with plus disease, with retinal vessels or ROP in Zone II in any quadrant, or
Zone I, stage 3 ROP without plus disease, with retinal vessels or ROP in zone II in any quadrant or
Zone II, stage 2 or 3 ROP with plus disease

Exclusion Criteria:
1.  Previous treatment for ROP
2.  Stage 4 or 5 ROP in either eye
3.  All ROP in zone I in either eye (no retinal vessels or ROP extend into zone II in any quadrant)
4.  Either treatment could not be done within 2 days of diagnosis of type 1 ROP
5.  Investigator unwilling to randomize or parent unwilling to accept random assignment to either treatment
6.  Transfer to another hospital not covered by study-certified examiners anticipated within the next 4 weeks
7.  Active ocular infection or purulent nasolacrimal duct obstruction in either eye

One eye will be excluded, and other eye may be eligible, if either of the following are present:
1. Visually significant ocular anomaly (e.g., cataract, coloboma)
2. Opacity that precludes an adequate view of the retina. DESCRIPTION is Infants with type 1 ROP and no prior treatment for ROP will be randomly assigned (1:1) to treatment with either intravitreous bevacizumab 0.063 mg or peripheral retinal laser ablation. Study exams will be at weeks 1, 2, and 4 weeks, and at 2 and 4-months post-treatment (and re-treatment when indicated). Additional study exams will occur at adjusted age 6 months, 1 year, and then annually for 5 more years. Non-study examinations will be at clinician discretion and are likely to occur more often. The primary outcome will be treatment success, defined as no worsening of ROP 5-13 days after treatment (or re-treatment if indicated), no plus disease or severe neovascularization 2 weeks to 6 months after treatment (or re-treatment if indicated), and no unfavorable structural outcome (or prior scleral buckle or vitrectomy) at 6 months adjusted age. Important secondary outcomes include the number of re-treatments, extent of retinal vascularization, refractive error, neurodevelopment assessed by the Bayley-4 test, IQ and neuropsychiatric testing, visual acuity, visual fields, and systemic morbidities.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Children. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T16:01:07. DEPARTMENT NAME is CCR. SPONSOR NAMES is Jaeb Center for Health Research. DISEASE SITES is Eye - Ophthalmologic, Retinopathy.
220. TITLE is Bevacizumab Treatment For Posterior Zone I Retinopathy of Prematurity. SHORT TITLE is Bevacizumab Treatment For Posterior Zone I ROP. INVESTIGATOR NAME is Donny Won Suh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is up to 6 Months   (Child)
Retinopathy of Prematurity. DETAILED ELIGIBILITY is Inclusion Criteria:

The study participant must have at least one eye meeting all of the inclusion criteria in order to be eligible to participate:
1.  Birth weight < 1251 grams
2.  Newly diagnosed (within 2 days) type 1 ROP (as defined in section 2.4.2), with ROP and retinal vessels all in zone I, in one or both eyes
3.  Parent understands the protocol and is willing to provide consent.

If both eyes are eligible, then both are included. If one eye is eligible and the other eye has type 1 ROP with ROP or vessels in zone 2, then both eyes will receive the treatment randomly assigned. If one eye is eligible and the fellow eye later develops type 1 ROP within 4 weeks of injection in the first eye, then the fellow eye will also receive the treatment randomly assigned to the first eye and the fellow eye will follow the same 4-week post-injection study exam schedule, unless the first eye has already met failure criteria, in which case treatment and follow-up for the fellow eye is at investigator discretion.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will be excluded from study participation.

1.  Previous treatment for ROP
2.  Stage 4 or 5 ROP in either eye
3.  Treatment could not be done within 2 days of diagnosis of type 1 ROP
4.  Investigator unwilling to randomize or parent unwilling to accept randomized assignment to either treatment
5.  Transfer to another hospital anticipated within the next 4 weeks where exams by study-certified examiners are not available. If hospital discharge is anticipated within the next 4 weeks, parents unable or unwilling to return to the PEDIG site for outpatient follow-up visits.
6.  Active ocular infection or purulent nasolacrimal duct obstruction in either eye

One eye will be excluded, and other eye may be eligible, if either of the following are present:
1.  Visually significant ocular anomaly (e.g., cataract, coloboma)
2.  Opacity that precludes an adequate view of the retina. DESCRIPTION is Infants with type 1 ROP and no prior treatment for ROP will be randomly assigned (1:1) to treatment with either intravitreous bevacizumab 0.063 mg or either intravitreous bevacizumab 0.25 mg. Study exams will be at 1 day, 4 days (if no improvement on day 1), 1, 2, 3, and 4 weeks, and at 2 and 4-months post-treatment (and re-treatment when indicated). Additional study exams will occur at adjusted age 6 and 12 months. Non-study examinations will be at clinician discretion and are likely to occur more often. The primary outcome will be treatment success within each dose group, defined as improvement by the day 4 exam and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks of injection. Important secondary outcomes include safety and efficacy. refractive outcomes, and the extent of retinal vascularization at 2 and 4 months post-injection between the two dose groups.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Children. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T16:01:54. DEPARTMENT NAME is CCR. SPONSOR NAMES is Jaeb Center for Health Research. DISEASE SITES is Eye - Ophthalmologic, Retinopathy.
221. TITLE is A multicenter, prospective, randomized, clinical trial comparing the safety and effectiveness of the BAGUERA¬ÆC Cervical Disc Prosthesis to the Mobi-C¬Æ Cervical Disc for the treatment of patients with symptomatic cervical disc disease at a single level.. SHORT TITLE is SPINEART_BAGUERA C_Level 1. INVESTIGATOR NAME is Michael Oh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 22 Years to 69 Years   (Adult, Older Adult)
Cervical Spine Disease. DETAILED ELIGIBILITY is Criteria:

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

1.   Male or female; skeletally mature; age 22-69 years, inclusive.
2.  Diagnosis of radiculopathy or myeloradiculopathy of the cervical spine, with pain, paresthesia or paralysis in a specific nerve root distribution C3 through C7, including at least one of the following:

a.  Neck and/or arm pain (at least 40 mm on the 100 mm visual analogue scale [VAS] scale).
b.  Decreased muscle strength of at least one level on the clinical evaluation 0 to 5 scale.
c.  Abnormal sensation including hyperesthesia or hypoesthesia; and/or
d.  Abnormal reflexes.

3.  Symptomatic cervical disc disease (SCDD) at one level from C3 to C7.
4.  Radiographically determined pathology at the level to be treated correlating to primary symptoms including at least one of the following:

a.  Decreased disc height on radiography, computed tomography (CT), or magnetic resonance imaging (MRI) in comparison to a normal adjacent disc.
b.  Degenerative spondylosis on CT or MRI.
c.  Disc herniation on CT or MRI.

5.  NDI Score of &#8805; 30% (raw score of &#8805;15/50).
6.  Preoperative neck or arm pain &#8805; 40 (out of 100) on Preoperative Neck and Arm Pain Questionnaire.
7.  Unresponsive to non-operative, conservative treatment (including but not necessarily limited to: rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) for:

a.  Approximately six weeks from radiculopathy or myeloradiculopathy symptom onset; or
b.  Have the presence of progressive symptoms or signs of nerve root/spinal cord compression despite continued non-operative conservative treatment.

8.  Appropriate for treatment using an anterior surgical approach, including having no prior surgery at the operative level and no prior cervical fusion or cervical artificial disc procedure at any level.
9.  Medically cleared for surgery.
10.  Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol.
11.  Written informed consent provided by subject.

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:22:57. DEPARTMENT NAME is CCR. SPONSOR NAMES is SPINEART USA Inc.. DISEASE SITES is Spine, Muscles and Bones - Musculoskeletal.
222. TITLE is A Multicenter, Prospective, Randomized, Clinical Trial Comparing the Safety and Effectiveness of the BAGUERA C Cervical Disc Prosthesis to the Mobi-C¬Æ Cervical Disc for the Treatment of Patients With Symptomatic Cervical Disc Disease at Two Contiguous Levels. SHORT TITLE is SpineArt_BAGUERA Level 2 . INVESTIGATOR NAME is Michael Oh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 22 Years to 69 Years   (Adult, Older Adult)
Cervical Disc Disease. DETAILED ELIGIBILITY is Inclusion Criteria

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

1.  Male or female; skeletally mature; age 22-69 years, inclusive.
2.  Diagnosis of radiculopathy or myeloradiculopathy of the cervical spine, with pain, paresthesia or paralysis in a specific nerve root distribution C3 through C7, including at least one of the following:

a.  Neck and/or arm pain (at least 40 mm on the 100 mm visual analogue scale [VAS] scale).
b.  Decreased muscle strength of at least one level on the clinical evaluation 0 to 5 scale.
c.  Abnormal sensation including hyperesthesia or hypoesthesia; and/or
d.  Abnormal reflexes.

3.  Symptomatic cervical disc disease (SCDD) at two contiguous levels from C3 to C7.
4.  Radiographically determined pathology at the level to be treated correlating to primary symptoms including at least one of the following:

a.  Decreased disc height on radiography, computed tomography (CT), or magnetic resonance imaging (MRI) in comparison to a normal adjacent disc.
b.  Degenerative spondylosis on CT or MRI.
c.  Disc herniation on CT or MRI.

5.  NDI Score of &#8805; 30% (raw score of &#8805;15/50).
6.  Preoperative neck or arm pain &#8805; 40 (out of 100) on Preoperative Neck and Arm Pain Questionnaire.
7.  Unresponsive to non-operative, conservative treatment (including but not necessarily limited to: rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) for:

a.  Approximately six weeks from radiculopathy or myeloradiculopathy symptom onset; or
b.  Have the presence of progressive symptoms or signs of nerve root/spinal cord compression despite continued non-operative conservative treatment.

8.  Appropriate for treatment using an anterior surgical approach, including having no prior surgery at the operative level and no prior cervical fusion or cervical artificial disc procedure at any level.
9.  Medically cleared for surgery.
10.  Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol.
11.  Written informed consent provided by Subject

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-04T17:24:38. DEPARTMENT NAME is CCR. SPONSOR NAMES is SPINEART USA Inc.. DISEASE SITES is Muscles and Bones - Musculoskeletal, Spine.
223. TITLE is A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease. SHORT TITLE is The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis. INVESTIGATOR NAME is Xiao-Tang Kong. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Autoimmune Encephalitis
Encephalitis. DETAILED ELIGIBILITY is Inclusion Criteria:

- Inclusion Criteria 1. Diagnosis of NMDAR encephalitis, defined by both (a) and (b):

1. A subacute onset of change in mental status consistent with autoimmune encephalitis,
2. A positive cell-based assay for anti-NMDA receptor IgG antibody in the CSF confirmed in study-specified laboratories.

2. Age &#8805; 18 years 3. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the United States of America (USA), European Union [EU] Data Privacy Directive in the EU) obtained from the participant/legal representative prior to performing any protocol-related procedures, including screening evaluations.

4. Females of childbearing potential who are sexually active with a nonsterilized male partner must agree to use a highly effective method of contraception beginning at screening or upon discharge from hospitalization/inpatient rehabilitation (for participants who were incapacitated at the time of screening), and to continue precautions for 6 months after the final dose of investigational product.

5. Nonsterilized males who are sexually active with a female partner of childbearing potential must agree to use a highly effective method of contraception at screening or upon discharge from hospitalization/inpatient rehabilitation (for participants who were incapacitated at the time of screening), and to continue precautions for 3 months after the final dose of investigational product. Male patients with female partners of childbearing potential must have that female partner use at least one form of highly effective contraception, starting at least one menstrual cycle before (the male patient's) first study drug administration and continuing until at least 3 months after their male partner's last dose of the study drug.

6. Willing to forego other immunomodulatory therapies (investigational or otherwise) for NMDAR encephalitis during the study.

7. Patient must have received at least 3 days of methylprednisolone 1000 mg IV or equivalent corticosteroid within 30 days prior to randomization (Day 1). In addition, patients must have received EITHER of the following treatments within 30 days before randomization.

1. IVIg, at a minimum dose of 2 g/kg
2. Plasma exchange or plasmapheresis, with a minimum of 5 treatments. NOTE: These treatments may be provided during the screening period, but must be completed prior to randomization.

8. mRS of &#8805;3 at the screening visit, indicating at least moderate disability. 9. Ability and willingness to attend study visits and complete the study

. DESCRIPTION is N-methyl-D-aspartate receptor (NMDAR) encephalitis is one of the most common causes of autoimmune encephalitis, with prevalence exceeding herpes encephalitis in industrialized nations. Typically, the disease affects patients age 10-50 causing prominent psychiatric symptoms, altered consciousness, seizures, movement disorders and life-threatening dysautonomia. Intensive care, including cardiorespiratory support is required in 75% of cases. The diagnosis is confirmed by detection of IgG autoantibodies against central nervous system NMDAR in the cerebrospinal fluid. Despite the severity of the illness, NMDAR encephalitis is a treatable neurological disease, with retrospective case series establishing the benefit of off-label intravenous steroids and immunoglobulins. These treatments are presumed to work through effects on IgG NMDAR autoantibody levels in the CSF, although prospective data informing predictors of treatment responses are limited. Even with prompt treatment, ~50% of patients remain disabled, requiring prolonged hospital admissions. Various off-label therapies have been proposed as "second-line" treatments in NMDAR encephalitis. The majority of second-line treatments target circulating B-cells with various degrees of blood brain penetrance and efficacy, and poor consensus on the timing, dose and route of delivery of candidate agents. High-quality evidence is needed to inform the treatment of NMDAR encephalitis. Inebilizumab is a promising therapeutic monoclonal antibody for the treatment of NMDAR encephalitis. This humanized monoclonal antibody against the B-cell surface antigen CD19 was recently shown to be safe and efficacious in the treatment of neuromyelitis optica spectrum disorder-another antibody-mediated disorder of the central nervous system. Compared to other off label B-cell depleting therapies, such as rituximab, inebilizumab not only depletes CD20+ B-cells, but also CD20- plasmablasts and plasma cells, resulting in robust and sustained suppression of B-cell expression. The ExTINGUISH Trial will randomize 116 participants with moderate-to-severe NMDAR encephalitis to receive either inebilizumab or placebo in addition to first-line therapies. Patient outcomes will be ascertained at standard intervals using the modified Rankin scale and accepted safety measures (primary outcomes at 16 weeks), together with comprehensive validated neuropsychological tests, bedside cognitive screening tools, quality of life/ functional indices, and outcome prediction measures. Clinical data will be combined with quantitative measures of NMDAR autoantibody titers and cytokines implicated in B-cell activation and antibody production within the intrathecal compartment to identify treatment responders, inform the biologic contributors to outcomes, and evaluate for biomarkers that may serve as early predictors of favorable outcomes in future clinical trials in NMDAR encephalitis. The ExTINGUISH Trial will prospectively study an optimized B-cell depletion therapy to promote better long-term outcomes in NMDAR encephalitis, to determine more meaningful cognitive endpoints, and to identify better biologic biomarkers to predict outcome.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T16:03:09. DEPARTMENT NAME is CCR. SPONSOR NAMES is NIH, Massachusetts General Hospital . DISEASE SITES is Brain - Neurologic/ Psychologic, Encephalitis.
224. TITLE is A randomized, double-blind placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2-PREVENT). SHORT TITLE is Study of inclisiran to prevent cardiovascular (CV) events in participants w/established CV disease.. INVESTIGATOR NAME is Ailin Barseghian Elfarra. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Atherosclerotic Cardiovascular Disease
40 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Fasting LDL-C greater than or equal to 70 mg/dL at randomization visit
2.  Stable (greater than or equal to 4 weeks) and well-tolerated lipid-lowering regimen (including e.g. with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin greater than or equal to 40 mg QD or rosuvastatin greater than or equal to 20 mg QD.
3.  Established CV disgreater than or equal to 4 weeks from screening visit, b) History of ischemic stroke occurred greater than or equal to 4 weeks prior to the Screening visit, and c)  Symptomatic peripheral arterial disease (PAD) evidenced by either intermittent claudication with ankle brachial index (ABI) < 0.85, prior peripheral arterial revascularization procedure, or, amputation due to atherosclerotic disease.

Exclusion Criteria:
1.  Acute coronary syndrome, stroke, peripheral arterial revascularization procedure or amputation due to atherosclerotic disease < 4 weeks before screening visit
2.  Treatment with PCSK9 inhibitors (e.g. evolocumab, alirocumab) within 90 days or planned use post first study visit
3.  Planned or expected cardiac, cerebrovascular or peripheral artery surgery or re-vascularization within the 6 months after the first study visit
4.  Heart failure NYHA class III or IV
5.  Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver
6.  Previous exposure to inclisiran or any other non-mAb PCSK9-targeted therapy, either as an investigational or marketed drug within 2 years
7.  Severe concomitant non-CV disease that is expected to reduce life expectancy to less than 5 years
8.  History of malignancy that required surgery radiation therapy and/or systemic therapy during the 3 years prior to the first study visit
9.  Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.. DESCRIPTION is Purpose of this study is to test the hypothesis that treatment with inclisiran sodium 300 mg s.c. administered on Day 1, Month 3 (Day 90), and every 6 months thereafter taken in addition to well-tolerated high-intensity statin therapy in participants with established ASCVD will significantly reduce the risk of 3-Point-Major Adverse Cardiovascular Events (3P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI) and non-fatal ischemic stroke. This will be compared to placebo in adjunct to well-tolerated high-intensity statin therapy.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T16:05:39. DEPARTMENT NAME is CCR. SPONSOR NAMES is Novartis. DISEASE SITES is Heart - Cardiovascular/ Circulatory.
225. TITLE is Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis CAPTIVA. SHORT TITLE is CAPTIVA. INVESTIGATOR NAME is Wengui Yu. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Intracranial Arteriosclerosis
Stroke
30 Years to 80 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Symptoms or signs of any duration associated with an infarct on brain imaging that occurred within 30 days prior to randomization
2.  Index infarct is attributed to 70-99% stenosis (or flow gap on MRA) of a major intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar artery) documented by CTA, MRA, or catheter angiography
3.  Modified Rankin score of less than or equal to 4
4.  Ability to swallow pills
5.  Age 30-80 years, inclusive, at time of consent
6.  Subjects 30-49 years of age are required to meet at least ONE of the following additional criteria below to qualify for the study:

a)  diabetes treated with insulin for at least 15 years
b)  at least 2 of the following atherosclerotic risk factors: hypertension (BP > 140/90 or on antihypertensive therapy); dyslipidemia (LDL > 130 mg /dl or HDL < 40 mg/dl or fasting triglycerides > 150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; any of the following vascular events occurring in a parent or sibling who was < 55 years of age for men or < 65 years of age for women at the time of the event: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery for atherosclerotic disease
c)  personal history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease
d)  any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic
e)  aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography
f)  any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic

7.  Negative pregnancy test in a female who has had any menses in the last 18 months and has not had surgery that would make her unable to become pregnant
8.  Subject is willing and able to return for all follow-up visits required by the protocol
9.  Subject is available by phone
10.  Subject understands the purpose and requirements of the study and can make him/herself understood
11.  Subject has provided informed consent (use of a LAR is not permitted)

Other Protocol defined inclusion/ exclusion criteria may apply. DESCRIPTION is The proposed study is relevant to public health because narrowing of brain arteries is one of the most common causes of stroke worldwide. Compelling evidence suggests novel antithrombotic medications could reduce the rate of stroke in patients with narrowed brain arteries. The proposed study will directly compare novel antithrombotic medications to standard care antiplatelet medications for preventing stroke and death from vascular causes in patients with narrowed brain arteries.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T16:06:32. DEPARTMENT NAME is CCR. SPONSOR NAMES is NIH/NINDS. DISEASE SITES is Stroke, Brain - Neurologic/ Psychologic.
226. TITLE is A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) Worl Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality. SHORT TITLE is A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality. INVESTIGATOR NAME is Bassam Yaghmour. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 75 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Documented diagnostic right heart catheterization prior to screening confirming the diagnosis of World Health Organization (WHO) pulmonary arterial hypertension (PAH) Group 1 in any of the following subtypes: Idiopathic PAH; Heritable PAH; Drug/toxin-induced PAH; PAH associated with connective tissue diseases (CTD); PAH associated with simple, congenital systemic to pulmonary shunts at least 1 year following repair
Symptomatic PAH classified as WHO functional class (FC) III or IV
2.  Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 risk score of &#8805;9
3.  Right heart catheterization performed during screening (or within 2 weeks prior to screening, if done at the clinical study site) documenting a minimum pulmonary vascular resistance (PVR) of &#8805;5 Wood units and a pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of &#8804;15 mmHg
4.  Clinically stable and on stable doses of maximum tolerated (per investigator's judgment) double or triple background PAH therapies for at least 30 days prior to screening
5.  Females of childbearing potential must:Have 2 negative urine or serum pregnancy tests as verified by the investigator prior to starting study therapy; must agree to ongoing urine or serum pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug.  If sexually active with a male partner, have used, and agree to use highly effective contraception without interruption per protocol; for at least 28 days prior to starting the investigational product, during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment
6.  Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
7.  Male participants must:Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy.  Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
8.  Ability to adhere to study visit schedule and understand and comply with all protocol requirements
9.  Ability to understand and provide written informed consent

Exclusion Criteria:  Consult the study investigator for more information.
. DESCRIPTION is This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to maximum tolerated background PAH therapy on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of &#8805;24 hours, in participants with WHO FC IV PAH or WHO FC III PAH at high risk of mortality.

Participants with symptomatic PAH (WHO FC III or FC IV at high risk of mortality) who present with idiopathic or heritable PAH, PAH associated with connective tissue diseases (CTD), drug- or toxin-induced, post-shunt correction PAH, or PAH presenting at least 1 year following the correction of congenital heart defect. Participants must have a Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 risk score of &#8805;9 and be on maximum tolerated combination background PAH therapy.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-03T16:07:25. DEPARTMENT NAME is CCR. SPONSOR NAMES is Acceleron, PPD Investigator Services, LLC. DISEASE SITES is Pulmonary Arterial Hypertension (PAH), Lung - Pulmonary.
227. TITLE is A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan. SHORT TITLE is MG0017. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 85 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Participant has been treated with an intravenous (IV) complement component 5 (C5) inhibitor approved for the treatment of generalized myasthenia gravis (gMG) at the recommended dose regimen for at least 3 months (for eculizumab) or 4 months (for ravulizumab) prior to Screening with a clinically stable disease as per the Investigator's judgment.
2.  Participant is willing to switch from his/her current IV C5 inhibitor to subcutaneous (SC) zilucoplan (ZLP)
3.  Participant has a documented diagnosis of gMG (Myasthenia Gravis Foundation of America; MGFA Class II-IVa) at Screening based on participant history and supported by previous evaluations
4.  Participant has a well-documented record of positive serology for acetylcholine receptor binding autoantibodies prior to Screening
Participant has no more than a 2-point change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Baseline compared with the Screening Visit
5.  Participant has had no change in corticosteroid dose during the Screening Period and no change in corticosteroid dose is anticipated to occur during the 12-week Main Treatment Period
6.  Participant has had no change in immunosuppressive therapy, including dose, during the Screening Period and no change in immunosuppressive therapy is anticipated to occur during the 12-week Main Treatment Period
7.  Participant has a record of vaccination with at least 1 dose of a quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14 days prior to the first dose of ZLP if not vaccinated within 3 years prior to the start of study medication
8.  Male and/or female
9.  A male participant is recommended to agree to use contraception during the study and for at least 40 days (5 half lives) after the last dose of study medication, and refrain from donating sperm during this period.
10.  A female participant is eligible to participate if she is not pregnant; not breastfeeding, and at least one of the following conditions applies:
Not a woman of childbearing potential (WOCBP) OR
11.  A WOCBP who agrees to follow the contraceptive guidance during the study and for at least 40 days (5 half lives) after the last dose of study medication.
12.  Participant is capable of giving signed informed consent.

Other Protocol defined inclusion/ exclusion criteria may apply. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-04-14T12:55:19. DEPARTMENT NAME is CCR. SPONSOR NAMES is UCB Biosciences, Inc.. DISEASE SITES is Brain - Neurologic/ Psychologic, Myasthenia Gravis.
228. TITLE is 	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS). SHORT TITLE is This study will assess the effects and safety of PTC857 treatment in participants diagnosed with ALS. INVESTIGATOR NAME is Namita Goyal. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years to 70 Years   (Adult, Older Adult)
Amyotrophic Lateral Sclerosis. DETAILED ELIGIBILITY is Key Inclusion Criteria:

- Males or females aged between 18 and 70 years with a body mass index between 18 and 35 kilograms/meters squared
- ALS with preserved function, defined as:

1. Onset of the first symptom leading to the diagnosis of ALS &#8805;7 and &#8804;18 months at the time of the initial Screening Visit
2. Revised EL Escorial criteria of either:
(i) Clinically definite ALS (ii) Clinically probable ALS

- A total ALSFRS-R score of at least 34 at the start of the Screening Period
- No significant respiratory compromise as evidenced by slow vital capacity &#8805;60%
- All concomitant medications (both prescription and over the counter) and non-pharmacologic therapy regimens should be stable and unchanged from 30 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study, with the exception of prohibited medications

Key Exclusion Criteria:

- Females who are pregnant or nursing or plan to become pregnant during the study
- Participants with clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular/ischemic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or impact the validity of the study results
- Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator or the medical monitor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant
- Current participation in any other investigational study with an investigational product or participation within 30 days prior to the start of the Screening Period or 5 half-lives of the previously taken investigational drug, whichever is longer
- Participant has previously received PTC857
- Edaravone treatment, where applicable, within 30 days prior to the start of the Screening Period. DESCRIPTION is Participants will be randomized to 1 of 2 treatment groups: PTC857 or matching placebo. Following successful completion of the 24-week Treatment Period, participants have the option to receive open-label PTC857 in the Long-term Extension Period for 28 weeks.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-03T16:09:30. DEPARTMENT NAME is CCR. SPONSOR NAMES is PTC THERAPEUTICS, Worldwide Clinical Trials, Inc., Medidata, Inc.. DISEASE SITES is Amyotrophic Lateral Sclerosis (ALS), Brain - Neurologic/ Psychologic.
229. TITLE is A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group
Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active
Idiopathic Inflammatory Myopathies. SHORT TITLE is Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory . INVESTIGATOR NAME is Namita Goyal. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Disease classification criteria: Participant meets the diagnostic criteria of probable or definite idiopathic inflammatory myopathies (IIM) based on 2017 The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for adult IIM at least 6 weeks prior to first administration of the study intervention
2.  If a participant is on regular or as needed treatment with low potency topical glucocorticoids (GC) that are allowed in the study or topical tacrolimus (TAC) to treat skin lesions, the dose and frequency should be stable for greater than or equal to (>=) 4 weeks prior to first administration of the study intervention as well as maintained at the same dose until Week 52 of the study
3.  Antibody positivity criteria: Any 1 of the myositis-specific antibodies (MSAs) positive: dermatomyositis (DM): anti-Mi-2 (Mi-2/nucleosome remodeling and deacetylase [NuRD] complex), anti-transcription intermediary factor 1-Gamma (TIF1-Gamma), anti- nuclear matrix protein 2 (NXP-2), anti-small ubiquitin-like modifier-1 activating enzyme; anti- antimelanoma differentiation-associated gene 5 (MDA-5) antibodies. Or immune-mediated necrotizing myopathy (IMNM): anti- signal recognition particle (SRP) and anti- 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies. Or anti-synthetase syndrome (ASyS): anti- histidyl- ribonucleic acid [tRNA] synthetase (Jo-1), anti- threonyl-tRNA synthetase (PL7), anti- alanyl-tRNA synthetase (PL12), anti- isoleucyl-tRNA synthetase (OJ), and anti- glycyl-tRNA synthetase (EJ) antibodies. If all MSAs are negative or more than 1 MSA is positive (defined by the central laboratory) at screening, the tests should be repeated during the screening period. If the same results are observed at retesting, the participant should not be enrolled in the study


Exclusion Criteria:

1.  Has a juvenile myositis diagnosis and now >=18 years old
2.  Has cancer-associated myositis defined as cancer diagnosis within 3 years of myositis diagnosis except for cervical carcinoma in situ and non-melanoma skin cancer (squamous cell carcinoma, basal cell carcinoma of the skin)
3.  Has comorbidities (example, asthma, chronic obstructive pulmonary disease [COPD]) which have required 3 or more courses of oral GC within 1 year prior to screening
4.  Has a history of primary immunodeficiency or secondary immunodeficiency not related to the treatment of the participants IIM
5.  Has experienced myocardial infarction (MI), unstable ischemic heart disease, or stroke within 12 weeks of screening. DESCRIPTION is IIM is considered as a group of rare diseases that is characterized by common features of insidious painless, proximal skeletal muscle weakness, low endurance, and elevated serum muscle enzyme levels. Due to muscle weakness and progressive muscular atrophy, decreasing endurance, internal organ involvement (mainly given the pulmonary, gastrointestinal and cardiac manifestations) and limited therapeutic options, IIM often leads to physical disability and decreased quality of life. Nipocalimab is a fully human aglycosylated immunoglobulin G1 (IgG1) monoclonal antibody (mAb) designed to selectively bind, saturate, and block the immunoglobulin G (IgG) binding site on the endogenous neonatal fragment crystallizable receptor (FcRn) that binds, salvages, and recycles IgG into circulation or transport IgG across the placenta, following nonspecific pinocytosis into endothelial cells and cells of the reticuloendothelial system. At homeostasis, FcRn recycles IgG to maintain serum IgG levels and extend IgG half-life and also regulates immune cell inflammatory responses to IgG complexes. By targeting the IgG binding site on FcRn, nipocalimab is expected to block the binding and, hence, recycling of IgG, resulting in a decrease in circulating IgG antibody levels, including pathogenic IgG autoantibodies and alloantibodies. Therefore, nipocalimab has potential in the treatment of active IIM by decreasing pathogenic IgG antibody concentrations. The total duration of the study is up to 112 weeks, consisting of 4 study periods: a less than or equal to (<=) 6-week screening period, a 52-week double-blind period, a 48-week long term extension (LTE), and a safety follow-up 8 weeks post last administration of study intervention. Safety assessments include adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs), laboratory parameters (hematology and chemistry, including lipid panel), vital signs, and physical examination.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:18:13. DEPARTMENT NAME is CCR. SPONSOR NAMES is Janssen Research & Development, LLC. DISEASE SITES is Brain - Neurologic/ Psychologic, Idiopathic Inflammatory Myopathies, Myositis.
230. TITLE is A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation . SHORT TITLE is CLASP II TR Pivotal Clinical Trial. INVESTIGATOR NAME is Antonio Frangieh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Tricuspid Regurgitation
Tricuspid Valve Insufficiency
Tricuspid Valve Disease
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Eighteen (18) years of age or older
2.  Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR.
3.  Severe or greater tricuspid regurgitation
4.  New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the prior 12 months
5.  Patient is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon with concurrence by the local Heart Team
6.  Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements

Exclusion Criteria:
1.  Tricuspid valve anatomy not evaluable by TTE or TEE
2.  Tricuspid valve anatomy precludes proper device deployment and function
3.  Patient with refractory heart failure requiring, advanced intervention (i.e. patient has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D heart failure)
4.  Presence of trans-tricuspid pacemaker or defibrillator leads which meet one of the following: a) Would prevent proper TR reduction due to interaction of the lead with the leaflets; b) Were implanted in the RV within the last 90 days prior to the point of enrollment.
5.  Primary non-degenerative tricuspid disease
6.  Previous tricuspid valve repair or replacement that would interfere with placement of PASCAL
7.  Clinically significant, untreated coronary artery disease requiring revascularization, unstable angina, evidence of acute coronary syndrome, recent myocardial infarction
8.  Significant intra-cardiac mass, thrombus, or vegetation per core lab assessment
9.  Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 180 days
10.  Recent Stroke
11.  Active gastrointestinal (GI) bleeding
12.  Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid, amyloidosis, sarcoidosis, hemochromatosis) or significant congenital heart disease, including but not limited to atrial septal defect, RV dysplasia, and arrhythmogenic RV
13.  Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days
14.  Any of the following cardiovascular procedures: a) Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days prior to the point of enrollment; b) Carotid surgery within 30 days prior to the point of enrollment; c) Direct current cardioversion within the last 30 days prior to the point of enrollment; d) Leadless RV pacemaker implant within the last 30 days prior to the point of enrollment; and, e) Cardiac surgery within 90 days prior to the point of enrollment.
15.  Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation
16.  Known history of untreated severe symptomatic carotid stenosis or asymptomatic carotid stenosis
17.  Active endocarditis or recent infection requiring antibiotic therapy
18.  Chronic obstructive pulmonary disease (COPD) requiring continuous home oxygen
19.  Pregnant or planning pregnancy within the next 12 months
20.  Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
21.  Patient is currently participating in another investigational biologic, drug, or device clinical study
22.  Patient has other medical, social, or psychological conditions that preclude appropriate consent and follow-up, or the patient is under guardianship
23.  Any patient considered to be vulnerable. DESCRIPTION is A Prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation. Patients will be seen for follow-up visits at discharge, 30 days, 3 months, 6 months, and annually through 5 years.. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-25T09:36:08. DEPARTMENT NAME is CCR. SPONSOR NAMES is Edwards Lifesciences . DISEASE SITES is Heart - Cardiovascular/ Circulatory.
231. TITLE is An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Biomarkers. SHORT TITLE is EMBARK-HFpEF. INVESTIGATOR NAME is Dawn Lombardo. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Heart Failure With Preserved Ejection Fraction
50 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Key Inclusion Criteria:
1.  Is at least 50 years old at Screening.
2.  Body weight is greater than 45 kg at Screening.
3.  Documented prior objective evidence of heart failure as shown by 1 or more of the following criteria:

 - Previous hospitalization for heart failure with documented radiographic evidence of pulmonary congestion.
 - Elevated LV end-diastolic pressure or pulmonary capillary wedge pressure at rest (&#8805;15 mm Hg) or with exercise (&#8805;25 mm Hg).
 - Elevated level of NT-proBNP (>400 pg/mL) or brain natriuretic peptide (BNP) (>200 pg/mL).
 - Echocardiographic evidence of medial E/e' ratio &#8805; 15 or left atrial enlargement (left atrial volume index >34 mL/m2) together with chronic treatment with spironolactone, eplerenone, or a loop diuretic.

4.  Meets 1 or more of the following criteria:

 -  A screening hs-cTnT greater than or equal to 99th percentile AND a screening NT-proBNP > 200 pg/mL (if not in atrial fibrillation or atrial flutter) or > 500 pg/mL (if in atrial fibrillation or atrial flutter) OR if the screened participant is of African descent or has a body mass index (BMI) greater than or equal to 30.0 kg/m2, a screening hs-cTnT greater than or equal to 99th percentile, AND a screening NT-proBNP > 160 pg/mL (if not in atrial fibrillation or atrial flutter) or > 400 pg/mL (if in atrial fibrillation or atrial flutter).
 - A screening NT-proBNP > 300 pg/mL (if not in atrial fibrillation or atrial flutter) or > 750 pg/mL (if in atrial fibrillation or atrial flutter) OR if the screened participant is of African descent or has a BMI greater than or equal to  30.0 kg/m2, a screening NT-proBNP > 240 pg/mL (if not in atrial fibrillation or atrial flutter) or > 600 pg/mL (if in atrial fibrillation or atrial flutter).

5.  Has documented LVEF greater than or equal to 60% at the Screening visit and no history of prior LVEF less than or equal to 45%.
6.  Has maximal left ventricular wall thickness greater than or equal to12 mm OR documented elevated left ventricular mass index by 2-dimensional imaging (>95 g/m2 if female and >115 g/m2 if male).
7.  Has high quality TTEs without or with echocardiographic contrast agents.
8.  Has NYHA class II or III symptoms at Screening.

Other Protocol defined inclusion/ exclusion criteria may apply
. DESCRIPTION is This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and elevation of NT-proBNP with or without elevation of cTnT. Data from this study will inform future study designs of mavacamten in patients with HFpEF.
. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:18:30. DEPARTMENT NAME is CCR. SPONSOR NAMES is Bristol-Myers Squibb, Myokardia, Inc.. DISEASE SITES is Heart Failure, Heart - Cardiovascular/ Circulatory.
232. TITLE is A randomized, double-blind, placebo-controlled, study to investigate the safety, pharmacokinetics, and pharmacodynamics of CSL312 in subjects with idiopathic pulmonary fibrosis . SHORT TITLE is CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Interstitial Pulmonary Fibrosis . INVESTIGATOR NAME is Huawei Dong. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Idiopathic Pulmonary Fibrosis
40 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Male or female patients &#8805; 40 years of age
2.  Documented diagnosis of IPF


Exclusion Criteria:
1.  History of clinically significant cardiovascular disease, including myocardial infarction, unstable ischemic heart disease, congestive heart failure, or angina during the 6 months before screening
2.  Sinoatrial or atrioventricular block, uncontrolled hypertension
3.  Active bleeding or current clinically significant coagulopathy. DESCRIPTION is This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:19:59. DEPARTMENT NAME is CCR. SPONSOR NAMES is CSL Behring LLC. DISEASE SITES is Lung - Pulmonary, Idiopathic Pulmoary Fibrosis (IPF).
233. TITLE is A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG). SHORT TITLE is IMVT-1401-3101. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Generalized Myasthenia Gravis
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Are greater than or equal to 18 years of age at the Screening Visit.
2.  Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification Class II, III, or IVa at the Screening Visit.
3.  Have a QMG score greater than or equal to 11 at the Screening and Baseline Visits.
4.  Have a MG-ADL score of greater than or equal to 5 at the Screening and Baseline Visits.
5.  Additional inclusion criteria are defined in the protocol.


Exclusion Criteria:
1.  Have experienced myasthenic crisis within 3 months of the Screening Visit.
2.  Have had a thymectomy performed < 6 months prior to the Screening Visit or have a planned thymectomy during the study period.
3.  Have any active or untreated malignant thymoma.
4.  Have received any agent or therapy (exclusive of those identified within inclusion criteria) with immunosuppressive properties (e.g., stem cell therapy, chemotherapies, etc.) within the past year.
5.  Have used anti-FcRN treatment within 6 months prior to the Screening Visit or have a documented history of non-response to prior anti-FcRN treatment.
6.  Additional exclusion criteria are defined in the protocol.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:20:39. DEPARTMENT NAME is CCR. SPONSOR NAMES is Syneos Health, Immunovant Sciences GmbH. DISEASE SITES is Brain - Neurologic/ Psychologic, Myasthenia Gravis.
234. TITLE is A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. SHORT TITLE is Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV
2.  Positive serological test for autoantibodies against AChR.

Exclusion Criteria:
1.  History of thymectomy or any other thymic surgery within 12 months prior to Screening
2.  Untreated thymic malignancy, carcinoma, or thymoma
3.  History of Neisseria meningitidis infection
4.  Pregnancy, breastfeeding, or intention to conceive during the course of the study.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-16T17:47:11. DEPARTMENT NAME is CCR. SPONSOR NAMES is Alexion Pharmaceuticals, Inc.. DISEASE SITES is Brain - Neurologic/ Psychologic, Myasthenia Gravis.
235. TITLE is Long-Term Follow-Up Study of Patients With Spinal Muscular Atrophy Receiving Risdiplam Treatment. SHORT TITLE is Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA). INVESTIGATOR NAME is Manisha Korb. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Spinal Muscular Atrophy
2 Months and older   (Child, Adult, Older Adult)
. DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Confirmed diagnosis of 5q-autosomal recessive SMA
2.  Prescribed or continued risdiplam based on clinical judgment of prescriber, as per the Evrysdi¬Æ USPI, after U.S. FDA approval (07 August 2020)

Exclusion Criteria:

1.  Hypersensitivity to risdiplam
2.  Participated in a registrational trial for risdiplam (i.e., Firefish [NCT02913482], Sunfish [NCT02908685], Jewelfish [NCT03032172], and Rainbowfish [NCT03779334])
3.  Aged >/=2 years with a score </=3 on the HFMSE or RULM at study entry. PHASE DESC is IV. TREATMENT TYPE DESC is OBS - Chart review. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:21:12. DEPARTMENT NAME is CCR. SPONSOR NAMES is United BioSource, Syneos Health, Genentech, Inc.. DISEASE SITES is Brain - Neurologic/ Psychologic, Spinal Muscular Atrophy, Muscles and Bones - Musculoskeletal.
236. TITLE is A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 in Patients Hospitalized with Confirmed Severe COVID-19 Disease . SHORT TITLE is AV-001 for Hospitalized Patients With COVID-19 Disease. INVESTIGATOR NAME is Richard Lee. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Able and willing to give signed informed consent
2.  Patients hospitalized with a presumed diagnosis of pneumonia of < 48 hours duration requiring supplemental oxygen therapy. Eligible patients include those hospitalized for a separate non-infectious reason who subsequently develop a presumed pneumonia;
3.  Radiologic imaging (chest x-ray, CT scan, etc.) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation.
4.  Signs and symptoms:
     At least 1 of the following signs:
        - respiratory rate > 30 breaths/min;
        - fever (> 38.0¬∫C or > 100.4o F);
        - leukopenia (less than or equal to 4,000 WBC/mm3 or leukocytosis (&#8805; 12,000 WBC/mm3);
        - adults greater than or equal to 70 years of age; altered mental status with no other recognized cause;

    AND at least 1 of the following symptoms:
        - New onset of purulent sputum or change in character of sputum or increased respiratory secretions;
        - New onset or worsening cough, or dyspnea, or tachypnea;
        - Rales or bronchial breath sounds;

5.  Female patients of reproductive potential must be on an effective contraceptive method

Exclusion Criteria:
1.  Pregnant and/or lactating women
2.  Patients included in any other interventional trial
3.  Use of endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at screening
4.  Any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to:
     - Septic shock as defined by systolic blood pressure (SBP) < 90 mmHg or diastolic blood pressure (DBP) of < 60 mmHg;
     - Multiple organ failure;
     - Are moribund irrespective of the provision of treatments;
     - Any significant bleeding disorder or vasculitis;
     - Any serious, nonhealing wound, peptic ulcer or bone fracture;
     - Liver cirrhosis;
     - History of a hypertensive crisis or hypertensive encephalopathy, or current, poorly controlled hypertension or hypotension;
     - Severe renal insufficiency or end stage renal disease as determined by estimated glomerular filtration rate <30mL/min/1.73m2;
     - ARDS risk factors of aspiration pneumonia, non-cardiac shock, trauma, blood transfusion or drug overdose.

5.  Any thromboembolic event within the past 3 months;
6.  Symptomatic congestive heart failure or symptomatic or poorly controlled cardiac arrhythmia > class II as per New York Heart Association (NYHA) classification;
7.  History of autonomic disorders or uncontrolled hypotension
8.  Hypersensitivity to drug products containing polyethylene glycol (PEG)
9.  Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study.. DESCRIPTION is AV-001 is a synthetic Angiopoietin-1 (Angpt-1) mimetic that has been shown to activate the Tie2 receptor tyrosine kinase; a transmembrane protein target most highly expressed on the surface of endothelial cells in the vasculature. The Tie2/Angiopoietin signaling axis has been identified as a nonredundant gatekeeper of vascular homeostasis. In healthy individuals, Tie2 is highly activated and signals the endothelium to fortify intracellular junctions and reduce expression of adhesion molecules, which serve as leukocyte tethers upon inflammation. As such, homeostatic activation results in the promotion of barrier defense against vascular leakage.

The study population for this Phase 2a study will consist of male and non-pregnant female patients, greater than or equal to 18 years of age, hospitalized with presumed pneumonia secondary to SARS-CoV-2 or other viral or bacterial infection with acute onset to a respiratory compromise requiring supplemental oxygen therapy.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:21:50. DEPARTMENT NAME is CCR. SPONSOR NAMES is Vasomune Therapeutics, Inc. . DISEASE SITES is Lung - Pulmonary, COVID-19, Pneumonia, Coronavirus Infection.
237. TITLE is Clinical Procedures to Support Research in ALS (CAPTURE-ALS). SHORT TITLE is Clinical Procedures to Support Research in ALS. INVESTIGATOR NAME is Namita Goyal. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Amyotrophic Lateral Sclerosis
ALS-Frontotemporal Dementia
Primary Lateral Sclerosis
Progressive Muscular Atrophy
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Diagnosis of ALS or a related disorder (e.g. primary lateral sclerosis, progressive muscular atrophy).
2.  Receiving care at a clinical center that uses Epic as its EHR.
3.  Able and willing to provide informed consent (or informed consent obtainable from a designated proxy).

Exclusion Criteria:
1.  Inability to understand English and/or Spanish. DESCRIPTION is The study will consent patients with ALS or related disorders that are receiving care at a clinical center in the CReATe consortium that uses Epic as its electronic health record (EHR) system. The study aims to systematically gather a clinical dataset through the EHR using a standardized approach to characterize the natural history of ALS and related diseases.. TREATMENT TYPE DESC is OBS - Registry. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-07T13:22:48. DEPARTMENT NAME is CCR. SPONSOR NAMES is NIH, Muscular Dystrophy Association. DISEASE SITES is Amyotrophic Lateral Sclerosis (ALS), Brain - Neurologic/ Psychologic.
238. TITLE is An Open Label Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan. SHORT TITLE is Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria. INVESTIGATOR NAME is Zahra Pakbaz. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Paroxysmal Nocturnal Hemoglobinuria
18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion criteria:
1.  Male and female participants greater than or equal to 18 years of age with a diagnosis of PNH who have completed the treatment extension period (without tapering down) of Phase II iptacopan studies (CLNP023X2204, CLNP023X2201), Period 4 of LFG316X2201 or Phase III (CLNP023C12302 and CLNP023C12301) clinical studies at the time point of enrollment visit in this roll over extension.
2.  Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections
3.  Per investigator's clinical judgement benefit from continued treatment with iptacopan and has been clinically stable on iptacopan monotherapy for at least 3 months


Exclusion Criteria:
1.  Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
2.  History of recurrent invasive infections caused by encapsulated organisms, such as Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae
3.  History of hematopoietic stem cell transplantation
4.  Other protocol-defined inclusion/exclusion criteria may apply.. DESCRIPTION is The purpose of this phase 3 open-label, single arm, multicenter study is to evaluate the long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide access to patients who have completed (without tapering down) Phase 2 and Phase 3 trials and derived benefit from iptacopan treatment.. PHASE DESC is IV. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-02-07T13:24:10. DEPARTMENT NAME is CCR. SPONSOR NAMES is Novartis. DISEASE SITES is Paroxysmal Nocturnal Hemoglobinuria (PNH), Blood - Hematologic.
239. TITLE is Embolization of the Middle Meningeal Artery with ONYX  Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma (EMBOLISE). SHORT TITLE is EMBOLISE. INVESTIGATOR NAME is Shuichi Suzuki. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Subdural Hematoma
18 Years to 90 Years   (Adult, Older Adult)
. DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Pre-morbid Modified Rankin Score greater than or equal to 3
2.  Confirmed diagnosis of subacute or chronic subdural hematoma
3.  Completed informed consent
4.  Meets criteria for Surgery or Observation Cohort

Exclusion Criteria:
1.  Life expectancy <1 year
2.  Unable to complete follow-up
3.  Pregnant, lactating, or has a positive pregnancy test at time of admission
4.  Diagnosed with acute SDH
5.  Potentially dangerous anatomic variations leading to increased procedural risk or unsafe access for MMA embolization
6.  Pre-randomized Markwalder Grading Scale score &#8805; 3
7.  Unmanaged, uncontrolled bleeding disorders/blood diathesis
8.  Presumed septic embolus, or suspicion of microbial superinfection
9.  Known active COVID-19 infection
10.  CT or MRI evidence of intra-cranial tumor or mass lesion Contraindication to angiography
11.  Participation in another clinical trial
12.  Contraindicated for the use of Onyx LES
13.  Cannot be taken off corticosteroids (intended to treat subacute or chronic SDH) for at least 90 days post-randomization. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-06-09T09:01:50. DEPARTMENT NAME is CCR. SPONSOR NAMES is Medtronic, Inc.. DISEASE SITES is Brain - Neurologic/ Psychologic.
240. TITLE is Randomized Trial of Full-Time Occlusion Therapy for Intermittent Exotropia in Children. SHORT TITLE is IXT7. INVESTIGATOR NAME is Donny Won Suh. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Intermittent Exotropia
3 Years to 8 Years   (Child). DETAILED ELIGIBILITY is Inclusion Criteria - Children under the care of a pediatric optometrist or pediatric ophthalmologist will be eligible for the study if they meet all the following criteria:

1.  Age 3 to < 9 years
2.  IXT meeting all of the following criteria:

a.  Intermittent or constant XT at distance (mean distance control 2.0 or more) with at least 1 control measure of 3, 4 or 5 (i.e., indicating spontaneous tropia)
b.  Either IXT, exophoria, or orthophoria at near (cannot have control score of 5 on all 3 near assessments)
c.  Distance exodeviation between 15&#8710; and 50&#8710; by PACT
d.  Near exodeviation between 0&#8710; and 50&#8710; by PACT
e.  Near exodeviation does not exceed distance by more than 10&#8710; by PACT (convergence insufficiency-type IXT excluded)

3.  Age-normal visual acuity in both eyes:

a.  3 years: 20/50 or better (>=63 letters)
b.  4 years: 20/40 or better (>=68 letters)
c.  5-6 years: 20/32 or better (>=73 letters)
d.  7-<9 years: 20/25 or better (>=78 letters)

4.  Interocular difference in distance VA of 2 logMAR lines or less (10 letters or less on E-ETDRS for patients &#8805;7 years old). Testing by ATS HOTV for participants 3 to < 7 years old and by E-ETDRS for participants &#8805;7 years old.
5.  Cycloplegic refraction within the last 7 months.
6.  Refractive error between -6.00 D SE and +2.00 D SE (inclusive) based on a cycloplegic refraction within 7 months

Other Protocol defined inclusion/ exclusion criteria may apply.. DESCRIPTION is Understanding the effectiveness of intensive patching has important implications for managing children with IXT. If full-time patching is associated with improvement in distance control vs an observation group, then future studies can be conducted to evaluate different durations of full-time patching treatment, whether the effect is maintained off-treatment, and how full-time patching compares to other treatment strategies.

The purpose of this study is to determine whether full-time patching is more effective than observation for improving distance control of IXT after 3 months of treatment (on-treatment outcome).. PHASE DESC is III. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Children. SCOPE DESC is National. MODIFIED DATE is 2023-04-11T17:25:11. DEPARTMENT NAME is CCR. SPONSOR NAMES is Jaeb Center for Health Research, The National Eye Institute of the National Institutes of Health. DISEASE SITES is Eye - Ophthalmologic.
241. TITLE is A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults.. SHORT TITLE is Enlighten 2. INVESTIGATOR NAME is Naveen Bhandarkar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult)
Chronic Sinusitis
Chronic Rhinosinusitis (Diagnosis). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  18 years and older
2.  Diagnosed as having CRS
3.  Undergone at least 2 trials of medical treatments in the past
4.  Mean 3 cardinal symptom (3CS) score
5.  Bilateral ethmoid disease confirmed on CT
6.  Has been informed of the nature of the study and provided written informed consent
7.  Agrees to comply with all study requirements

Exclusion Criteria:
1.  Inability to tolerate topical anesthesia
2.  Previous nasal surgery
3.  Presence of nasal polyp grade 2 or higher
4.  Seasonal allergic rhinitis
5.  Perennial rhinitis with symptoms that are well controlled by regular use of intranasal corticosteroids
6.  Severe asthma
7.  History or clinical evidence or suspicion of invasive fungal sinusitis, allergic fungal rhinosinusitis, atrophic rhinitis, or odontogenic sinusitis
8.  Obstruction preventing proper placement and retention of LYR-210 as seen on endoscopy
9.  Anatomic variation that, in the opinion of the investigator, would adversely impact placement of LYR-210 as seen on CT
10.  Known history of hypersensitivity or intolerance to corticosteroids
11.  Known history of hypothalamic pituitary adrenal axial dysfunction
12.  Previous pituitary or adrenal surgery
13.  Dental procedure/implant on maxillary dentition within 4 weeks of the Screening visit.
14.  Past or present acute or chronic intracranial or orbital complications of CRS
15.  History or diagnosis (in either eye) of glaucoma or ocular hypertension
16.  Past or present functional vision in only 1 eye
17.  Past, present, or planned organ transplant or chemotherapy with immunosuppression
18.  Currently positive for COVID-19 or residual sinonasal symptoms from a previous COVID-19 infection
19.  Pregnant or breast feeding. Females of child-bearing potential must test negative for pregnancy at the time of screening
20.  Evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments
21.  Currently participating in an investigational drug or device study
22.  Determined by the investigator as not suitable to be enrolled. DESCRIPTION is This is a 24-week, multicenter, phase III, randomized, blinded, controlled, parallel group with a 24-week treatment period to evaluate the efficacy and safety of LYR-210 compared with sham control for treatment in adults with CRS.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-11T12:32:13. DEPARTMENT NAME is CCR. SPONSOR NAMES is Medpace, Inc., Lyra Therapeutics, Inc.. DISEASE SITES is Ear/ Nose/ Throat (ENT) - Otolaryngologic.
242. TITLE is A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients with Thalassemia or Sickle Cell Disease . SHORT TITLE is A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease. INVESTIGATOR NAME is Zahra Pakbaz. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 12 Years to 65 Years   (Child, Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Provision of consent
2.  Female patients of childbearing potential must use acceptable methods of contraception, male patients are willing to use barrier methods of contraception

Cohort A (Sickle Cell Disease Transfusion Cohort) - INCLUSION
1.  Confirmed diagnosis of sickle cell disease
2.  Chronically red blood cell transfused (sample or exchange [manual or via electrophoresis]) for primary stroke prevention or due to previous stroke. Chronic red blood cell transfusion is defined as: greater than or equal to 6 red blood cell units in the previous 24 weeks before the first dose of study treatment and no transfusion-free period for > 35 days during that period
3.  At least 24 months of chronic monthly red blood cell transfusions for secondary stroke prevention/treatment of primary stroke (initial completed overt clinical stroke with documented infarction on brain computed tomography [CT] or magnetic resonance imaging [MRI])
4.  Prior to screening OR at least 12 months of chronic RBC transfusions for primary stroke prevention (abnormal TCD) prior to screening
5.  Documented adequate monthly transfusions with average HbS greater than or equal to 45% (the upper limit of the established academic community standard) for the previous 12 weeks of red blood cell transfusions before the first dose of study treatment

Cohort B (Thalassemia Transfusion Cohort) - INCLUSION
1.  Documented diagnosis of B-thalassemia, Hemoglobin E/ &#946;-thalassemia or Hemoglobin H (&#945;-thalassemia), or other thalassemia variant
2.  Chronically transfused, defined as greater than or equal to  6 red blood cell units in the previous 24 weeks before the first dose of study treatment and no transfusion-free period for > 35 days during that period

Cohort C (Thalassemia Non-transfused Cohort) - INCLUSION
Documented diagnosis of B-thalassemia, Hemoglobin E/ &#946;-thalassemia or Hemoglobin H (&#945;-thalassemia), or other thalassemia variant
Hemoglobin less than or equal to 10 g/dL

Exclusion Criteria:
1.  Female who is breast feeding or pregnant
2.  Hepatic dysfunction characterized by:
3.  Known human immunodeficiency virus (HIV) positivity
4.  Active hepatitis B or hepatitis C infection
5.  Severe renal dysfunction or on chronic dialysis
6.  History of malignancy within the past 2 years prior to treatment Day 1 requiring systemic chemotherapy and/or radiation.
7.  History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
. DESCRIPTION is Etavopivat is a potent, selective, orally bioavailable, small-molecule activator of pyruvate kinase red blood cell (PKR) being developed by Forma Therapeutics, Inc and is intended for use as a treatment for patients with sickle cell disease (SCD) or other inherited hemoglobinopathies or refractory anemias. This study is a multicenter, Phase 2, open-label, multiple-cohort study examining the safety and efficacy of etavopivat for the treatment of patients, age 12 to 65 years, with SCD or thalassemia. Three treatment cohorts based on the patients hemoglobinopathy (SCD or thalassemia) and transfusion requirements will be evaluated.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-03-29T12:50:47. DEPARTMENT NAME is CCR. SPONSOR NAMES is FORMA Therapeutics, Inc.. DISEASE SITES is Sickle Cell Disease (SCD), Blood - Hematologic.
243. TITLE is A Randomized, Double-Blind, Placebo-Controlled, Two Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components. SHORT TITLE is BK-JM-201. INVESTIGATOR NAME is Anna E Morenkova. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Dyskinesia
Parkinson
18 Years to 85 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Is able to read, understand, and provide written, dated informed consent prior to Screening Visit.
2.  Is male or female, between 18 and 85 years of age at Screening Visit.
3.  Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria
4.  Has experienced dyskinesia
5.  Has stable peak-effect dyskinesia
6.  Has more than one hour of "ON" time with troublesome dyskinesia

Exclusion Criteria:
1.  Has undergone surgery for the treatment of PD
2.  Has a current diagnosis of Substance Use
3.  Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses
4.  Has current seizure disorders requiring treatment with anticonvulsants.
5.  Other criteria related to other medical conditions to be referred to the protocol.. DESCRIPTION is This is a two-part, Phase 2, double-blind, placebo-controlled, randomized, multicentre study.

Subjects with a diagnosis of PD and dyskinesias in PD will complete a Screening Visit to assess eligibility to participate in the study.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-04-27T13:55:40. DEPARTMENT NAME is CCR. SPONSOR NAMES is Syneos Health, Bukwang Pharmaceutical Co., LTD.. DISEASE SITES is Parkinson Disease, Brain - Neurologic/ Psychologic.
244. TITLE is Defining Endpoints in Becker Muscular Dystrophy. SHORT TITLE is Defining Endpoints in Becker Muscular Dystrophy. INVESTIGATOR NAME is Tahseen Mozaffar. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 8 Years and older   (Child, Adult, Older Adult). DETAILED ELIGIBILITY is nclusion Criteria:

For ages 8-16
- Clinically affected (defined as weakness on bedside evaluation in a pattern consistent with BMD)
- Genetic confirmation of an in-frame dystrophin mutation
- Ambulatory
- Willing and able to give informed consent and follow all procedures and requirements

For ages 17-older
- Clinically affected (defined as weakness on bedside evaluation in a pattern consistent with BMD)
- Genetic confirmation of a dystrophin mutation
- Willing and able to give informed consent and follow all procedures and requirements

For participants in the MRI substudy:
- Ambulatory, as defined as able to walk 10 meters without assistive devices (orthotics allowed)

Exclusion Criteria:

For ages 8-16
- Out of frame dystrophin mutation
- Use of chronic corticosteroids at baseline, defined as greater than 6 months of chronic use, will be limited to 20% of the overall population
- Non-ambulatory, defined as the inability to walk 10 meters without assistive device (excluding orthotics)
- >16 hours of ventilatory support
- Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator.
- Under the age of 8 at time of enrollment
- For MR Cohort: Have contraindications to MRI or MRS (e.g., non-MR compatible implanted medical devices or severe claustrophobia)

For ages 17-older
- Loss of ambulation prior to age 16
- Use of chronic corticosteroids, defined as greater than 6 months of chronic use, will be limited to 20% of the overall population
- Less than 30% of the overall population will be non-ambulatory, defined as the inability to walk 10 meters without assistive device (excluding orthotics)
- >16 hours of ventilatory support
- For MR Cohort: Have contraindications to MRI or MRS (e.g., non-MR compatible implanted medical devices or severe claustrophobia). DESCRIPTION is Becker Muscular Dystrophy (BMD) is most frequently due to in-frame mutations in the dystrophin gene that are associated with reduced levels of frequently shortened dystrophin, though other mutations may be related to the Becker phenotype. There is wide variation in the age of onset and degree of progression, ranging from childhood to late adulthood. The more severe form of dystrophinopathy, Duchenne muscular dystrophy, has a more characteristic rate of progression and overall natural history. The wide variation in severity of progression has led to challenges in the design and conduct of approaching therapeutic trials. There is a need for a more rigorous natural history study to assist in the design of these promising therapeutic trials.. TREATMENT TYPE DESC is OBS - Plus drug/device/survey. AGE DESCRIPTION is Both. MODIFIED DATE is 2023-02-16T16:21:41. DEPARTMENT NAME is CCR. SPONSOR NAMES is Edgewise Therapeutics, Virginia Commonwealth University. DISEASE SITES is Brain - Neurologic/ Psychologic, Muscular Dystrophy.
245. TITLE is A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity. SHORT TITLE is A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults With Obesity. INVESTIGATOR NAME is Andy Lee. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Obesity
Overweight
40 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1.  Have a body mass index (BMI) greater than or equal to 27.0 kilogram/square meter (kg/m ¬≤)
2.  Are either: individuals greater than or equal to 40 years of age with established cardiovascular disease (CVD); 
CVD is defined as meeting at least one of the following (Coronary artery disease, Cerebrovascular disease)
3.  Peripheral arterial disease OR
4.  individuals without established CVD but have the presence of cardiovascular (CV) risk factors (primary prevention)

a.  women 55-69 years of age or men 50-64 years of age with at least 3 risk factors like tobacco use, dyslipidemia, hypertension at screening, or
b.  women greater than or equal to 70 years of age or men, greater than or equal to 65 years of age with at least 2 risk factors at screening.

Exclusion Criteria:
1.  Have type 1 diabetes (T1D) or (T2D), history of ketoacidosis, or hyperosmolar state/coma
2.  Have laboratory evidence diagnostic of diabetes mellitus at screening of HbA1c greater than or equal to 6.5% (greater than or equal to 48 millimole/mole (mmol/mol) or fasting glucose (FG) greater than or equal to 126 milligram/deciliter (greater than or equal to 7.0 millimole/liter (mmol/L).
3.  Any one of the following CV conditions within 90 days prior to screening (MI, acute coronary syndrome, stroke, coronary or peripheral arterial revascularization procedure, which may also include carotid artery revascularization, or acute decompensated heart failure
4.  Have a known clinically significant gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction or have undergone or currently planning any gastric bypass (metabolic) surgery or restrictive bariatric surgery. Note: Liposuction or abdominoplasty are not considered as gastric bypass procedures.
5.  Have a history of chronic or acute pancreatitis
6.  Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
7.  Have acute or chronic hepatitis, or clinical signs or symptoms of any other liver disease, or have elevated liver enzyme measurements, determined by the central laboratory at screening
8.  Have a presence or history of malignant neoplasms within the past 5 years prior to screening.. PHASE DESC is III. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-04-27T13:56:58. DEPARTMENT NAME is CCR. SPONSOR NAMES is Eli Lilly and Company. DISEASE SITES is Hormone - Endocrine/ Metabolic.
246. TITLE is NIMBLE Network Biorepository including MGNet (Neuroimmunology Biosample; Myathenia Gravis Network). SHORT TITLE is EXPLORE MG2 Nat Hx and Biorepository. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Key Inclusion Criteria:
1. Male or female patients 18 years or older
2. Patient with documented diagnosis of myasthenia gravis (MG) based on medical history and supported by previous evaluations as described in the protocol
3. Documented prior history of positive serologic test or a positive result during screening of anti-acetylcholine receptor (AChR) antibodies or anti-LRP4 antibodies.
4. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IVa at screening
5. Myasthenia Gravis-Activities of Daily Living (MG-ADL) score &#8805;6 at screening. Ocular items should not contribute more than 50% of MG-ADL total score
6. Currently receiving an acetylcholinesterase inhibitor or documented reason for not using acetylcholinesterase inhibitor therapy per investigator 
7. Currently receiving an immunosuppressive therapy (IST) for MG, or documented reason why the patient is not taking an IST per investigator
8. If currently receiving an IST, not anticipated to have IST dosage changed before randomization or during double-blind treatment period (DBTP).

Key Exclusion Criteria:
1. Patients with antibody profile that is only positive for muscle specific tyrosine kinase (MuSK) (MuSK positivity is based on a documented prior history of positive serologic test for antibodies to MuSK or a positive result during screening
2. History of thymectomy within 12 months prior to screening or planned during the study
3. History of malignant thymoma (patients with stage 1 may be enrolled), or history of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer
4. Myasthenic crisis or Myasthenia Gravis Foundation of America (MGFA) Class V within 1 month of screening
5. No documented meningococcal vaccination within 5 years prior to screening visit unless vaccination will be administered during the screening period and prior to initiation of study treatment
6. Known contraindication to meningococcal vaccines (group ACWY conjugate and group B vaccines) as described in the protocol
7. Patients who require antibiotics for meningococcal prophylaxis and have a contraindication, warning, or precaution precluding the use of penicillin class and penicillin-alternative antibiotics planned to be used for prophylaxis, or a history of intolerance leading to the discontinuation of these antibiotics
8. Positive hepatitis B surface antigen or hepatitis C virus ribonucleic acid (RNA) during screening. NOTE: Cases with unclear interpretation should be discussed with the medical monitor
9. History of HIV infection or a positive test at screening per local requirements

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply. DESCRIPTION is DBTP- Double blind treatment plan (24 weeks) ETP - Extension treatment plan (28 weeks) OLTP- Open label treatment plan (68 weeks) Off-treatment follow up period (52 weeks). TREATMENT TYPE DESC is OBS - Biorepository. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-02-16T20:12:10. DEPARTMENT NAME is CCR. SPONSOR NAMES is NIH/NINDS. DISEASE SITES is Brain - Neurologic/ Psychologic, Myasthenia Gravis.
247. TITLE is A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE). SHORT TITLE is A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE). INVESTIGATOR NAME is Dena Moskowitz. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 18 Years and older   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population
2.  Individual with diagnosis of overactive bladder with urgency urinary incontinence.
3.  Individual has at least one urgency urinary incontinence episode on each of three days as determined on a 3-day voiding diary.
4.  Individual gives written informed consent.
5.  Individual is mentally competent and able to understand all study requirements.
6.  Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.
7.  Individual is without pharmacological treatment of overactive bladder  for 2 weeks prior to baseline or longer if the physician judges that the therapeutic effect is still present.
8.  Individual is intolerant of or has an inadequate response to any of anticholinergics, 3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).
9.  Individual is determined to be a suitable surgical candidate by physician.
10.  Individual is appropriate for eCoin treatment based on the US FDA-approved IFU requirements.

Other Protocol defined inclusion/ exclusion criteria may apply. DESCRIPTION is Participants will be implanted with eCoin ¬Æ and complete voiding diaries and patient reported-outcomes through 12 months of eCoin ¬Æ therapy.. TREATMENT TYPE DESC is INT - Device. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-04-27T14:06:57. DEPARTMENT NAME is CCR. SPONSOR NAMES is Valencia Technologie. DISEASE SITES is Urinary Incontinence, Genital/ Bladder - Genitourinary.
248. TITLE is Individual Patient Expanded Access Protocol for Iptacopan.
. SHORT TITLE is Iptacopan Expanded Access . INVESTIGATOR NAME is Zahra Pakbaz. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is C3 Glomerulopathy (C3G). DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria for his category:

A) Patients with native kidneys:
1.   Adult male and female (greater than or equal to 18 years) who are able and willing to provide written informed consent.
2.  C3 Glomerulopathy confirmed by kidney biopsy within last five years.
3.  Estimated GFR (using the CKD-EPI formula) or measured GFR greater than or equal to 30 mL/min per 1.73m2.
UPCR greater than or equal to 1.0 g/g.
4.  On supportive care, including a maximally tolerated dose of ACEi or ARB for at least 90 days.
5.  Vaccination against Neisseria meningitidis and Streptococcus pneumoniae is required prior to the start of treatment. If the patient has not been previously vaccinated or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of iptacopan. If iptacopan has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment must be initiated per local standard of care.
6.  Vaccination against Haemophilus influenzae (or a booster, if required) should be given, if available and according to local regulations, at least 2 weeks prior to first dosing.

B) Patient with transplanted kidney:
1.  Adult male and female (&#8805; 18 years) who are able and willing to provide written informed consent.
2.  C3G recurrence after kidney transplantation confirmed by kidney biopsy.
3.  Estimated GFR (using the CKD-EPI formula) or measured GFR greater than or equal to 30 mL/min/1.73m2
4.  Vaccination against Neisseria meningitidis and Streptococcus pneumoniae is required prior to the start of treatment. If the patient has not been previously vaccinated or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of iptacopan. If iptacopan has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment must be initiated.
5.  Vaccination against Haemophilus influenzae (or a booster, if required) should be given, if available and according to local regulations, at least 2 weeks prior to first dosing.

Other Protocol defined inclusion/ exclusion criteria may apply. TREATMENT TYPE DESC is Expanded access. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-04-27T14:15:00. DEPARTMENT NAME is CCR. SPONSOR NAMES is Novartis. DISEASE SITES is Blood - Hematologic.
249. TITLE is RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR GENE TRANSFER (AAV2-GDNF) IN MULTIPLE SYSTEM ATROPHY. SHORT TITLE is SAFETY STUDY OF AAV2-GDNF IN MSA. INVESTIGATOR NAME is Nicolas Phielipp. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is Inclusion Criteria:

Male and female adults 35-75 years of age (inclusive)
Diagnosed with MSA with sporadic, adult-onset (>30 yo) with predominant parkinsonian symptoms
Less than 4 years from clinical diagnosis of MSA with expected survival > 3 years
Stable medication regimen
Ability to walk with or without an assistive device

Exclusion Criteria:

Presence of idiopathic Parkinson's disease or other neurological diseases
Myocardial sympathetic denervation inconsistent with an MSA diagnosis
Presence of dementia, psychosis, substance abuse or poorly controlled depression
Prior brain surgery (i.e. deep brain stimulator) or other brain imaging abnormalities
Receiving an investigational drug
History of cancer or poorly controlled medical conditions that would increase surgical risk
Inability to tolerate laying flat in an MRI or allergy to gadolinium
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.. PHASE DESC is I. TREATMENT TYPE DESC is INT - Biological/vaccine. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-04-06T08:15:00. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is KCR U.S. Inc., AskBio, Brain Neurotherapy Bio, Inc. DISEASE SITES is Neurodegenerative Diseases.
250. TITLE is Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis. SHORT TITLE is Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Gen. INVESTIGATOR NAME is Ali A Habib. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is A patient must meet the following criteria to be eligible for inclusion in the study:
1. Male or female patients &#8805;18 years of age at screening (or &#8805; legal age of adulthood based 
on local regulations, whichever is older) 
2. Patient with documented diagnosis of MG based on medical history and supported by 
previous evaluations. Examples of supportive evaluations include any one of the 
following: 
&#8722; History of abnormal neuromuscular transmission by repetitive nerve stimulation / 
single-fiber electromyography
&#8722; History of positive anticholinesterase test 
&#8722; Positive response (improvement in signs) with anticholinesterase treatment, as 
assessed by the treating physician
3. Documented prior history of positive serologic test or a positive result during screening 
of anti-AChR antibodies or anti-LRP4 antibodies. One retest is allowed
4. MGFA Clinical Classification Class II to IVa at screening
5. MG-ADL score &#8805;6 at screening (either week -5 or week -2) and baseline (day 1). Ocular 
items should not contribute more than 50% of MG-ADL total score
6. Currently receiving an acetylcholinesterase inhibitor or documented reason for not using 
acetylcholinesterase inhibitor therapy per investigator
7. Currently receiving an IST for MG, or documented reason why the patient is not taking 
an IST per investigator
Note: ISTs include, but are not limited to, systemic corticosteroids, azathioprine, 
mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus, or cyclophosphamide
8. If currently receiving an IST, not anticipated to have IST dosage changed before 
randomization or during DBTP. Patients who require time to stabilize their treatment 
regimen may be rescreened
9. Patient agrees to participate in the study and sign the study consent
10. Willing and able to comply with clinic visits and study-related procedures
11. Able to understand and complete study-related questionnaires
7.2.2. Exclusion Criteria
A patient who meets any of the following criteria will be excluded from the study. Patients may 
be rescreened up to 2 times after discussion between the investigator and the sponsor.
1. Patients with a positive serologic test for antibodies to MuSK during screening
2. History of thymectomy within 12 months prior to screening or planned during the study
3. History of malignant thymoma (patients with stage 1 may be enrolled), or history of 
cancer within the past 5 years, except for adequately treated basal cell skin cancer, 
squamous cell skin cancer, or in situ cervical cancer
4. Myasthenic crisis or MGFA Class V within 1 month of screening
5. Any systemic bacterial or other infection that was clinically significant in the opinion of 
the investigator and had not been treated with appropriate therapy within 2 weeks of 
screening or during the screening period
6. Unresolved meningococcal infection
7. No documented meningococcal vaccination within 5 years prior to screening visit unless 
vaccination will be administered during the screening period and prior to initiation of 
study treatment
8. Known contraindication to meningococcal vaccines (group ACWY conjugate and 
group B vaccines). Refer to the most recent local product information for each vaccine, if 
approved, for the current list of contraindications
9. Patients who require antibiotics for meningococcal prophylaxis and have a 
contraindication, warning, or precaution precluding the use of penicillin class and 
penicillin-alternative antibiotics planned to be used for prophylaxis, or a history of 
intolerance leading to the discontinuation of these antibiotics
10. Positive hepatitis B surface antigen or hepatitis C virus RNA during screening. 
NOTE: Cases with unclear interpretation should be discussed with the medical monitor
11. History of HIV infection
12. Patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2
(according to the Chronic Kidney Disease Epidem. PHASE DESC is III. TREATMENT TYPE DESC is INT - Gene transfer/stem cell/recombinant DNA. AGE DESCRIPTION is Adults. MODIFIED DATE is 2022-06-01T21:00:09. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is Regeneron Pharmaceuticals, Inc, PPD Investigator Services, LLC. DISEASE SITES is Other.
251. TITLE is A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (RGX 314-2104). SHORT TITLE is A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and S. INVESTIGATOR NAME is Baruch Kuppermann. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is 50 Years to 89 Years   (Adult, Older Adult). DETAILED ELIGIBILITY is Inclusion Criteria:
1. Age greater than or equal to; 50 years andl ess than or equal to 89 years
2. An ETDRS BCVA letter score between less than or equal to 78 and greater than or equal to 40 in the study eye
3. Diagnosis of subfoveal CNV secondary to AMD in the study eye previously treated with anti-VEGF
4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye.
5. Willing and able to provide written, signed informed consent for this study
6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry

Exclusion Criteria:
1. CNV or macular edema in the study eye secondary to any causes other than AMD
2. Subfoveal fibrosis or atrophy in the study eye
3. Any condition in the investigator's opinion that could limit VA improvement in the study eye
4. Active or history of retinal detachment in the study eye
5. Uncontrolled glaucoma in the study eye
6. History of intraocular surgery in the study eye within 12 weeks prior to Screening Visit 1
7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational product, other than anti-VEGF therapy, in the 6 months prior to Screening Visit 1.
8. Prior treatment with gene therapy.
9. Recent myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months.. DESCRIPTION is RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. RGX-314 is being developed as a potential one-time treatment for wet AMD.. PHASE DESC is II/III. TREATMENT TYPE DESC is INT - Gene transfer/stem cell/recombinant DNA. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-06-16T16:45:10. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is REGENXBIO Inc.. DISEASE SITES is Macular Degeneration, Eye - Ophthalmologic.
252. TITLE is A Phase 1/2, Multi-center, Three-part Dose Escalation and Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Efficacy of Gene Therapy APB-102 in ALS Patients with SOD1 Mutations. SHORT TITLE is A Phase 1/2, Multi-center, Three-part Dose Escalation and Randomized, Double-blind Study to Evaluate. INVESTIGATOR NAME is Namita Goyal. STATUS is RA SIGNOFF. DETAILED ELIGIBILITY is Inclusion Criteria
1. Subjects diagnosed with mutant SOD1-mediated ALS experiencing signs and/or symptoms 
of lower motor neuron dysfunction (weakness, atrophy, cramps, fasciculations), with or 
without upper motor neuron symptoms (weakness, brisk reflexes, spasticity) 
&#8226; SOD1-mediated is defined by the presence of a SOD1 coding mutation on a gene 
test conducted by an accredited lab; specifically, the variation/mutation must be 
listed in the National Center for Biotechnology Information (NCBI ) ClinVar 
database (https://urldefense.com/v3/__https://www.ncbi.nlm.nih.gov/clinvar/__;!!OLgoXmg!X3XOGgZgxwQ0K5eZ2_3uHMJxiHOHF6nDLh67FE-4yWEWh58WXLkKNQATvFxoVAfJhn6EhlagWE7pIEB0MEg$ ) as Pathogenic, 
Pathogenic/Likely Pathogenic, or Likely Pathogenic within the SOD1 gene. 
2. Subjects with rapidly progressing disease (&#8220;fast&#8221; progressors), defined as average 
ALSFRS-R decline &#8805;1.0 per month calculated from score at onset of symptoms compared 
to score at Screening ALSFRS-R
&#8226; ALSFRS-R score of 48 is assigned at onset of symptoms of weakness unless 
otherwise documented in medical history. 
3. ALSFRS-R score &#8805; 25 at Screening
4. Male or female aged 18 years or older
5. Slow vital capacity (SVC) &#8805;65% of predicted normal value on Screening assessment
6. King&#8217;s stage &#8804;3 at Screening
7. Capable of providing informed consent and complying with trial procedures, in the 
documented opinion of the Investigator, including:
a) Medically able to undergo lumbar puncture for treatment and collection of CSF, in 
consideration of known medical status (e.g. bleeding diatheses, allergy to local 
anesthetics, skin infection at or near the lumbar puncture site, indications of possible 
raised intracranial pressure, abnormal spine skeletal issues)
b) Physically and mentally able to lie in protocol-required position for the duration of the 
intrathecal infusion 
c) Willing to forego addition of any new FDA-approved treatments for ALS or 
participation in other clinical studies of treatment for ALS through at least 6 months 
after initial APB-102/placebo treatment in Part 1 or Part 2 of the study.
d) Has a responsible caregiver able to attend all clinic visits with the subject
8. Titer for neutralizing antibodies (NAb) to AAV rh10 >[1:50] at Screening
9. Normal renal clearance at Screening defined as creatinine clearance &#8805; 60 milliliters per 
minute (mL/min) using the Cockroft-Gault equation
10. Normal coagulation function, defined as international normalized ratio (INR) &#8804; 1.1 (based 
on Screening labs prior to enrollment/randomization and Day -7 labs prior to APB 102/placebo treatment) 
11. Platelet count >150 10^3/mm^3 (based on Screening labs prior to 
enrollment/randomization and Day -7 labs prior to APB-102/placebo treatment)
12. For subjects on anticoagulant or antiplatelet therapy: able to temporarily stop or bridge 
therapy for the APB-102/placebo administration procedures
6.2 Exclusion Criteria
1. SOD1 mutation in positions 2-12 of the MiR targeting sequence, also defined as 
complementary deoxyribonucleic acid (cDNA) position 128-139, which also corresponds 
to amino acid regions 43-47. (Position 1 is defined as the start codon ATG.) 
&#8226; Documentation for this criterion must be reviewed and confirmed by the Sponsor.
&#8226; Note: The fast-progressing mutation H43R is excluded from this study because it falls 
within the MiR targeting region. 
2. Homozygosity for the D91A (formerly D90A) SOD1 gene mutation
3. History of significant chronic pain or sensory syndrome such as fibromyalgia, complex 
regional pain syndrome, or peripheral neuropathy that, in the Investigator&#8217;s opinion, would 
preclude enrollment of such subject in the study
4. Presence of unstable psychiatric illness defined as psychosis (hallucinations or delusions) 
or untreated major depression within 90 days of signing the informed consent form (ICF) 
5. Active suicidal ideation within 6 months prior to screening, defined as an ans. PHASE DESC is I/II. TREATMENT TYPE DESC is INT - Gene transfer/stem cell/recombinant DNA. AGE DESCRIPTION is Adults. MODIFIED DATE is 2022-10-14T10:58:17. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is Apic Bio, Inc, Worldwide Clinical Trials, Inc.. DISEASE SITES is Other.
253. TITLE is AN OPEN-LABEL DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF IMM01-STEM IN PARTICIPANTS WITH MUSCLE ATROPHY RELATED TO KNEE OSTEOARTHRITIS. SHORT TITLE is An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participa. INVESTIGATOR NAME is Dean Wang. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is 5.1 Inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age
1. Study participant must be 50 to 75 years of age, inclusive, at the time of signing the informed 
consent.
Type of participant and disease characteristics
2a. Study participant has moderate KOA (defined as Kellgren-Lawrence [KL] grade 2 to 3) on 
affected limb.
3a. Study participants has quadriceps weakness (<7.5N/kg/m2) (see Appendix 9 [Section 10.9] 
for the measurement methodology).
4. Study participant can ambulate >50 feet unassisted.
5. Study participant must have negative laboratory test results for human immunodeficiency 
virus, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) at the Screening 
Visit.
Weight
6. Study participant has a body mass index (BMI) of <40kg/m2
Sex and contraceptive/barrier requirements
7. The study participant is male or female.
A male participant must agree to use contraception as detailed in Appendix 4 (Section 10.4) 
of this protocol during the treatment period and for at least 3 months after the last dose of 
study treatment and refrain from donating sperm during this period.
A female participant is eligible to participate if she is not pregnant (see Appendix 4 
[Section 10.4]), not breastfeeding, and at least one of the following conditions applies:
a. Not a woman of childbearing potential (WOCBP) as defined Appendix 4 (Section 10.4).
OR
b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 4 
(Section 10.4) during the treatment period and for at least 3 months after the last dose of 
study treatment.
Female participant has a negative pregnancy test result at Screening and prior to 
investigational medicinal product (IMP) administration.
Informed consent
8. Capable of giving signed informed consent as described in Appendix 1 which includes 
compliance with the requirements and restrictions listed in the informed consent form (ICF) 
and in this protocol.
9. Study participant is able to speak, read, and understand English, in order to understand the 
nature of this study.
10. Study participant is willing and able to comply with all study requirements, according to the 
judgment of the Investigator.
Other criteria
11. Participant has discontinued systemic oral or intravenous steroid use for 6 months prior to 
Screening.
12. Participant has vital sign measurements within the following ranges at Baseline (predose at 
Visit 2): heart rate >50 and <100 bpm, systolic blood pressure >100 and <170 mmHg, 
diastolic blood pressure >50 and <90 mmHg, and blood oxygenation (by pulse-oximetry) 
>95%
13. Participant has undergone and failed at least 1 3-month or longer treatment regimen (ie, 
activity modification, weight loss, physical therapy, anti-inflammatory medications, or 
injection therapy) within a 2-year period prior to the Screening visit.
5.2 Exclusion criteria
Study participants are excluded from the study if any of the following criteria apply:
Medical conditions
1. Study participant has moderate to severe KOA (defined as KL grade >3) on contralateral 
limb.
2. Study participant has had prior total knee arthroplasty.
3. Study participant has a known hypersensitivity to any components of the study medication or 
comparative drugs (and/or an investigational device) as stated in this protocol.
4. Study participant has current or past history of malignancy (10y) excluding nonmelanoma 
skin cancer.
5. Study participant has neurological, vascular, or cardiac condition that limit function, or, in 
the opinion of the investigator, could jeopardize or would compromise the study participant&#8217;s 
ability to participate in this study.
6a. Study participant has uncontrolled comorbidities including diabetes (hemoglobin A1c level 
>7.0%), Hypertension (resting heart rate >100 bpm, systolic blood pressure >170 mmHg, or 
diastolic blood pre. PHASE DESC is I/II. TREATMENT TYPE DESC is INT - Gene transfer/stem cell/recombinant DNA. AGE DESCRIPTION is Adults. MODIFIED DATE is 2022-10-14T10:42:08. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is Immunis, Inc.. DISEASE SITES is Other.
254. TITLE is Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles as Early Goal Directed Therapy for COVID-19 Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS): A Phase III Clinical Trial. SHORT TITLE is Bone Marrow Mesenchymal Stem Cell for COVID-19 related ARDS. INVESTIGATOR NAME is Alpesh Amin. STATUS is OPEN TO ACCRUAL. DETAILED ELIGIBILITY is Inclusion Criteria
To be eligible to participate in this study, a patient must meet all of the following criteria:
1. Admitted to hospital with symptoms suggestive of COVID-19 infection.
2. Subject (or legally authorized representative) provides informed consent prior to the 
initiation of any study procedures. 
3. Subject (or legally authorized representative) understands and agrees to comply with 
planned study procedures. 
4. Male or nonpregnant female aged 18-85 of age at time of enrollment. 
5. Women of childbearing potential must agree to either abstinence or use at least one primary 
form of contraception not including hormonal contraception from time of screening 
through Day 61. 
6. Meets criteria for either severe or critical COVID-19 as evidenced by 
a. Severe COVID-19:
i. SARS-CoV-2 PCR positive in sample collected within one week prior to 
randomization 
ii. Severe symptoms suggestive of severe systemic illness with COVID-19, 
which could include any symptom of moderate illness or shortness of breath 
at rest, or respiratory distress
iii. Clinical signs indicative of severe systemic illness with COVID-19, such as 
respiratory rate &#8805; 30 per minute, heart rate &#8805; 125 per minute, SpO2 &#8804; 93% 
on room air at sea level 
b. Critical COVID-19: 
i. SARS-CoV-2 PCR positive in sample collected within one week prior to 
randomization 
ii. Evidence of critical illness, defined by at least one of the following:
1. Respiratory failure defined based on resource utilization requiring 
at least one of the following: 
Endotracheal intubation and mechanical ventilation, oxygen 
delivery by high flow nasal cannula (heated, humidified, oxygen 
delivered via reinforced nasal cannula at flow rates > 20 L/min with 
fraction of delivered oxygen &#8805; 0.5), oxygen delivery by high flow 
nasal cannula (heated, humidified, oxygen delivered via reinforced 
nasal cannula at flow rates > 20 L/min with fraction of delivered 
oxygen &#8805; 0.5), noninvasive positive pressure ventilation, or clinical 
diagnosis of respiratory failure (i.e. clinical need for one of the 
preceding therapies, but preceding therapies not able to be 
administered in setting of resource limitation).
2. Shock (defined by systolic blood pressure < 90 mmHg, or diastolic 
blood pressure 60 mmHg or requiring pressors) 
3. Multi-organ dysfunction/failure 
7. PaO2/FiO2 (P/F ratio) &#8804; 200.
Note for Inclusion Criterion #7: 
&#8226; PaO2 will be obtained from ABG. 
&#8226; FiO2 may be obtained from the setting on MV, CPAP, BIPAP, HFNO, or HFOV. If the 
patient is on RA, NC, FM, or NRB, Appendix Section 10.3 will be used for estimating
FiO2 from oxygen delivery.
5.2 Exclusion Criteria
Any individual who meets any of the following criteria will be excluded from participation in this 
study: 
1. Active malignancy requiring treatment within the last five years.
2. Any uncontrolled chronic respiratory disease, such as asthma or COPD. 
3. Use of extracorporeal membrane oxygenation (ECMO) during the current hospitalization. 
4. ALT or AST > 5 x Upper Limit of Normal (ULN).
5. Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min.
6. Overt Disseminated Intravascular Coagulopathy (DIC) as evidenced by a total score of &#8805;
5 on the following DIC score from International Society of Thrombosis & Hemostasis:
&#8226; INR &#8804; 1.3 (0 Points); 1.3- 1.7 (1 Point); > 1.7 (2 Points) 
&#8226; Fibrinogen > 100 mg/dL (0 Points); < 100 mg/dL (1 Point) 
&#8226; D-dimer < 400 ng/dL (0 Points); 400-4000 ng/mL (2 Points); >4,000 ng/ml (3 Points) 
&#8226; Platelets > 100,000/uL (0 Points); 50,000-100,000/uL (1 Point); < 50,000/uL (2 Points)
7. Pneumonia that is primarily attributable to a non-COVID-19 related process, including 
tuberculosis, mycoplasma, aspiration pneumonia or pneumonia that is exclusively bacterial, 
or originating from a diagnosed alternative virus (e.g., influenza). 
8. DNR order, as in . PHASE DESC is III. TREATMENT TYPE DESC is INT - Gene transfer/stem cell/recombinant DNA. AGE DESCRIPTION is Adults. MODIFIED DATE is 2022-10-14T10:15:13. DEPARTMENT NAME is Alpha Stem Cell Clinic. SPONSOR NAMES is Biorasi, Direct Biologics, LLC. DISEASE SITES is Other.
255. TITLE is A Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products. SHORT TITLE is Long Term Follow Up Patients Previously Tx w/ Mustang Bio, Inc. CAR-T Cell Investigational Products. INVESTIGATOR NAME is Susan O'Brien. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adutls. DETAILED ELIGIBILITY is AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- received any Mustang Bio CAR-T cell product in a Mustang Bio-sponsored clinical study.
. DESCRIPTION is A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
. TREATMENT TYPE DESC is Other. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-05-26T11:19:27. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Mustang. DISEASE SITES is Lymphoid Leukemia, Non-Hodgkin's Lymphoma.
256. TITLE is A Phase III Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide . SHORT TITLE is PhIII TeclistamabMonother VSPomalidomide Bortezomib/Carfilzomib Dexamethasone RelapOR Refr MultiMyel. INVESTIGATOR NAME is Lisa Xingguang Lee. STATUS is IRB INITIAL APPROVAL. ELIGIBILITY is Adults 18years and older
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:  	No. DETAILED ELIGIBILITY is Criteria
Inclusion Criteria:

Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion Criteria:

Received any prior B cell maturation antigen (BCMA)-directed therapy
A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma.
Received a live, attenuated vaccine within 4 weeks before randomization
Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis
Received a maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14 days prior to randomization. DESCRIPTION is Multiple myeloma is an incurable, malignant, plasma cell disorder. Teclistamab (JNJ-64007957) is a full-size, Immunoglobulin G (IgG) 4 proline, alanine, and alanine (PAA) bispecific antibody that targets the cluster of differentiation (CD3) receptor expressed on the surface of T cells and B cell maturation antigen (BCMA). With its dual binding sites, teclistamab is able to draw CD3 positive T cells in close proximity to BCMA positive cells, resulting in T-cell activation and subsequent lysis of BCMA positive cells. Pomalidomide is a third-generation immunomodulatory imide drug (IMiD) that exerts potent, direct tumoricidal and immune-enhancing effects and Carfilzomib is a second-generation proteasome inhibitor that inhibits proteasome which results in disruption of protein turnover and induces apoptosis. The primary hypothesis of this study is that teclistamab monotherapy (Arm A) will significantly improve progression free survival (PFS) compared with investigator's choice of PVd or Kd (Arm B) in participants with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide. The study will include a screening phase, treatment phase, and follow-up phase. Safety will be assessed by physical examinations, neurologic examinations, eastern cooperative oncology group (ECOG) performance status, clinical laboratory tests, vital signs, and AE monitoring. The overall duration of the study will be up to 9 years.. PHASE DESC is III. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-05-26T16:43:31. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is Janssen Research & Development, LLC. DISEASE SITES is Multiple Myeloma. DRUG NAMES is 
      .
257. TITLE is A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma. SHORT TITLE is Ph I CA-4948 in Comb w/ Gemcitabine and Nab-Paclitaxel in Meta or UnresePancreatic Ductal Carcinoma. INVESTIGATOR NAME is Farshid Dayyani. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult. DETAILED ELIGIBILITY is Inclusion Criteria

-Adults 18 years of age or older
-Patients with  confirmed adenocarcimona of the pancreas that is metastatic or unresectable and for which standard curative or palliative measure do not exist or are no longer effective.

Exclusion Criteria

-Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
-Patients who are receiving any other investigational agents
-Patients who are pregnant. DESCRIPTION is This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.. PHASE DESC is I. TREATMENT TYPE DESC is Treatment. AGE DESCRIPTION is Adults. SCOPE DESC is National. MODIFIED DATE is 2023-05-17T08:45:30. DEPARTMENT NAME is CFCCC. SPONSOR NAMES is ETCTN. DISEASE SITES is Pancreas.
258. TITLE is Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk. SHORT TITLE is Nulliparous Pregnancy Outcomes Study:  Monitoring Mothers-to-Be (nuMoM2b). INVESTIGATOR NAME is Judith Chung. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Pregnant Female age 13 years and older (Child, Adult, Older Adult) . DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Nullipara - Pregnant women with no prior pregnancy lasting 20 weeks 0 days or greater.
2.  Viable singleton gestation - a single living fetus with fetal cardiac activity at the most recent ultrasound before enrollment
3.  Between 6 weeks 0 days and 13 weeks 6 days project estimated gestational age (EGA) at first study visit.
4.  Intend to deliver at a participating hospital.

Exclusion Criteria:

1.  Participant age <13 years.
2.  History of 3 or more spontaneous abortions.
3.  Fetal malformation evident at or before enrollment that is likely lethal (e.g., anencephaly, hydrops, diffuse subcutaneous edema or cystic hygroma, ectopic cordis, encephalocele).
4.  Known fetal aneuploidy (based on chorionic villus sampling).
5.  Surrogate pregnancy (donor oocyte pregnancy).
6.  Multifetal reduction.
7.  Participating in an intervention study that is anticipated to influence maternal or fetal morbidities/mortality unless it is determined before enrollment that the study code will be made available.
8.  Woman previously enrolled in this study, including those consented but delivered before 20 weeks 0 days gestation.
9.  Planned pregnancy termination.
10.  Unable to provide informed consent.. DESCRIPTION is The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) established the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b) to study women for whom the current pregnancy will lead to their first delivery (nulliparas). About 40% of pregnant women in the United States are nulliparas. Because little or no information from previous pregnancy outcomes is available to guide assignment of risk or mitigating interventions, adverse pregnancy outcomes in nulliparas are especially unpredictable. The underlying mechanisms of adverse pregnancy outcomes such as preterm birth, preeclampsia, fetal growth restriction and stillbirth are interrelated and therefore will be evaluated as part of this study. The information gained will benefit women who are pregnant or who are considering pregnancy and their physicians. In addition, the knowledge will support future research aimed at improving care and health outcomes for a critical group of at-risk women who are currently understudied.

The study is a prospective cohort study of a racially/ethnically/geographically diverse population of 10,038 nulliparous women with singleton gestations. The women undergo intensive research assessments during the course of their pregnancies to study the mechanisms for and prediction of adverse pregnancy outcomes (APOs) in women in their first pregnancy. The APOs of primary interest are preterm birth, preeclampsia and fetal growth restriction.

The goals of the study are to 1) determine maternal characteristics, including genetics, epigenetics, and physiological response to pregnancy as well as environmental factors that influence and/or predict adverse pregnancy outcome; 2) identify specific aspects of placental development and function that lead to adverse pregnancy outcome; and 3) characterize genetic, growth, and developmental parameters of the fetus that are associated with adverse pregnancy outcome.

Eight academic medical centers or sites had primary responsibility for enrollment and follow-up of study participants. Several of these sites collected data through additional academic research centers or nearby hospitals (subsites). A Data Coordinating and Analysis Center (DCAC) provided input to the protocol, manages the data, and analyzes the data. Investigators from these institutions have established a partnership with NICHD staff to develop and implement the study protocol and ancillary studies that acquire and analyze data to identify biomarkers and understand the mechanism and prediction of preterm birth and other adverse pregnancy outcomes.. TREATMENT TYPE DESC is INT - Procedure/Surgery. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-10T10:05:59. DEPARTMENT NAME is SOM/Obstetrics and Gynecology. SPONSOR NAMES is National Institute of Child Health and Human Development. DISEASE SITES is Pregnancy, Women¬ís Health ¬ñ OB/GYN.
259. TITLE is Effect of Ultra-Low Dose Naloxone on Remifentanil-Induced Hyperalgesia. SHORT TITLE is Effect of Ultra-Low Dose Naloxone on Remifentanil-Induced Hyperalgesia. INVESTIGATOR NAME is Ariana Nelson. STATUS is OPEN TO ACCRUAL. ELIGIBILITY is Adult, Older Adult 18 years with Hyperalgesia. DETAILED ELIGIBILITY is Inclusion Criteria:

1.  Subjects who provide written informed consent.
2.  Age 18 years old or older (no upper age limit for inclusion)
3.  Gender: male or female.
4.  Surgery: Posterior spinal fusions

Exclusion Criteria:

1.  Allergy to opiates
2.  Chronic pain other than the primary indication for surgery
3.  Psychiatric illness
4.  History of substance abuse problem including alcohol &/or cannabis
5.  BMI > 35
6.  Subjects under 18 years of age.
7.  Subject without the capacity to give written informed consent. 8. Female subjects who are pregnant. DESCRIPTION is The purpose of this study is to evaluate whether using ultra-low dose naloxone, an opioid antagonist, has the potential to block remifentanil-induced hyperalgesia and tolerance following surgery.

The hypothesis of the study is that occurrence of remifentanil-induced HI group.. PHASE DESC is II. TREATMENT TYPE DESC is INT - Drug. AGE DESCRIPTION is Adults. MODIFIED DATE is 2023-05-10T10:05:27. DEPARTMENT NAME is SOM/Anesthesiology. SPONSOR NAMES is Department of Anesthesiology. DISEASE SITES is Hyperalgesia, Anesthesia.
